WO2013170052A1 - Saccharide protective coating for pharmaceutical package - Google Patents

Saccharide protective coating for pharmaceutical package Download PDF

Info

Publication number
WO2013170052A1
WO2013170052A1 PCT/US2013/040380 US2013040380W WO2013170052A1 WO 2013170052 A1 WO2013170052 A1 WO 2013170052A1 US 2013040380 W US2013040380 W US 2013040380W WO 2013170052 A1 WO2013170052 A1 WO 2013170052A1
Authority
WO
WIPO (PCT)
Prior art keywords
injection
drug comprises
drug
solution
test material
Prior art date
Application number
PCT/US2013/040380
Other languages
French (fr)
Inventor
John T. Felts
Thomas E. Fisk
Robert S. Abrams
John Ferguson
Jonathan R. Freedman
Robert J. Pangborn
Peter Sagona
Christopher Weikart
Jacob ISRAELACHVILI
Original Assignee
Sio2 Medical Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sio2 Medical Products, Inc. filed Critical Sio2 Medical Products, Inc.
Priority to EP13723390.4A priority Critical patent/EP2846755A1/en
Priority to CA2887352A priority patent/CA2887352A1/en
Priority to US14/399,678 priority patent/US9545360B2/en
Publication of WO2013170052A1 publication Critical patent/WO2013170052A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00—Medical syringes, e.g. enemata; Irrigators
    • A61M3/02—Enemata; Irrigators
    • A61M3/0233—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs
    • A61M3/0254—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped
    • A61M3/0262—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped manually, e.g. by squeezing a bulb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2096—Combination of a vial and a syringe for transferring or mixing their contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2200/00—General characteristics or adaptations
    • A61J2200/50—Insulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/10—Materials for lubricating medical devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/08—Coatings comprising two or more layers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
    • Y10T428/1379—Contains vapor or gas barrier, polymer derived from vinyl chloride or vinylidene chloride, or polymer containing a vinyl alcohol unit
    • Y10T428/1383—Vapor or gas barrier, polymer derived from vinyl chloride or vinylidene chloride, or polymer containing a vinyl alcohol unit is sandwiched between layers [continuous layer]

Definitions

  • European patent applications describe apparatus, vessels, precursors, coatings or layers and methods (in particular coating methods and test methods for examining the coatings or layers) which can generally be used in performing the present invention, unless stated otherwise herein. They also describe SiO x barrier coatings or layers to which reference is made herein.
  • the present invention relates to the technical field of coated surfaces, for example interior surfaces of pharmaceutical packages or other vessels for storing or other contact with fluids.
  • suitable fluids include foods or biologically active compounds or body fluids, for example blood.
  • the present invention also relates to a pharmaceutical package or other vessel and to a method for coating an inner or interior surface of a pharmaceutical package or other vessel.
  • the present invention also relates more generally to medical devices, including devices other than packages or vessels, for example catheters.
  • the present disclosure also relates to improved methods for processing pharmaceutical packages or other vessels, for example multiple identical pharmaceutical packages or other vessels used for pharmaceutical preparation storage and delivery, venipuncture and other medical sample collection, and other purposes.
  • Such pharmaceutical packages or other vessels are used in large numbers for these purposes, and must be relatively economical to manufacture and yet highly reliable in storage and use.
  • borosilicate glass vessels such as vials or pre-filled syringes.
  • the relatively strong, impermeable and inert surface of borosilicate glass has performed adequately for most drug products.
  • the recent advent of costly, complex and sensitive biologies as well as such advanced delivery systems as auto injectors has exposed the physical and chemical shortcomings of glass pharmaceutical packages or other vessels, including possible contamination from metals, flaking, and breakage, among other problems.
  • glass contains several components which can leach out during storage and cause damage to the stored material.
  • borosilicate pharmaceutical packages or other vessels exhibit a number of drawbacks:
  • Glass is manufactured from sand containing a heterogeneous mixture of many elements (silicon, oxygen, boron, aluminum, sodium, calcium) with trace levels of other alkali and earth metals.
  • Type I borosilicate glass consists of approximately 76% Si0 2 , 10.5% B 2 0 3 , 5% Al 2 0 3 , 7% Na20 and 1 .5% CaO and often contains trace metals such as iron, magnesium, zinc, copper and others.
  • the heterogeneous nature of borosilicate glass creates a non-uniform surface chemistry at the molecular level. Glass forming processes used to create glass vessels expose some portions of the vessels to temperatures as great as 1200°C.
  • silicon oil is typically used as a lubricant to allow the plunger to slide in the barrel. Silicon oil has been implicated in the precipitation of protein solutions such as insulin and some other biologies. Additionally, the silicon oil coating or layer is often non-uniform, resulting in syringe failures in the market.
  • Plastic allows small molecule gases to permeate into (or out of) the device.
  • the permeability of plastics to gases is significantly greater than that of glass and, in many cases (as with oxygen-sensitive drugs such as epinephrine), plastics have been unacceptable for that reason.
  • Plastic pharmaceutical packages or other vessels contain organic compounds that can leach out or be extracted into the drug product. These compounds can contaminate the drug and/or negatively impact the drug's stability.
  • plastic and glass pharmaceutical packages or other vessels each offer certain advantages in pharmaceutical primary packaging, neither is optimal for all drugs, biologies or other therapeutics.
  • plastic pharmaceutical packages or other vessels in particular plastic syringes, with gas and solute barrier properties which approach the properties of glass.
  • plastic syringes with sufficient lubricity and/or protective properties and a lubricity and/or protective coating or layer which is compatible with the syringe contents.
  • Prefilled syringes are commonly prepared and sold so the syringe does not need to be filled before use, and can be disposed of after use.
  • the syringe can be prefilled with saline solution, a dye for injection, or a pharmaceutically active preparation, for some examples.
  • the prefilled syringe is capped at the distal end, as with a cap, and is closed at the proximal end by its drawn plunger.
  • the prefilled syringe can be wrapped in a sterile package before use.
  • the packaging and cap are removed, optionally a hypodermic needle or another delivery conduit is attached to the distal end of the barrel, the delivery conduit or syringe is moved to a use position (such as by inserting the hypodermic needle into a patient's blood vessel or into apparatus to be rinsed with the contents of the syringe), and the plunger is advanced in the barrel to inject the contents of the barrel.
  • An aspect of the invention is a filled package comprising a vessel, a barrier coating and a protective coating on the vessel, and a fluid composition contained in the vessel.
  • the calculated shelf life of the package is more than six months at a storage temperature of 4°C.
  • the vessel has a lumen defined at least in part by a wall.
  • the wall has an interior surface facing the lumen and an outer surface.
  • the barrier coating comprises SiO x , wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick.
  • the barrier coating of SiO x has an interior surface facing the lumen and an outer surface facing the wall interior surface. The barrier coating is effective to reduce the ingress of atmospheric gas into the lumen compared to an vessel without a protective coating.
  • the protective coating comprises a protective coating or layer of a saccharide.
  • the protective coating has an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating.
  • the protective coating is effective to increase the calculated shelf life of the package (total Si / Si dissolution rate).
  • the fluid composition is contained in the lumen and has a pH between 5 and 9.
  • Another aspect of the invention is a filled package comprising a vessel, a saccharide protective coating on the vessel, and a fluid composition contained in the vessel.
  • the vessel has a lumen defined at least in part by a wall.
  • the wall has an interior surface comprising glass facing the lumen and an outer surface.
  • the protective coating comprises a protective coating or layer of a saccharide.
  • the protective coating has an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating.
  • the protective coating is effective to decrease the Si dissolution rate of the glass interior surface.
  • the fluid composition is contained in the lumen and has a pH between 5 and
  • Still another aspect of the invention is an article comprising a wall, a barrier coating, and a saccharide protective coating.
  • the wall has a surface.
  • the barrier coating comprises SiO x , wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick.
  • the barrier coating of SiO x has an interior surface facing the lumen and an outer surface facing the wall interior surface. The barrier coating is effective to reduce the ingress of atmospheric gas through the wall compared to an uncoated wall.
  • the protective coating of any embodiment is on the barrier coating and comprises a protective coating or layer of a saccharide.
  • the protective coating is contemplated to be formed by binding a coupling agent to the barrier coating, then binding the saccharide to the binding agent, either directly or through intermediate agents.
  • the coupling agent can first be bound to the saccharide, then the saccharide-binder combination can be bonded to the barrier coating or layer.
  • the rate of erosion of the protective coating, if directly contacted by a fluid composition having a pH at some point between 5 and 9, is less than the rate of erosion of the barrier coating, if directly contacted by the fluid composition.
  • Even another aspect of the invention is a vessel comprising a wall, a fluid contained in the vessel, a barrier coating, and a protective coating.
  • the wall is a thermoplastic wall having an interior surface enclosing a lumen.
  • the fluid is disposed in the lumen and has a pH greater than 5.
  • the barrier coating comprises SiO x , in which x is between 1 .5 and 2.9.
  • the barrier coating is applied by PECVD.
  • the barrier coating is positioned between the interior surface of the thermoplastic wall and the fluid, and supported by the thermoplastic wall.
  • the barrier coating has the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid.
  • the protective coating comprises a saccharide.
  • the protective coating is positioned between the barrier coating and the fluid.
  • the protective coating is supported by the thermoplastic wall.
  • the protective coating is effective to keep the barrier coating at least substantially undissolved as a result of attack by the fluid for a period of at least six months.
  • a syringe having a barrel, a plunger movable axially in the barrel, and an O-ring or other toroidal band interfacing between the plunger and the barrel. It is contemplated that the O-ring will function to reduce the "sticktion" force preventing initial movement of the plunger in the barrel by rolling along the plunger and barrel when the plunger is first subjected to an advancing force.
  • FIG. 1 is a schematic sectional view of a vessel holder in a coating station according to an embodiment of the disclosure.
  • FIG. 2 is a section taken along section lines A— A of FIG. 1 .
  • FIG. 3 is a view similar to FIG. 1 of another embodiment for processing syringe barrels and other pharmaceutical packages or other vessels.
  • FIG. 4 is an enlarged detail view of the processing vessel of FIG. #3.
  • FIG. 5 is a schematic view of an assembly for treating pharmaceutical packages or other vessels.
  • the assembly is usable with the apparatus in any of the preceding figures.
  • FIG. 6 shows a TEM image of an Si0 2 barrier coating or layer which is coated on a COC substrate.
  • FIG. 7 is an assembly view of a prefilled syringe provided with a barrier layer, a protective coating or layer, and a lubricity layer and filled and closed to provide a pharmaceutical package.
  • FIG. 8 is a schematic view of a pharmaceutical package in the form of a vial provided with a barrier layer, a protective coating or layer, and optionally a lubricity layer.
  • FIG. 9 is a schematic view of a pharmaceutical package in the form of a blister package provided with a barrier layer and a protective coating or layer.
  • RF is radio frequency
  • an "organosilicon precursor” is a compound having at least one of the linkages: — O— Si— C— H or
  • a volatile organosilicon precursor defined as such a precursor that can be supplied as a vapor in a PECVD apparatus, is an optional organosilicon precursor.
  • the organosilicon precursor is selected from the group consisting of a linear siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, an alkyl trimethoxysilane, a linear silazane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, and a combination of any two or more of these precursors.
  • the feed amounts of PECVD precursors, gaseous reactant or process gases, and carrier gas are sometimes expressed in "standard volumes" in the specification and claims.
  • the standard volume of a charge or other fixed amount of gas is the volume the fixed amount of the gas would occupy at a standard temperature and pressure (without regard to the actual temperature and pressure of delivery).
  • Standard volumes can be measured using different units of volume, and still be within the scope of the present disclosure and claims.
  • the same fixed amount of gas could be expressed as the number of standard cubic centimeters, the number of standard cubic meters, or the number of standard cubic feet.
  • Standard volumes can also be defined using different standard temperatures and pressures, and still be within the scope of the present disclosure and claims.
  • the standard temperature might be 0°C and the standard pressure might be 760 Torr (as is conventional), or the standard temperature might be 20 °C and the standard pressure might be 1 Torr. But whatever standard is used in a given case, when comparing relative amounts of two or more different gases without specifying particular parameters, the same units of volume, standard temperature, and standard pressure are to be used relative to each gas, unless otherwise indicated.
  • the corresponding feed rates of PECVD precursors, gaseous reactant or process gases, and carrier gas are expressed in standard volumes per unit of time in the specification.
  • the flow rates are expressed as standard cubic centimeters per minute, abbreviated as seem.
  • other units of time can be used, such as seconds or hours, but consistent parameters are to be used when comparing the flow rates of two or more gases, unless otherwise indicated.
  • a "vessel" in the context of the present invention can be any type of vessel with at least one opening and a wall defining an inner or interior surface.
  • the substrate can be the inside wall of a vessel having a lumen. Though the invention is not necessarily limited to pharmaceutical packages or other vessels of a particular volume, pharmaceutical packages or other vessels are contemplated in which the lumen has a void volume of from 0.5 to 50 ml_, optionally from 1 to 10 ml_, optionally from 0.5 to 5 ml_, optionally from 1 to 3 ml_.
  • the substrate surface can be part or all of the inner or interior surfaceinner or interior surface of a vessel having at least one opening and an inner or interior surfaceinner or interior surface.
  • a vessel in the context of the present invention has one or more openings.
  • One or two openings like the openings of a sample tube (one opening) or a syringe barrel (two openings) are preferred. If the vessel has two openings, they can be of same or different size. If there is more than one opening, one opening can be used for the gas inlet for a PECVD coating method according to the present invention, while the other openings are either capped or open.
  • a vessel according to the present invention can be a sample tube, for example for collecting or storing biological fluids like blood or urine, a syringe (or a part thereof, for example a syringe barrel) for storing or delivering a biologically active compound or composition, for example a medicament or pharmaceutical composition, a vial for storing biological materials or biologically active compounds or compositions, a pipe, for example a catheter for transporting biological materials or biologically active compounds or compositions, or a cuvette for holding fluids, for example for holding biological materials or biologically active compounds or compositions.
  • a sample tube for example for collecting or storing biological fluids like blood or urine
  • a syringe or a part thereof, for example a syringe barrel
  • a biologically active compound or composition for example a medicament or pharmaceutical composition
  • a vial for storing biological materials or biologically active compounds or compositions
  • a pipe for example a catheter for transporting biological materials or biologically active compounds or compositions
  • a vessel can be of any shape, a vessel having a substantially cylindrical wall adjacent to at least one of its open ends being preferred.
  • the interior wall of the vessel is cylindrically shaped, like, for example in a sample tube or a syringe barrel. Sample tubes and syringes or their parts (for example syringe barrels) are contemplated.
  • a "lubricity and/or protective coating” is a coating or layer which has a lower frictional resistance than the uncoated surface, which is a lubricity layer, and/or protects an underlying surface or layer from a fluid composition contacting the layer, which is a protective coating or layer (as more extensively defined elsewhere in this specification). In other words, respecting a lubricity layer, it reduces the frictional resistance of the coated surface in comparison to a reference surface that is uncoated.
  • the present lubricity and/or protective coatings are primarily defined as lubricity layers by their lower frictional resistance than the uncoated surface and the process conditions providing lower frictional resistance than the uncoated surface.
  • One of the optional embodiments of the present invention is a syringe part, for example a syringe barrel or plunger, coated with a lubricity and/or protective coating.
  • the relevant static frictional resistance in the context of the present invention is the breakout force as defined herein
  • the relevant kinetic frictional resistance in the context of the present invention is the plunger sliding force as defined herein.
  • the plunger sliding force as defined and determined herein is suitable to determine the presence or absence and the lubricity and/or protective characteristics of a lubricity and/or protective coating or layer in the context of the present invention whenever the coating or layer is applied to any syringe or syringe part, for example to the inner wall of a syringe barrel.
  • the breakout force is of particular relevance for evaluation of the coating or layer effect on a prefilled syringe, i.e. a syringe which is filled after coating and can be stored for some time, for example several months or even years, before the plunger is moved again (has to be "broken out").
  • the "plunger sliding force” (synonym to “glide force,” “maintenance force”, or Fm, also used in this description) in the context of the present invention is the force required to maintain movement of a plunger in a syringe barrel, for example during aspiration or dispense. It can advantageously be determined using the ISO 7886-1 :1993 test described herein and known in the art. A synonym for “plunger sliding force” often used in the art is “plunger force” or “pushing force”.
  • the "plunger breakout force” (synonym to “breakout force”, “break loose force”, “initation force”, Fi, also used in this description) in the context of the present invention is the initial force required to move the plunger in a syringe, for example in a prefilled syringe.
  • Sliding force and breakout force are sometimes used herein to describe the forces required to advance a stopper or other closure into a pharmaceutical package or other vessel, such as a medical sample tube or a vial, to seat the stopper in a vessel to close the vessel. Its use is analogous to use in the context of a syringe and its plunger, and the measurement of these forces for a vessel and its closure are contemplated to be analogous to the measurement of these forces for a syringe, except that at least in most cases no liquid is ejected from a vessel when advancing the closure to a seated position.
  • Solidably means that the plunger, closure, or other removable part is permitted to slide in a syringe barrel or other vessel.
  • Coatings of SiO x are deposited by plasma enhanced chemical vapor deposition (PECVD) or other chemical vapor deposition processes on the vessel of a pharmaceutical package, in particular a thermoplastic package, to serve as a barrier coating or layer preventing oxygen, carbon dioxide, or other gases from entering the vessel and/or to prevent leaching of the pharmaceutical material into or through the package wall.
  • PECVD plasma enhanced chemical vapor deposition
  • the inventors have found, however, that such barrier layers or coatings of SiOx are eroded or dissolved by some fluid compositions, for example aqueous compositions having a pH above about 5.
  • coatings applied by chemical vapor deposition can be very thin - tens to hundreds of nanometers thick - even a relatively slow rate of erosion can remove or reduce the effectiveness of the barrier layer in less time than the desired shelf life of a product package.
  • This is particularly a problem for fluid pharmaceutical compositions, since many of them have a pH of roughly 7, or more broadly in the range of 5 to 9, similar to the pH of blood and other human or animal fluids. The higher the pH of the pharmaceutical preparation, the more quickly it erodes or dissolves the SiO x coating.
  • FIGS. #7 TO #9 Three embodiments of the invention having many common features are those of FIGS. #7 TO #9. Some of their common features are the following, indicated in many cases by common reference characters or names. The nature of the features of each embodiment can be as described later in the specification.
  • the pharmaceutical packages 210 of FIGS. #7 TO #9 each include a vessel, a fluid composition, a barrier coating, and a protective coating.
  • the vessel 250 has a lumen 212 defined at least in part by a wall 214 made of thermoplastic material.
  • the wall 214 has an interior surface 254 facing the lumen 212 and an outer surface 216.
  • the fluid composition 218 is contained in the lumen 212 and has a pH between 5 and 9.
  • the barrier coating 288 comprises or consists essentially of SiO x , wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick, the barrier coating 288 of SiO x having an interior surface 220 facing the lumen 212 and an outer surface 222 facing the wall 214 interior surface 254, the barrier coating 288 being effective to reduce the ingress of atmospheric gas into the lumen 212 compared to an uncoated vessel 250.
  • One suitable barrier composition is one where x is 2.3, for example.
  • the protective coating 286 is made of a saccharide.
  • the protective coating 286 has an interior surface 224 facing the lumen 212 and an outer surface 226 facing the interior surface 220 of the barrier coating 288.
  • the rate of erosion of the protective coating 286, if directly contacted by the fluid composition 218, is less than the rate of erosion of the barrier coating 288, if directly contacted by the fluid composition 218.
  • the protective coating 286 is effective to isolate the fluid composition 218 from the barrier coating 288.
  • At least a portion of the wall 214 of the vessel 250 comprises or consists essentially of a polymer, for example a polyolefin (for example a cyclic olefin polymer, a cyclic olefin copolymer, or polypropylene), a polyester, for example polyethylene terephthalate, a polycarbonate, or any combination or copolymer of any of these.
  • a polyolefin for example a cyclic olefin polymer, a cyclic olefin copolymer, or polypropylene
  • a polyester for example polyethylene terephthalate, a polycarbonate, or any combination or copolymer of any of these.
  • at least a portion of the wall 214 of the vessel 250 comprises or consists essentially of glass, for example borosilicate glass. A combination of any two or more of the materials in this paragraph can also be used.
  • the vessel 250 comprises a syringe barrel 250.
  • the vessel 250 comprises a vial that is an embodiment of the pharmaceutical package 210.
  • the vessel 250 comprises a blister package that is an embodiment of the pharmaceutical package 210287.
  • the fluid composition 218 has a pH between 5 and 6, optionally between 6 and 7, optionally between 7 and 8, optionally between 8 and 9, optionally between 6.5 and 7.5, optionally between 7.5 and 8.5, optionally between 8.5 and 9.
  • the fluid composition 218 is a liquid at 20°C and ambient pressure at sea level, which is defined as a pressure of 760 mm Hg.
  • the fluid composition 218 is an aqueous liquid.
  • the barrier coating 288 is from 4 nm to 500 nm thick, optionally from 7 nm to 400 nm thick, optionally from 10 nm to 300 nm thick, optionally from 20 nm to 200 nm thick, optionally from 30 nm to 100 nm thick.
  • the protective coating 286 comprises or consists essentially of a saccharide.
  • the protective coating 286 as applied is between 1000 and 5000 nm thick.
  • the thickness does not need to be uniform throughout the vessel, and will typically vary from the preferred values in portions of a vessel.
  • the rate of erosion of the protective coating 286, if directly contacted by a fluid composition 218 having a pH of 8, is less than 20%, optionally less than 15%, optionally less than 10%, optionally less than 7% , optionally from 5% to 20% , optionally 5% to 15% , optionally 5% to 10%, optionally 5% to 7%, of the rate of erosion of the barrier coating 288, if directly contacted by the same fluid composition 218 under the same conditions.
  • the protective coating 286 is at least coextensive with the barrier coating 288.
  • the protective coating 286 alternatively can be less extensive than the barrier coating, as when the fluid composition does not contact or seldom is in contact with certain parts of the barrier coating absent the protective coating.
  • the protective coating 286 alternatively can be more extensive than the barrier coating, as it can cover areas that are not provided with a barrier coating.
  • the pharmaceutical package 210 can have a shelf life, after the pharmaceutical package 210 is assembled, of at least one year, alternatively at least two years.
  • the shelf life is measured at 3°C, alternatively at 4°C or higher, alternatively at 20 °C or higher, alternatively at 23 °C, alternatively at 40 °C.
  • the pH of the fluid composition 218 is between 5 and 6 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life.
  • the pH of the fluid composition 218 is between 6 and 7 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life.
  • the pH of the fluid composition 218 is between 7 and 8 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life.
  • the pH of the fluid composition 218 is between 8 and 9 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life.
  • the pH of the fluid composition 218 is between 5 and 6 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life.
  • the pH of the fluid composition 218 is between 6 and 7 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life.
  • the pH of the fluid composition 218 is between 7 and 8 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life.
  • the pH of the fluid composition 218 is between 8 and 9 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life.
  • the fluid composition 218 removes the protective coating 286 at a rate of 1 nm or less of lubricity and/or protective coating thickness per 44 hours of contact with the fluid composition 218 (200 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 88 hours of contact with the fluid composition 218 (100 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 175 hours of contact with the fluid composition 218 (50 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 250 hours of contact with the fluid composition 218 (35 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 350 hours of contact with the fluid composition 218 (25 nm per year).
  • the rate of removing the protective coating can be determined by TEM from samples exposed to the fluid composition for known periods.
  • the protective coating 286 is effective to provide a lower frictional resistance than the uncoated interior surface 254.
  • the frictional resistance is reduced by at least 25 %, more preferably by at least 45%, even more preferably by at least 60% in comparison to the uncoated interior surface 254.
  • the protective coating 286 preferably is effective to reduce the frictional resistance between a portion of the wall 214 contacted by the fluid composition 218 and a relatively sliding part 258 after the pharmaceutical package 210 is assembled.
  • the protective coating 286 is effective to reduce the frictional resistance between the wall 214 and a relatively sliding part 258 at least two years after the pharmaceutical package 210 is assembled.
  • the fluid composition 218 comprises a member or a combination of two or more members selected from the group consisting of:
  • Acetadote (Acetylcysteine Injection)
  • Acetazolamide Injection (Acetazolamide Injection)
  • Acetylcysteine Injection (Acetadote)
  • Adenoscan (Adenosine Injection)
  • Adenosine Injection (Adenoscan)
  • AdreView (lobenguane I 123 Injection for Intravenous Use) Afluria
  • Aloprim Allopurinol Sodium for Injection
  • Amiodarone HCI Injection Amiodarone HCI Injection
  • Amobarbital Sodium Injection Amytal Sodium
  • Amytal Sodium Amytal Sodium
  • Atenolol Inj (Tenormin I.V. Injection)
  • Atracurium Besylate Injection (Atracurium Besylate Injection) Avastin
  • Betamethasone Injectable Suspension (Celestone Soluspan)
  • Botox Cosmetic OnabotulinumtoxinA for Injection
  • Capreomycin for Injection Capastat Sulfate
  • Chloramphenicol Sodium Succinate Chloramphenicol Sodium Succinate Injection
  • Chloramphenicol Sodium Succinate Injection Chloramphenicol Sodium Succinate
  • Cholestagel Colesevelam HCL
  • Corticorelin Ovine Triflutate for Injection Acthrel
  • Corvert Ibutilide Fumarate Injection
  • DDAVP Injection Desmopressin Acetate Injection
  • Doxercalciferol Injection Hectorol Injection
  • Doxil Doxorubicin Hcl Liposome Injection
  • Emend Injection Frasaprepitant Dimeglumine Injection
  • Fabrazyme (Adalsidase beta)
  • Feridex I.V. Feridex Injectable Solution
  • Ferumoxides Injectable Solution Ferumoxides Injectable Solution (Feridex I.V.)
  • Foscavir Foscarnet Sodium Injection
  • Gadobenate Dimeglumine Injection Multihance
  • Gadofosveset Trisodium Injection Ablavar
  • Gadoteridol Injection Solution Gadoteridol Injection Solution
  • OptiMARK Gadoversetamide Injection
  • Insulin Glargine [rDNA origin] Injection (Lantus)
  • Invega Sustenna Paliperidone Palmitate Extended- Release Injectable Suspension
  • Invirase saquinavir mesylate
  • lobenguane I 123 Injection for Intravenous Use AdreView
  • Methohexital Sodium for Injection (Brevital Sodium)
  • Minocycline Inj Minocin Injection
  • Nafcillin Injection Nafcillin Sodium
  • NeoProfen Ibuprofen Lysine Injection
  • Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection)
  • NeoTect (Technetium Tc 99m Depreotide Injection)
  • Oxacillin (Oxacillin for Injection)
  • Penicillin G Benzathine and Penicillin G Procaine
  • Plasma-Lyte 148 Multiple Electrolytes Inj
  • Plasma-Lyte 56 and Dextrose Multiple Electrolytes and Dextrose Injection
  • Polidocanol Injection (Asclera)
  • Ringer's Injection Ringer Injection
  • Serostim LQ Somatropin (rDNA origin) Injection
  • Taxotere Docetaxel for Injection
  • Tev-Tropin Somatropin, rDNA Origin, for Injection
  • Thymoglobulin Anti-Thymocyte Globulin (Rabbit) Thyrogen (Thyrotropin Alfa for Injection)
  • Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy)
  • Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg)
  • Trivaris Triamcinolone Acetonide Injectable Suspension
  • Vancomycin Hydrochloride Vancomycin Hydrochloride Injection
  • Vancomycin Hydrochloride Injection Vancomycin Hydrochloride Injection
  • Vaprisol Conivaptan Hcl Injection
  • Vasovist (Gadofosveset Trisodium Injection for Intravenous Use)
  • Vinblastine Sulfate (Vinblastine Sulfate Injection)
  • Vincasar PFS Vincristine Sulfate Injection
  • Agenerase Oral Solution (Amprenavir Oral Solution)
  • Astepro (Azelastine Hydrochloride Nasal Spray)
  • Atrovent Nasal Spray Ipratropium Bromide Nasal Spray
  • Azelex (Azelaic Acid Cream)
  • Ciloxan Ophthalmic Solution Ciprofloxacin HCL Ophthalmic Solution
  • Ciprofloxacin HCL Ophthalmic Solution Ciprofloxacin HCL Ophthalmic Solution
  • Feridex I.V. Ferumoxides Injectable Solution
  • Ketorolac Tromethamine Ophthalmic Solution (Acular LS) Kaletra
  • Lumigan (Bimatoprost Ophthalmic Solution 0.03% for Glaucoma)
  • Lupron Depot 1 1 .25 mg (Leuprolide Acetate for Depot Suspension)
  • Megestrol Acetate Oral Suspension Megestrol Acetate Oral Suspension
  • Methyldopate Hcl Metaldopate Hydrochloride Injection, Solution
  • Methylin Oral Solution Methylin Oral Solution (Methylphenidate HCI Oral Solution 5 mg/5 mL and 10 mg/5 mL)
  • Nevanac Napafenac Ophthalmic Suspension
  • Noxafil (Posaconazole Oral Suspension)
  • Pataday Olatadine Hydrochloride Ophthalmic Solution
  • Patanase Nasal Spray (Olopatadine Hydrochloride Nasal Spray)
  • PENNSAID Diaclofenac Sodium Topical Solution
  • Rotarix Rotarix (Rotavirus Vaccine, Live, Oral Suspension)
  • Tobradex ST Tobramycin / Dexamethasone Ophthalmic Suspension 0.3%/0.05%)
  • Vitamin K1 Fluid Colloidal Solution of Vitamin K1

Abstract

A method for providing a saccharide based lubricating or protective coating or layer on a substrate surface is provided. In particular, a lubricity and/or protective coating or layer made by said method is provided. Pharmaceutical packages or other vessels coated by said method and the use of such pharmaceutical packages or other vessels protecting a compound or composition contained or received in said vessel with a protective coating against mechanical and/or chemical effects of the surface of the vessel without a protective coating material are also provided.

Description

PCT PATENT APPLICATION
SACCHARIDE PROTECTIVE COATING FOR PHARMACEUTICAL PACKAGE
[01] The priority of U.S. Provisional Serial No. 61644961, filed May 9, 2012, is claimed. That patent application is incorporated here by reference in its entirety.
[02] U.S. Provisional Serial Nos.61/177,984 filed May 13, 2009; 61/222,727, filed July 2, 2009; 61/213,904, filed July 24, 2009; 61/234,505, filed Aug. 17, 2009; 61/261,321, filed November 14, 2009; 61/263,289, filed November 20, 2009; 61/285,813, filed December 11, 2009; 61/298,159, filed January 25, 2010; 61/299,888, filed January 29, 2010; 61/318,197, filed March 26, 2010; 61/333,625, filed May 11, 2010; 61/413,334, filed November 12, 2010; 12/779,007, filed May 12, 2010, now U.S. Pat. No.7,985,188; International Application PCT/US11/36097, filed May 11, 2011; and U.S. Ser. No. 61/558,885, filed November 11, 2011; are all incorporated here by reference in their entirety.
[03] Also incorporated by reference in their entirety are the following European patent applications: EP10162755.2 filed May 12, 2010; EP10162760.2 filed May 12, 2010; EP10162756.0 filed May 12, 2010; EP10162758.6 filed May 12, 2010; EP10162761.0 filed May 12, 2010; and EP10162757.8 filed May 12, 2010. These European patent applications describe apparatus, vessels, precursors, coatings or layers and methods (in particular coating methods and test methods for examining the coatings or layers) which can generally be used in performing the present invention, unless stated otherwise herein. They also describe SiOx barrier coatings or layers to which reference is made herein.
FIELD OF THE INVENTION
[04] The present invention relates to the technical field of coated surfaces, for example interior surfaces of pharmaceutical packages or other vessels for storing or other contact with fluids. Examples of suitable fluids include foods or biologically active compounds or body fluids, for example blood. The present invention also relates to a pharmaceutical package or other vessel and to a method for coating an inner or interior surface of a pharmaceutical package or other vessel. The present invention also relates more generally to medical devices, including devices other than packages or vessels, for example catheters.
[05] The present disclosure also relates to improved methods for processing pharmaceutical packages or other vessels, for example multiple identical pharmaceutical packages or other vessels used for pharmaceutical preparation storage and delivery, venipuncture and other medical sample collection, and other purposes. Such pharmaceutical packages or other vessels are used in large numbers for these purposes, and must be relatively economical to manufacture and yet highly reliable in storage and use.
BACKGROUND OF THE INVENTION
[06] One important consideration in manufacturing pharmaceutical packages or other vessels for storing or other contact with fluids, for example vials and pre-filled syringes, is that the contents of the pharmaceutical package or other vessel desirably will have a substantial shelf life. During this shelf life, it is important to isolate the material filling the pharmaceutical package or other vessel from the vessel wall containing it, or from barrier layers or other functional layers applied to the pharmaceutical package or other vessel wall to avoid leaching material from the pharmaceutical package or other vessel wall, barrier layer, or other functional layers into the prefilled contents or vice versa.
[07] Since many of these pharmaceutical packages or other vessels are inexpensive and used in large quantities, for certain applications it will be useful to reliably obtain the necessary shelf life without increasing the manufacturing cost to a prohibitive level.
[08] For decades, most parenteral therapeutics have been delivered to end users in Type I medical grade borosilicate glass vessels such as vials or pre-filled syringes. The relatively strong, impermeable and inert surface of borosilicate glass has performed adequately for most drug products. However, the recent advent of costly, complex and sensitive biologies as well as such advanced delivery systems as auto injectors has exposed the physical and chemical shortcomings of glass pharmaceutical packages or other vessels, including possible contamination from metals, flaking, and breakage, among other problems. Moreover, glass contains several components which can leach out during storage and cause damage to the stored material. In more detail, borosilicate pharmaceutical packages or other vessels exhibit a number of drawbacks:
[09] Glass is manufactured from sand containing a heterogeneous mixture of many elements (silicon, oxygen, boron, aluminum, sodium, calcium) with trace levels of other alkali and earth metals. Type I borosilicate glass consists of approximately 76% Si02, 10.5% B203, 5% Al203, 7% Na20 and 1 .5% CaO and often contains trace metals such as iron, magnesium, zinc, copper and others. The heterogeneous nature of borosilicate glass creates a non-uniform surface chemistry at the molecular level. Glass forming processes used to create glass vessels expose some portions of the vessels to temperatures as great as 1200°C. Under such high temperatures alkali ions migrate to the local surface and form oxides. The presence of ions extracted from borosilicate glass devices may be involved in degradation, aggregation and denaturation of some biologies. Many proteins and other biologies must be lyophilized (freeze dried), because they are not sufficiently stable in solution in glass vials or syringes.
[10] In glass syringes, silicon oil is typically used as a lubricant to allow the plunger to slide in the barrel. Silicon oil has been implicated in the precipitation of protein solutions such as insulin and some other biologies. Additionally, the silicon oil coating or layer is often non-uniform, resulting in syringe failures in the market.
[1 1 ] Glass pharmaceutical packages or other vessels are prone to breakage or degradation during manufacture, filling operations, shipping and use, which means that glass particulates may enter the drug. The presence of glass particles has led to many FDA Warning Letters and to product recalls.
[12] Glass-forming processes do not yield the tight dimensional tolerances required for some of the newer auto-injectors and delivery systems. [13] As a result, some companies have turned to plastic pharmaceutical packages or other vessels, which provide greater dimensional tolerance and less breakage than glass but lack its impermeability.
[14] Although plastic is superior to glass with respect to breakage, dimensional tolerances and surface uniformity, its use for primary pharmaceutical packaging remains limited due to the following shortcomings:
[15] · Gas (oxygen) permeability: Plastic allows small molecule gases to permeate into (or out of) the device. The permeability of plastics to gases is significantly greater than that of glass and, in many cases (as with oxygen-sensitive drugs such as epinephrine), plastics have been unacceptable for that reason.
[16] · Water vapor transmission: Plastics allow water vapors to pass through devices to a greater degree than glass. This can be detrimental to the shelf life of a solid (lyophilized) drug. Alternatively, a liquid product may lose water in an arid environment.
[17] · Leachables and extractables: Plastic pharmaceutical packages or other vessels contain organic compounds that can leach out or be extracted into the drug product. These compounds can contaminate the drug and/or negatively impact the drug's stability.
[18] Clearly, while plastic and glass pharmaceutical packages or other vessels each offer certain advantages in pharmaceutical primary packaging, neither is optimal for all drugs, biologies or other therapeutics. Thus, there is a desire for plastic pharmaceutical packages or other vessels, in particular plastic syringes, with gas and solute barrier properties which approach the properties of glass. Moreover, there is a need for plastic syringes with sufficient lubricity and/or protective properties and a lubricity and/or protective coating or layer which is compatible with the syringe contents.
[19] There are additional considerations to be taken into account when manufacturing a prefilled syringe. Prefilled syringes are commonly prepared and sold so the syringe does not need to be filled before use, and can be disposed of after use. The syringe can be prefilled with saline solution, a dye for injection, or a pharmaceutically active preparation, for some examples. [20] Commonly, the prefilled syringe is capped at the distal end, as with a cap, and is closed at the proximal end by its drawn plunger. The prefilled syringe can be wrapped in a sterile package before use. To use the prefilled syringe, the packaging and cap are removed, optionally a hypodermic needle or another delivery conduit is attached to the distal end of the barrel, the delivery conduit or syringe is moved to a use position (such as by inserting the hypodermic needle into a patient's blood vessel or into apparatus to be rinsed with the contents of the syringe), and the plunger is advanced in the barrel to inject the contents of the barrel.
[21 ] An important consideration regarding medical syringes is to ensure that the plunger can move at a constant speed and with a constant force when it is pressed into the barrel. A similar consideration applies to vessels such as pharmaceutical vials which have to be closed by a stopper, and to the stopper itself, and more generally to any surface which has to provide smooth operation of moving parts and/or be protectively coated.
[22] A non-exhaustive list of documents of possible relevance includes US Pat. Nos. 7,901 ,783; 6,068,884; 4,844,986; and 8067070 and U.S. Publ. Appl. Nos. 2008/0090039, 201 1 /0152820, 2006/0046006 and 2004/0267194. These documents are all incorporated by reference.
SUMMARY OF THE INVENTION
[23] An aspect of the invention is a filled package comprising a vessel, a barrier coating and a protective coating on the vessel, and a fluid composition contained in the vessel. The calculated shelf life of the package is more than six months at a storage temperature of 4°C.
[24] The vessel has a lumen defined at least in part by a wall. The wall has an interior surface facing the lumen and an outer surface.
[25] The barrier coating comprises SiOx, wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick. The barrier coating of SiOx has an interior surface facing the lumen and an outer surface facing the wall interior surface. The barrier coating is effective to reduce the ingress of atmospheric gas into the lumen compared to an vessel without a protective coating.
[26] The protective coating comprises a protective coating or layer of a saccharide. The protective coating has an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating. The protective coating is effective to increase the calculated shelf life of the package (total Si / Si dissolution rate).
[27] The fluid composition is contained in the lumen and has a pH between 5 and 9.
[28] Another aspect of the invention is a filled package comprising a vessel, a saccharide protective coating on the vessel, and a fluid composition contained in the vessel.
[29] The vessel has a lumen defined at least in part by a wall. The wall has an interior surface comprising glass facing the lumen and an outer surface.
[30] The protective coating comprises a protective coating or layer of a saccharide. The protective coating has an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating. The protective coating is effective to decrease the Si dissolution rate of the glass interior surface.
[31 ] The fluid composition is contained in the lumen and has a pH between 5 and
9.
[32] Still another aspect of the invention is an article comprising a wall, a barrier coating, and a saccharide protective coating.
[33] The wall has a surface.
[34] The barrier coating comprises SiOx, wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick. The barrier coating of SiOx has an interior surface facing the lumen and an outer surface facing the wall interior surface. The barrier coating is effective to reduce the ingress of atmospheric gas through the wall compared to an uncoated wall.
[35] The protective coating of any embodiment is on the barrier coating and comprises a protective coating or layer of a saccharide. The protective coating is contemplated to be formed by binding a coupling agent to the barrier coating, then binding the saccharide to the binding agent, either directly or through intermediate agents. Alternatively, the coupling agent can first be bound to the saccharide, then the saccharide-binder combination can be bonded to the barrier coating or layer.
[36] The rate of erosion of the protective coating, if directly contacted by a fluid composition having a pH at some point between 5 and 9, is less than the rate of erosion of the barrier coating, if directly contacted by the fluid composition.
[37] Even another aspect of the invention is a vessel comprising a wall, a fluid contained in the vessel, a barrier coating, and a protective coating.
[38] The wall is a thermoplastic wall having an interior surface enclosing a lumen.
[39] The fluid is disposed in the lumen and has a pH greater than 5.
[40] The barrier coating comprises SiOx, in which x is between 1 .5 and 2.9. The barrier coating is applied by PECVD. The barrier coating is positioned between the interior surface of the thermoplastic wall and the fluid, and supported by the thermoplastic wall. The barrier coating has the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid.
[41 ] The protective coating comprises a saccharide. The protective coating is positioned between the barrier coating and the fluid. The protective coating is supported by the thermoplastic wall. The protective coating is effective to keep the barrier coating at least substantially undissolved as a result of attack by the fluid for a period of at least six months.
[42] Also expressly contemplated is a syringe having a barrel, a plunger movable axially in the barrel, and an O-ring or other toroidal band interfacing between the plunger and the barrel. It is contemplated that the O-ring will function to reduce the "sticktion" force preventing initial movement of the plunger in the barrel by rolling along the plunger and barrel when the plunger is first subjected to an advancing force.
[43] Other aspects of the invention will become apparent to a person of ordinary skill in the art after reviewing the present disclosure and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[44] FIG. 1 is a schematic sectional view of a vessel holder in a coating station according to an embodiment of the disclosure.
[45] FIG. 2 is a section taken along section lines A— A of FIG. 1 .
[46] FIG. 3 is a view similar to FIG. 1 of another embodiment for processing syringe barrels and other pharmaceutical packages or other vessels.
[47] FIG. 4 is an enlarged detail view of the processing vessel of FIG. #3.
[48] FIG. 5 is a schematic view of an assembly for treating pharmaceutical packages or other vessels. The assembly is usable with the apparatus in any of the preceding figures.
[49] FIG. 6 shows a TEM image of an Si02 barrier coating or layer which is coated on a COC substrate.
[50] FIG. 7 is an assembly view of a prefilled syringe provided with a barrier layer, a protective coating or layer, and a lubricity layer and filled and closed to provide a pharmaceutical package.
[51 ] FIG. 8 is a schematic view of a pharmaceutical package in the form of a vial provided with a barrier layer, a protective coating or layer, and optionally a lubricity layer.
[52] FIG. 9 is a schematic view of a pharmaceutical package in the form of a blister package provided with a barrier layer and a protective coating or layer.
[53] The following reference characters are used in the drawing figures:
Figure imgf000011_0001
344 Dog
574 Main vacuum valve
576 Vacuum line
578 Manual bypass valve
580 Bypass line
582 Vent valve
584 Main reactant gas valve
586 Main reactant feed line
588 Organosilicon liquid reservoir
Organosilicon feed line
590
(capillary)
592 Organosilicon shut-off valve
594 Oxygen tank
596 Oxygen feed line
598 Mass flow controller
600 Oxygen shut-off valve
614 Headspace
616 Pressure source
618 Pressure line
620 Capillary connection
DETAILED DESCRIPTION
[54] The present invention will now be described more fully, with reference to the accompanying drawings, in which several embodiments are shown. This invention can, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth here. Rather, these embodiments are examples of the invention, which has the full scope indicated by the language of the claims. Like numbers refer to like or corresponding elements throughout. The following disclosure relates to all embodiments unless specifically limited to a certain embodiment.
DEFINITION SECTION
[55] In the context of the present invention, the following definitions and abbreviations are used:
[56] RF is radio frequency.
[57] The term "at least" in the context of the present invention means "equal or more" than the integer following the term. The word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality unless indicated otherwise. Whenever a parameter range is indicated, it is intended to disclose the parameter values given as limits of the range and all values of the parameter falling within said range.
[58] "First" and "second" or similar references to, for example, processing stations or processing devices refer to the minimum number of processing stations or devices that are present, but do not necessarily represent the order or total number of processing stations and devices. These terms do not limit the number of processing stations or the particular processing carried out at the respective stations.
[59] For purposes of the present invention, an "organosilicon precursor" is a compound having at least one of the linkages: — O— Si— C— H or
— NH— Si— C— H
which is a tetravalent silicon atom connected to an oxygen or nitrogen atom and an organic carbon atom (an organic carbon atom being a carbon atom bonded to at least one hydrogen atom). A volatile organosilicon precursor, defined as such a precursor that can be supplied as a vapor in a PECVD apparatus, is an optional organosilicon precursor. Optionally, the organosilicon precursor is selected from the group consisting of a linear siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, an alkyl trimethoxysilane, a linear silazane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, and a combination of any two or more of these precursors.
[60] The feed amounts of PECVD precursors, gaseous reactant or process gases, and carrier gas are sometimes expressed in "standard volumes" in the specification and claims. The standard volume of a charge or other fixed amount of gas is the volume the fixed amount of the gas would occupy at a standard temperature and pressure (without regard to the actual temperature and pressure of delivery). Standard volumes can be measured using different units of volume, and still be within the scope of the present disclosure and claims. For example, the same fixed amount of gas could be expressed as the number of standard cubic centimeters, the number of standard cubic meters, or the number of standard cubic feet. Standard volumes can also be defined using different standard temperatures and pressures, and still be within the scope of the present disclosure and claims. For example, the standard temperature might be 0°C and the standard pressure might be 760 Torr (as is conventional), or the standard temperature might be 20 °C and the standard pressure might be 1 Torr. But whatever standard is used in a given case, when comparing relative amounts of two or more different gases without specifying particular parameters, the same units of volume, standard temperature, and standard pressure are to be used relative to each gas, unless otherwise indicated.
[61 ] The corresponding feed rates of PECVD precursors, gaseous reactant or process gases, and carrier gas are expressed in standard volumes per unit of time in the specification. For example, in the working examples the flow rates are expressed as standard cubic centimeters per minute, abbreviated as seem. As with the other parameters, other units of time can be used, such as seconds or hours, but consistent parameters are to be used when comparing the flow rates of two or more gases, unless otherwise indicated.
[62] A "vessel" in the context of the present invention can be any type of vessel with at least one opening and a wall defining an inner or interior surface. The substrate can be the inside wall of a vessel having a lumen. Though the invention is not necessarily limited to pharmaceutical packages or other vessels of a particular volume, pharmaceutical packages or other vessels are contemplated in which the lumen has a void volume of from 0.5 to 50 ml_, optionally from 1 to 10 ml_, optionally from 0.5 to 5 ml_, optionally from 1 to 3 ml_. The substrate surface can be part or all of the inner or interior surfaceinner or interior surface of a vessel having at least one opening and an inner or interior surfaceinner or interior surface.
[63] The term "at least" in the context of the present invention means "equal or more" than the integer following the term. Thus, a vessel in the context of the present invention has one or more openings. One or two openings, like the openings of a sample tube (one opening) or a syringe barrel (two openings) are preferred. If the vessel has two openings, they can be of same or different size. If there is more than one opening, one opening can be used for the gas inlet for a PECVD coating method according to the present invention, while the other openings are either capped or open. A vessel according to the present invention can be a sample tube, for example for collecting or storing biological fluids like blood or urine, a syringe (or a part thereof, for example a syringe barrel) for storing or delivering a biologically active compound or composition, for example a medicament or pharmaceutical composition, a vial for storing biological materials or biologically active compounds or compositions, a pipe, for example a catheter for transporting biological materials or biologically active compounds or compositions, or a cuvette for holding fluids, for example for holding biological materials or biologically active compounds or compositions.
[64] A vessel can be of any shape, a vessel having a substantially cylindrical wall adjacent to at least one of its open ends being preferred. Generally, the interior wall of the vessel is cylindrically shaped, like, for example in a sample tube or a syringe barrel. Sample tubes and syringes or their parts (for example syringe barrels) are contemplated.
[65] A "lubricity and/or protective coating" according to the present invention is a coating or layer which has a lower frictional resistance than the uncoated surface, which is a lubricity layer, and/or protects an underlying surface or layer from a fluid composition contacting the layer, which is a protective coating or layer (as more extensively defined elsewhere in this specification). In other words, respecting a lubricity layer, it reduces the frictional resistance of the coated surface in comparison to a reference surface that is uncoated. The present lubricity and/or protective coatings are primarily defined as lubricity layers by their lower frictional resistance than the uncoated surface and the process conditions providing lower frictional resistance than the uncoated surface.
[66] "Frictional resistance" can be static frictional resistance and/or kinetic frictional resistance.
[67] One of the optional embodiments of the present invention is a syringe part, for example a syringe barrel or plunger, coated with a lubricity and/or protective coating. In this contemplated embodiment, the relevant static frictional resistance in the context of the present invention is the breakout force as defined herein, and the relevant kinetic frictional resistance in the context of the present invention is the plunger sliding force as defined herein. For example, the plunger sliding force as defined and determined herein is suitable to determine the presence or absence and the lubricity and/or protective characteristics of a lubricity and/or protective coating or layer in the context of the present invention whenever the coating or layer is applied to any syringe or syringe part, for example to the inner wall of a syringe barrel. The breakout force is of particular relevance for evaluation of the coating or layer effect on a prefilled syringe, i.e. a syringe which is filled after coating and can be stored for some time, for example several months or even years, before the plunger is moved again (has to be "broken out").
[68] The "plunger sliding force" (synonym to "glide force," "maintenance force", or Fm, also used in this description) in the context of the present invention is the force required to maintain movement of a plunger in a syringe barrel, for example during aspiration or dispense. It can advantageously be determined using the ISO 7886-1 :1993 test described herein and known in the art. A synonym for "plunger sliding force" often used in the art is "plunger force" or "pushing force".
[69] The "plunger breakout force" (synonym to "breakout force", "break loose force", "initation force", Fi, also used in this description) in the context of the present invention is the initial force required to move the plunger in a syringe, for example in a prefilled syringe.
[70] Both "plunger sliding force" and "plunger breakout force" and methods for their measurement are described in more detail in subsequent parts of this description. These two forces can be expressed in N, lbs or kg and all three units are used herein. These units correlate as follows: 1 N = 0.102 kg = 0.2248 lbs (pounds).
[71 ] Sliding force and breakout force are sometimes used herein to describe the forces required to advance a stopper or other closure into a pharmaceutical package or other vessel, such as a medical sample tube or a vial, to seat the stopper in a vessel to close the vessel. Its use is analogous to use in the context of a syringe and its plunger, and the measurement of these forces for a vessel and its closure are contemplated to be analogous to the measurement of these forces for a syringe, except that at least in most cases no liquid is ejected from a vessel when advancing the closure to a seated position.
[72] "Slidably" means that the plunger, closure, or other removable part is permitted to slide in a syringe barrel or other vessel.
[73] Coatings of SiOx are deposited by plasma enhanced chemical vapor deposition (PECVD) or other chemical vapor deposition processes on the vessel of a pharmaceutical package, in particular a thermoplastic package, to serve as a barrier coating or layer preventing oxygen, carbon dioxide, or other gases from entering the vessel and/or to prevent leaching of the pharmaceutical material into or through the package wall. The inventors have found, however, that such barrier layers or coatings of SiOx are eroded or dissolved by some fluid compositions, for example aqueous compositions having a pH above about 5. Since coatings applied by chemical vapor deposition can be very thin - tens to hundreds of nanometers thick - even a relatively slow rate of erosion can remove or reduce the effectiveness of the barrier layer in less time than the desired shelf life of a product package. This is particularly a problem for fluid pharmaceutical compositions, since many of them have a pH of roughly 7, or more broadly in the range of 5 to 9, similar to the pH of blood and other human or animal fluids. The higher the pH of the pharmaceutical preparation, the more quickly it erodes or dissolves the SiOx coating.
[74] The inventors have further found that certain protective coatings of a saccharide do not erode quickly when exposed to fluid compositions, and in fact erode or dissolve more slowly when the fluid compositions have higher pHs within the range of 5 to 9. For example, at pH 8, the dissolution rate of a protective coating made from a saccharide is quite slow. These protective coatings can therefore be used to cover a barrier layer of SiOx, retaining the benefits of the barrier layer by protecting it from the fluid composition in the pharmaceutical package.
[75] Three embodiments of the invention having many common features are those of FIGS. #7 TO #9. Some of their common features are the following, indicated in many cases by common reference characters or names. The nature of the features of each embodiment can be as described later in the specification.
[76] The pharmaceutical packages 210 of FIGS. #7 TO #9 each include a vessel, a fluid composition, a barrier coating, and a protective coating. The vessel 250 has a lumen 212 defined at least in part by a wall 214 made of thermoplastic material.
[77] The wall 214 has an interior surface 254 facing the lumen 212 and an outer surface 216. [78] The fluid composition 218 is contained in the lumen 212 and has a pH between 5 and 9.
[79] The barrier coating 288 comprises or consists essentially of SiOx, wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick, the barrier coating 288 of SiOx having an interior surface 220 facing the lumen 212 and an outer surface 222 facing the wall 214 interior surface 254, the barrier coating 288 being effective to reduce the ingress of atmospheric gas into the lumen 212 compared to an uncoated vessel 250. One suitable barrier composition is one where x is 2.3, for example.
[80] The protective coating 286 is made of a saccharide. The protective coating 286 has an interior surface 224 facing the lumen 212 and an outer surface 226 facing the interior surface 220 of the barrier coating 288.
[81 ] The rate of erosion of the protective coating 286, if directly contacted by the fluid composition 218, is less than the rate of erosion of the barrier coating 288, if directly contacted by the fluid composition 218.
[82] The protective coating 286 is effective to isolate the fluid composition 218 from the barrier coating 288.
[83] Optionally for any of the embodiments of FIGS. #7 TO #9, at least a portion of the wall 214 of the vessel 250 comprises or consists essentially of a polymer, for example a polyolefin (for example a cyclic olefin polymer, a cyclic olefin copolymer, or polypropylene), a polyester, for example polyethylene terephthalate, a polycarbonate, or any combination or copolymer of any of these. Optionally for any of the embodiments of FIGS. #7 TO #9, at least a portion of the wall 214 of the vessel 250 comprises or consists essentially of glass, for example borosilicate glass. A combination of any two or more of the materials in this paragraph can also be used.
[84] Optionally for the embodiments of FIG. 7, the vessel 250 comprises a syringe barrel 250.
[85] Optionally for the embodiments of FIG. 8, the vessel 250 comprises a vial that is an embodiment of the pharmaceutical package 210.
[86] Optionally for the embodiments of FIG. 9, the vessel 250 comprises a blister package that is an embodiment of the pharmaceutical package 210287. [87] Optionally for any of the embodiments of FIGS. 7 TO 9, the fluid composition 218 has a pH between 5 and 6, optionally between 6 and 7, optionally between 7 and 8, optionally between 8 and 9, optionally between 6.5 and 7.5, optionally between 7.5 and 8.5, optionally between 8.5 and 9.
[88] Optionally for any of the embodiments of FIGS. 7 TO 9, the fluid composition 218 is a liquid at 20°C and ambient pressure at sea level, which is defined as a pressure of 760 mm Hg.
[89] Optionally for any of the embodiments of FIGS. 7 TO 9, the fluid composition 218 is an aqueous liquid.
[90] Optionally for any of the embodiments of FIGS. 7 TO 9, the barrier coating 288 is from 4 nm to 500 nm thick, optionally from 7 nm to 400 nm thick, optionally from 10 nm to 300 nm thick, optionally from 20 nm to 200 nm thick, optionally from 30 nm to 100 nm thick.
[91 ] Optionally for any of the embodiments of FIGS. 7 TO 9, the protective coating 286 comprises or consists essentially of a saccharide.
[92] Optionally for any of the embodiments of FIGS. 7 TO 9, the protective coating 286 as applied is between 1000 and 5000 nm thick. The thickness does not need to be uniform throughout the vessel, and will typically vary from the preferred values in portions of a vessel.
[93] Optionally for any of the embodiments of FIGS. 7 TO 9, the rate of erosion of the protective coating 286, if directly contacted by a fluid composition 218 having a pH of 8, is less than 20%, optionally less than 15%, optionally less than 10%, optionally less than 7% , optionally from 5% to 20% , optionally 5% to 15% , optionally 5% to 10%, optionally 5% to 7%, of the rate of erosion of the barrier coating 288, if directly contacted by the same fluid composition 218 under the same conditions.
[94] Optionally for any of the embodiments of FIGS. 7 TO 9, the protective coating 286 is at least coextensive with the barrier coating 288. The protective coating 286 alternatively can be less extensive than the barrier coating, as when the fluid composition does not contact or seldom is in contact with certain parts of the barrier coating absent the protective coating. The protective coating 286 alternatively can be more extensive than the barrier coating, as it can cover areas that are not provided with a barrier coating.
[95] Optionally for any of the embodiments of FIGS. 7 TO 9, the pharmaceutical package 210 can have a shelf life, after the pharmaceutical package 210 is assembled, of at least one year, alternatively at least two years.
[96] Optionally for any of the embodiments of FIGS. 7 TO 9, the shelf life is measured at 3°C, alternatively at 4°C or higher, alternatively at 20 °C or higher, alternatively at 23 °C, alternatively at 40 °C.
[97] Optionally for any of the embodiments of FIGS. 7 TO 9, the pH of the fluid composition 218 is between 5 and 6 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid composition 218 is between 6 and 7 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid composition 218 is between 7 and 8 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid composition 218 is between 8 and 9 and the thickness by TEM of the protective coating 286 is at least 80 nm at the end of the shelf life. Alternatively, the pH of the fluid composition 218 is between 5 and 6 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life. Alternatively, the pH of the fluid composition 218 is between 6 and 7 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life. Alternatively, the pH of the fluid composition 218 is between 7 and 8 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life. Alternatively, the pH of the fluid composition 218 is between 8 and 9 and the thickness by TEM of the protective coating 286 is at least 150 nm at the end of the shelf life.
[98] Optionally for any of the embodiments of FIGS. 7 TO 9, the fluid composition 218 removes the protective coating 286 at a rate of 1 nm or less of lubricity and/or protective coating thickness per 44 hours of contact with the fluid composition 218 (200 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 88 hours of contact with the fluid composition 218 (100 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 175 hours of contact with the fluid composition 218 (50 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 250 hours of contact with the fluid composition 218 (35 nm per year), alternatively 1 nm or less of lubricity and/or protective coating thickness per 350 hours of contact with the fluid composition 218 (25 nm per year). The rate of removing the protective coating can be determined by TEM from samples exposed to the fluid composition for known periods.
[99] Optionally for any of the embodiments of FIGS. 7 TO 9, the protective coating 286 is effective to provide a lower frictional resistance than the uncoated interior surface 254. Preferably the frictional resistance is reduced by at least 25 %, more preferably by at least 45%, even more preferably by at least 60% in comparison to the uncoated interior surface 254. For example, the protective coating 286 preferably is effective to reduce the frictional resistance between a portion of the wall 214 contacted by the fluid composition 218 and a relatively sliding part 258 after the pharmaceutical package 210 is assembled. Preferably, the protective coating 286 is effective to reduce the frictional resistance between the wall 214 and a relatively sliding part 258 at least two years after the pharmaceutical package 210 is assembled.
[100] Optionally for any of the embodiments of FIGS. 7 TO 9, the fluid composition 218 comprises a member or a combination of two or more members selected from the group consisting of:
Inhalation Anesthetics
Aliflurane
Chloroform
Cyclopropane
Desflurane (Suprane)
Diethyl Ether
Enflurane (Ethrane)
Ethyl Chloride
Ethylene Halothane (Fluothane)
Isoflurane (Forane, Isoflo)
Isopropenyl vinyl ether
Methoxyflurane
methoxyflurane,
Methoxypropane
Nitrous Oxide
Roflurane
Sevoflurane (Sevorane, Ultane, Sevoflo)
Teflurane
Trichloroethylene
Vinyl Ether
Xenon
Injectable Drugs
Ablavar (Gadofosveset Trisodium Injection) Abarelix Depot
Abobotulinumtoxin A Injection (Dysport)
ABT-263
ABT-869
ABX-EFG
Accretropin (Somatropin Injection)
Acetadote (Acetylcysteine Injection)
Acetazolamide Injection (Acetazolamide Injection)
Acetylcysteine Injection (Acetadote)
Actemra (Tocilizumab Injection)
Acthrel (Corticorelin Ovine Triflutate for Injection)
Actummune
Activase
Acyclovir for Injection (Zovirax Injection) Adacel
Adalimumab
Adenoscan (Adenosine Injection)
Adenosine Injection (Adenoscan)
Adrenaclick
AdreView (lobenguane I 123 Injection for Intravenous Use) Afluria
Ak-Fluor (Fluorescein Injection)
Aldurazyme (Laronidase)
Alglucerase Injection (Ceredase)
Alkeran Injection (Melphalan Hcl Injection)
Allopurinol Sodium for Injection (Aloprim)
Aloprim (Allopurinol Sodium for Injection)
Alprostadil
Alsuma (Sumatriptan Injection)
ALTU-238
Amino Acid Injections
Aminosyn
Apidra
Apremilast
Alprostadil Dual Chamber System for Injection (Caverject Im
AMG 009
AMG 076
AMG 102
AMG 108
AMG 1 14
AMG 162
AMG 220
AMG 221
AMG 222 AMG 317
AMG 379
AMG 386
AMG 403
AMG 477
AMG 479
AMG 517
AMG 531
AMG 557
AMG 623
AMG 655
AMG 706
AMG 714
AMG 745
AMG 785
AMG 81 1
AMG 827
AMG 837
AMG 853
AMG 951
Amiodarone HCI Injection (Amiodarone HCI Injection) Amobarbital Sodium Injection (Amytal Sodium) Amytal Sodium (Amobarbital Sodium Injection)
Anakinra
Anti -Abeta
Anti -Beta7
Anti -Beta20
Anti -CD4
Anti -CD20
23 Anti -CD40
Anti -IFNalpha
Anti -IL13
Anti -OX40L
Anti -oxLDS
Anti -NGF
Anti -NRP1
Arixtra
Amphadase (Hyaluronidase Inj)
Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection) Anaprox
Anzemet Injection (Dolasetron Mesylate Injection)
Apidra (Insulin Glulisine [rDNA origin] Inj)
Apomab
Aranesp (darbepoetin alfa)
Argatroban (Argatroban Injection)
Arginine Hydrochloride Injection (R-Gene 10
Aristocort
Aristospan
Arsenic Trioxide Injection (Trisenox)
Articane HCI and Epinephrine Injection (Septocaine)
Arzerra (Ofatumumab Injection)
Asclera (Polidocanol Injection)
Ataluren
Ataluren-DMD
Atenolol Inj (Tenormin I.V. Injection)
Atracurium Besylate Injection (Atracurium Besylate Injection) Avastin
Azactam Injection (Aztreonam Injection)
Azithromycin (Zithromax Injection) Aztreonam Injection (Azactam Injection)
Baclofen Injection (Lioresal Intrathecal)
Bacteriostatic Water (Bacteriostatic Water for Injection)
Baclofen Injection (Lioresal Intrathecal)
Bal in Oil Ampules (Dimercarprol Injection)
BayHepB
BayTet
Benadryl
Bendamustine Hydrochloride Injection (Treanda)
Benztropine Mesylate Injection (Cogentin)
Betamethasone Injectable Suspension (Celestone Soluspan)
Bexxar
Bicillin C-R 900/300 (Penicillin G Benzathine and Penicillin G Procaine Injection)
Blenoxane (Bleomycin Sulfate Injection)
Bleomycin Sulfate Injection (Blenoxane)
Boniva Injection (Ibandronate Sodium Injection)
Botox Cosmetic (OnabotulinumtoxinA for Injection)
BR3-FC
Bravelle (Urofollitropin Injection)
Bretylium (Bretylium Tosylate Injection )
Brevital Sodium (Methohexital Sodium for Injection)
Brethine
Briobacept
BTT-1023
Bupivacaine HCI
Byetta
Ca-DTPA (Pentetate Calcium Trisodium Inj)
Cabazitaxel Injection (Jevtana)
Caffeine Alkaloid (Caffeine and Sodium Benzoate Injection)
Calcijex Injection (Calcitrol) Calcitrol (Calcijex Injection)
Calcium Chloride (Calcium Chloride Injection 10%)
Calcium Disodium Versenate (Edetate Calcium Disodium Injection)
Campath (Altemtuzumab)
Camptosar Injection (Irinotecan Hydrochloride)
Canakinumab Injection (Maris)
Capastat Sulfate (Capreomycin for Injection)
Capreomycin for Injection (Capastat Sulfate)
Cardiolite (Prep kit for Technetium Tc99 Sestamibi for Injection)
Carticel
Cathflo
Cefazolin and Dextrose for Injection (Cefazolin Injection)
Cefepime Hydrochloride
Cefotaxime
Ceftriaxone
Cerezyme
Carnitor Injection
Caverject
Celestone Soluspan
Celsior
Cerebyx (Fosphenytoin Sodium Injection)
Ceredase (Alglucerase Injection)
Ceretec (Technetium Tc99m Exametazime Injection)
Certolizumab
CF-101
Chloramphenicol Sodium Succinate (Chloramphenicol Sodium Succinate Injection) Chloramphenicol Sodium Succinate Injection (Chloramphenicol Sodium Succinate) Cholestagel (Colesevelam HCL)
Choriogonadotropin Alfa Injection (Ovidrel)
Cimzia Cisplatin (Cisplatin Injection)
Clolar (Clofarabine Injection)
Clomiphine Citrate
Clonidine Injection (Duraclon)
Cogentin (Benztropine Mesylate Injection)
Colistimethate Injection (Coly-Mycin M)
Coly-Mycin M (Colistimethate Injection)
Com path
Conivaptan Hcl Injection (Vaprisol)
Conjugated Estrogens for Injection (Premarin Injection)
Copaxone
Corticorelin Ovine Triflutate for Injection (Acthrel) Corvert (Ibutilide Fumarate Injection)
Cubicin (Daptomycin Injection)
CF-101
Cyanokit (Hydroxocobalamin for Injection)
Cytarabine Liposome Injection (DepoCyt)
Cyanocobalamin
Cytovene (ganciclovir)
D.H.E. 45
Dacetuzumab
Dacogen (Decitabine Injection)
Dalteparin
Dantrium IV (Dantrolene Sodium for Injection)
Dantrolene Sodium for Injection (Dantrium IV)
Daptomycin Injection (Cubicin)
Darbepoietin Alfa
DDAVP Injection (Desmopressin Acetate Injection) Decavax
Decitabine Injection (Dacogen) Dehydrated Alcohol (Dehydrated Alcohol Injection)
Denosumab Injection (Prolia)
Delatestryl
Delestrogen
Delteparin Sodium
Depacon (Valproate Sodium Injection)
Depo Medrol (Methylprednisolone Acetate Injectable Suspension
DepoCyt (Cytarabine Liposome Injection)
DepoDur (Morphine Sulfate XR Liposome Injection)
Desmopressin Acetate Injection (DDAVP Injection)
Depo-Estradiol
Depo-Provera 104mg/ml
Depo-Provera 150mg/ml
Depo-Testosterone
Dexrazoxane for Injection, Intravenous Infusion Only (Totect) Dextrose / Electrolytes
Dextrose and Sodium Chloride Inj (Dextrose 5% in 0.9% Sodium Dextrose
Diazepam Injection (Diazepam Injection)
Digoxin Injection (Lanoxin Injection)
Dilaudid-HP (Hydromorphone Hydrochloride Injection)
Dimercarprol Injection (Bal in Oil Ampules)
Diphenhydramine Injection (Benadryl Injection)
Dipyridamole Injection (Dipyridamole Injection)
DMOAD
Docetaxel for Injection (Taxotere)
Dolasetron Mesylate Injection (Anzemet Injection)
Doribax (Doripenem for Injection)
Doripenem for Injection (Doribax)
Doxercalciferol Injection (Hectorol Injection) Doxil (Doxorubicin Hcl Liposome Injection)
Doxorubicin Hcl Liposome Injection (Doxil)
Duraclon (Clonidine Injection)
Duramorph (Morphine Injection)
Dysport (Abobotulinumtoxin A Injection)
Ecallantide Injection (Kalbitor)
EC-Naprosyn (naproxen)
Edetate Calcium Disodium Injection (Calcium Disodium Versenate)
Edex (Alprostadil for Injection)
Engerix
Edrophonium Injection (Enlon)
Eliglustat Tartate
Eloxatin (Oxaliplatin Injection)
Emend Injection (Fosaprepitant Dimeglumine Injection)
Enalaprilat Injection (Enalaprilat Injection)
Enlon (Edrophonium Injection)
Enoxaparin Sodium Injection (Lovenox)
Eovist (Gadoxetate Disodium Injection)
Enbrel (etanercept)
Enoxaparin
Epicel
Epinepherine
Epipen
Epipen Jr.
Epratuzumab
Erbitux
Ertapenem Injection (Invanz)
Erythropoieten
Essential Amino Acid Injection (Nephramine)
Estradiol Cypionate Estradiol Valerate
Etanercept
Exenatide Injection (Byetta)
Evlotra
Fabrazyme (Adalsidase beta)
Famotidine Injection
FDG (Fludeoxyglucose F 18 Injection)
Feraheme (Ferumoxytol Injection)
Feridex I.V. (Ferumoxides Injectable Solution)
Fertinex
Ferumoxides Injectable Solution (Feridex I.V.)
Ferumoxytol Injection (Feraheme)
Flagyl Injection (Metronidazole Injection)
Fluarix
Fludara (Fludarabine Phosphate)
Fludeoxyglucose F 18 Injection (FDG)
Fluorescein Injection (Ak-Fluor)
Follistim AQ Cartridge (Follitropin Beta Injection)
Follitropin Alfa Injection (Gonal-f RFF)
Follitropin Beta Injection (Follistim AQ Cartridge)
Folotyn (Pralatrexate Solution for Intravenous Injection)
Fondaparinux
Forteo (Teriparatide (rDNA origin) Injection)
Fostamatinib
Fosaprepitant Dimeglumine Injection (Emend Injection) Foscarnet Sodium Injection (Foscavir)
Foscavir (Foscarnet Sodium Injection)
Fosphenytoin Sodium Injection (Cerebyx)
Fospropofol Disodium Injection (Lusedra)
Fragmin Fuzeon (enfuvirtide)
GA101
Gadobenate Dimeglumine Injection (Multihance) Gadofosveset Trisodium Injection (Ablavar) Gadoteridol Injection Solution (ProHance) Gadoversetamide Injection (OptiMARK)
Gadoxetate Disodium Injection (Eovist)
Ganirelix (Ganirelix Acetate Injection)
Gardasil
GC1008
GDFD
Gemtuzumab Ozogamicin for Injection (Mylotarg) Genotropin
Gentamicin Injection
GENZ-1 12638
Golimumab Injection (Simponi Injection)
Gonal-f RFF (Follitropin Alfa Injection)
Granisetron Hydrochloride (Kytril Injection)
Gentamicin Sulfate
Glatiramer Acetate
Glucagen
Glucagon
HAE1
Haldol (Haloperidol Injection)
Havrix
Hectorol Injection (Doxercalciferol Injection)
Hedgehog Pathway Inhibitor
Heparin
Herceptin
hG-CSF Humalog
Human Growth Hormone
Humatrope
HuMax
Humegon
Humira
Humulin
Ibandronate Sodium Injection (Boniva Injection)
Ibuprofen Lysine Injection (NeoProfen)
Ibutilide Fumarate Injection (Corvert)
Idamycin PFS (Idarubicin Hydrochloride Injection)
Idarubicin Hydrochloride Injection (Idamycin PFS)
Maris (Canakinumab Injection)
Imipenem and Cilastatin for Injection (Primaxin I.V.)
Imitrex
Incobotulinumtoxin A for Injection (Xeomin)
Increlex (Mecasermin [rDNA origin] Injection)
Indocin IV (Indomethacin Inj)
Indomethacin Inj (Indocin IV)
Infanrix
Innohep
Insulin
Insulin Aspart [rDNA origin] Inj (NovoLog)
Insulin Glargine [rDNA origin] Injection (Lantus)
Insulin Glulisine [rDNA origin] Inj (Apidra)
Interferon alfa-2b, Recombinant for Injection (Intron A)
Intron A (Interferon alfa-2b, Recombinant for Injection)
Invanz (Ertapenem Injection)
Invega Sustenna (Paliperidone Palmitate Extended- Release Injectable Suspension) Invirase (saquinavir mesylate) lobenguane I 123 Injection for Intravenous Use (AdreView)
lopromide Injection (Ultravist)
loversol Injection (Optiray Injection)
Iplex (Mecasermin Rinfabate [rDNA origin] Injection)
Iprivask
Irinotecan Hydrochloride (Camptosar Injection)
Iron Sucrose Injection (Venofer)
Istodax (Romidepsin for Injection)
Itraconazole Injection (Sporanox Injection)
Jevtana (Cabazitaxel Injection)
Jonexa
Kalbitor (Ecallantide Injection)
KCL in D5NS (Potassium Chloride in 5% Dextrose and Sodium Chloride Injection) KCL in D5W
KCL in NS
Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension)
Kepivance (Palifermin)
Keppra Injection (Levetiracetam)
Keratinocyte
KFG
Kinase Inhibitor
Kineret (Anakinra)
Kinlytic (Urokinase Injection)
Kinrix
Klonopin (clonazepam)
Kytril Injection (Granisetron Hydrochloride)
lacosamide Tablet and Injection (Vimpat)
Lactated Ringer's
Lanoxin Injection (Digoxin Injection)
Lansoprazole for Injection (Prevacid I.V.) Lantus
Leucovorin Calcium (Leucovorin Calcium Injection)
Lente (L)
Leptin
Levemir
Leukine Sargramostim
Leuprolide Acetate
Levothyroxine
Levetiracetam (Keppra Injection)
Lovenox
Levocarnitine Injection (Carnitor Injection)
Lexiscan (Regadenoson Injection)
Lioresal Intrathecal (Baclofen Injection)
Liraglutide [rDNA] Injection (Victoza)
Lovenox (Enoxaparin Sodium Injection)
Lucentis (Ranibizumab Injection)
Lumizyme
Lupron (Leuprolide Acetate Injection)
Lusedra (Fospropofol Disodium Injection)
Maci
Magnesium Sulfate (Magnesium Sulfate Injection)
Mannitol Injection (Mannitol IV)
Marcaine (Bupivacaine Hydrochloride and Epinephrine Injection)
Maxipime (Cefepime Hydrochloride for Injection)
MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection)
Mecasermin [rDNA origin] Injection (Increlex)
Mecasermin Rinfabate [rDNA origin] Injection (Iplex)
Melphalan Hcl Injection (Alkeran Injection)
Methotrexate
Menactra Menopur (Menotropins Injection)
Menotropins for Injection (Repronex)
Methohexital Sodium for Injection (Brevital Sodium)
Methyldopate Hydrochloride Injection, Solution (Methyldopate Hcl)
Methylene Blue (Methylene Blue Injection)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
MetMab
Metoclopramide Injection (Reglan Injection)
Metrodin (Urofollitropin for Injection)
Metronidazole Injection (Flagyl Injection)
Miacalcin
Midazolam (Midazolam Injection)
Mimpara (Cinacalet)
Minocin Injection (Minocycline Inj)
Minocycline Inj (Minocin Injection)
Mipomersen
Mitoxantrone for Injection Concentrate (Novantrone)
Morphine Injection (Duramorph)
Morphine Sulfate XR Liposome Injection (DepoDur)
Morrhuate Sodium (Morrhuate Sodium Injection)
Motesanib
Mozobil (Plerixafor Injection)
Multihance (Gadobenate Dimeglumine Injection)
Multiple Electrolytes and Dextrose Injection
Multiple Electrolytes Injection
Mylotarg (Gemtuzumab Ozogamicin for Injection)
Myozyme (Alglucosidase alfa)
Nafcillin Injection (Nafcillin Sodium)
Nafcillin Sodium (Nafcillin Injection)
Naltrexone XR Inj (Vivitrol) Naprosyn (naproxen)
NeoProfen (Ibuprofen Lysine Injection)
Nandrol Decanoate
Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection)
NEO-GAA
NeoTect (Technetium Tc 99m Depreotide Injection)
Nephramine (Essential Amino Acid Injection)
Neulasta (pegfilgrastim)
Neupogen (Filgrastim)
Novolin
Novolog
NeoRecormon
Neutrexin (Trimetrexate Glucuronate Inj)
NPH (N)
Nexterone (Amiodarone HCI Injection)
Norditropin (Somatropin Injection)
Normal Saline (Sodium Chloride Injection)
Novantrone (Mitoxantrone for Injection Concentrate)
Novolin 70/30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection)
NovoLog (Insulin Aspart [rDNA origin] Inj)
Nplate (romiplostim)
Nutropin (Somatropin (rDNA origin) for Inj)
Nutropin AQ
Nutropin Depot (Somatropin (rDNA origin) for Inj)
Octreotide Acetate Injection (Sandostatin LAR)
Ocrelizumab
Ofatumumab Injection (Arzerra)
Olanzapine Extended Release Injectable Suspension (Zyprexa Relprevv)
Omnitarg Omnitrope (Somatropin [ rDNA origin] Injection)
Ondansetron Hydrochloride Injection (Zofran Injection)
OptiMARK (Gadoversetamide Injection)
Optiray Injection (loversol Injection)
Orencia
Osmitrol Injection in Aviva (Mannitol Injection in Aviva Plastic Vessel 250)
Osmitrol Injection in Viaflex (Mannitol Injection in Viaflex Plastic Vessel 250) Osteoprotegrin
Ovidrel (Choriogonadotropin Alfa Injection)
Oxacillin (Oxacillin for Injection)
Oxaliplatin Injection (Eloxatin)
Oxytocin Injection (Pitocin)
Paliperidone Palmitate Extended- Release Injectable Suspension (Invega Sustenna) Pamidronate Disodium Injection (Pamidronate Disodium Injection)
Panitumumab Injection for Intravenous Use (Vectibix)
Papaverine Hydrochloride Injection (Papaverine Injection)
Papaverine Injection (Papaverine Hydrochloride Injection)
Parathyroid Hormone
Paricalcitol Injection Fliptop Vial (Zemplar Injection)
PARP Inhibitor
Pediarix
PEGIntron
Peginterferon
Pegfilgrastim
Penicillin G Benzathine and Penicillin G Procaine
Pentetate Calcium Trisodium Inj (Ca-DTPA)
Pentetate Zinc Trisodium Injection (Zn-DTPA)
Pepcid Injection (Famotidine Injection)
Pergonal
Pertuzumab Phentolamine Mesylate (Phentolamine Mesylate for Injection)
Physostigmine Salicylate (Physostigmine Salicylate (injection))
Physostigmine Salicylate (injection) (Physostigmine Salicylate)
Piperacillin and Tazobactam Injection (Zosyn)
Pitocin (Oxytocin Injection)
Plasma-Lyte 148 (Multiple Electrolytes Inj)
Plasma-Lyte 56 and Dextrose (Multiple Electrolytes and Dextrose Injection
Plastic Vessel 250)
PlasmaLyte
Plerixafor Injection (Mozobil)
Polidocanol Injection (Asclera)
Potassium Chloride
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pramlintide Acetate Injection (Symlin)
Premarin Injection (Conjugated Estrogens for Injection)
Prep kit for Technetium Tc99 Sestamibi for Injection (Cardiolite)
Prevacid I.V. (Lansoprazole for Injection)
Primaxin I.V. (Imipenem and Cilastatin for Injection)
Prochymal
Procrit
Progesterone
ProHance (Gadoteridol Injection Solution)
Prolia (Denosumab Injection)
Promethazine HCI Injection (Promethazine Hydrochloride Injection)
Propranolol Hydrochloride Injection (Propranolol Hydrochloride Injection)
Quinidine Gluconate Injection (Quinidine Injection)
Quinidine Injection (Quinidine Gluconate Injection)
R-Gene 10 (Arginine Hydrochloride Injection)
Ranibizumab Injection (Lucentis)
Ranitidine Hydrochloride Injection (Zantac Injection) Raptiva
Reclast (Zoledronic Acid Injection)
Recombivarix HB
Regadenoson Injection (Lexiscan)
Reglan Injection (Metoclopramide Injection)
Remicade
Renagel
Renvela (Sevelamer Carbonate)
Repronex (Menotropins for Injection)
Retrovir IV (Zidovudine Injection)
rhApo2L/TRAIL
Ringer's and 5% Dextrose Injection (Ringers in Dextrose)
Ringer's Injection (Ringers Injection)
Rituxan
Rituximab
Rocephin (ceftriaxone)
Rocuronium Bromide Injection (Zemuron)
Roferon-A (interferon alfa-2a)
Romazicon (flumazenil)
Romidepsin for Injection (Istodax)
Saizen (Somatropin Injection)
Sandostatin LAR (Octreotide Acetate Injection)
Sclerostin Ab
Sensipar (cinacalcet)
Sensorcaine (Bupivacaine HCI Injections)
Septocaine (Articane HCI and Epinephrine Injection)
Serostim LQ (Somatropin (rDNA origin) Injection)
Simponi Injection (Golimumab Injection)
Sodium Acetate (Sodium Acetate Injection)
Sodium Bicarbonate (Sodium Bicarbonate 5% Injection) Sodium Lactate (Sodium Lactate Injection in AVIVA)
Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul)
Somatropin (rDNA origin) for Inj (Nutropin)
Sporanox Injection (Itraconazole Injection)
Stelara Injection (Ustekinumab)
Stemgen
Sufenta (Sufentanil Citrate Injection)
Sufentanil Citrate Injection (Sufenta )
Sumavel
Sumatriptan Injection (Alsuma)
Symlin
Symlin Pen
Systemic Hedgehog Antagonist
Synvisc-One (Hylan G-F 20 Single Intra-articular Injection) Tarceva
Taxotere (Docetaxel for Injection)
Technetium Tc 99m
Telavancin for Injection (Vibativ)
Temsirolimus Injection (Torisel)
Tenormin I.V. Injection (Atenolol Inj)
Teriparatide (rDNA origin) Injection (Forteo)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Propionate
Tev-Tropin (Somatropin, rDNA Origin, for Injection)
tgAAC94
Thallous Chloride
Theophylline
Thiotepa (Thiotepa Injection)
Thymoglobulin (Anti-Thymocyte Globulin (Rabbit) Thyrogen (Thyrotropin Alfa for Injection)
Ticarcillin Disodium and Clavulanate Potassium Galaxy (Timentin Injection)
Tigan Injection (Trimethobenzamide Hydrochloride Injectable)
Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy)
TNKase
Tobramycin Injection (Tobramycin Injection)
Tocilizumab Injection (Actemra)
Torisel (Temsirolimus Injection)
Totect (Dexrazoxane for Injection, Intravenous Infusion Only )
Trastuzumab-DM1
Travasol (Amino Acids (Injection))
Treanda (Bendamustine Hydrochloride Injection)
Trelstar (Triptorelin Pamoate for Injectable Suspension)
Triamcinolone Acetonide
Triamcinolone Diacetate
Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg)
Triesence (Triamcinolone Acetonide Injectable Suspension)
Trimethobenzamide Hydrochloride Injectable (Tigan Injection)
Trimetrexate Glucuronate Inj (Neutrexin)
Triptorelin Pamoate for Injectable Suspension (Trelstar)
Twinject
Trivaris (Triamcinolone Acetonide Injectable Suspension)
Trisenox (Arsenic Trioxide Injection)
Twinrix
Typhoid Vi
Ultravist (lopromide Injection)
Urofollitropin for Injection (Metrodin)
Urokinase Injection (Kinlytic)
Ustekinumab (Stelara Injection)
Ultralente (U) Valium (diazepam)
Valproate Sodium Injection (Depacon)
Valtropin (Somatropin Injection)
Vancomycin Hydrochloride (Vancomycin Hydrochloride Injection) Vancomycin Hydrochloride Injection (Vancomycin Hydrochloride) Vaprisol (Conivaptan Hcl Injection)
VAQTA
Vasovist (Gadofosveset Trisodium Injection for Intravenous Use)
Vectibix (Panitumumab Injection for Intravenous Use)
Venofer (Iron Sucrose Injection)
Verteporfin Inj (Visudyne)
Vibativ (Telavancin for Injection)
Victoza (Liraglutide [rDNA] Injection)
Vimpat (lacosamide Tablet and Injection)
Vinblastine Sulfate (Vinblastine Sulfate Injection)
Vincasar PFS (Vincristine Sulfate Injection)
Victoza
Vincristine Sulfate (Vincristine Sulfate Injection)
Visudyne (Verteporfin Inj)
Vitamin B-12
Vivitrol (Naltrexone XR Inj)
Voluven (Hydroxyethyl Starch in Sodium Chloride Injection) Xeloda
Xenical (orlistat)
Xeomin (Incobotulinumtoxin A for Injection)
Xolair
Zantac Injection (Ranitidine Hydrochloride Injection)
Zemplar Injection (Paricalcitol Injection Fliptop Vial)
Zemuron (Rocuronium Bromide Injection)
Zenapax (daclizumab) Zevalin
Zidovudine Injection (Retrovir IV)
Zithromax Injection (Azithromycin)
Zn-DTPA (Pentetate Zinc Trisodium Injection)
Zofran Injection (Ondansetron Hydrochloride Injection)
Zingo
Zoledronic Acid for Inj (Zometa)
Zoledronic Acid Injection (Reclast)
Zometa (Zoledronic Acid for Inj)
Zosyn (Piperacillin and Tazobactam Injection)
Zyprexa Relprevv (Olanzapine Extended Release Injectable Suspension)
Liquid Drugs (Non-lnjectable)
Ability
AccuNeb (Albuterol Sulfate Inhalation Solution)
Actidose Aqua (Activated Charcoal Suspension)
Activated Charcoal Suspension (Actidose Aqua)
Advair
Agenerase Oral Solution (Amprenavir Oral Solution)
Akten (Lidocaine Hydrochloride Ophthalmic Gel)
Alamast (Pemirolast Potassium Ophthalmic Solution)
Albumin (Human) 5% Solution (Buminate 5%)
Albuterol Sulfate Inhalation Solution
Alinia
Alocril
Alphagan
Alrex
Alvesco
Amprenavir Oral Solution
Analpram-HC Arformoterol Tartrate Inhalation Solution (Brovana)
Aristospan Injection 20 mg (Triamcinolone Hexacetonide Injectable Suspension)
Asacol
Asmanex
Astepro
Astepro (Azelastine Hydrochloride Nasal Spray)
Atrovent Nasal Spray (Ipratropium Bromide Nasal Spray)
Atrovent Nasal Spray .06
Augmentin ES-600
Azasite (Azithromycin Ophthalmic Solution)
Azelaic Acid (Finacea Gel)
Azelastine Hydrochloride Nasal Spray (Astepro)
Azelex (Azelaic Acid Cream)
Azopt (Brinzolamide Ophthalmic Suspension)
Bacteriostatic Saline
Balanced Salt
Bepotastine
Bactroban Nasal
Bactroban
Beclovent
Benzac W
Betimol
Betoptic S
Bepreve
Bimatoprost Ophthalmic Solution
Bleph 10 (Sulfacetamide Sodium Ophthalmic Solution 10%)
Brinzolamide Ophthalmic Suspension (Azopt)
Bromfenac Ophthalmic Solution (Xibrom)
Bromhist
Brovana (Arformoterol Tartrate Inhalation Solution) Budesonide Inhalation Suspension (Pulmicort Respules)
Cambia (Diclofenac Potassium for Oral Solution)
Capex
Carac
Carboxine-PSE
Carnitor
Cayston (Aztreonam for Inhalation Solution)
Cellcept
Centany
Cerumenex
Ciloxan Ophthalmic Solution (Ciprofloxacin HCL Ophthalmic Solution) Ciprodex
Ciprofloxacin HCL Ophthalmic Solution (Ciloxan Ophthalmic Solution)
Clemastine Fumarate Syrup (Clemastine Fumarate Syrup)
CoLyte (PEG Electrolytes Solution)
Combiven
Comtan
Condylox
Cord ran
Cortisporin Ophthalmic Suspension
Cortisporin Otic Suspension
Cromolyn Sodium Inhalation Solution (Intal Nebulizer Solution)
Cromolyn Sodium Ophthalmic Solution (Opticrom)
Crystalline Amino Acid Solution with Electrolytes (Aminosyn Electrolytes)
Cutivate
Cuvposa (Glycopyrrolate Oral Solution)
Cyanocobalamin (CaloMist Nasal Spray)
Cyclosporine Oral Solution (Gengraf Oral Solution)
Cyclogyl
Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution) DermOtic Oil (Fluocinolone Acetonide Oil Ear Drops)
Desmopressin Acetate Nasal Spray
DDAVP
Derma-Smoothe/FS
Dexamethasone Intensol
Dianeal Low Calcium
Dianeal PD
Diclofenac Potassium for Oral Solution (Cambia)
Didanosine Pediatric Powder for Oral Solution (Videx)
Differin
Dilantin 125 (Phenytoin Oral Suspension)
Ditropan
Dorzolamide Hydrochloride Ophthalmic Solution (Trusopt)
Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution (Cosopt)
Dovonex Scalp (Calcipotriene Solution)
Doxycycline Calcium Oral Suspension (Vibramycin Oral)
Efudex
Elaprase (Idursulfase Solution)
Elestat (Epinastine HCI Ophthalmic Solution)
Elocon
Epinastine HCI Ophthalmic Solution (Elestat)
Epivir HBV
Epogen (Epoetin alfa)
Erythromycin Topical Solution 1 .5% (Staticin)
Ethiodol (Ethiodized Oil)
Ethosuximide Oral Solution (Zarontin Oral Solution)
Eurax
Extraneal (lcodextrin Peritoneal Dialysis Solution)
Felbatol
Feridex I.V. (Ferumoxides Injectable Solution) Flovent
Floxin Otic (Ofloxacin Otic Solution)
Flo-Pred (Prednisolone Acetate Oral Suspension)
Fluoroplex
Flunisolide Nasal Solution (Flunisolide Nasal Spray .025%)
Fluorometholone Ophthalmic Suspension (FML)
Flurbiprofen Sodium Ophthalmic Solution (Ocufen)
FML
Fo radii
Formoterol Fumarate Inhalation Solution (Perforomist)
Fosamax
Furadantin (Nitrofurantoin Oral Suspension)
Furoxone
Gammagard Liquid (Immune Globulin Intravenous (Human) 10%)
Gantrisin (Acetyl Sulfisoxazole Pediatric Suspension)
Gatifloxacin Ophthalmic Solution (Zymar)
Gengraf Oral Solution (Cyclosporine Oral Solution)
Glycopyrrolate Oral Solution (Cuvposa)
Halcinonide Topical Solution (Halog Solution)
Halog Solution (Halcinonide Topical Solution)
HEP-LOCK U/P (Preservative-Free Heparin Lock Flush Solution)
Heparin Lock Flush Solution (Hepflush 10
Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview)
Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab El
Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution)
IAP Antagonist
Isopto
Ipratropium Bromide Nasal Spray (Atrovent Nasal Spray)
Itraconazole Oral Solution (Sporanox Oral Solution)
Ketorolac Tromethamine Ophthalmic Solution (Acular LS) Kaletra
Lanoxin
Lexiva
Leuprolide Acetate for Depot Suspension (Lupron Depot 1 1 .25 mg)
Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon)
Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor)
Levofloxacin Ophthalmic Solution 0.5% (Quixin)
Lidocaine HCI Sterile Solution (Xylocaine MPF Sterile Solution)
Lok Pak (Heparin Lock Flush Solution)
Lorazepam Intensol
Lortab Elixir (Hydrocodone Bitartrate and Acetaminophen Oral Solution)
Lotemax (Loteprednol Etabonate Ophthalmic Suspension)
Loteprednol Etabonate Ophthalmic Suspension (Alrex)
Low Calcium Peritoneal Dialysis Solutions (Dianeal Low Calcium)
Lumigan (Bimatoprost Ophthalmic Solution 0.03% for Glaucoma)
Lupron Depot 1 1 .25 mg (Leuprolide Acetate for Depot Suspension)
Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension)
MEK Inhibitor
Mepron
Mesnex
Mestinon
Mesalamine Rectal Suspension Enema (Rowasa)
Melquin-3 Topical Solution (Hydroquinone 3% Topical Solution)
MetMab
Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution)
Methylin Oral Solution (Methylphenidate HCI Oral Solution 5 mg/5 mL and 10 mg/5 mL)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
Methylphenidate HCI Oral Solution 5 mg/5 mL and 10 mg/5 mL (Methylin Oral Solution)
Methylprednisolone sodium succinate (Solu Medrol)
Metipranolol Ophthalmic Solution (Optipranolol) Migranal
Miochol-E (Acetylcholine Chloride Intraocular Solution)
Micro-K for Liquid Suspension (Potassium Chloride Extended Release Formulation for Liquid Suspension)
Minocin (Minocycline Hydrochloride Oral Suspension)
Nasacort
Neomycin and Polymyxin B Sulfates and Hydrocortisone
Nepafenac Ophthalmic Suspension (Nevanac)
Nevanac (Nepafenac Ophthalmic Suspension)
Nitrofurantoin Oral Suspension (Furadantin)
Noxafil (Posaconazole Oral Suspension)
Nystatin (oral) (Nystatin Oral Suspension)
Nystatin Oral Suspension (Nystatin (oral))
Ocufen (Flurbiprofen Sodium Ophthalmic Solution)
Ofloxacin Ophthalmic Solution (Ofloxacin Ophthalmic Solution)
Ofloxacin Otic Solution (Floxin Otic)
Olopatadine Hydrochloride Ophthalmic Solution (Pataday)
Opticrom (Cromolyn Sodium Ophthalmic Solution)
Optipranolol (Metipranolol Ophthalmic Solution)
Patanol
Pediapred
PerioGard
Phenytoin Oral Suspension (Dilantin 125)
Phisohex
Posaconazole Oral Suspension (Noxafil)
Potassium Chloride Extended Release Formulation for Liquid Suspension (Micro-K for Liquid Suspension)
Pataday (Olopatadine Hydrochloride Ophthalmic Solution)
Patanase Nasal Spray (Olopatadine Hydrochloride Nasal Spray)
PEG Electrolytes Solution (CoLyte) Pemirolast Potassium Ophthalmic Solution (Alamast)
Penlac (Ciclopirox Topical Solution)
PENNSAID (Diclofenac Sodium Topical Solution)
Perforomist (Formoterol Fumarate Inhalation Solution)
Peritoneal Dialysis Solution
Phenylephrine Hydrochloride Ophthalmic Solution (Neo-Synephrine)
Phospholine Iodide (Echothiophate Iodide for Ophthalmic Solution)
Podofilox (Podofilox Topical Solution)
Pred Forte (Prednisolone Acetate Ophthalmic Suspension)
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pred Mild
Prednisone Intensol
Prednisolone Acetate Ophthalmic Suspension (Pred Forte)
Prevacid
PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution)
Pro Air
Proglycem
ProHance (Gadoteridol Injection Solution)
Proparacaine Hydrochloride Ophthalmic Solution (Alcaine)
Propine
Pulmicort
Pulmozyme
Quixin (Levofloxacin Ophthalmic Solution 0.5%)
QVAR
Rapamune
Rebetol
Relacon-HC
Rotarix (Rotavirus Vaccine, Live, Oral Suspension)
Rotavirus Vaccine, Live, Oral Suspension (Rotarix)
Rowasa (Mesalamine Rectal Suspension Enema) Sabril (Vigabatrin Oral Solution)
Sacrosidase Oral Solution (Sucraid)
Sandimmune
Sepra
Serevent Diskus
Solu Cortef (Hydrocortisone Sodium Succinate)
Solu Medrol (Methylprednisolone sodium succinate)
Spiriva
Sporanox Oral Solution (Itraconazole Oral Solution)
Staticin (Erythromycin Topical Solution 1 .5%)
Stalevo
Starlix
Sterile Hemofiltration Hemodiafiltration Solution (PrismaSol Solution)
Stimate
Sucralfate (Carafate Suspension)
Sulfacetamide Sodium Ophthalmic Solution 10% (Bleph 10
Synarel Nasal Solution (Nafarelin Acetate Nasal Solution for Endometriosis)
Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension)
Tamiflu
Tobi
TobraDex
Tobradex ST (Tobramycin / Dexamethasone Ophthalmic Suspension 0.3%/0.05%)
Tobramycin / Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST)
Timolol
Timoptic
Travatan Z
Treprostinil Inhalation Solution (Tyvaso)
Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution)
Tyvaso (Treprostinil Inhalation Solution)
Ventolin Vfend
Vibramycin Oral (Doxycycline Calcium Oral Suspension)
Videx (Didanosine Pediatric Powder for Oral Solution)
Vigabatrin Oral Solution (Sabril)
Viokase
Viracept
Viramune
Vitamin K1 (Fluid Colloidal Solution of Vitamin K1 )
Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution)
Zarontin Oral Solution (Ethosuximide Oral Solution)
Ziagen
Zyvox
Zymar (Gatifloxacin Ophthalmic Solution)
Zymaxid (Gatifloxacin Ophthalmic Solution)
Drug Classes
5-alpha-reductase inhibitors
5-aminosalicylates
5HT3 receptor antagonists
adamantane antivirals
adrenal cortical steroids
adrenal corticosteroid inhibitors
adrenergic bronchodilators
agents for hypertensive emergencies
agents for pulmonary hypertension
aldosterone receptor antagonists
alkylating agents
alpha-adrenoreceptor antagonists
alpha-glucosidase inhibitors
alternative medicines amebicides
aminoglycosides
aminopenicillins
aminosalicylates
amylin analogs
Analgesic Combinations
Analgesics
androgens and anabolic steroids angiotensin converting enzyme inhibitors angiotensin II inhibitors
anorectal preparations
anorexiants
antacids
anthelmintics
anti-angiogenic ophthalmic agents anti-CTLA-4 monoclonal antibodies anti-infectives
antiadrenergic agents, centrally acting antiadrenergic agents, peripherally acting antiandrogens
antianginal agents
antiarrhythmic agents
antiasthmatic combinations
antibiotics/antineoplastics
anticholinergic antiemetics
anticholinergic antiparkinson agents anticholinergic bronchodilators anticholinergic chronotropic agents anticholinergics/antispasmodics anticoagulants ant convulsants
ant depressants
ant diabetic agents
ant diabetic combinations
ant diarrheals
ant diuretic hormones
ant dotes
ant emetic/antivertigo agents ant fungals
ant gonadotropic agents
ant gout agents
ant histamines
ant hyperlipidemic agents
ant hyperlipidemic combinations ant hypertensive combinations ant hyperuricemic agents
ant malarial agents
ant malarial combinations
ant malarial quinolines
ant metabolites
ant migraine agents
ant neoplastic detoxifying agents ant neoplastic interferons
ant neoplastic monoclonal antibodies ant neoplastics
ant parkinson agents
ant platelet agents
ant pseudomonal penicillins ant psoriatics
ant psychotics antirheumatics
antiseptic and germicides
antithyroid agents
antitoxins and antivenins
antituberculosis agents
antituberculosis combinations antitussives
antiviral agents
antiviral combinations
antiviral interferons
anxiolytics, sedatives, and hypnotics aromatase inhibitors
atypical antipsychotics
azole antifungals
bacterial vaccines
barbiturate anticonvulsants barbiturates
BCR-ABL tyrosine kinase inhibitors benzodiazepine anticonvulsants benzodiazepines
beta-adrenergic blocking agents beta-lactamase inhibitors
bile acid sequestrants
biologicals
bisphosphonates
bone resorption inhibitors
bronchodilator combinations bronchodilators
calcitonin
calcium channel blocking agents carbamate anticonvulsants
carbapenems
carbonic anhydrase inhibitor anticonvulsants carbonic anhydrase inhibitors
cardiac stressing agents
cardioselective beta blockers
cardiovascular agents
catecholamines
CD20 monoclonal antibodies
CD33 monoclonal antibodies
CD52 monoclonal antibodies
central nervous system agents
cephalosporins
cerumenolytics
chelating agents
chemokine receptor antagonist
chloride channel activators
cholesterol absorption inhibitors
cholinergic agonists
cholinergic muscle stimulants
cholinesterase inhibitors
CNS stimulants
coagulation modifiers
colony stimulating factors
contraceptives
corticotropin
coumarins and indandiones
cox-2 inhibitors
decongestants
dermatological agents diagnostic radiopharmaceuticals
dibenzazepine anticonvulsants
digestive enzymes
dipeptidyl peptidase 4 inhibitors
diuretics
dopaminergic antiparkinsonism agents
drugs used in alcohol dependence
echinocandins
EGFR inhibitors
estrogen receptor antagonists
estrogens
expectorants
factor Xa inhibitors
fatty acid derivative anticonvulsants
fibric acid derivatives
first generation cephalosporins
fourth generation cephalosporins
functional bowel disorder agents
gallstone solubilizing agents
gamma-aminobutyric acid analogs
gamma-aminobutyric acid reuptake inhibitors gamma-aminobutyric acid transaminase inhibitors gastrointestinal agents
general anesthetics
genitourinary tract agents
Gl stimulants
glucocorticoids
glucose elevating agents
glycopeptide antibiotics
glycoprotein platelet inhibitors glycylcyclines
gonadotropin releasing hormones
gonadotropin-releasing hormone antagonists gonadotropins
group I antiarrhythmics
group II antiarrhythmics
group III antiarrhythmics
group IV antiarrhythmics
group V antiarrhythmics
growth hormone receptor blockers growth hormones
H. pylori eradication agents
H2 antagonists
hematopoietic stem cell mobilizer
heparin antagonists
heparins
HER2 inhibitors
herbal products
histone deacetylase inhibitors
hormone replacement therapy
hormones
hormones/antineoplastics
hydantoin anticonvulsants
illicit (street) drugs
immune globulins
immunologic agents
immunosuppressive agents
impotence agents
in vivo diagnostic biologicals
incretin mimetics inhaled anti-infectives
inhaled corticosteroids
inotropic agents
insulin
insulin-like growth factor
integrase strand transfer inhibitor interferons
intravenous nutritional products
iodinated contrast media
ionic iodinated contrast media
iron products
ketolides
laxatives
leprostatics
leukotriene modifiers
lincomycin derivatives
lipoglycopeptides
local injectable anesthetics
loop diuretics
lung surfactants
lymphatic staining agents
lysosomal enzymes
macrolide derivatives
macrolides
magnetic resonance imaging contrast media mast cell stabilizers
medical gas
meglitinides
metabolic agents
methylxanthines mineralocorticoids
minerals and electrolytes
miscel laneous agents
miscel laneous analgesics
miscel laneous antibiotics
miscel laneous anticonvulsants
miscel laneous antidepressants
miscel laneous antidiabetic agents
miscel laneous antiemetics
miscel laneous antifungals
miscel laneous antihyperlipidemic agents miscel laneous antimalarials
miscel laneous antineoplastics
miscel laneous antiparkinson agents
miscel laneous antipsychotic agents
miscel laneous antituberculosis agents
miscel laneous antivirals
miscel laneous anxiolytics, sedatives and hypnotics miscel laneous biologicals
miscel laneous bone resorption inhibitors miscel laneous cardiovascular agents
miscel laneous central nervous system agents miscel laneous coagulation modifiers
miscel laneous diuretics
miscel laneous genitourinary tract agents miscel laneous Gl agents
miscel laneous hormones
miscel laneous metabolic agents
miscel laneous ophthalmic agents
miscel laneous otic agents miscellaneous respiratory agents miscellaneous sex hormones
miscellaneous topical agents
miscellaneous uncategorized agents miscellaneous vaginal agents mitotic inhibitors
monoamine oxidase inhibitors monoclonal antibodies
mouth and throat products
mTOR inhibitors
mTOR kinase inhibitors
mucolytics
multikinase inhibitors
muscle relaxants
mydriatics
narcotic analgesic combinations narcotic analgesics
nasal anti-infectives
nasal antihistamines and decongestants nasal lubricants and irrigations nasal preparations
nasal steroids
natural penicillins
neuraminidase inhibitors
neuromuscular blocking agents next generation cephalosporins nicotinic acid derivatives
nitrates
NNRTIs
non-cardioselective beta blockers non-iodinated contrast media
non-ionic iodinated contrast media
non-sulfonylureas
nonsteroidal anti-inflammatory agents
norepinephrine reuptake inhibitors
norepinephrine-dopamine reuptake inhibitors nucleoside reverse transcriptase inhibitors (NRTIs) nutraceutical products
nutritional products
ophthalmic anesthetics
ophthalmic anti-infectives
ophthalmic anti-inflammatory agents
ophthalmic antihistamines and decongestants ophthalmic diagnostic agents
ophthalmic glaucoma agents
ophthalmic lubricants and irrigations
ophthalmic preparations
ophthalmic steroids
ophthalmic steroids with anti-infectives
ophthalmic surgical agents
oral nutritional supplements
otic anesthetics
otic anti-infectives
otic preparations
otic steroids
otic steroids with anti-infectives
oxazolidinedione anticonvulsants
parathyroid hormone and analogs
penicillinase resistant penicillins
penicillins peripheral opioid receptor antagonists peripheral vasodilators
peripherally acting antiobesity agents phenothiazine antiemetics
phenothiazine antipsychotics phenylpiperazine antidepressants plasma expanders
platelet aggregation inhibitors platelet-stimulating agents
polyenes
potassium-sparing diuretics probiotics
progesterone receptor modulators progestins
prolactin inhibitors
prostaglandin D2 antagonists protease inhibitors
proton pump inhibitors
psoralens
psychotherapeutic agents
psychotherapeutic combinations purine nucleosides
pyrrolidine anticonvulsants
quinolones
radiocontrast agents
radiologic adjuncts
radiologic agents
radiologic conjugating agents radiopharmaceuticals
RANK ligand inhibitors recombinant human erythropoietins renin inhibitors
respiratory agents
respiratory inhalant products
rifamycin derivatives
salicylates
sclerosing agents
second generation cephalosporins selective estrogen receptor modulators selective serotonin reuptake inhibitors serotonin-norepinephrine reuptake inhibitors serotoninergic neuroenteric modulators sex hormone combinations
sex hormones
skeletal muscle relaxant combinations skeletal muscle relaxants
smoking cessation agents
somatostatin and somatostatin analogs spermicides
statins
sterile irrigating solutions
streptomyces derivatives
succinimide anticonvulsants
sulfonamides
sulfonylureas
synthetic ovulation stimulants
tetracyclic antidepressants
tetracyclines
therapeutic radiopharmaceuticals
thiazide diuretics thiazolidinediones
thioxanthenes
third generation cephalosporins thrombin inhibitors
thrombolytics
thyroid drugs
tocolytic agents
topical acne agents
topical agents
topical anesthetics
topical anti-infectives
topical antibiotics
topical antifungals
topical antihistamines
topical antipsoriatics
topical antivirals
topical astringents
topical debriding agents
topical depigmenting agents topical emollients
topical keratolytics
topical steroids
topical steroids with anti-infectives toxoids
triazine anticonvulsants
tricyclic antidepressants
trifunctional monoclonal antibodies tumor necrosis factor (TNF) inhibitors tyrosine kinase inhibitors
ultrasound contrast media upper respiratory combinations urea anticonvulsants
urinary anti-infectives
urinary antispasmodics
urinary pH modifiers
uterotonic agents
vaccine
vaccine combinations
vaginal anti-infectives
vaginal preparations
vasodilators
vasopressin antagonists
vasopressors
VEGF/VEGFR inhibitors
viral vaccines
viscosupplementation agents vitamin and mineral combinations vitamins
Diagnostic Tests
17-Hydroxyprogesterone
ACE (Angiotensin I converting enzyme)
Acetaminophen
Acid phosphatase
ACTH
Activated clotting time
Activated protein C resistance
Adrenocorticotropic hormone (ACTH) Alanine aminotransferase (ALT) Albumin Aldolase
Aldosterone
Alkaline phosphatase
Alkaline phosphatase (ALP)
Alphal -antitrypsin
Alpha-fetoprotein
Alpha-fetoprotien
Ammonia levels
Amylase
ANA (antinuclear antbodies)
ANA (antinuclear antibodies)
Angiotensin-converting enzyme (ACE) Anion gap
Anticardiolipin antibody
Anticardiolipin antivbodies (ACA)
Anti-centromere antibody
Antidiuretic hormone
Anti-DNA
Anti-Dnase-B
Anti-Gliadin antibody
Anti-glomerular basement membrane antibody Anti-HBc (Hepatitis B core antibodies
Anti-HBs (Hepatitis B surface antibody Antiphospholipid antibody
Anti-RNA polymerase
Anti-Smith (Sm) antibodies
Anti-Smooth Muscle antibody
Antistreptolysin O (ASO)
Antithrombin III
Anti-Xa activity Anti-Xa assay
Apolipoproteins
Arsenic
Aspartate aminotransferase (AST) B12
Basophil
Beta-2-Microglobulin
Beta-hydroxybutyrate
B-HCG
Bilirubin
Bilirubin, direct
Bilirubin, indirect
Bilirubin, total
Bleeding time
Blood gases (arterial)
Blood urea nitrogen (BUN)
BUN
BUN (blood urea nitrogen)
CA 125
CA 15-3
CA 19-9
Calcitonin
Calcium
Calcium (ionized)
Carbon monoxide (CO)
Carcinoembryonic antigen (CEA)
CBC
CEA
CEA (carcinoembryonic antigen) Ceruloplasmin CH50Chloride
Cholesterol
Cholesterol, HDL
Clot lysis time
Clot retraction time
CMP
C02
Cold agglutinins
Complement C3
Copper
Corticotrophin releasing hormone (CRH) stimulation test Cortisol
Cortrosyn stimulation test
C-peptide
CPK (Total)
CPK-MB
C-reactive protein
Creatinine
Creatinine kinase (CK)
Cryoglobulins
DAT (Direct antiglobulin test)
D-Dimer
Dexamethasone suppression test
DHEA-S
Dilute Russell viper venom
Elliptocytes
Eosinophil
Erythrocyte sedimentation rate (ESR)
Estradiol
Estriol Ethanol
Ethylene glycol
Euglobulin lysis
Factor V Leiden
Factor VIII inhibitor
Factor VIII level
Ferritin
Fibrin split products
Fibrinogen
Folate
Folate (serum
Fractional excretion of sodium (FENA) FSH (follicle stimulating factor) FTA-ABS
Gamma glutamyl transferase (GGT) Gastrin
GGTP (Gamma glutamyl transferase) Glucose
Growth hormone
Haptoglobin
HBeAg (Hepatitis Be antigen)
HBs-Ag (Hepatitis B surface antigen)
Helicobacter pylori
Hematocrit
Hematocrit (HCT)
Hemoglobin
Hemoglobin A1 C
Hemoglobin electrophoresis
Hepatitis A antibodies
Hepatitis C antibodies IAT (Indirect antiglobulin test)
Immunofixation (IFE)
Iron
Lactate dehydrogenase (LDH)
Lactic acid (lactate)
LDH
LH (Leutinizing hormone
Lipase
Lupus anticoagulant
Lymphocyte
Magnesium
MCH (mean corpuscular hemoglobin
MCHC (mean corpuscular hemoglobin concentration)
MCV (mean corpuscular volume)
Methylmalonate
Monocyte
MPV (mean platelet volume)
Myoglobin
Neutrophil
Parathyroid hormone (PTH)
Phosphorus
Platelets (pit)
Potassium
Prealbumin
Prolactin
Prostate specific antigen (PSA)
Protein C
Protein S
PSA (prostate specific antigen)
PT (Prothrombin time) PTT (Partial thromboplastin time)
RDW (red cell distribution width)
Renin
Rennin
Reticulocyte count
reticulocytes
Rheumatoid factor (RF)
Sed Rate
Serum glutamic-pyruvic transaminase (SGPT
Serum protein electrophoresis (SPEP)
Sodium
T3-resin uptake (T3RU)
T4, Free
Thrombin time
Thyroid stimulating hormone (TSH)
Thyroxine (T4
Total iron binding capacity (TIBC)
Total protein
Transferrin
Transferrin saturation
Triglyceride (TG)
Troponin
Uric acid
Vitamin B12
White blood cells (WBC)
Widal test
[101 ] As several examples, the fluid composition 218 can be an inhalation anesthetic, a drug, or a diagnostic test material. Any of these fluid compositions 218 can be an injectable material, a volatile material capable of being inhaled, or otherwise capable of being introduced into a subject.
[102] In the embodiment of FIG. 7 in particular, the pharmaceutical package 210 is a syringe. The syringe can comprise a syringe barrel 250 and a plunger 258. The wall 214 can define at least a portion of the syringe barrel 250. The plunger 258 can be a relatively sliding part of the syringe, with respect to the syringe barrel 250. The term "syringe," however, is broadly defined to include cartridges, injection "pens," and other types of barrels or reservoirs adapted to be assembled with one or more other components to provide a functional syringe. "Syringe" is also broadly defined to include related articles such as auto-injectors, which provide a mechanism for dispensing the contents.
[103] Another aspect of the invention illustrated by Figures 24-26 is an article such as any of the pharmaceutical packages or other vessels 210 including a wall 214, a fluid composition 218, a barrier coating or layer 288, and a protective coating 286.
[104] The wall 214 has an inner or interior surface 254.
[105] The fluid composition 218 is contained in the lumen 212 and has a pH between 5 and 9.
[106] The barrier coating or layer 288 is made at least in part of SiOx, wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick. The barrier coating or layer 288 of SiOx has an interior surface 220 facing the lumen 212 and an outer surface 222 facing the wall inner or interior surface 254. The barrier coating or layer 288 is effective to reduce the ingress of atmospheric gas into the lumen 212, compared to an uncoated container otherwise the same as the pharmaceutical package or other vessel 210.
[107] The protective coating 286 is made at least in part of a saccharide. The protective coating 286 has an interior surface 224 facing the lumen 212 and an outer surface 226 facing the interior surface 254 of the barrier coating or layer 288. Other specific examples of precursors within this broad definition are provided elsewhere in this specification.
[108] The rate of erosion, dissolution, or leaching (different names for related concepts) of the protective coating 286, if directly contacted by the fluid composition 218, is less than the rate of erosion of the barrier coating or layer 288, if directly contacted by the fluid composition 218.
[109] The protective coating 286 is effective to isolate the fluid composition 218 from the barrier coating or layer 288, at least for sufficient time to allow the barrier coating to act as a barrier during the shelf life of the pharmaceutical package or other vessel 210.
[1 10] Still another aspect of the invention, again illustrated by Figs. 7 to 9, is a pharmaceutical package or other vessel 210 including a thermoplastic wall 214 having an inner or interior surface 220 enclosing a lumen 212. A fluid composition 218 contained in the lumen 212 has a pH greater than 5.
[1 1 1 ] A barrier coating or layer 286 of SiOx, in which x is between 1 .5 and 2.9, is applied by plasma enhanced chemical vapor deposition (PECVD) directly or indirectly to the thermoplastic wall 214 so that in the filled pharmaceutical package or other vessel 210 the barrier coating or layer 286 is located between the inner or interior surface 220 of the thermoplastic wall 214 and the fluid composition 218. The barrier coating or layer 286 of SiOx is supported by the thermoplastic wall 214. The barrier coating or layer 286 has the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid composition 218. The barrier coating or layer 286 as described elsewhere in this specification, or in U.S. Patent No. 7,985,188, can be used in any embodiment.
[1 12] The barrier improvement factor (BIF) of the barrier layer can be determined by providing two groups of identical containers, adding a barrier layer to one group of containers, testing a barrier property (such as the rate of outgassing in micrograms per minute or another suitable measure) on containers having a barrier, doing the same test on containers lacking a barrier, and taking a ratio of the properties of the materials with versus without a barrier. For example, if the rate of outgassing through the barrier is one-third the rate of outgassing without a barrier, the barrier has a BIF of 3.
[1 13] A protective coating 286 of a saccharide is applied by directly or indirectly to the barrier coating or layer 288 so it is located between the barrier coating or layer 288 and the fluid composition 218 in the finished article. The protective coating 286 is supported by the thermoplastic wall 214. The protective coating 286 is effective to keep the barrier coating or layer 288 at least substantially undissolved as a result of attack by the fluid composition 218 for a period of at least six months.
[1 14] Any embodiment of Figures 24-26 can further optionally include a lubricity layer 287. The lubricity layer 287 can be applied between the protective coating and the lumen. Lubricity layers 287 as described in U.S. Patent No. 7,985,188 can be used in any embodiment.
[1 15] Any embodiment of Figures 24-26 can further optionally include a further coating applied adjacent to the inner surface of the protective coating, the further coating having an outer surface facing the interior surface of the thermoplastic wall and an inner surface facing the lumen.
[1 16] Optionally, any embodiment of Figures 24-26 can further include a fluid composition 218 in contact with the protective coating
[1 17] The protective and lubricity layers 286 and 287 of any embodiment of Figures 24-26 can be either separate layers with a sharp transition or a single, graduated layer that transitions between the protective coating 286 and the lubricity layer 287, without a sharp interface between them.
[1 18] Optionally, in any embodiment of Figures 24-26 the silicon dissolution rate by a 50 mM potassium phosphate buffer diluted in water for injection, adjusted to pH 8 with concentrated nitric acid, and containing 0.2 wt. % polysorbate-80 surfactant, (measured in the absence of the medicament, to avoid changing the dissolution reagent), at 40 °C, is less than 170 ppb/day. (Polysorbate-80 is a common ingredient of pharmaceutical preparations, available for example as Tween®-80 from Uniqema Americas LLC, Wilmington Delaware.) As will be seen from the working examples, the silicon dissolution rate is measured by determining the total silicon leached from the vessel into its contents, and does not distinguish between the silicon derived from the protective coating 286, the lubricity layer 287, the barrier coating or layer 288, or other materials present.
[1 19] Optionally, in any embodiment of Figures 24-26 the silicon dissolution rate is less than 160 ppb/day, or less than 140 ppb/day, or less than 120 ppb/day, or less than 100 ppb/day, or less than 90 ppb/day, or less than 80 ppb/day. Optionally, in any embodiment of Figures 24-26 the silicon dissolution rate is more than 10 ppb/day, or more than 20 ppb/day, or more than 30 ppb/day, or more than 40 ppb/day, or more than 50 ppb/day, or more than 60 ppb/day. Any minimum rate stated here can be combined with any maximum rate stated here, as an alternative embodiment of the invention of FIGS. 7 TO 9.
[120] Optionally, in any embodiment of Figures 24-26 the total silicon content of the protective coating and barrier coating, upon dissolution into a test composition with a pH of 8 from the vessel, is less than 66 ppm, or less than 60 ppm, or less than 50 ppm, or less than 40 ppm, or less than 30 ppm, or less than 20 ppm.
[121 ] Optionally, in any embodiment of Figures 24-26 the calculated shelf life of the package (total Si / Si dissolution rate) is more than six months, or more than 1 year, or more than 18 months, or more than 2 years, or more than 2½ years, or more than 3 years, or more than 4 years, or more than 5 years, or more than 10 years, or more than 20 years. Optionally, in any embodiment of Figures 24-26 the calculated shelf life of the package (total Si / Si dissolution rate) is less than 60 years.
[122] Any minimum time stated here can be combined with any maximum time stated here, as an alternative embodiment of the invention of FIGS. 7 TO 9.
[123] Optionally, in any embodiment of Figures 24-26, the thermoplastic wall is a syringe barrel. A plunger is positioned for sliding in the barrel and a lubricity coating or layer is present on at least a portion of the plunger.
[124] Optionally, in any embodiment of Figures 24-26, the lubricity coating or layer is configured to provide a lower piston sliding force or breakout force than the uncoated substrate.
[125] Optionally, in any embodiment of Figures 24-26, the lubricity layer has one of the atomic ratios previously defined for the lubricity and/or protective coating, measured by X-ray photoelectron spectroscopy (XPS). The lubricity layer has a thickness by transmission electron microscopy (TEM) between 10 and 500 nm; the lubricity layer deposited by plasma enhanced chemical vapor deposition (PECVD) under conditions effective to form a coating from a precursor selected from a linear siloxane, a monocyclic siloxane, a polycyclic siloxane, a polysilsesquioxane, a linear silazane, a monocyclic silazane, a polycyclic silazane, a polysilsesquiazane, a silatrane, a silquasilatrane, a silproatrane, an azasilatrane, an azasilquasiatrane, an azasilproatrane, or a combination of any two or more of these precursors.
[126] Even another aspect of the invention, exemplified in FIGS. 7 TO 9, is a composite material including a substrate such as a wall 214, a barrier coating or layer 288 disposed on the substrate or wall 214, and a passivation layer or protective coating 286 on the barrier layer or coating 288. Several examples of articles made from such a composite material are a syringe barrel, a vial, and a medical device of any kind. The saccharide passivation layer or protective coating 286 is deposited as explained below.
PECVD APPARATUS AND METHODS FOR PROTECTIVE COATING
[127] Suitable methods and apparatus for applying a barrier or lubricity coating or layer such as 90 to a substrate such as the vessel 80 (FIG. 1 ) or a vial are described, for example, in U.S. Patent No. 7,985,188 or the EP applications cited in paragraph [002], under conditions effective to form a coating or layer.
[128] Another embodiment is a vessel such as the vessel 80 (FIG. 1 ) including a lumen defined by a surface defining a substrate. A protective coating or layer is present on at least a portion of the substrate, typically deposited over an SiOx barrier layer to protect the barrier layer from dissolution. The protective coating or layer is made by the previously defined process.
[129] Still another embodiment is a chemical vapor deposition apparatus such as the apparatus 28 illustrated in FIG. 5 (or any other illustrated coating apparatus, such as the apparatus illustrated in FIGS. 1 -4).
[130] Referring now to FIG. 5, suitable chemical vapor deposition apparatus is shown.
[131 ] Referring to FIG. 7, yet another embodiment is a syringe such as 252 comprising a plunger 258, a barrel 250, and a protective coating or layer on the inner or interior surface 264. The barrel 250 is a vessel and has an inner or interior surface 264 defining the vessel lumen 274 and receiving the plunger 258 for sliding. The vessel inner or interior surface 264 is a substrate. A protective coating or layer can be applied on the substrate 264, the plunger 258, or both, by chemical vapor deposition. In addition to this protective coating or layer, the syringe may contain one or more other coatings or layers, for example an SiOx barrier coating or layer. Said additional coating(s) or layer(s) may be located under the lubricity and/or barrier coating or layer, i.e. nearer to the barrel of the syringe.
[132] For any embodiment of a syringe such as 252, in particular a syringe that is stored or intended to be stored for an extended time while prefilled, the plunger 258 optionally is provided with a lubricity layer, at least on its surface in contact with the barrel interior surface 264, and the barrel interior surface 264 is provided with an SiOx barrier layer protected by a protective coating or layer wherever it is in contact or likely to be in contact with a fluid pharmaceutical composition contained in the syringe. An advantage of this construction is that the protective coating or layer, which is in contact with the fluid pharmaceutical composition when the syringe is stored prefilled, can be optimized for protection of the SiOx barrier layer, while the lubricity layer, which is located where the plunger typically contacts the inner surface 264 at a fixed location during storage, can be optimized for lubricity. The lubricity coating or layer on the plunger is in the right position to prevent "sticktion" during storage and to continue to lower the friction between the plunger and barrel when the plunger is advanced, and if applied by CVD is contemplated to be less subject to displacement by the force exerted by the plunger on the barrel than traditional silicon oil coatings or layers and more uniformly applied as a uniform coating rather than as isolated droplets of liquid. As a further option, an adhesion layer or coating of SiOxCy can be applied to the substrate and the barrier layer can be applied to the adhesion layer to improve adhesion of the SiOx barrier layer or coating to the substrate.
[133] A concern of converting from glass to plastic syringes centers around the potential for leachable materials from plastics. With plasma coating technology, the coatings or layers derived from non-metal gaseous precursors, for example HMDSO or OMCTS or other organosilicon compounds, will itself contain no trace metals and function as a barrier to inorganic, metals and organic solutes, preventing leaching of these species from the coated substrate into syringe fluids. In addition to leaching control of plastic syringes, the same plasma protective coating or layer technology offers potential to provide a solute barrier to the plunger tip, typically made of elastomeric plastic compositions containing even higher levels of leachable organic oligomers and catalysts.
[134] Moreover, certain syringes prefilled with synthetic and biological pharmaceutical formulations are very oxygen and moisture sensitive. A critical factor in the conversion from glass to plastic syringe barrels will be the improvement of plastic oxygen and moisture barrier performance. The plasma protective coating or layer technology is suitable to maintain the SiOx barrier coating or layer for protection against oxygen and moisture over an extended shelf life.
[135] Even another embodiment is a plunger 258 for a syringe 252, comprising a piston or tip, a protective coating or layer, and a push rod. The piston or tip has a front face, a generally cylindrical side face that slides within the barrel 250, comprising a substrate, and a back portion. The side face is configured to movably seat within a syringe barrel. The protective coating or layer is on the substrate and is a lubricity and/or protective coating interfacing with the side face. The lubricity and/or protective coating is produced from a chemical vapor deposition (CVD) process employing the previously defined precursor feed or process gas. The push rod engages the back portion of the piston and is configured for advancing the piston in a syringe barrel.
[136] Even another embodiment is a medical or diagnostic kit including a vessel having a coating or layer as defined in any embodiment herein on a substrate as defined in any embodiment above. Optionally, the kit additionally includes a medicament or diagnostic agent which is contained in the vessel with a protective coating in contact with the coating or layer; and/or a hypodermic needle, double-ended needle, or other delivery conduit; and/or an instruction sheet.
[137] Other aspects of the invention include any one or more of the following:
[138] Use of the protective coating or layer according to any embodiment described above for treating a surface and thereby preventing or reducing mechanical and/or chemical effects of the surface on a compound or composition in contact with the protective coating or layer;
[139] Use of the coating or layer according to any described embodiment as a lubricity and/or protective coating;
[140] Use of the coating or layer according to any described embodiment for protecting a compound or composition contacting the protective coating or layer against mechanical and/or chemical effects of the surface of the vessel material without a protective coating;
[141 ] Use of the coating or layer according to any described embodiment for preventing or reducing precipitation and/or clotting or platelet activation of a compound or a component of the composition in contact with the coating or layer.
[142] As one option, the compound or a component of the composition is insulin, and precipitation of the insulin is prevented or reduced. As another option, the compound or a component of the composition is blood or a blood fraction, and blood clotting or platelet activation is prevented or reduced. As still another option, the vessel with a protective coating is a blood collection tube. Optionally, the blood collection tube can contain an agent for preventing blood clotting or platelet activation, for example ethylenediamineteetraacetic acid (EDTA), a sodium salt thereof, or heparin.
[143] Additional options for use of the invention include any one or more of the following:
[144] Use of a coated substrate according to any described embodiment, for example a vessel such as a sample collection tube, for example a blood collection tube and/or a closed-ended sample collection tube; a vial; a conduit; a cuvette; or a vessel part, for example a stopper; or a syringe, or a syringe part, for example a barrel or piston for reception and/or storage and/or delivery of a compound or composition.
[145] The use of a coated substrate according to any described embodiment is contemplated for storing insulin.
[146] The use of a coated substrate according to any described embodiment is contemplated for storing blood. Optionally, the stored blood is viable for return to the vascular system of a patient. [147] Use of a coating or layer according to any described embodiment is contemplated as (i) a lubricity coating having a lower frictional resistance than the uncoated surface; and/or (ii) a protective coating preventing dissolution of the barrier coating in contact with a fluid, and/or (iii) a hydrophobic layer that is more hydrophobic than the uncoated surface.
[148] Other aspects of the invention include any of the uses defined above in the summary section.
DETAILED DESCRIPTION
[149] The following is a more detailed description of the invention. It starts with a general description of the present invention, then describes the equipment suitable to prepare the protective coating or layer of the present invention and subsequently describes the protective coating or layer embodiments, the coated pharmaceutical packages or other vessels, and the methods for their production.
Substrate
[150] The substrate of the protective coating or layer in any embodiment is typically a vessel having a surface made of plastic (for example the inner or interior surface of a plastic syringe or vial). Typical plastic substrates are listed elsewhere in the present description and in referenced patents. Particularly suitable substrates in the context of the present invention are COC (cyclic olefin copolymer), COP (cyclic olefin polymer), PET (polyethylene terephthalate), and polypropylene, with COC being specifically suitable.
Barrier Layer
[151 ] The barrier coating or layer for any embodiment defined in this specification (unless otherwise specified in a particular instance) is a coating or layer, optionally applied by PECVD as indicated in U.S. Pat. No. 7,985,188. The barrier layer optionally is characterized as an "SiOx" coating, and contains silicon, oxygen, and optionally other elements, in which x, the ratio of oxygen to silicon atoms, is from about 1 .5 to about 2.9, or 1 .5 to about 2.6, or about 2. These alternative definitions of x apply to any use of the term SiOx in this specification. The barrier coating or layer is applied, for example to the interior of a pharmaceutical package or other vessel, for example a sample collection tube, a syringe barrel, a vial, or another type of vessel.
Protective Layer
[152] The protective layer is applied over at least a portion of the SiOx layer to protect the SiOx layer from contents stored in a vessel, where the contents otherwise would be in contact with the SiOx layer.
Precursors for Protective Coating or Layer
[153] The present lubricating or protective coating or layer is a saccharide coupled to the SiOx barrier layer by a substituted silane coupling agent.
[154] The silane coupling agent can be, for example, trimethoxysilylpropyl isocyanate. The silane functional group interacts with an SiOx barrier layer. The isocyanate functional group reacts with a hydroxyl group of the saccharide to provide a urethane linkage. The coupling agent thus functions to anchor the saccharide, which provides a lubricated surface in an aqueous environment, in this case the contents of the container, to the barrier layer to prevent the saccharide from dispersing in the aqueous environment.
[155] The silane coupling agent can instead be, for example, 3- Aminopropyltriethoxysilane (APTES). The silane functional group interacts with an SiOx barrier layer. The amino functional group reacts with N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS) in the presence of haluronic acid (HA). EDC/NHS can chemically graft HA onto APTES.
[156] The coupling agent thus functions to anchor the saccharide, which provides a lubricated surface in an aqueous environment, in this case the contents of the container, to the barrier layer to prevent the saccharide from dispersing in the aqueous environment.
[157] The saccharide precursor for use to provide a protective coating or layer is contemplated to be a water soluble or dispersible saccharide, dispersed or dissolved in water. The precursor may be present as from about 0.05% to about 15% by weight, or from about 0.2 to about 10% by weight, or from about 0.5% to about 6% by weight, or from about 1 .5% to about 3% by weight, of the composition.
[158] The saccharide can be selected from the group consisting of mono- and polysaccharides (or, more broadly, carbohydrates) and their derivatives. Saccharide (which for the present purpose includes disaccharide and higher saccharide) materials contemplated for use herein include any sugar, for example sorbitan, corn starch, other starches, and saccharide gums. Saccharide gums contemplated for use herein include agar, Arabic, xanthan (for example, KELZAN industrial grade xanthan gum, available from the Kelco Div. of Merck & Co, Inc. of Rahway, N.J.), pectin, alginate, tragacanath, dextran, and other gums. Derivative saccharides contemplated for use herein include cellulose acetates, cellulose nitrates, methylcellulose, and carboxymethylcellulose. Hemi-cellulose saccharides contemplated for use herein include d-gluco-d-mannans, d- galacto-d-gluco-d-mannans, and others. Haluronic acid is also specifically contemplated, as is sorbitan.
[159] Also contemplated herein as saccharides are alkylcelluloses or carboxyalkylcelluloses, their low- and medium-viscosity alkali metal salts (e.g. sodium carboxymethylcellulose, or "CMC"), cellulose ethers, and nitrocellulose. Examples of such saccharides include KLUCEL hydroxypropylcellulose; AQUALON CMC 7L sodium carboxymethylcellulose, and NATROSOL hydroxyethylcellulose. These are all commercially available from Aqualon Company of Hopewell, Va. Saccharides contemplated herein further include ethylcellulose, available from Hercules of Wilmington, Del. ; METHOCEL cellulose ethers, available from Dow Chemical Co., Midland, Mich. ; and nitrocellulose, which is also available from Hercules. Method of Applying a Lubricity Coating or Layer
[160] A method of applying a lubricity coating or layer derived from an organosilicon precursor, and the resulting protective coating or layer and coated item are described for example in U.S. Pat. No. 7,985,188. A "lubricity coating" or any similar term is generally defined as a coating or layer that reduces the frictional resistance of the coated surface, relative to the uncoated surface, which can include a coating which is a saccharide or a coating as described in U.S. Pat. No. 7,985,188. If the coated object is a syringe (or syringe part, for example syringe barrel) or any other item generally containing a plunger or movable part in sliding contact with the coated surface, the frictional resistance has two main aspects - breakout force and plunger sliding force.
[161 ] It should be understood that a coating optionally can be both a lubricity coating or layer and a protective coating or layer, respectively as explained in this description.
Barrier Coating or Layer
[162] Any barrier coating or layer described in U.S. Patent No. 7,985,188 is contemplated for use in any embodiment of the present invention.
Measurement of Coating Thickness
[163] The thickness of a coating or layer such as the protective coating or layer, the barrier coating or layer, the lubricity coating or layer, and/or a composite of any two or more of these layers can be measured, for example, by transmission electron microscopy (TEM). An exemplary TEM image for an Si02 barrier coating or layer is shown in Fig. 6.
[164] The TEM can be carried out, for example, as follows. Samples can be prepared for Focused Ion Beam (FIB) cross-sectioning in two ways. Either the samples can be first coated with a thin layer of carbon (50-1 OOnm thick) and then coated with a sputtered coating or layer of platinum (50-1 OOnm thick) using a K575X Emitech protective coating or layer system, or the samples can be coated directly with the protective sputtered Pt layer. The coated samples can be placed in an FEI FIB200 FIB system. An additional coating or layer of platinum can be FIB-deposited by injection of an organometallic gas while rastering the 30kV gallium ion beam over the area of interest. The area of interest for each sample can be chosen to be a location half way down the length of the syringe barrel. Thin cross sections measuring approximately 15 m ("micrometers") long, 2 m wide and 15 m deep can be extracted from the die surface using an in-situ FIB lift-out technique. The cross sections can be attached to a 200 mesh copper TEM grid using FIB-deposited platinum. One or two windows in each section, measuring about δμηι wide, can be thinned to electron transparency using the gallium ion beam of the FEI FIB.
[165] Cross-sectional image analysis of the prepared samples can be performed utilizing either a Transmission Electron Microscope (TEM), or a Scanning Transmission Electron Microscope (STEM), or both. All imaging data can be recorded digitally. For STEM imaging, the grid with the thinned foils can be transferred to a Hitachi HD2300 dedicated STEM. Scanning transmitted electron images can be acquired at appropriate magnifications in atomic number contrast mode (ZC) and transmitted electron mode (TE). The following instrument settings can be used.
Instrument Scanning Transmission Electron Microscope
Manufacturer/Model Hitachi HD2300
Accelerating Voltage 200kV
Objective Aperture #2
Condenser Lens 1 Setting 1 .672
Condenser Lens 2 Setting 1 .747
Approximate Objective Lens Setting 5.86
ZC Mode Projector Lens 1 .149
TE Mode Projector Lens 0.7 Instrument Scanning Transmission Electron Microscope
Image Acquisition
Pixel Resolution 1280x960
Acquisition Time 20sec.(x4
[166] For TEM analysis the sample grids can be transferred to a Hitachi HF2000 transmission electron microscope. Transmitted electron images can be acquired at appropriate magnifications. The relevant instrument settings used during image acquisition can be those given below.
Instrument Transmission Electron Microscope
Manufacturer/Model Hitachi HF2000
Accelerating Voltage 200 kV
Condenser Lens 1 0.78
Condenser Lens 2 0
Objective Lens 6.34
Condenser Lens Aperture #1
Objective Lens Aperture for #3
imaging
Selective Area Aperture for N/A
SAD
Liquid-applied protective coating or layer
[167] Another example of a suitable barrier or other type of protective coating or layer, usable in conjunction with the PECVD-applied protective coating or layer or other PECVD treatment as disclosed here, can be a liquid barrier, lubricant, surface energy tailoring, or protective coating or layer 90 applied to the inner or interior surface of a pharmaceutical package or other vessel, either directly or with one or more intervening PECVD-applied coatings or layers described in this specification, for example SiOx, a lubricity coating or layer and/or a protective coating or layer, or both.
[168] A suitable liquid barrier, lubricity, or protective coating or layer 90 also optionally can be applied, for example, by applying a liquid monomer or other polymerizable or curable material to the inner or interior surface of the vessel 80 and curing, polymerizing, or crosslinking the liquid monomer to form a solid polymer, or by applying a solvent-dispersed polymer to the surface 88 and removing the solvent.
[169] Any of the above methods can include as a step forming a protective coating or layer 90 on the interior 88 of a vessel 80 via the vessel port 92 at a processing station or device 28. One example is applying a liquid protective coating or layer, for example of a curable monomer, prepolymer, or polymer dispersion, to the inner or interior surface 88 of a vessel 80 and curing it to form a film that physically isolates the contents of the vessel 80 from its inner or interior surface 88. The prior art describes polymer protective coating or layer technology as suitable for treating plastic blood collection tubes. For example, the acrylic and polyvinylidene chloride (PVdC) protective coating materials and methods described in US Patent 6,165,566, which is hereby incorporated by reference, optionally can be used.
[170] Any of the above methods can also include as a step forming a coating or layer on the exterior outer wall of a vessel 80. The exterior coating or layer optionally can be a barrier coating or layer, optionally an oxygen barrier coating or layer, or optionally a water barrier coating or layer. The exterior coating or layer can also be an armor layer that protects the outer wall of a vessel 80. One example of a suitable exterior coating or layer is polyvinylidene chloride, which functions both as a water barrier and an oxygen barrier. Optionally, the exterior coating or layer can be applied as a water-based coating or layer. The exterior coating or layer optionally can be applied by dipping the vessel in it, spraying it on the pharmaceutical package or other vessel, or other expedients. PECVD TREATED PHARMACEUTICAL PACKAGES OR OTHER VESSELS Coated Pharmaceutical Packages or Other Vessels
[171 ] Pharmaceutical packages or other vessels, such as a prefilled syringe (schematically shown in FIG. 7) or a vial (schematically shown in FIGS. #8 and 9) are contemplated having a barrier coating or layer such as 288 at least partially covered by a protective coating or layer such as 286.
[172] The pharmaceutical package 210 as shown in any embodiment, for example FIGS. 7 TO 9, comprises a vessel or vessel part such as 250; optionally a barrier coating or layer such as 288 on the vessel or vessel part; a protective coating or layer such as 286 on the vessel, vessel part, or barrier coating or layer; and a pharmaceutical composition or preparation such as 218 contained within the vessel.
[173] The barrier coating or layer such as 288 can be an SiOx barrier coating or layer applied as described in any embodiment of this specification or in U.S. Patent No. 7,985,188. For example, the barrier coating or layer such as 288 of any embodiment can be applied at a thickness of at least 2 nm, or at least 4 nm, or at least 7 nm, or at least 10 nm, or at least 20 nm, or at least 30 nm, or at least 40 nm, or at least 50 nm, or at least 100 nm, or at least 150 nm, or at least 200 nm, or at least 300 nm, or at least 400 nm, or at least 500 nm, or at least 600 nm, or at least 700 nm, or at least 800 nm, or at least 900 nm. The barrier coating or layer can be up to 1000 nm, or at most 900 nm, or at most 800 nm, or at most 700 nm, or at most 600 nm, or at most 500 nm, or at most 400 nm, or at most 300 nm, or at most 200 nm, or at most 100 nm, or at most 90 nm, or at most 80 nm, or at most 70 nm, or at most 60 nm, or at most 50 nm, or at most 40 nm, or at most 30 nm, or at most 20 nm, or at most 10 nm, or at most 5 nm thick. Specific thickness ranges composed of any one of the minimum thicknesses expressed above, plus any equal or greater one of the maximum thicknesses expressed above, are expressly contemplated. The thickness of the SiOx or other barrier coating or layer can be measured, for example, by transmission electron microscopy (TEM), and its composition can be measured by X-ray photoelectron spectroscopy (XPS). The protective coating or layer described herein can be applied to a variety of pharmaceutical packages or other vessels made from plastic or glass, for example to plastic tubes, vials, and syringes.
[174] The protective coating or layer such as 286 can be a saccharide protective coating or layer applied as described in any embodiment of this specification.
Vessel Made Of Glass
[175] Another embodiment is a pharmaceutical package 210 as shown in any embodiment, for example FIGS. 7 TO 9, comprising a vessel or vessel part such as 214 or 250 made of glass; optionally a barrier coating or layer such as 288 on the vessel or vessel part; a protective coating or layer such as 286 on the vessel, vessel part, or barrier coating or layer; and a pharmaceutical composition or preparation such as 218 contained within the vessel. In this embodiment the barrier coating or layer is optional because a glass vessel wall in itself is an extremely good barrier layer. It is contemplated to optionally provide a barrier layer primarily to provide isolation: in other words, to prevent contact and interchange of material of any kind, such as ions of the glass or constituents of the pharmaceutical composition or preparation between the vessel wall and the contents of the vessel. The protective layer as defined in this specification is contemplated to perform the isolation function independently, at least to a degree. This protection layer is contemplated to provide a useful function on glass in contact with the pharmaceutical composition or preparation, as the present working examples show that borosilicate glass, commonly used today for pharmaceutical packaging, is dissolved by a fluid composition having a pH exceeding 5. Particularly in applications where such dissolution is disadvantageous or perceived to be disadvantageous, the present protective coatings or layers will find utility.
[176] The vessel can be made, for example of glass of any type used in medical or laboratory applications, such as soda-lime glass, borosilicate glass, or other glass formulations. One function of a protective coating or layer on a glass vessel can be to reduce the ingress of ions in the glass, either intentionally or as impurities, for example sodium, calcium, or others, from the glass to the contents of the pharmaceutical package or other vessel, such as a reagent or blood in an evacuated blood collection tube. Alternatively, a dual functional protective / lubricity coating or layer can be used on a glass vessel in whole or in part, such as selectively at surfaces contacted in sliding relation to other parts, to provide lubricity, for example to ease the insertion or removal of a stopper or passage of a sliding element such as a piston in a syringe, as well as to provide the isolation of a protective coating or layer. Still another reason to coat a glass vessel, for example with a dual functional hydrophobic and protective coating or layer, is to prevent a reagent or intended sample for the pharmaceutical package or other vessel, such as blood, from sticking to the wall of the vessel or an increase in the rate of coagulation of the blood in contact with the wall of the vessel, as well as to provide the isolation of a protective coating or layer.
[177] A related embodiment is a vessel as described in the previous paragraphs, in which the barrier coating or layer is made of soda lime glass, borosilicate glass, or another type of glass coating or layer on a substrate.
Vessels Generally
[178] A vessel with a protective coating as described herein and/or prepared according to a method described herein can be used for reception and/or storage and/or delivery of a compound or composition. The compound or composition can be sensitive, for example air-sensitive, oxygen-sensitive, sensitive to humidity and/or sensitive to mechanical influences. It can be a biologically active compound or composition, for example a pharmaceutical preparation or medicament like insulin or a composition comprising insulin. In another aspect, it can be a biological fluid, optionally a bodily fluid, for example blood or a blood fraction. In certain aspects of the present invention, the compound or composition can be a product to be administrated to a subject in need thereof, for example a product to be injected, like blood (as in transfusion of blood from a donor to a recipient or reintroduction of blood from a patient back to the patient) or insulin.
[179] A vessel with a protective coating as described herein and/or prepared according to a method described herein can further be used for protecting a compound or composition contained in its interior space against mechanical and/or chemical effects of the surface of the vessel material. For example, it can be used for preventing or reducing precipitation and/or clotting or platelet activation of the compound or a component of the composition, for example insulin precipitation or blood clotting or platelet activation.
[180] It can further be used for protecting a compound or composition contained in its interior against the environment outside of the pharmaceutical package or other vessel, for example by preventing or reducing the entry of one or more compounds from the environment surrounding the vessel into the interior space of the vessel. Such environmental compound can be a gas or liquid, for example an atmospheric gas or liquid containing oxygen, air, and/or water vapor.
[181 ] A vessel with a protective coating as described herein can also be evacuated and stored in an evacuated state. For example, the protective coating or layer allows better maintenance of the vacuum in comparison to a corresponding vessel without a protective coating. In one aspect of this embodiment, the vessel with a protective coating is a blood collection tube. The tube can also contain an agent for preventing blood clotting or platelet activation, for example EDTA or heparin.
[182] Any of the above-described embodiments can be made, for example, by providing as the vessel a length of tubing from about 1 cm to about 200 cm, optionally from about 1 cm to about 150 cm, optionally from about 1 cm to about 120 cm, optionally from about 1 cm to about 100 cm, optionally from about 1 cm to about 80 cm, optionally from about 1 cm to about 60 cm, optionally from about 1 cm to about 40 cm, optionally from about 1 cm to about 30 cm long, and processing it with a probe electrode as described below. Particularly for the longer lengths in the above ranges, it is contemplated that relative motion between the probe and the vessel can be useful during protective coating or layer formation. This can be done, for example, by moving the vessel with respect to the probe or moving the probe with respect to the vessel.
[183] In these embodiments, it is contemplated that the barrier coating or layer can be thinner or less complete than would be preferred to provide the high gas barrier integrity needed in an evacuated blood collection tube. In these embodiments, it is contemplated that the protective coating or layer can be thinner or less complete than would be preferred to provide the long shelf life needed to store a liquid material in contact with the barrier layer for an extended period.
[184] As an optional feature of any of the foregoing embodiments the vessel has a central axis.
[185] As an optional feature of any of the foregoing embodiments the vessel wall is sufficiently flexible to be flexed at least once at 20 °C, without breaking the wall, over a range from at least substantially straight to a bending radius at the central axis of not more than 100 times as great as the outer diameter of the vessel.
[186] As an optional feature of any of the foregoing embodiments the bending radius at the central axis is not more than 90 times as great as, or not more than 80 times as great as, or not more than 70 times as great as, or not more than 60 times as great as, or not more than 50 times as great as, or not more than 40 times as great as, or not more than 30 times as great as, or not more than 20 times as great as, or not more than 10 times as great as, or not more than 9 times as great as, or not more than 8 times as great as, or not more than 7 times as great as, or not more than 6 times as great as, or not more than 5 times as great as, or not more than 4 times as great as, or not more than 3 times as great as, or not more than 2 times as great as, or not more than, the outer diameter of the vessel.
[187] As an optional feature of any of the foregoing embodiments the vessel wall can be a fluid-contacting surface made of flexible material.
[188] As an optional feature of any of the foregoing embodiments the vessel lumen can be the fluid flow passage of a pump.
[189] As an optional feature of any of the foregoing embodiments the vessel can be a blood bag adapted to maintain blood in good condition for medical use.
[190] As an optional feature of any of the foregoing embodiments the polymeric material can be a silicone elastomer or a thermoplastic polyurethane, as two examples, or any material suitable for contact with blood, or with insulin.
[191 ] In an optional embodiment, the vessel has an inner diameter of at least 2 mm, or at least 4 mm. [192] As an optional feature of any of the foregoing embodiments the vessel is a tube.
[193] As an optional feature of any of the foregoing embodiments the lumen has at least two open ends.
Vessel Containing Viable Blood, Having a Protective Coating or Layer Deposited from an Organosilicon Precursor
[194] Even another embodiment is a blood containing vessel. Several non-limiting examples of such a vessel are a blood transfusion bag, a blood sample collection vessel in which a sample has been collected, the tubing of a heart-lung machine, a flexible-walled blood collection bag, or tubing used to collect a patient's blood during surgery and reintroduce the blood into the patient's vasculature. If the vessel includes a pump for pumping blood, a particularly suitable pump is a centrifugal pump or a peristaltic pump. The vessel has a wall; the wall has an inner or interior surface defining a lumen. The inner or interior surface of the wall has an at least partial protective coating or layer of a protective layer, which optionally also presents a hydrophobic surface. The protective coating or layer can be as thin as monomolecular thickness or as thick as about 1000 nm. The vessel contains blood viable for return to the vascular system of a patient disposed within the lumen in contact with the hydrophobic layer.
[195] An embodiment is a blood containing vessel including a wall and having an inner or interior surface defining a lumen. The inner or interior surface has an at least partial protective coating or layer that optionally also presents a hydrophobic surface. The protective coating or layer can also comprise or consist essentially of SiOxCy where x and y are as defined in this specification. The thickness of the hydrophobic coating or layer is within the range from monomolecular thickness to about 1000 nm thick on the inner or interior surface. The vessel contains blood viable for return to the vascular system of a patient disposed within the lumen in contact with the hydrophobic coating or layer. Common Conditions for All Embodiments
[196] In any embodiment contemplated here, many common conditions can be used, for example any of the following, in any combination. Alternatively, any different conditions described elsewhere in this specification or claims can be employed.
I. COATING RECEIVER OF ANY EMBODIMENT
Vessel of any embodiment
[197] The vessel can be a sample collection tube, for example a blood collection tube, or a syringe, or a syringe part, for example a barrel or piston or plunger; a vial; a conduit; or a cuvette. The substrate can be a closed-ended tube, for example a medical sample collection tube. The substrate can be the inside wall of a vessel having a lumen, the lumen having a void volume of from 0.5 to 50 ml_, optionally from 1 to 10 ml_, optionally from 0.5 to 5 ml_, optionally from 1 to 3 ml_. The substrate surface can be part or all of the inner or interior surface of a vessel having at least one opening and an inner or interior surface, and wherein the gaseous reactant, also known in any embodiment as a precursor feed, fills the interior lumen of the vessel and the plasma can be generated in part or all of the interior lumen of the vessel.
Syringe and parts
[198] The substrate can be a syringe barrel. The syringe barrel can have a plunger sliding surface and the protective coating or layer can be disposed on at least a portion of the plunger sliding surface. The protective coating or layer can be a lubricity and/or protective coating. The lubricity and/or protective coating or layer can be on the barrel inner or interior surface. The lubricity and/or protective coating or layer can be on the plunger. In a particular aspect, the substrate is a staked needle syringe or part of a staked needle syringe. Vessel to receive stopper
[199] The substrate can be a stopper receiving surface in the mouth of a vessel. The substrate can be a generally conical or cylindrical inner or interior surface of an opening of a vessel adapted to receive a stopper.
Stopper
[200] The substrate can be a sliding surface of a stopper. The substrates can be coated by providing a multiplicity of the stoppers located in a single substantially evacuated vessel. The chemical vapor deposition can be plasma-enhanced chemical vapor deposition and the stopper can be contacted with the plasma. The chemical vapor deposition can be plasma-enhanced chemical vapor deposition. The plasma can be formed upstream of the stopper, producing plasma product, and the plasma product can be contacted with the stopper.
[201 ] A closure can define a substrate coated with a protective coating or layer, optionally a stopper coated with a lubricity and/or protective coating. The substrate can be a closure seated in a vessel defining a lumen and a surface of the closure facing the lumen can be coated with the protective coating or layer.
[202] The protective coating or layer can be effective to reduce the transmission of a metal ion constituent of the stopper into the lumen of the vessel.
Substrate of any embodiment
[203] The substrate can be a vessel wall. A portion of the vessel wall in contact with a wall-contacting surface of a closure can be coated with the protective coating or layer. The protective coating or layer can be a composite of material having first and second layers. The first coating or layer can interface with the elastomeric stopper. The first layer of the protective coating or layer can be effective to reduce the transmission of one or more constituents of the stopper into the vessel lumen. The second protective coating or layer can interface with the inner wall of the vessel. The second layer can be effective to reduce friction between the stopper and the inner wall of the vessel when the stopper is seated on the vessel.
[204] Alternatively, the first and second layers of any embodiment can be defined by a protective coating or layer of graduated properties containing carbon and hydrogen, in which the proportions of carbon and hydrogen are less in the first coating or layer (applied to the substrate) than in the second coating or layer (exposed to the contents of the vessel).
[205] The protective coating or layer of any embodiment can be applied by plasma enhanced chemical vapor deposition.
[206] The substrate of any embodiment can comprise glass, alternatively a polymer, alternatively a polycarbonate polymer, alternatively an olefin polymer, alternatively a cyclic olefin copolymer, alternatively a polypropylene polymer, alternatively a polyester polymer, alternatively a polyethylene terephthalate polymer, alternatively a polyethylene naphthalate polymer, alternatively a combination, composite or blend of any two or more of the above materials.
EXAMPLE Polysaccharide-grafted SiOx-Coated Plastic Syringe Barrel
[207] 3-Aminopropyltriethoxysilane (APTES) grafting. (Method 1 -Step 1 )
[208] To a freshly SiOx-plasma coated COP syringe 1 ml_ staked needle syringe barrel, under vacuum, APTES (Sigma-Aldrich) vapor is pumped through the syringe barrel and allowed to react with and be deposited on the SiOx surface for 2 h, ideally resulting in a monolayer. During the reaction, a low pressure is maintained to minimize the condensation of microscopic droplets of APTES on the surfaces. Following the deposition, covalent APTES grafting was done by annealing the surface in a vacuum oven for 30 min at 80 °C.
[209] Haluronic Acid (HA) Grafting (Method 1-Step 2)
[210] A 3 mg/mL HA (average MW = 1 .6 MDa, Sigma- Aldrich) solution is put into the APTES-grafted SiOx surface barrel interior for 3 h. The right amounts of N-(3- dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) and N- hydroxysulfosuccinimide (NHS) (Sigma-Aldrich) were added into the HA solution to bring the EDC and NHS concentrations to 1 M for each component (50/50 EDC/NHS mixture). EDC/NHS can chemically graft HA onto APTES as well as cross-link the grafted HA layer, forming a gel-like HA layer. The interior syringe barrel surface is then rinsed thoroughly using phosphate buffered saline (PBS) buffer and capped to prevent dessication of bound water to the grafted polysaccharide.
[21 1 ] Adapted from Jing Yu, Xavier Banquy, George W. Greene, Daniel D. Lowrey, and Jacob N. Israelachvili, The Boundary Lubrication of Chemically Grafted and Cross- Linked Hyaluronic Acid in Phosphate Buffered Saline and Lipid Solutions Measured by the Surface Forces Apparatus, Langmuir 2012, 28, 2244-2250, Department of Chemical Engineering and Materials Department, University of California, Santa Barbara, California 93106.
[212] While the invention has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive; the invention is not limited to the disclosed embodiments. Other variations to the disclosed embodiments can be understood and effected by those skilled in the art and practicing the claimed invention, from a study of the drawings, the disclosure, and the appended claims. In the claims, the word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.

Claims

1 . A filled package comprising:
• a vessel having a lumen defined at least in part by a wall, the wall having an interior surface facing the lumen and an outer surface;
• a barrier coating of SiOx, wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick, the barrier coating of SiOx having an interior surface facing the lumen and an outer surface facing the wall interior surface, the barrier coating being effective to reduce the ingress of atmospheric gas into the lumen compared to an vessel without a barrier coating;
• a protective coating or layer of a saccharide, the protective coating or layer having an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating, the protective coating or layer being effective to increase the calculated shelf life of the package (total Si / Si dissolution rate); and
• a fluid composition contained in the lumen and having a pH between 5 and 9; wherein the calculated shelf life of the package is more than six months at a storage temperature of 4°C.
2. A filled package comprising:
• a vessel having a lumen defined at least in part by a wall, the wall having an interior surface comprising glass facing the lumen and an outer surface;
• a protective coating or layer of a saccharide, the protective coating or layer having an interior surface facing the lumen and an outer surface facing the interior surface of the barrier coating, the protective coating or layer being effective to decrease the Si dissolution rate of the glass interior surface; and
• a fluid composition contained in the lumen and having a pH between 5 and 9.
3. An article comprising:
• a wall having a surface;
• a barrier coating of SiOx, wherein x is from 1 .5 to 2.9, from 2 to 1000 nm thick, the barrier coating of SiOx having an interior surface facing the lumen and an outer surface facing the wall interior surface, the barrier coating being effective to reduce the ingress of atmospheric gas through the wall compared to an uncoated wall; and
• a protective coating or layer of a saccharide on the barrier coating, the protective coating or layer being formed by depositing a saccharide coating from a dispersion, followed by chemical vapor deposition on the saccharide surface of a volatile silane precursor;
• in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH at some point between 5 and 9, is less than the rate of erosion of the barrier coating, if directly contacted by the fluid composition.
4. A vessel comprising:
• a thermoplastic wall having an interior surface enclosing a lumen;
• a fluid contained in the lumen having a pH greater than 5 disposed in the lumen;
• a barrier coating of SiOx, in which x is between 1 .5 and 2.9, the barrier coating applied by PECVD, positioned between the interior surface of the thermoplastic wall and the fluid, and supported by the thermoplastic wall, the barrier coating having the characteristic of being subject to being measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid; and
• a protective coating or layer of a saccharide positioned between the barrier coating and the fluid, and supported by the thermoplastic wall, the protective coating or layer being effective to keep the barrier coating at least substantially undissolved as a result of attack by the fluid for a period of at least six months.
5. The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises:
• a polyolefin,
• a polyester or
• a combination of a polyolefin and a polyester.
6. The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a polyolefin.
7. The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a polyolefin.
8. The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a cyclic olefin polymer.
9. The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a cyclic olefin polymer.
10. The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a cyclic olefin copolymer.
1 1 . The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a cyclic olefin copolymer.
12. The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises polypropylene.
13. The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of polypropylene.
14. The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises a polyester.
15. The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of a polyester.
16. The invention of any preceding claim, in which at least a portion of the wall of the vessel comprises polyethylene terephthalate.
17. The invention of any preceding claim, in which at least a portion of the wall of the vessel consists essentially of polyethylene terephthalate.
18. The invention of any preceding claim, in which the vessel comprises a syringe barrel.
19. The invention of any preceding claim 1 to 17, in which the vessel comprises a vial.
20. The invention of any preceding claim 1 to 17, in which the vessel comprises a blister package.
21 . The invention of any preceding claim 1 , 2, 4-38, or 49-20, in which the fluid composition has a pH between 5 and 6.
22. The invention of any preceding claim 1 , 2, 4-38, or 49-20, in which the fluid composition has a pH between 6 and 7.
23. The invention of any preceding claim 1 , 2, 4-38, or 49-20, in which the fluid composition has a pH between 7 and 8.
24. The invention of any preceding claim 1 , 2, 4-38, or 49-20, in which the fluid composition has a pH between 8 and 9.
25. The invention of any preceding claim, in which the fluid composition has a pH between 6.5 and 7.5.
26. The invention of any preceding claim, in which the fluid composition has a pH between 7.5 and 8.5.
27. The invention of any preceding claim, in which the fluid composition has a pH between 8.5 and 9.
28. The invention of any preceding claim, in which the fluid composition is a liquid at 20 °C and 760 mm Hg. atmospheric pressure.
29. The invention of any preceding claim, in which the fluid composition is an aqueous liquid.
30. The invention of any preceding claim 1 or 3-38, in which the barrier coating is from 500 nm to 5000 nm thick.
31 . The invention of any preceding claim in which the protective coating further comprises a coupling agent linking the saccharide to the SiOx barrier coating.
32. The invention of any preceding claim 31 , in which the saccharide is a sugar.
33. The invention of claim 32, in which the sugar is a sorbitan.
34. The invention of claim 32, in which the sugar comprises haluronic acid.
35. The invention of any preceding claim 31 -34, in which the coupling agent has a functionality reactive with a saccharide hydroxyl functional group.
36. The invention of claim 35, in which the functionality reactive with a saccharide hydroxyl functional group is an isocyanate moiety.
37. The invention of any preceding claim 31 -36, in which the coupling agent comprises a silane functional group that interacts with an SiOx barrier layer.
38. The invention of any preceding claim 31 -37, in which the coupling agent comprises trimethoxysilylpropyl isocyanate.
39. The invention of any preceding claim 31 -38, in which the coupling agent comprises 3-Aminopropyltriethoxysilane (APTES)
40. The invention of any preceding claim 31 -39, in which the coupling agent anchors the saccharide to the barrier layer to prevent the saccharide from dispersing in an aqueous environment in contact with the saccharide.
41 . The invention of any preceding claim 1 , 2, or 4-40, in which the protective coating or layer contacting the fluid composition is between 10 and 1000 nm thick two years after the invention is assembled.
42. The invention of any preceding claim 1 , 2, or 4-41 , in which the protective coating or layer contacting the fluid composition is between 20 and 700 nm thick two years after the invention is assembled.
43. The invention of any preceding claim 1 , 2, or 4-40, in which the protective coating or layer contacting the fluid composition is between 50 and 500 nm thick two years after the invention is assembled.
44. The invention of any preceding claim 1 , 2, or 4-40, in which the protective coating or layer contacting the fluid composition is between 100 and 400 nm thick two years after the invention is assembled.
45. The invention of any preceding claim 1 , 2, or 4-40, in which the protective coating or layer contacting the fluid composition is between 150 and 300 nm thick two years after the invention is assembled.
46. The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 20% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
47. The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 15% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
48. The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 10% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
49. The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is less than 7% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
50. The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 20% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
51 . The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 15% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
52. The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 10% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
53. The invention of any preceding claim 1 , 3-40, or 41 -45, in which the rate of erosion of the protective coating or layer, if directly contacted by a fluid composition having a pH of 8, is from 5% to 7% of the rate of erosion of the barrier coating, if directly contacted by the same fluid composition under the same conditions.
54. The invention of any preceding claim 1 , 3-40, or 41 -51 , in which the protective coating or layer is at least coextensive with the barrier coating.
55. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least one year.
56. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least two years.
57. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least three years.
58. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least four years.
59. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least five years.
60. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least six years.
61 . The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least seven years.
62. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least eight years.
63. The invention of any preceding claim 1 , 2, 4-40, or 41 -54, having a shelf life, after the invention is assembled, of at least nine years.
64. The invention of any preceding claim 55-63, having a shelf life, after the invention is assembled, of at most ten years.
65. The invention of any preceding claim 63-64, in which the shelf life is determined at 3°C.
66. The invention of any preceding claim 63-64, in which the shelf life is determined at 4°C.
67. The invention of any preceding claim 63-64, in which the shelf life is determined at 20 °C.
68. The invention of any preceding claim 63-64, in which the shelf life is determined at 23 °C.
69. The invention of any preceding claim 63-64, in which the shelf life is determined at 40 °C.
70. The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 5 and 6 and the thickness of the protective coating or layer is at least 80 nm at the end of the shelf life.
71 . The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 6 and 7 and the thickness of the protective coating or layer is at least 80 nm at the end of the shelf life.
72. The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 7 and 8 and the thickness of the protective coating or layer is at least 80 nm at the end of the shelf life.
73. The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 8 and 9 and the thickness of the protective coating or layer is at least 80 nm at the end of the shelf life.
74. The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 5 and 6 and the thickness of the protective coating or layer is at least 150 nm at the end of the shelf life.
75. The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 6 and 7 and the thickness of the protective coating or layer is at least 150 nm at the end of the shelf life.
76. The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 7 and 8 and the thickness of the protective coating or layer is at least 150 nm at the end of the shelf life.
77. The invention of any preceding claim 55 to 69, in which the pH of the fluid composition is between 8 and 9 and the thickness of the protective coating or layer is at least 150 nm at the end of the shelf life.
78. The invention of any preceding claim, in which the fluid composition removes the protective coating or layer at a rate of 1 nm or less of protective coating or layer thickness per 44 hours of contact with the fluid composition.
79. The invention of any preceding claim, in which the fluid composition removes the protective coating or layer at a rate of 1 nm or less of protective coating or layer thickness per 88 hours of contact with the fluid composition.
80. The invention of any preceding claim, in which the fluid composition removes the protective coating or layer at a rate of 1 nm or less of protective coating or layer thickness per 175 hours of contact with the fluid composition.
81 . The invention of any preceding claim, in which the fluid composition removes the protective coating or layer at a rate of 1 nm or less of protective coating or layer thickness per 250 hours of contact with the fluid composition.
82. The invention of any preceding claim, in which the fluid composition removes the protective coating or layer at a rate of 1 nm or less of protective coating or layer thickness per 350 hours of contact with the fluid composition.
83. The invention of any preceding claim, in which the protective coating or layer is effective to provide a lower frictional resistance than the uncoated interior surface.
84. The invention of claim 83 wherein the frictional resistance is reduced by at least 25% in comparison to the uncoated interior surface.
85. The invention of claim 83 wherein the frictional resistance is reduced by at least 45% in comparison to the uncoated interior surface.
86. The invention of claim 83 wherein the frictional resistance is reduced by at least 60% in comparison to the uncoated interior surface.
87. The invention of any preceding claim, in which the protective coating or layer is effective to reduce the frictional resistance between a portion of the wall contacted by the fluid composition and a relatively sliding part after the invention is assembled.
88. The invention of any preceding claim, in which the protective coating or layer is effective to reduce the frictional resistance between the wall and a relatively sliding part at least two years after the invention is assembled.
89. The invention of any preceding claim 83 to 88, in which the invention is a syringe.
90. The invention of claim 89, in which the syringe comprises a barrel, a plunger having a generally cylindrical surface movable axially in the barrel, and an O- ring or other toroidal band interfacing between the generally cylindrical surface and the barrel.
91 . The invention of any preceding claim 83 to 90, in which the invention is a syringe comprising a syringe barrel.
92. The invention of any preceding claim 83 to 90, in which the invention is a syringe comprising a plunger.
93. The invention of any preceding claim 83 to 90, in which the invention is a syringe comprising a syringe barrel and a plunger.
94. The invention of any preceding claim 83 to 90, in which the invention is a syringe comprising a syringe barrel and a plunger and the wall defines at least a portion of the syringe barrel.
95. The invention of any preceding claim 83 to 90, in which the invention is a syringe comprising a syringe barrel and a plunger, the wall defines at least a portion of the syringe barrel, and the relatively sliding part comprises the syringe plunger.
96. The invention of any preceding claim, further comprising
• a lubricity coating applied between the protective coating or layer and the lumen;
• optionally, a further coating applied adjacent to the inner surface of the protective coating or layer, the further coating having an outer surface facing the interior surface of the thermoplastic wall and an inner surface facing the lumen; and
• fluid in contact with the protective coating or layer.
97. The invention of any preceding claim, in which the silicon dissolution rate by a 50 mM potassium phosphate buffer diluted in water for injection, adjusted to pH 8 with concentrated nitric acid, and containing 0.2 wt. % polysorbate-80 surfactant from the vessel is less than 170 ppb/day.
98. The invention of claim 97, in which the silicon dissolution rate is less than 160 ppb/day.
99. The invention of claim 97, in which the silicon dissolution rate is less than 140 ppb/day.
100. The invention of claim 97, in which the silicon dissolution rate is less than 120 ppb/day.
101 . The invention of claim 97, in which the silicon dissolution rate is less than 100 ppb/day.
102. The invention of claim 97, in which the silicon dissolution rate is less than 90 ppb/day.
103. The invention of claim 97, in which the silicon dissolution rate is less than 80 ppb/day.
104. The invention of any preceding claim 1 , 3-40, or 41 -1 14, in which the total silicon content of the protective coating and barrier coating, upon dissolution into 0.1 N potassium hydroxide aqueous solution at 40 °C from the vessel, is less than 66 ppm.
Ill
105. The invention of claim 104, in which the total silicon content is less than 60 ppm.
106. The invention of claim 104, in which the total silicon content is less than 50 ppm.
107. The invention of claim 104, in which the total silicon content is less than 40 ppm.
108. The invention of claim 104, in which the total silicon content is less than 30 ppm.
109. The invention of claim 104, in which the total silicon content is less than 20 ppm.
1 10. The invention of any preceding claim 1 , 2, 4-40, or 41 -109, in which the calculated shelf life (total Si / Si dissolution rate) is more than 1 year.
1 1 1 . The invention of claim 1 , 2, 4-40, or 41 -109, in which the calculated shelf life (total Si / Si dissolution rate) is more than 18 months.
1 12. The invention of claim 1 , 2, 4-40, or 41 -109, in which the calculated shelf life (total Si / Si dissolution rate) is more than 2 years.
1 13. The invention of claim 1 , 2, 4-40, or 41 -109, in which the calculated shelf life (total Si / Si dissolution rate) is more than 21/2 years.
1 14. The invention of claim 1 , 2, or 4-109, in which the calculated shelf life (total Si / Si dissolution rate) is more than 3 years.
1 15. The invention of any preceding claim 1 , 2, or 4-1 14, in which the calculated shelf life (total Si / Si dissolution rate) is less than 4 years.
1 16. The invention of any preceding claim 1 , 2, or 4-1 14, in which the
calculated shelf life (total Si / Si dissolution rate) is less than 5 years.
1 17. The invention of any preceding claim, comprising a syringe barrel coated on its interior wall with a protective layer, the invention further comprising a plunger positioned for sliding in the barrel and a lubricity coating or layer on at least a portion of the plunger.
1 18. The invention of claim 1 17, in which the lubricity coating or layer is configured to provide a lower piston sliding force or breakout force than the uncoated substrate
1 19-177. (Canceled)
178. The invention of any preceding claim, in which the fluid composition comprises a member selected from the group consisting of:
Inhalation Anesthetics
Aliflurane
Chloroform
Cyclopropane
Desflurane (Suprane)
Diethyl Ether
Enflurane (Ethrane)
Ethyl Chloride
Ethylene
Halothane (Fluothane) Isoflurane (Forane, Isoflo)
Isopropenyl vinyl ether
Methoxyflurane
methoxyflurane,
Methoxypropane
Nitrous Oxide
Roflurane
Sevoflurane (Sevorane, Ultane, Sevoflo)
Teflurane
Trichloroethylene
Vinyl Ether
Xenon
Injectable Drugs
Ablavar (Gadofosveset Trisodium Injection) Abarelix Depot
Abobotulinumtoxin A Injection (Dysport)
ABT-263
ABT-869
ABX-EFG
Accretropin (Somatropin Injection)
Acetadote (Acetylcysteine Injection)
Acetazolamide Injection (Acetazolamide Injection)
Acetylcysteine Injection (Acetadote)
Actemra (Tocilizumab Injection)
Acthrel (Corticorelin Ovine Triflutate for Injection)
Actummune
Activase
Acyclovir for Injection (Zovirax Injection)
Adacel Adalimumab
Adenoscan (Adenosine Injection)
Adenosine Injection (Adenoscan)
Adrenaclick
AdreView (lobenguane I 123 Injection for Intravenous Use) Afluria
Ak-Fluor (Fluorescein Injection)
Aldurazyme (Laronidase)
Alglucerase Injection (Ceredase)
Alkeran Injection (Melphalan Hcl Injection)
Allopurinol Sodium for Injection (Aloprim)
Aloprim (Allopurinol Sodium for Injection)
Alprostadil
Alsuma (Sumatriptan Injection)
ALTU-238
Amino Acid Injections
Aminosyn
Apidra
Apremilast
Alprostadil Dual Chamber System for Injection (Caverject Im
AMG 009
AMG 076
AMG 102
AMG 108
AMG 1 14
AMG 162
AMG 220
AMG 221
AMG 222
AMG 223 AMG 317
AMG 379
AMG 386
AMG 403
AMG 477
AMG 479
AMG 517
AMG 531
AMG 557
AMG 623
AMG 655
AMG 706
AMG 714
AMG 745
AMG 785
AMG 81 1
AMG 827
AMG 837
AMG 853
AMG 951
Amiodarone HCI Injection (Amiodarone HCI Injection) Amobarbital Sodium Injection (Amytal Sodium) Amytal Sodium (Amobarbital Sodium Injection)
Anakinra
Anti -Abeta
Anti -Beta7
Anti -Beta20
Anti -CD4
Anti -CD20
Anti -CD40 Anti -IFNalpha
Anti -IL13
Anti -OX40L
Anti -oxLDS
Anti -NGF
Anti -NRP1
Arixtra
Amphadase (Hyaluronidase Inj)
Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection) Anaprox
Anzemet Injection (Dolasetron Mesylate Injection)
Apidra (Insulin Glulisine [rDNA origin] Inj)
Apomab
Aranesp (darbepoetin alfa)
Argatroban (Argatroban Injection)
Arginine Hydrochloride Injection (R-Gene 10)
Aristocort
Aristospan
Arsenic Trioxide Injection (Trisenox)
Articane HCI and Epinephrine Injection (Septocaine)
Arzerra (Ofatumumab Injection)
Asclera (Polidocanol Injection)
Ataluren
Ataluren-DMD
Atenolol Inj (Tenormin I.V. Injection)
Atracurium Besylate Injection (Atracurium Besylate Injection) Avastin
Azactam Injection (Aztreonam Injection)
Azithromycin (Zithromax Injection)
Aztreonam Injection (Azactam Injection) Baclofen Injection (Lioresal Intrathecal)
Bacteriostatic Water (Bacteriostatic Water for Injection)
Baclofen Injection (Lioresal Intrathecal)
Bal in Oil Ampules (Dimercarprol Injection)
BayHepB
BayTet
Benadryl
Bendamustine Hydrochloride Injection (Treanda)
Benztropine Mesylate Injection (Cogentin)
Betamethasone Injectable Suspension (Celestone Soluspan)
Bexxar
Bicillin C-R 900/300 (Penicillin G Benzathine and Penicillin G Procaine Injection)
Blenoxane (Bleomycin Sulfate Injection)
Bleomycin Sulfate Injection (Blenoxane)
Boniva Injection (Ibandronate Sodium Injection)
Botox Cosmetic (OnabotulinumtoxinA for Injection)
BR3-FC
Bravelle (Urofollitropin Injection)
Bretylium (Bretylium Tosylate Injection )
Brevital Sodium (Methohexital Sodium for Injection)
Brethine
Briobacept
BTT-1023
Bupivacaine HCI
Byetta
Ca-DTPA (Pentetate Calcium Trisodium Inj)
Cabazitaxel Injection (Jevtana)
Caffeine Alkaloid (Caffeine and Sodium Benzoate Injection)
Calcijex Injection (Calcitrol)
Calcitrol (Calcijex Injection) Calcium Chloride (Calcium Chloride Injection 10%)
Calcium Disodium Versenate (Edetate Calcium Disodium Injection)
Campath (Altemtuzumab)
Camptosar Injection (Irinotecan Hydrochloride)
Canakinumab Injection (Maris)
Capastat Sulfate (Capreomycin for Injection)
Capreomycin for Injection (Capastat Sulfate)
Cardiolite (Prep kit for Technetium Tc99 Sestamibi for Injection)
Carticel
Cathflo
Cefazolin and Dextrose for Injection (Cefazolin Injection)
Cefepime Hydrochloride
Cefotaxime
Ceftriaxone
Cerezyme
Carnitor Injection
Caverject
Celestone Soluspan
Celsior
Cerebyx (Fosphenytoin Sodium Injection)
Ceredase (Alglucerase Injection)
Ceretec (Technetium Tc99m Exametazime Injection)
Certolizumab
CF-101
Chloramphenicol Sodium Succinate (Chloramphenicol Sodium Succinate Injection) Chloramphenicol Sodium Succinate Injection (Chloramphenicol Sodium Succinate) Cholestagel (Colesevelam HCL)
Choriogonadotropin Alfa Injection (Ovidrel)
Cimzia
Cisplatin (Cisplatin Injection) Clolar (Clofarabine Injection)
Clomiphine Citrate
Clonidine Injection (Duraclon)
Cogentin (Benztropine Mesylate Injection)
Colistimethate Injection (Coly-Mycin M)
Coly-Mycin M (Colistimethate Injection)
Com path
Conivaptan Hcl Injection (Vaprisol)
Conjugated Estrogens for Injection (Premarin Injection)
Copaxone
Corticorelin Ovine Triflutate for Injection (Acthrel) Corvert (Ibutilide Fumarate Injection)
Cubicin (Daptomycin Injection)
CF-101
Cyanokit (Hydroxocobalamin for Injection)
Cytarabine Liposome Injection (DepoCyt)
Cyanocobalamin
Cytovene (ganciclovir)
D.H.E. 45
Dacetuzumab
Dacogen (Decitabine Injection)
Dalteparin
Dantrium IV (Dantrolene Sodium for Injection)
Dantrolene Sodium for Injection (Dantrium IV)
Daptomycin Injection (Cubicin)
Darbepoietin Alfa
DDAVP Injection (Desmopressin Acetate Injection) Decavax
Decitabine Injection (Dacogen)
Dehydrated Alcohol (Dehydrated Alcohol Injection) Denosumab Injection (Prolia)
Delatestryl
Delestrogen
Delteparin Sodium
Depacon (Valproate Sodium Injection)
Depo Medrol (Methylprednisolone Acetate Injectable Suspension
DepoCyt (Cytarabine Liposome Injection)
DepoDur (Morphine Sulfate XR Liposome Injection)
Desmopressin Acetate Injection (DDAVP Injection)
Depo-Estradiol
Depo-Provera 104mg/ml
Depo-Provera 150mg/ml
Depo-Testosterone
Dexrazoxane for Injection, Intravenous Infusion Only (Totect) Dextrose / Electrolytes
Dextrose and Sodium Chloride Inj (Dextrose 5% in 0.9% Sodium Dextrose
Diazepam Injection (Diazepam Injection)
Digoxin Injection (Lanoxin Injection)
Dilaudid-HP (Hydromorphone Hydrochloride Injection)
Dimercarprol Injection (Bal in Oil Ampules)
Diphenhydramine Injection (Benadryl Injection)
Dipyridamole Injection (Dipyridamole Injection)
DMOAD
Docetaxel for Injection (Taxotere)
Dolasetron Mesylate Injection (Anzemet Injection)
Doribax (Doripenem for Injection)
Doripenem for Injection (Doribax)
Doxercalciferol Injection (Hectorol Injection)
Doxil (Doxorubicin Hcl Liposome Injection) Doxorubicin Hcl Liposome Injection (Doxil)
Duraclon (Clonidine Injection)
Duramorph (Morphine Injection)
Dysport (Abobotulinumtoxin A Injection)
Ecallantide Injection (Kalbitor)
EC-Naprosyn (naproxen)
Edetate Calcium Disodium Injection (Calcium Disodium Versenate)
Edex (Alprostadil for Injection)
Engerix
Edrophonium Injection (Enlon)
Eliglustat Tartate
Eloxatin (Oxaliplatin Injection)
Emend Injection (Fosaprepitant Dimeglumine Injection)
Enalaprilat Injection (Enalaprilat Injection)
Enlon (Edrophonium Injection)
Enoxaparin Sodium Injection (Lovenox)
Eovist (Gadoxetate Disodium Injection)
Enbrel (etanercept)
Enoxaparin
Epicel
Epinepherine
Epipen
Epipen Jr.
Epratuzumab
Erbitux
Ertapenem Injection (Invanz)
Erythropoieten
Essential Amino Acid Injection (Nephramine)
Estradiol Cypionate
Estradiol Valerate Etanercept
Exenatide Injection (Byetta)
Evlotra
Fabrazyme (Adalsidase beta)
Famotidine Injection
FDG (Fludeoxyglucose F 18 Injection)
Feraheme (Ferumoxytol Injection)
Feridex I.V. (Ferumoxides Injectable Solution)
Fertinex
Ferumoxides Injectable Solution (Feridex I.V.)
Ferumoxytol Injection (Feraheme)
Flagyl Injection (Metronidazole Injection)
Fluarix
Fludara (Fludarabine Phosphate)
Fludeoxyglucose F 18 Injection (FDG)
Fluorescein Injection (Ak-Fluor)
Follistim AQ Cartridge (Follitropin Beta Injection)
Follitropin Alfa Injection (Gonal-f RFF)
Follitropin Beta Injection (Follistim AQ Cartridge)
Folotyn (Pralatrexate Solution for Intravenous Injection)
Fondaparinux
Forteo (Teriparatide (rDNA origin) Injection)
Fostamatinib
Fosaprepitant Dimeglumine Injection (Emend Injection) Foscarnet Sodium Injection (Foscavir)
Foscavir (Foscarnet Sodium Injection)
Fosphenytoin Sodium Injection (Cerebyx)
Fospropofol Disodium Injection (Lusedra)
Fragmin
Fuzeon (enfuvirtide) GA101
Gadobenate Dimeglumine Injection (Multihance) Gadofosveset Trisodium Injection (Ablavar) Gadoteridol Injection Solution (ProHance) Gadoversetamide Injection (OptiMARK)
Gadoxetate Disodium Injection (Eovist)
Ganirelix (Ganirelix Acetate Injection)
Gardasil
GC1008
GDFD
Gemtuzumab Ozogamicin for Injection (Mylotarg) Genotropin
Gentamicin Injection
GENZ-1 12638
Golimumab Injection (Simponi Injection)
Gonal-f RFF (Follitropin Alfa Injection)
Granisetron Hydrochloride (Kytril Injection)
Gentamicin Sulfate
Glatiramer Acetate
Glucagen
Glucagon
HAE1
Haldol (Haloperidol Injection)
Havrix
Hectorol Injection (Doxercalciferol Injection)
Hedgehog Pathway Inhibitor
Heparin
Herceptin
hG-CSF
Humalog Human Growth Hormone
Humatrope
HuMax
Humegon
Humira
Humulin
Ibandronate Sodium Injection (Boniva Injection)
Ibuprofen Lysine Injection (NeoProfen)
Ibutilide Fumarate Injection (Corvert)
Idamycin PFS (Idarubicin Hydrochloride Injection)
Idarubicin Hydrochloride Injection (Idamycin PFS)
Maris (Canakinumab Injection)
Imipenem and Cilastatin for Injection (Primaxin I.V.)
Imitrex
Incobotulinumtoxin A for Injection (Xeomin)
Increlex (Mecasermin [rDNA origin] Injection)
Indocin IV (Indomethacin Inj)
Indomethacin Inj (Indocin IV)
Infanrix
Innohep
Insulin
Insulin Aspart [rDNA origin] Inj (NovoLog)
Insulin Glargine [rDNA origin] Injection (Lantus)
Insulin Glulisine [rDNA origin] Inj (Apidra)
Interferon alfa-2b, Recombinant for Injection (Intron A)
Intron A (Interferon alfa-2b, Recombinant for Injection)
Invanz (Ertapenem Injection)
Invega Sustenna (Paliperidone Palmitate Extended- Release Injectable Suspension) Invirase (saquinavir mesylate)
lobenguane I 123 Injection for Intravenous Use (AdreView) lopromide Injection (Ultravist)
loversol Injection (Optiray Injection)
Iplex (Mecasermin Rinfabate [rDNA origin] Injection)
Iprivask
Irinotecan Hydrochloride (Camptosar Injection)
Iron Sucrose Injection (Venofer)
Istodax (Romidepsin for Injection)
Itraconazole Injection (Sporanox Injection)
Jevtana (Cabazitaxel Injection)
Jonexa
Kalbitor (Ecallantide Injection)
KCL in D5NS (Potassium Chloride in 5% Dextrose and Sodium Chloride Injection) KCL in D5W
KCL in NS
Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension)
Kepivance (Palifermin)
Keppra Injection (Levetiracetam)
Keratinocyte
KFG
Kinase Inhibitor
Kineret (Anakinra)
Kinlytic (Urokinase Injection)
Kinrix
Klonopin (clonazepam)
Kytril Injection (Granisetron Hydrochloride)
lacosamide Tablet and Injection (Vimpat)
Lactated Ringer's
Lanoxin Injection (Digoxin Injection)
Lansoprazole for Injection (Prevacid I.V.)
Lantus Leucovorin Calcium (Leucovorin Calcium Injection)
Lente (L)
Leptin
Levemir
Leukine Sargramostim
Leuprolide Acetate
Levothyroxine
Levetiracetam (Keppra Injection)
Lovenox
Levocarnitine Injection (Carnitor Injection)
Lexiscan (Regadenoson Injection)
Lioresal Intrathecal (Baclofen Injection)
Liraglutide [rDNA] Injection (Victoza)
Lovenox (Enoxaparin Sodium Injection)
Lucentis (Ranibizumab Injection)
Lumizyme
Lupron (Leuprolide Acetate Injection)
Lusedra (Fospropofol Disodium Injection)
Maci
Magnesium Sulfate (Magnesium Sulfate Injection)
Mannitol Injection (Mannitol IV)
Marcaine (Bupivacaine Hydrochloride and Epinephrine Injection)
Maxipime (Cefepime Hydrochloride for Injection)
MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection)
Mecasermin [rDNA origin] Injection (Increlex)
Mecasermin Rinfabate [rDNA origin] Injection (Iplex)
Melphalan Hcl Injection (Alkeran Injection)
Methotrexate
Menactra
Menopur (Menotropins Injection) Menotropins for Injection (Repronex)
Methohexital Sodium for Injection (Brevital Sodium)
Methyldopate Hydrochloride Injection, Solution (Methyldopate Hcl)
Methylene Blue (Methylene Blue Injection)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
MetMab
Metoclopramide Injection (Reglan Injection)
Metrodin (Urofollitropin for Injection)
Metronidazole Injection (Flagyl Injection)
Miacalcin
Midazolam (Midazolam Injection)
Mimpara (Cinacalet)
Minocin Injection (Minocycline Inj)
Minocycline Inj (Minocin Injection)
Mipomersen
Mitoxantrone for Injection Concentrate (Novantrone)
Morphine Injection (Duramorph)
Morphine Sulfate XR Liposome Injection (DepoDur)
Morrhuate Sodium (Morrhuate Sodium Injection)
Motesanib
Mozobil (Plerixafor Injection)
Multihance (Gadobenate Dimeglumine Injection)
Multiple Electrolytes and Dextrose Injection
Multiple Electrolytes Injection
Mylotarg (Gemtuzumab Ozogamicin for Injection)
Myozyme (Alglucosidase alfa)
Nafcillin Injection (Nafcillin Sodium)
Nafcillin Sodium (Nafcillin Injection)
Naltrexone XR Inj (Vivitrol)
Naprosyn (naproxen) NeoProfen (Ibuprofen Lysine Injection)
Nandrol Decanoate
Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection)
NEO-GAA
NeoTect (Technetium Tc 99m Depreotide Injection)
Nephramine (Essential Amino Acid Injection)
Neulasta (pegfilgrastim)
Neupogen (Filgrastim)
Novolin
Novolog
NeoRecormon
Neutrexin (Trimetrexate Glucuronate Inj)
NPH (N)
Nexterone (Amiodarone HCI Injection)
Norditropin (Somatropin Injection)
Normal Saline (Sodium Chloride Injection)
Novantrone (Mitoxantrone for Injection Concentrate)
Novolin 70/30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection)
NovoLog (Insulin Aspart [rDNA origin] Inj)
Nplate (romiplostim)
Nutropin (Somatropin (rDNA origin) for Inj)
Nutropin AQ
Nutropin Depot (Somatropin (rDNA origin) for Inj)
Octreotide Acetate Injection (Sandostatin LAR)
Ocrelizumab
Ofatumumab Injection (Arzerra)
Olanzapine Extended Release Injectable Suspension (Zyprexa Relprevv)
Omnitarg
Omnitrope (Somatropin [ rDNA origin] Injection) Ondansetron Hydrochloride Injection (Zofran Injection)
OptiMARK (Gadoversetamide Injection)
Optiray Injection (loversol Injection)
Orencia
Osmitrol Injection in Aviva (Mannitol Injection in Aviva Plastic Vessel)
Osmitrol Injection in Viaflex (Mannitol Injection in Viaflex Plastic Vessel)
Osteoprotegrin
Ovidrel (Choriogonadotropin Alfa Injection)
Oxacillin (Oxacillin for Injection)
Oxaliplatin Injection (Eloxatin)
Oxytocin Injection (Pitocin)
Paliperidone Palmitate Extended-Release Injectable Suspension (Invega Sustenna) Pamidronate Disodium Injection (Pamidronate Disodium Injection)
Panitumumab Injection for Intravenous Use (Vectibix)
Papaverine Hydrochloride Injection (Papaverine Injection)
Papaverine Injection (Papaverine Hydrochloride Injection)
Parathyroid Hormone
Paricalcitol Injection Fliptop Vial (Zemplar Injection)
PARP Inhibitor
Pediarix
PEGIntron
Peginterferon
Pegfilgrastim
Penicillin G Benzathine and Penicillin G Procaine
Pentetate Calcium Trisodium Inj (Ca-DTPA)
Pentetate Zinc Trisodium Injection (Zn-DTPA)
Pepcid Injection (Famotidine Injection)
Pergonal
Pertuzumab
Phentolamine Mesylate (Phentolamine Mesylate for Injection) Physostigmine Salicylate (Physostigmine Salicylate (injection))
Physostigmine Salicylate (injection) (Physostigmine Salicylate)
Piperacillin and Tazobactam Injection (Zosyn)
Pitocin (Oxytocin Injection)
Plasma-Lyte 148 (Multiple Electrolytes Inj)
Plasma-Lyte 56 and Dextrose (Multiple Electrolytes and Dextrose Injection
Plastic Vessel)
PlasmaLyte
Plerixafor Injection (Mozobil)
Polidocanol Injection (Asclera)
Potassium Chloride
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pramlintide Acetate Injection (Symlin)
Premarin Injection (Conjugated Estrogens for Injection)
Prep kit for Technetium Tc99 Sestamibi for Injection (Cardiolite)
Prevacid I.V. (Lansoprazole for Injection)
Primaxin I.V. (Imipenem and Cilastatin for Injection)
Prochymal
Procrit
Progesterone
ProHance (Gadoteridol Injection Solution)
Prolia (Denosumab Injection)
Promethazine HCI Injection (Promethazine Hydrochloride Injection)
Propranolol Hydrochloride Injection (Propranolol Hydrochloride Injection)
Quinidine Gluconate Injection (Quinidine Injection)
Quinidine Injection (Quinidine Gluconate Injection)
R-Gene 10 (Arginine Hydrochloride Injection)
Ranibizumab Injection (Lucentis)
Ranitidine Hydrochloride Injection (Zantac Injection)
Raptiva Reclast (Zoledronic Acid Injection)
Recombivarix HB
Regadenoson Injection (Lexiscan)
Reglan Injection (Metoclopramide Injection)
Remicade
Renagel
Renvela (Sevelamer Carbonate)
Repronex (Menotropins for Injection)
Retrovir IV (Zidovudine Injection)
rhApo2L/TRAIL
Ringer's and 5% Dextrose Injection (Ringers in Dextrose)
Ringer's Injection (Ringers Injection)
Rituxan
Rituximab
Rocephin (ceftriaxone)
Rocuronium Bromide Injection (Zemuron)
Roferon-A (interferon alfa-2a)
Romazicon (flumazenil)
Romidepsin for Injection (Istodax)
Saizen (Somatropin Injection)
Sandostatin LAR (Octreotide Acetate Injection)
Sclerostin Ab
Sensipar (cinacalcet)
Sensorcaine (Bupivacaine HCI Injections)
Septocaine (Articane HCI and Epinephrine Injection)
Serostim LQ (Somatropin (rDNA origin) Injection)
Simponi Injection (Golimumab Injection)
Sodium Acetate (Sodium Acetate Injection)
Sodium Bicarbonate (Sodium Bicarbonate 5% Injection)
Sodium Lactate (Sodium Lactate Injection in AVIVA) Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul)
Somatropin (rDNA origin) for Inj (Nutropin)
Sporanox Injection (Itraconazole Injection)
Stelara Injection (Ustekinumab)
Stemgen
Sufenta (Sufentanil Citrate Injection)
Sufentanil Citrate Injection (Sufenta )
Sumavel
Sumatriptan Injection (Alsuma)
Symlin
Symlin Pen
Systemic Hedgehog Antagonist
Synvisc-One (Hylan G-F 20 Single Intra-articular Injection) Tarceva
Taxotere (Docetaxel for Injection)
Technetium Tc 99m
Telavancin for Injection (Vibativ)
Temsirolimus Injection (Torisel)
Tenormin I.V. Injection (Atenolol Inj)
Teriparatide (rDNA origin) Injection (Forteo)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Propionate
Tev-Tropin (Somatropin, rDNA Origin, for Injection)
tgAAC94
Thallous Chloride
Theophylline
Thiotepa (Thiotepa Injection)
Thymoglobulin (Anti-Thymocyte Globulin (Rabbit)
Thyrogen (Thyrotropin Alfa for Injection) Ticarcillin Disodium and Clavulanate Potassium Galaxy (Timentin Injection)
Tigan Injection (Trimethobenzamide Hydrochloride Injectable)
Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy)
TNKase
Tobramycin Injection (Tobramycin Injection)
Tocilizumab Injection (Actemra)
Torisel (Temsirolimus Injection)
Totect (Dexrazoxane for Injection, Intravenous Infusion Only )
Trastuzumab-DM1
Travasol (Amino Acids (Injection))
Treanda (Bendamustine Hydrochloride Injection)
Trelstar (Triptorelin Pamoate for Injectable Suspension)
Triamcinolone Acetonide
Triamcinolone Diacetate
Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg)
Triesence (Triamcinolone Acetonide Injectable Suspension)
Trimethobenzamide Hydrochloride Injectable (Tigan Injection)
Trimetrexate Glucuronate Inj (Neutrexin)
Triptorelin Pamoate for Injectable Suspension (Trelstar)
Twinject
Trivaris (Triamcinolone Acetonide Injectable Suspension)
Trisenox (Arsenic Trioxide Injection)
Twinrix
Typhoid Vi
Ultravist (lopromide Injection)
Urofollitropin for Injection (Metrodin)
Urokinase Injection (Kinlytic)
Ustekinumab (Stelara Injection)
Ultralente (U)
Valium (diazepam) Valproate Sodium Injection (Depacon)
Valtropin (Somatropin Injection)
Vancomycin Hydrochloride (Vancomycin Hydrochloride Injection) Vancomycin Hydrochloride Injection (Vancomycin Hydrochloride) Vaprisol (Conivaptan Hcl Injection)
VAQTA
Vasovist (Gadofosveset Trisodium Injection for Intravenous Use)
Vectibix (Panitumumab Injection for Intravenous Use)
Venofer (Iron Sucrose Injection)
Verteporfin Inj (Visudyne)
Vibativ (Telavancin for Injection)
Victoza (Liraglutide [rDNA] Injection)
Vimpat (lacosamide Tablet and Injection)
Vinblastine Sulfate (Vinblastine Sulfate Injection)
Vincasar PFS (Vincristine Sulfate Injection)
Victoza
Vincristine Sulfate (Vincristine Sulfate Injection)
Visudyne (Verteporfin Inj)
Vitamin B-12
Vivitrol (Naltrexone XR Inj)
Voluven (Hydroxyethyl Starch in Sodium Chloride Injection) Xeloda
Xenical (orlistat)
Xeomin (Incobotulinumtoxin A for Injection)
Xolair
Zantac Injection (Ranitidine Hydrochloride Injection)
Zemplar Injection (Paricalcitol Injection Fliptop Vial)
Zemuron (Rocuronium Bromide Injection)
Zenapax (daclizumab)
Zevalin Zidovudine Injection (Retrovir IV)
Zithromax Injection (Azithromycin)
Zn-DTPA (Pentetate Zinc Trisodium Injection)
Zofran Injection (Ondansetron Hydrochloride Injection)
Zingo
Zoledronic Acid for Inj (Zometa)
Zoledronic Acid Injection (Reclast)
Zometa (Zoledronic Acid for Inj)
Zosyn (Piperacillin and Tazobactam Injection)
Zyprexa Relprevv (Olanzapine Extended Release Injectable Suspension)
Liquid Drugs (Non-lnjectable)
Ability
AccuNeb (Albuterol Sulfate Inhalation Solution)
Actidose Aqua (Activated Charcoal Suspension)
Activated Charcoal Suspension (Actidose Aqua)
Advair
Agenerase Oral Solution (Amprenavir Oral Solution)
Akten (Lidocaine Hydrochloride Ophthalmic Gel)
Alamast (Pemirolast Potassium Ophthalmic Solution)
Albumin (Human) 5% Solution (Buminate 5%)
Albuterol Sulfate Inhalation Solution
Alinia
Alocril
Alphagan
Alrex
Alvesco
Amprenavir Oral Solution
Analpram-HC
Arformoterol Tartrate Inhalation Solution (Brovana) Aristospan Injection 20 mg (Triamcinolone Hexacetonide Injectable Suspension)
Asacol
Asmanex
Astepro
Astepro (Azelastine Hydrochloride Nasal Spray)
Atrovent Nasal Spray (Ipratropium Bromide Nasal Spray)
Atrovent Nasal Spray .06
Augmentin ES-600
Azasite (Azithromycin Ophthalmic Solution)
Azelaic Acid (Finacea Gel)
Azelastine Hydrochloride Nasal Spray (Astepro)
Azelex (Azelaic Acid Cream)
Azopt (Brinzolamide Ophthalmic Suspension)
Bacteriostatic Saline
Balanced Salt
Bepotastine
Bactroban Nasal
Bactroban
Beclovent
Benzac W
Betimol
Betoptic S
Bepreve
Bimatoprost Ophthalmic Solution
Bleph 10 (Sulfacetamide Sodium Ophthalmic Solution 10%)
Brinzolamide Ophthalmic Suspension (Azopt)
Bromfenac Ophthalmic Solution (Xibrom)
Bromhist
Brovana (Arformoterol Tartrate Inhalation Solution)
Budesonide Inhalation Suspension (Pulmicort Respules) Cambia (Diclofenac Potassium for Oral Solution)
Capex
Carac
Carboxine-PSE
Carnitor
Cayston (Aztreonam for Inhalation Solution)
Cellcept
Centany
Cerumenex
Ciloxan Ophthalmic Solution (Ciprofloxacin HCL Ophthalmic Solution) Ciprodex
Ciprofloxacin HCL Ophthalmic Solution (Ciloxan Ophthalmic Solution)
Clemastine Fumarate Syrup (Clemastine Fumarate Syrup)
CoLyte (PEG Electrolytes Solution)
Combiven
Comtan
Condylox
Cord ran
Cortisporin Ophthalmic Suspension
Cortisporin Otic Suspension
Cromolyn Sodium Inhalation Solution (Intal Nebulizer Solution)
Cromolyn Sodium Ophthalmic Solution (Opticrom)
Crystalline Amino Acid Solution with Electrolytes (Aminosyn Electrolytes)
Cutivate
Cuvposa (Glycopyrrolate Oral Solution)
Cyanocobalamin (CaloMist Nasal Spray)
Cyclosporine Oral Solution (Gengraf Oral Solution)
Cyclogyl
Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution) DermOtic Oil (Fluocinolone Acetonide Oil Ear Drops) Desmopressin Acetate Nasal Spray
DDAVP
Derma-Smoothe/FS
Dexamethasone Intensol
Dianeal Low Calcium
Dianeal PD
Diclofenac Potassium for Oral Solution (Cambia)
Didanosine Pediatric Powder for Oral Solution (Videx)
Differin
Dilantin 125 (Phenytoin Oral Suspension)
Ditropan
Dorzolamide Hydrochloride Ophthalmic Solution (Trusopt)
Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution (Cosopt)
Dovonex Scalp (Calcipotriene Solution)
Doxycycline Calcium Oral Suspension (Vibramycin Oral)
Efudex
Elaprase (Idursulfase Solution)
Elestat (Epinastine HCI Ophthalmic Solution)
Elocon
Epinastine HCI Ophthalmic Solution (Elestat)
Epivir HBV
Epogen (Epoetin alfa)
Erythromycin Topical Solution 1 .5% (Staticin)
Ethiodol (Ethiodized Oil)
Ethosuximide Oral Solution (Zarontin Oral Solution)
Eurax
Extraneal (lcodextrin Peritoneal Dialysis Solution)
Felbatol
Feridex I.V. (Ferumoxides Injectable Solution)
Flovent Floxin Otic (Ofloxacin Otic Solution)
Flo-Pred (Prednisolone Acetate Oral Suspension)
Fluoroplex
Flunisolide Nasal Solution (Flunisolide Nasal Spray .025%)
Fluorometholone Ophthalmic Suspension (FML)
Flurbiprofen Sodium Ophthalmic Solution (Ocufen)
FML
Fo radii
Formoterol Fumarate Inhalation Solution (Perforomist)
Fosamax
Furadantin (Nitrofurantoin Oral Suspension)
Furoxone
Gammagard Liquid (Immune Globulin Intravenous (Human) 10%)
Gantrisin (Acetyl Sulfisoxazole Pediatric Suspension)
Gatifloxacin Ophthalmic Solution (Zymar)
Gengraf Oral Solution (Cyclosporine Oral Solution)
Glycopyrrolate Oral Solution (Cuvposa)
Halcinonide Topical Solution (Halog Solution)
Halog Solution (Halcinonide Topical Solution)
HEP-LOCK U/P (Preservative-Free Heparin Lock Flush Solution)
Heparin Lock Flush Solution (Hepflush 10)
Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview)
Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab El
Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution)
IAP Antagonist
Isopto
Ipratropium Bromide Nasal Spray (Atrovent Nasal Spray)
Itraconazole Oral Solution (Sporanox Oral Solution)
Ketorolac Tromethamine Ophthalmic Solution (Acular LS)
Kaletra Lanoxin
Lexiva
Leuprolide Acetate for Depot Suspension (Lupron Depot 1 1 .25 mg)
Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon)
Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor)
Levofloxacin Ophthalmic Solution 0.5% (Quixin)
Lidocaine HCI Sterile Solution (Xylocaine MPF Sterile Solution)
Lok Pak (Heparin Lock Flush Solution)
Lorazepam Intensol
Lortab Elixir (Hydrocodone Bitartrate and Acetaminophen Oral Solution)
Lotemax (Loteprednol Etabonate Ophthalmic Suspension)
Loteprednol Etabonate Ophthalmic Suspension (Alrex)
Low Calcium Peritoneal Dialysis Solutions (Dianeal Low Calcium)
Lumigan (Bimatoprost Ophthalmic Solution 0.03% for Glaucoma)
Lupron Depot 1 1 .25 mg (Leuprolide Acetate for Depot Suspension)
Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension)
MEK Inhibitor
Mepron
Mesnex
Mestinon
Mesalamine Rectal Suspension Enema (Rowasa)
Melquin-3 Topical Solution (Hydroquinone 3% Topical Solution)
MetMab
Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution)
Methylin Oral Solution (Methylphenidate HCI Oral Solution 5 mg/5 mL and 10 mg/5 mL)
Methylprednisolone Acetate Injectable Suspension (Depo Medrol)
Methylphenidate HCI Oral Solution 5 mg/5 mL and 10 mg/5 mL (Methylin Oral Solution)
Methylprednisolone sodium succinate (Solu Medrol)
Metipranolol Ophthalmic Solution (Optipranolol)
Migranal Miochol-E (Acetylcholine Chloride Intraocular Solution)
Micro-K for Liquid Suspension (Potassium Chloride Extended Release Formulation for Liquid Suspension)
Minocin (Minocycline Hydrochloride Oral Suspension)
Nasacort
Neomycin and Polymyxin B Sulfates and Hydrocortisone
Nepafenac Ophthalmic Suspension (Nevanac)
Nevanac (Nepafenac Ophthalmic Suspension)
Nitrofurantoin Oral Suspension (Furadantin)
Noxafil (Posaconazole Oral Suspension)
Nystatin (oral) (Nystatin Oral Suspension)
Nystatin Oral Suspension (Nystatin (oral))
Ocufen (Flurbiprofen Sodium Ophthalmic Solution)
Ofloxacin Ophthalmic Solution (Ofloxacin Ophthalmic Solution)
Ofloxacin Otic Solution (Floxin Otic)
Olopatadine Hydrochloride Ophthalmic Solution (Pataday)
Opticrom (Cromolyn Sodium Ophthalmic Solution)
Optipranolol (Metipranolol Ophthalmic Solution)
Patanol
Pediapred
PerioGard
Phenytoin Oral Suspension (Dilantin 125)
Phisohex
Posaconazole Oral Suspension (Noxafil)
Potassium Chloride Extended Release Formulation for Liquid Suspension (Micro-K for Liquid Suspension)
Pataday (Olopatadine Hydrochloride Ophthalmic Solution)
Patanase Nasal Spray (Olopatadine Hydrochloride Nasal Spray)
PEG Electrolytes Solution (CoLyte)
Pemirolast Potassium Ophthalmic Solution (Alamast) Penlac (Ciclopirox Topical Solution)
PENNSAID (Diclofenac Sodium Topical Solution)
Perforomist (Formoterol Fumarate Inhalation Solution)
Peritoneal Dialysis Solution
Phenylephrine Hydrochloride Ophthalmic Solution (Neo-Synephrine)
Phospholine Iodide (Echothiophate Iodide for Ophthalmic Solution)
Podofilox (Podofilox Topical Solution)
Pred Forte (Prednisolone Acetate Ophthalmic Suspension)
Pralatrexate Solution for Intravenous Injection (Folotyn)
Pred Mild
Prednisone Intensol
Prednisolone Acetate Ophthalmic Suspension (Pred Forte)
Prevacid
PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution)
Pro Air
Proglycem
ProHance (Gadoteridol Injection Solution)
Proparacaine Hydrochloride Ophthalmic Solution (Alcaine)
Propine
Pulmicort
Pulmozyme
Quixin (Levofloxacin Ophthalmic Solution 0.5%)
QVAR
Rapamune
Rebetol
Relacon-HC
Rotarix (Rotavirus Vaccine, Live, Oral Suspension)
Rotavirus Vaccine, Live, Oral Suspension (Rotarix)
Rowasa (Mesalamine Rectal Suspension Enema)
Sabril (Vigabatrin Oral Solution) Sacrosidase Oral Solution (Sucraid)
Sandimmune
Sepra
Serevent Diskus
Solu Cortef (Hydrocortisone Sodium Succinate)
Solu Medrol (Methylprednisolone sodium succinate)
Spiriva
Sporanox Oral Solution (Itraconazole Oral Solution)
Staticin (Erythromycin Topical Solution 1 .5%)
Stalevo
Starlix
Sterile Hemofiltration Hemodiafiltration Solution (PrismaSol Solution)
Stimate
Sucralfate (Carafate Suspension)
Sulfacetamide Sodium Ophthalmic Solution 10% (Bleph 10)
Synarel Nasal Solution (Nafarelin Acetate Nasal Solution for Endometriosis)
Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension)
Tamiflu
Tobi
TobraDex
Tobradex ST (Tobramycin / Dexamethasone Ophthalmic Suspension 0.3%/0.05%)
Tobramycin / Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST)
Timolol
Timoptic
Travatan Z
Treprostinil Inhalation Solution (Tyvaso)
Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution)
Tyvaso (Treprostinil Inhalation Solution)
Ventolin
Vfend Vibramycin Oral (Doxycycline Calcium Oral Suspension)
Videx (Didanosine Pediatric Powder for Oral Solution)
Vigabatrin Oral Solution (Sabril)
Viokase
Viracept
Viramune
Vitamin K1 (Fluid Colloidal Solution of Vitamin K1 )
Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution)
Zarontin Oral Solution (Ethosuximide Oral Solution)
Ziagen
Zyvox
Zymar (Gatifloxacin Ophthalmic Solution)
Zymaxid (Gatifloxacin Ophthalmic Solution)
Drug Classes
5-alpha-reductase inhibitors
5-aminosalicylates
5HT3 receptor antagonists
adamantane antivirals
adrenal cortical steroids
adrenal corticosteroid inhibitors
adrenergic bronchodilators
agents for hypertensive emergencies
agents for pulmonary hypertension
aldosterone receptor antagonists
alkylating agents
alpha-adrenoreceptor antagonists
alpha-glucosidase inhibitors
alternative medicines
amebicides aminoglycosides
aminopenicillins
aminosalicylates
amylin analogs
Analgesic Combinations
Analgesics
androgens and anabolic steroids angiotensin converting enzyme inhibitors angiotensin II inhibitors
anorectal preparations
anorexiants
antacids
anthelmintics
anti-angiogenic ophthalmic agents anti-CTLA-4 monoclonal antibodies anti-infectives
antiadrenergic agents, centrally acting antiadrenergic agents, peripherally acting antiandrogens
antianginal agents
antiarrhythmic agents
antiasthmatic combinations
antibiotics/antineoplastics
anticholinergic antiemetics
anticholinergic antiparkinson agents anticholinergic bronchodilators anticholinergic chronotropic agents anticholinergics/antispasmodics anticoagulants
anticonvulsants ant depressants
ant diabetic agents
ant diabetic combinations
ant diarrheals
ant diuretic hormones
ant dotes
ant emetic/antivertigo agents ant fungals
ant gonadotropic agents
ant gout agents
ant histamines
ant hyperlipidemic agents
ant hyperlipidemic combinations ant hypertensive combinations ant hyperuricemic agents
ant malarial agents
ant malarial combinations
ant malarial quinolines
ant metabolites
ant migraine agents
ant neoplastic detoxifying agents ant neoplastic interferons
ant neoplastic monoclonal antibodies ant neoplastics
ant parkinson agents
ant platelet agents
ant pseudomonal penicillins ant psoriatics
ant psychotics
ant rheumatics antiseptic and germicides antithyroid agents
antitoxins and antivenins
antituberculosis agents
antituberculosis combinations antitussives
antiviral agents
antiviral combinations
antiviral interferons
anxiolytics, sedatives, and hypnotics aromatase inhibitors
atypical antipsychotics
azole antifungals
bacterial vaccines
barbiturate anticonvulsants barbiturates
BCR-ABL tyrosine kinase inhibitors benzodiazepine anticonvulsants benzodiazepines
beta-adrenergic blocking agents beta-lactamase inhibitors
bile acid sequestrants
biologicals
bisphosphonates
bone resorption inhibitors
bronchodilator combinations bronchodilators
calcitonin
calcium channel blocking agents carbamate anticonvulsants carbapenems
carbonic anhydrase inhibitor anticonvulsants carbonic anhydrase inhibitors
cardiac stressing agents
cardioselective beta blockers
cardiovascular agents
catecholamines
CD20 monoclonal antibodies
CD33 monoclonal antibodies
CD52 monoclonal antibodies
central nervous system agents
cephalosporins
cerumenolytics
chelating agents
chemokine receptor antagonist
chloride channel activators
cholesterol absorption inhibitors
cholinergic agonists
cholinergic muscle stimulants
cholinesterase inhibitors
CNS stimulants
coagulation modifiers
colony stimulating factors
contraceptives
corticotropin
coumarins and indandiones
cox-2 inhibitors
decongestants
dermatological agents
diagnostic radiopharmaceuticals dibenzazepine anticonvulsants
digestive enzymes
dipeptidyl peptidase 4 inhibitors
diuretics
dopaminergic antiparkinsonism agents
drugs used in alcohol dependence
echinocandins
EGFR inhibitors
estrogen receptor antagonists
estrogens
expectorants
factor Xa inhibitors
fatty acid derivative anticonvulsants
fibric acid derivatives
first generation cephalosporins
fourth generation cephalosporins
functional bowel disorder agents
gallstone solubilizing agents
gamma-aminobutyric acid analogs
gamma-aminobutyric acid reuptake inhibitors gamma-aminobutyric acid transaminase inhibitors gastrointestinal agents
general anesthetics
genitourinary tract agents
Gl stimulants
glucocorticoids
glucose elevating agents
glycopeptide antibiotics
glycoprotein platelet inhibitors
glycylcyclines gonadotropin releasing hormones gonadotropin-releasing hormone antagonists gonadotropins
group I antiarrhythmics
group II antiarrhythmics
group III antiarrhythmics
group IV antiarrhythmics
group V antiarrhythmics
growth hormone receptor blockers growth hormones
H. pylori eradication agents
H2 antagonists
hematopoietic stem cell mobilizer
heparin antagonists
heparins
HER2 inhibitors
herbal products
histone deacetylase inhibitors
hormone replacement therapy
hormones
hormones/antineoplastics
hydantoin anticonvulsants
illicit (street) drugs
immune globulins
immunologic agents
immunosuppressive agents
impotence agents
in vivo diagnostic biologicals
incretin mimetics
inhaled anti-infectives inhaled corticosteroids
inotropic agents
insulin
insulin-like growth factor
integrase strand transfer inhibitor interferons
intravenous nutritional products
iodinated contrast media
ionic iodinated contrast media
iron products
ketolides
laxatives
leprostatics
leukotriene modifiers
lincomycin derivatives
lipoglycopeptides
local injectable anesthetics
loop diuretics
lung surfactants
lymphatic staining agents
lysosomal enzymes
macrolide derivatives
macrolides
magnetic resonance imaging contrast media mast cell stabilizers
medical gas
meglitinides
metabolic agents
methylxanthines
mineralocorticoids minerals and electrolytes
miscel laneous agents
miscel laneous analgesics
miscel laneous antibiotics
miscel laneous anticonvulsants
miscel laneous antidepressants
miscel laneous antidiabetic agents
miscel laneous antiemetics
miscel laneous antifungals
miscel laneous antihyperlipidemic agents miscel laneous antimalarials
miscel laneous antineoplastics
miscel laneous antiparkinson agents
miscel laneous antipsychotic agents
miscel laneous antituberculosis agents
miscel laneous antivirals
miscel laneous anxiolytics, sedatives and hypnotics miscel laneous biologicals
miscel laneous bone resorption inhibitors miscel laneous cardiovascular agents
miscel laneous central nervous system agents miscel laneous coagulation modifiers
miscel laneous diuretics
miscel laneous genitourinary tract agents miscel laneous Gl agents
miscel laneous hormones
miscel laneous metabolic agents
miscel laneous ophthalmic agents
miscel laneous otic agents
miscel laneous respiratory agents miscellaneous sex hormones miscellaneous topical agents
miscellaneous uncategorized agents miscellaneous vaginal agents mitotic inhibitors
monoamine oxidase inhibitors monoclonal antibodies
mouth and throat products
mTOR inhibitors
mTOR kinase inhibitors
mucolytics
multikinase inhibitors
muscle relaxants
mydriatics
narcotic analgesic combinations narcotic analgesics
nasal anti-infectives
nasal antihistamines and decongestants nasal lubricants and irrigations nasal preparations
nasal steroids
natural penicillins
neuraminidase inhibitors
neuromuscular blocking agents next generation cephalosporins nicotinic acid derivatives
nitrates
NNRTIs
non-cardioselective beta blockers non-iodinated contrast media non-ionic iodinated contrast media
non-sulfonylureas
nonsteroidal anti-inflammatory agents
norepinephrine reuptake inhibitors
norepinephrine-dopamine reuptake inhibitors nucleoside reverse transcriptase inhibitors (NRTIs) nutraceutical products
nutritional products
ophthalmic anesthetics
ophthalmic anti-infectives
ophthalmic anti-inflammatory agents
ophthalmic antihistamines and decongestants ophthalmic diagnostic agents
ophthalmic glaucoma agents
ophthalmic lubricants and irrigations
ophthalmic preparations
ophthalmic steroids
ophthalmic steroids with anti-infectives
ophthalmic surgical agents
oral nutritional supplements
otic anesthetics
otic anti-infectives
otic preparations
otic steroids
otic steroids with anti-infectives
oxazolidinedione anticonvulsants
parathyroid hormone and analogs
penicillinase resistant penicillins
penicillins
peripheral opioid receptor antagonists peripheral vasodilators
peripherally acting antiobesity agents phenothiazine antiemetics
phenothiazine antipsychotics phenylpiperazine antidepressants plasma expanders
platelet aggregation inhibitors platelet-stimulating agents
polyenes
potassium-sparing diuretics probiotics
progesterone receptor modulators progestins
prolactin inhibitors
prostaglandin D2 antagonists protease inhibitors
proton pump inhibitors
psoralens
psychotherapeutic agents
psychotherapeutic combinations purine nucleosides
pyrrolidine anticonvulsants quinolones
radiocontrast agents
radiologic adjuncts
radiologic agents
radiologic conjugating agents radiopharmaceuticals
RANK ligand inhibitors
recombinant human erythropoietins renin inhibitors
respiratory agents
respiratory inhalant products
rifamycin derivatives
salicylates
sclerosing agents
second generation cephalosporins selective estrogen receptor modulators selective serotonin reuptake inhibitors serotonin-norepinephrine reuptake inhibitors serotoninergic neuroenteric modulators sex hormone combinations
sex hormones
skeletal muscle relaxant combinations skeletal muscle relaxants
smoking cessation agents
somatostatin and somatostatin analogs spermicides
statins
sterile irrigating solutions
streptomyces derivatives
succinimide anticonvulsants
sulfonamides
sulfonylureas
synthetic ovulation stimulants
tetracyclic antidepressants
tetracyclines
therapeutic radiopharmaceuticals
thiazide diuretics
thiazolidinediones thioxanthenes
third generation cephalosporins thrombin inhibitors
thrombolytics
thyroid drugs
tocolytic agents
topical acne agents
topical agents
topical anesthetics
topical anti-infectives
topical antibiotics
topical antifungals
topical antihistamines
topical antipsoriatics
topical antivirals
topical astringents
topical debriding agents
topical depigmenting agents topical emollients
topical keratolytics
topical steroids
topical steroids with anti-infectives toxoids
triazine anticonvulsants
tricyclic antidepressants
trifunctional monoclonal antibodies tumor necrosis factor (TNF) inhibitors tyrosine kinase inhibitors
ultrasound contrast media
upper respiratory combinations urea anticonvulsants
urinary anti-infectives
urinary antispasmodics
urinary pH modifiers
uterotonic agents
vaccine
vaccine combinations
vaginal anti-infectives
vaginal preparations
vasodilators
vasopressin antagonists
vasopressors
VEGF/VEGFR inhibitors
viral vaccines
viscosupplementation agents vitamin and mineral combinations vitamins
Diagnostic Tests
17-Hydroxyprogesterone
ACE (Angiotensin I converting enzyme)
Acetaminophen
Acid phosphatase
ACTH
Activated clotting time
Activated protein C resistance
Adrenocorticotropic hormone (ACTH)
Alanine aminotransferase (ALT)
Albumin
Aldolase Aldosterone
Alkaline phosphatase
Alkaline phosphatase (ALP)
Alphal -antitrypsin
Alpha-fetoprotein
Alpha-fetoprotien
Ammonia levels
Amylase
ANA (antinuclear antbodies)
ANA (antinuclear antibodies)
Angiotensin-converting enzyme (ACE) Anion gap
Anticardiolipin antibody
Anticardiolipin antivbodies (ACA)
Anti-centromere antibody
Antidiuretic hormone
Anti-DNA
Anti-Dnase-B
Anti-Gliadin antibody
Anti-glomerular basement membrane antibody
Anti-HBc (Hepatitis B core antibodies
Anti-HBs (Hepatitis B surface antibody
Antiphospholipid antibody
Anti-RNA polymerase
Anti-Smith (Sm) antibodies
Anti-Smooth Muscle antibody
Antistreptolysin O (ASO)
Antithrombin III
Anti-Xa activity
Anti-Xa assay Apolipoproteins
Arsenic
Aspartate aminotransferase (AST) B12
Basophil
Beta-2-Microglobulin
Beta-hydroxybutyrate
B-HCG
Bilirubin
Bilirubin, direct
Bilirubin, indirect
Bilirubin, total
Bleeding time
Blood gases (arterial)
Blood urea nitrogen (BUN)
BUN
BUN (blood urea nitrogen)
CA 125
CA 15-3
CA 19-9
Calcitonin
Calcium
Calcium (ionized)
Carbon monoxide (CO)
Carcinoembryonic antigen (CEA)
CBC
CEA
CEA (carcinoembryonic antigen)
Ceruloplasmin
CH50Chloride Cholesterol
Cholesterol, HDL
Clot lysis time
Clot retraction time
CMP
C02
Cold agglutinins
Complement C3
Copper
Corticotrophin releasing hormone (CRH) stimulation test Cortisol
Cortrosyn stimulation test
C-peptide
CPK (Total)
CPK-MB
C-reactive protein
Creatinine
Creatinine kinase (CK)
Cryoglobulins
DAT (Direct antiglobulin test)
D-Dimer
Dexamethasone suppression test
DHEA-S
Dilute Russell viper venom
Elliptocytes
Eosinophil
Erythrocyte sedimentation rate (ESR)
Estradiol
Estriol
Ethanol Ethylene glycol
Euglobulin lysis
Factor V Leiden
Factor VIII inhibitor
Factor VIII level
Ferritin
Fibrin split products
Fibrinogen
Folate
Folate (serum
Fractional excretion of sodium (FENA) FSH (follicle stimulating factor) FTA-ABS
Gamma glutamyl transferase (GGT) Gastrin
GGTP (Gamma glutamyl transferase) Glucose
Growth hormone
Haptoglobin
HBeAg (Hepatitis Be antigen)
HBs-Ag (Hepatitis B surface antigen)
Helicobacter pylori
Hematocrit
Hematocrit (HCT)
Hemoglobin
Hemoglobin A1 C
Hemoglobin electrophoresis
Hepatitis A antibodies
Hepatitis C antibodies
IAT (Indirect antiglobulin test) Immunofixation (IFE)
Iron
Lactate dehydrogenase (LDH)
Lactic acid (lactate)
LDH
LH (Leutinizing hormone
Lipase
Lupus anticoagulant
Lymphocyte
Magnesium
MCH (mean corpuscular hemoglobin
MCHC (mean corpuscular hemoglobin concentration)
MCV (mean corpuscular volume)
Methylmalonate
Monocyte
MPV (mean platelet volume)
Myoglobin
Neutrophil
Parathyroid hormone (PTH)
Phosphorus
Platelets (pit)
Potassium
Prealbumin
Prolactin
Prostate specific antigen (PSA)
Protein C
Protein S
PSA (prostate specific antigen)
PT (Prothrombin time)
PTT (Partial thromboplastin time) RDW (red cell distribution width)
Renin
Rennin
Reticulocyte count
reticulocytes
Rheumatoid factor (RF)
Sed Rate
Serum glutamic-pyruvic transaminase (SGPT
Serum protein electrophoresis (SPEP)
Sodium
T3-resin uptake (T3RU)
T4, Free
Thrombin time
Thyroid stimulating hormone (TSH)
Thyroxine (T4)
Total iron binding capacity (TIBC)
Total protein
Transferrin
Transferrin saturation
Triglyceride (TG)
Troponin
Uric acid
Vitamin B12
White blood cells (WBC)
Widal test
179. The invention of any preceding claim, wherein said fluid composition comprises an inhalation anesthetic.
180. The invention of claim 179, wherein said inhalation anesthetic comprises a fluoroether inhalation anesthetic agent.
181 . The invention of claim 179, wherein said inhalation anesthetic comprises sevoflurane, enflurane, isoflurane, methoxyflurane, desflurane, or a combination of any two or more of these.
182. The invention of any preceding claim, wherein said fluid composition comprises a drug.
183. The invention of claim 182, wherein said drug comprises Ablavar (Gadofosveset Trisodium Injection).
184. The invention of claim 182, wherein said drug comprises Abobotulinumtoxin A Injection (Dysport).
185. The invention of claim 182, wherein said drug comprises Accretropin (Somatropin Injection).
186. The invention of claim 182, wherein said drug comprises Acetadote (Acetylcysteine Injection).
187. The invention of claim 182, wherein said drug comprises Acetazolamide Injection (Acetazolamide Injection).
188. The invention of claim 182, wherein said drug comprises Acetylcysteine Injection (Acetadote).
189. The invention of claim 182, wherein said drug comprises Actemra (Tocilizumab Injection).
190. The invention of claim 182, wherein said drug comprises Acthrel (Corticorelin Ovine Triflutate for Injection).
191 . The invention of claim 182, wherein said drug comprises Acyclovir for Injection (Zovirax Injection).
192. The invention of claim 182, wherein said drug comprises Adacel.
193. The invention of claim 182, wherein said drug comprises Adalimumab.
194. The invention of claim 182, wherein said drug comprises Adenoscan (Adenosine Injection).
195. The invention of claim 182, wherein said drug comprises Adenosine Injection (Adenoscan).
196. The invention of claim 182, wherein said drug comprises Adrenaclick.
197. The invention of claim 182, wherein said drug comprises AdreView (lobenguane I 123 Injection for Intravenous Use).
198. The invention of claim 182, wherein said drug comprises Afluria.
199. The invention of claim 182, wherein said drug comprises Ak-Fluor (Fluorescein Injection).
200. The invention of claim 182, wherein said drug comprises Alglucerase Injection (Ceredase).
201 . The invention of claim 182, wherein said drug comprises Alkeran Injection (Melphalan Hcl Injection).
202. The invention of claim 182, wherein said drug comprises Allopurinol Sodium for Injection (Aloprim).
203. The invention of claim 182, wherein said drug comprises Aloprim (Allopurinol Sodium for Injection).
204. The invention of claim 182, wherein said drug comprises Alprostadil.
205. The invention of claim 182, wherein said drug comprises Alsuma (Sumatriptan Injection).
206. The invention of claim 182, wherein said drug comprises Amino Acid Injections.
207. The invention of claim 182, wherein said drug comprises Aminosyn.
208. The invention of claim 182, wherein said drug comprises Apidra.
209. The invention of claim 182, wherein said drug comprises Apremilast.
210. The invention of claim 182, wherein said drug comprises Alprostadil Dual Chamber System for Injection (Caverject Impulse).
21 1 . The invention of claim 182, wherein said drug comprises AMG 108.
212. The invention of claim 182, wherein said drug comprises AMG 714.
213. The invention of claim 182, wherein said drug comprises Amiodarone HCI Injection (Amiodarone HCI Injection).
214. The invention of claim 182, wherein said drug comprises Amobarbital Sodium Injection (Amytal Sodium).
215. The invention of claim 182, wherein said drug comprises Amytal Sodium (Amobarbital Sodium Injection).
216. The invention of claim 182, wherein said drug comprises Anakinra.
217. The invention of claim 182, wherein said drug comprises Arixtra.
218. The invention of claim 182, wherein said drug comprises Amphadase (Hyaluronidase Inj).
219. The invention of claim 182, wherein said drug comprises Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection).
220. The invention of claim 182, wherein said drug comprises Anzemet Injection (Dolasetron Mesylate Injection).
221 . The invention of claim 182, wherein said drug comprises Apidra (Insulin Glulisine [rDNA origin] Inj).
222. The invention of claim 182, wherein said drug comprises Argatroban (Argatroban Injection).
223. The invention of claim 182, wherein said drug comprises Arginine Hydrochloride Injection (R-Gene 10).
224. The invention of claim 182, wherein said drug comprises Aristocort.
225. The invention of claim 182, wherein said drug comprises Aristospan.
226. The invention of claim 182, wherein said drug comprises Arsenic Trioxide Injection (Trisenox).
227. The invention of claim 182, wherein said drug comprises Articane HCI and Epinephrine Injection (Septocaine).
228. The invention of claim 182, wherein said drug comprises Arzerra (Ofatumumab Injection).
229. The invention of claim 182, wherein said drug comprises Asclera (Polidocanol Injection).
230. The invention of claim 182, wherein said drug comprises Atenolol Inj (Tenormin I.V. Injection).
231 . The invention of claim 182, wherein said drug comprises Atracurium Besylate Injection (Atracurium Besylate Injection).
232. The invention of claim 182, wherein said drug comprises Avastin.
233. The invention of claim 182, wherein said drug comprises Azactam Injection (Aztreonam Injection).
234. The invention of claim 182, wherein said drug comprises Azithromycin (Zithromax Injection).
235. The invention of claim 182, wherein said drug comprises Aztreonam Injection (Azactam Injection).
236. The invention of claim 182, wherein said drug comprises Baclofen Injection (Lioresal Intrathecal).
237. The invention of claim 182, wherein said drug comprises Bacteriostatic Water (Bacteriostatic Water for Injection).
238. The invention of claim 182, wherein said drug comprises Baclofen Injection (Lioresal Intrathecal).
239. The invention of claim 182, wherein said drug comprises Bal in Oil Ampules (Dimercarprol Injection).
240. The invention of claim 182, wherein said drug comprises BayHepB.
241 . The invention of claim 182, wherein said drug comprises BayTet.
242. The invention of claim 182, wherein said drug comprises Benadryl.
243. The invention of claim 182, wherein said drug comprises Bendamustine Hydrochloride Injection (Treanda).
244. The invention of claim 182, wherein said drug comprises Benztropine Mesylate Injection (Cogentin).
245. The invention of claim 182, wherein said drug comprises Betamethasone Injectable Suspension (Celestone Soluspan).
246. The invention of claim 182, wherein said drug comprises Bexxar.
247. The invention of claim 182, wherein said drug comprises Bicillin C-R 900/300 (Penicillin G Benzathine and Penicillin G Procaine Injection).
248. The invention of claim 182, wherein said drug comprises Blenoxane (Bleomycin Sulfate Injection).
249. The invention of claim 182, wherein said drug comprises Bleomycin Sulfate Injection (Blenoxane).
250. The invention of claim 182, wherein said drug comprises Boniva Injection (Ibandronate Sodium Injection).
251 . The invention of claim 182, wherein said drug comprises Botox Cosmetic (OnabotulinumtoxinA for Injection).
252. The invention of claim 182, wherein said drug comprises Bravelle (Urofollitropin Injection).
253. The invention of claim 182, wherein said drug comprises Bretylium (Bretylium Tosylate Injection ).
254. The invention of claim 182, wherein said drug comprises Brevital Sodium (Methohexital Sodium for Injection).
255. The invention of claim 182, wherein said drug comprises Brethine.
256. The invention of claim 182, wherein said drug comprises Briobacept.
257. The invention of claim 182, wherein said drug comprises BTT-1023.
258. The invention of claim 182, wherein said drug comprises Bupivacaine HCI.
259. The invention of claim 182, wherein said drug comprises Byetta.
260. The invention of claim 182, wherein said drug comprises Ca-DTPA (Pentetate Calcium Trisodium Inj).
261 . The invention of claim 182, wherein said drug comprises Cabazitaxel Injection (Jevtana).
262. The invention of claim 182, wherein said drug comprises Caffeine Alkaloid (Caffeine and Sodium Benzoate Injection).
263. The invention of claim 182, wherein said drug comprises Calcijex Injection (Calcitrol).
264. The invention of claim 182, wherein said drug comprises Calcitrol (Calcijex Injection).
265. The invention of claim 182, wherein said drug comprises Calcium Chloride (Calcium Chloride Injection 10%).
266. The invention of claim 182, wherein said drug comprises Calcium Disodium Versenate (Edetate Calcium Disodium Injection).
267. The invention of claim 182, wherein said drug comprises Camptosar Injection (Irinotecan Hydrochloride).
268. The invention of claim 182, wherein said drug comprises Canakinumab Injection (Maris).
269. The invention of claim 182, wherein said drug comprises Capastat Sulfate (Capreomycin for Injection).
270. The invention of claim 182, wherein said drug comprises Capreomycin for Injection (Capastat Sulfate).
271 . The invention of claim 182, wherein said drug comprises Cardiolite (Prep kit for Technetium Tc99 Sestamibi for Injection).
272. The invention of claim 182, wherein said drug comprises Cefazolin and Dextrose for Injection (Cefazolin Injection).
273. The invention of claim 182, wherein said drug comprises Cefepime Hydrochloride.
274. The invention of claim 182, wherein said drug comprises Cefotaxime.
275. The invention of claim 182, wherein said drug comprises Ceftriaxone.
276. The invention of claim 182, wherein said drug comprises Carnitor Injection.
277. The invention of claim 182, wherein said drug comprises Caverject.
278. The invention of claim 182, wherein said drug comprises Celestone Soluspan.
279. The invention of claim 182, wherein said drug comprises Cerebyx (Fosphenytoin Sodium Injection).
280. The invention of claim 182, wherein said drug comprises Ceredase (Alglucerase Injection).
281 . The invention of claim 182, wherein said drug comprises Ceretec (Technetium Tc99m Exametazime Injection).
282. The invention of claim 182, wherein said drug comprises Certolizumab.
283. The invention of claim 182, wherein said drug comprises CF-101 .
284. The invention of claim 182, wherein said drug comprises Chloramphenicol Sodium Succinate (Chloramphenicol Sodium Succinate Injection).
285. The invention of claim 182, wherein said drug comprises Chloramphenicol Sodium Succinate Injection (Chloramphenicol Sodium Succinate).
286. The invention of claim 182, wherein said drug comprises Choriogonadotropin Alfa Injection (Ovidrel).
287. The invention of claim 182, wherein said drug comprises Cimzia.
288. The invention of claim 182, wherein said drug comprises Cisplatin (Cisplatin Injection).
289. The invention of claim 182, wherein said drug comprises Clomiphine Citrate.
290. The invention of claim 182, wherein said drug comprises Clonidine Injection (Duraclon).
291 . The invention of claim 182, wherein said drug comprises Cogentin (Benztropine Mesylate Injection).
292. The invention of claim 182, wherein said drug comprises Colistimethate Injection (Coly-Mycin M).
293. The invention of claim 182, wherein said drug comprises Coly-Mycin M (Colistimethate Injection).
294. The invention of claim 182, wherein said drug comprises Compath.
295. The invention of claim 182, wherein said drug comprises Conivaptan Hcl Injection (Vaprisol).
296. The invention of claim 182, wherein said drug comprises Conjugated Estrogens for Injection (Premarin Injection).
297. The invention of claim 182, wherein said drug comprises Copaxone.
298. The invention of claim 182, wherein said drug comprises Corticorelin Ovine Triflutate for Injection (Acthrel).
299. The invention of claim 182, wherein said drug comprises Corvert (Ibutilide Fumarate Injection).
300. The invention of claim 182, wherein said drug comprises Cubicin (Daptomycin Injection).
301 . The invention of claim 182, wherein said drug comprises CF-101 .
302. The invention of claim 182, wherein said drug comprises Cyanokit (Hydroxocobalamin for Injection).
303. The invention of claim 182, wherein said drug comprises Cytarabine Liposome Injection (DepoCyt).
304. The invention of claim 182, wherein said drug comprises Cyanocobalamin.
305. The invention of claim 182, wherein said drug comprises D.H.E. 45.
306. The invention of claim 182, wherein said drug comprises Dacogen (Decitabine Injection).
307. The invention of claim 182, wherein said drug comprises Dalteparin.
308. The invention of claim 182, wherein said drug comprises Dantrium IV (Dantrolene Sodium for Injection).
309. The invention of claim 182, wherein said drug comprises Dantrolene Sodium for Injection (Dantrium IV).
310. The invention of claim 182, wherein said drug comprises Daptomycin Injection (Cubicin).
31 1 . The invention of claim 182, wherein said drug comprises Darbepoietin
Alfa.
312. The invention of claim 182, wherein said drug comprises DDAVP Injection (Desmopressin Acetate Injection).
313. The invention of claim 182, wherein said drug comprises Decavax.
314. The invention of claim 182, wherein said drug comprises Decitabine Injection (Dacogen).
315. The invention of claim 182, wherein said drug comprises Dehydrated Alcohol (Dehydrated Alcohol Injection).
316. The invention of claim 182, wherein said drug comprises Denosumab Injection (Prolia).
317. The invention of claim 182, wherein said drug comprises Delatestryl.
318. The invention of claim 182, wherein said drug comprises Delestrogen.
319. The invention of claim 182, wherein said drug comprises Delteparin Sodium.
320. The invention of claim 182, wherein said drug comprises Depacon (Valproate Sodium Injection).
321 . The invention of claim 182, wherein said drug comprises Depo Medrol (Methylprednisolone Acetate Injectable Suspension).
322. The invention of claim 182, wherein said drug comprises DepoCyt (Cytarabine Liposome Injection).
323. The invention of claim 182, wherein said drug comprises DepoDur (Morphine Sulfate XR Liposome Injection).
324. The invention of claim 182, wherein said drug comprises Desmopressin Acetate Injection (DDAVP Injection).
325. The invention of claim 182, wherein said drug comprises Depo-Estradiol.
326. The invention of claim 182, wherein said drug comprises Depo-Provera 104mg/ml.
327. The invention of claim 182, wherein said drug comprises Depo-Provera 150mg/ml.
328. The invention of claim 182, wherein said drug comprises Depo- Testosterone.
329. The invention of claim 182, wherein said drug comprises Dexrazoxane for Injection, Intravenous Infusion Only (Totect).
330. The invention of claim 182, wherein said drug comprises Dextrose / Electrolytes.
331 . The invention of claim 182, wherein said drug comprises Dextrose and Sodium Chloride Inj (Dextrose 5% in 0.9% Sodium Chloride).
332. The invention of claim 182, wherein said drug comprises Dextrose.
333. The invention of claim 182, wherein said drug comprises Diazepam Injection (Diazepam Injection).
334. The invention of claim 182, wherein said drug comprises Digoxin Injection (Lanoxin Injection).
335. The invention of claim 182, wherein said drug comprises Dilaudid-HP (Hydromorphone Hydrochloride Injection).
336. The invention of claim 182, wherein said drug comprises Dimercarprol Injection (Bal in Oil Ampules).
337. The invention of claim 182, wherein said drug comprises Diphenhydramine Injection (Benadryl Injection).
338. The invention of claim 182, wherein said drug comprises Dipyridamole Injection (Dipyridamole Injection).
339. The invention of claim 182, wherein said drug comprises Docetaxel for Injection (Taxotere).
340. The invention of claim 182, wherein said drug comprises Dolasetron Mesylate Injection (Anzemet Injection).
341 . The invention of claim 182, wherein said drug comprises Doribax (Doripenem for Injection).
342. The invention of claim 182, wherein said drug comprises Doripenem for Injection (Doribax).
343. The invention of claim 182, wherein said drug comprises Doxercalciferol Injection (Hectorol Injection).
344. The invention of claim 182, wherein said drug comprises Doxil (Doxorubicin Hcl Liposome Injection).
345. The invention of claim 182, wherein said drug comprises Doxorubicin Hcl Liposome Injection (Doxil).
346. The invention of claim 182, wherein said drug comprises Duraclon (Clonidine Injection).
347. The invention of claim 182, wherein said drug comprises Duramorph (Morphine Injection).
348. The invention of claim 182, wherein said drug comprises Dysport (Abobotulinumtoxin A Injection).
349. The invention of claim 182, wherein said drug comprises Ecallantide Injection (Kalbitor).
350. The invention of claim 182, wherein said drug comprises Edetate Calcium Disodium Injection (Calcium Disodium Versenate).
351 . The invention of claim 182, wherein said drug comprises Edex (Alprostadil for Injection).
352. The invention of claim 182, wherein said drug comprises Engerix.
353. The invention of claim 182, wherein said drug comprises Edrophonium Injection (Enlon).
354. The invention of claim 182, wherein said drug comprises Eloxatin (Oxaliplatin Injection).
355. The invention of claim 182, wherein said drug comprises Emend Injection (Fosaprepitant Dimeglumine Injection).
356. The invention of claim 182, wherein said drug comprises Enalaprilat Injection (Enalaprilat Injection).
357. The invention of claim 182, wherein said drug comprises Enlon (Edrophonium Injection).
358. The invention of claim 182, wherein said drug comprises Enoxaparin Sodium Injection (Lovenox).
359. The invention of claim 182, wherein said drug comprises Eovist (Gadoxetate Disodium Injection).
360. The invention of claim 182, wherein said drug comprises Enbrel.
361 . The invention of claim 182, wherein said drug comprises Enoxaparin.
362. The invention of claim 182, wherein said drug comprises Epinepherine.
363. The invention of claim 182, wherein said drug comprises Epipen.
364. The invention of claim 182, wherein said drug comprises Epipen Jr.
365. The invention of claim 182, wherein said drug comprises Erbitux.
366. The invention of claim 182, wherein said drug comprises Ertapenem Injection (Invanz).
367. The invention of claim 182, wherein said drug comprises Erythropoieten.
368. The invention of claim 182, wherein said drug comprises Essential Amino Acid Injection (Nephramine).
369. The invention of claim 182, wherein said drug comprises Estradiol Cypionate.
370. The invention of claim 182, wherein said drug comprises Estradiol Valerate.
371 . The invention of claim 182, wherein said drug comprises Etanercept.
372. The invention of claim 182, wherein said drug comprises Exenatide Injection (Byetta).
373. The invention of claim 182, wherein said drug comprises Famotidine Injection.
374. The invention of claim 182, wherein said drug comprises FDG (Fludeoxyglucose F 18 Injection).
375. The invention of claim 182, wherein said drug comprises Feraheme (Ferumoxytol Injection).
376. The invention of claim 182, wherein said drug comprises Feridex I.V. (Ferumoxides Injectable Solution).
377. The invention of claim 182, wherein said drug comprises Fertinex.
378. The invention of claim 182, wherein said drug comprises Ferumoxides Injectable Solution (Feridex I.V.).
379. The invention of claim 182, wherein said drug comprises Ferumoxytol Injection (Feraheme).
380. The invention of claim 182, wherein said drug comprises Flagyl Injection (Metronidazole Injection).
381 . The invention of claim 182, wherein said drug comprises Fluarix.
382. The invention of claim 182, wherein said drug comprises Fludeoxyglucose F 18 Injection (FDG).
383. The invention of claim 182, wherein said drug comprises Fluorescein Injection (Ak-Fluor).
384. The invention of claim 182, wherein said drug comprises Follistim AQ Cartridge (Follitropin Beta Injection).
385. The invention of claim 182, wherein said drug comprises Follitropin Alfa Injection (Gonal-f RFF).
386. The invention of claim 182, wherein said drug comprises Follitropin Beta Injection (Follistim AQ Cartridge).
387. The invention of claim 182, wherein said drug comprises Folotyn (Pralatrexate Solution for Intravenous Injection).
388. The invention of claim 182, wherein said drug comprises Fondaparinux.
389. The invention of claim 182, wherein said drug comprises Forteo (Teriparatide (rDNA origin) Injection).
390. The invention of claim 182, wherein said drug comprises Fostamatinib.
391 . The invention of claim 182, wherein said drug comprises Fosaprepitant Dimeglumine Injection (Emend Injection).
392. The invention of claim 182, wherein said drug comprises Foscarnet Sodium Injection (Foscavir).
393. The invention of claim 182, wherein said drug comprises Foscavir (Foscarnet Sodium Injection).
394. The invention of claim 182, wherein said drug comprises Fosphenytoin Sodium Injection (Cerebyx).
395. The invention of claim 182, wherein said drug comprises Fospropofol Disodium Injection (Lusedra).
396. The invention of claim 182, wherein said drug comprises Fragmin.
397. The invention of claim 182, wherein said drug comprises Gadobenate Dimeglumine Injection (Multihance).
398. The invention of claim 182, wherein said drug comprises Gadofosveset Trisodium Injection (Ablavar).
399. The invention of claim 182, wherein said drug comprises Gadoteridol Injection Solution (ProHance).
400. The invention of claim 182, wherein said drug comprises Gadoversetamide Injection (OptiMARK).
401 . The invention of claim 182, wherein said drug comprises Gadoxetate Disodium Injection (Eovist).
402. The invention of claim 182, wherein said drug comprises Ganirelix (Ganirelix Acetate Injection).
403. The invention of claim 182, wherein said drug comprises Gardasil.
404. The invention of claim 182, wherein said drug comprises Gemtuzumab Ozogamicin for Injection (Mylotarg).
405. The invention of claim 182, wherein said drug comprises Genotropin.
406. The invention of claim 182, wherein said drug comprises Gentamicin Injection.
407. The invention of claim 182, wherein said drug comprises Golimumab Injection (Simponi Injection).
408. The invention of claim 182, wherein said drug comprises Gonal-f RFF (Follitropin Alfa Injection).
409. The invention of claim 182, wherein said drug comprises Granisetron Hydrochloride (Kytril Injection).
410. The invention of claim 182, wherein said drug comprises Gentamicin Sulfate.
41 1 . The invention of claim 182, wherein said drug comprises Glatiramer Acetate.
412. The invention of claim 182, wherein said drug comprises Glucagen.
413. The invention of claim 182, wherein said drug comprises Glucagon.
414. The invention of claim 182, wherein said drug comprises Haldol (Haloperidol Injection).
415. The invention of claim 182, wherein said drug comprises Havrix.
416. The invention of claim 182, wherein said drug comprises Hectorol InjectiZn (Doxercalciferol Injection).
417. The invention of claim 182, wherein said drug comprises Heparin.
418. The invention of claim 182, wherein said drug comprises Herceptin.
419. The invention of claim 182, wherein said drug comprises hG-CSF.
420. The invention of claim 182, wherein said drug comprises Humalog.
421 . The invention of claim 182, wherein said drug comprises Human Growth Hormone.
422. The invention of claim 182, wherein said drug comprises Humatrope.
423. The invention of claim 182, wherein said drug comprises HuMax.
424. The invention of claim 182, wherein said drug comprises Humegon.
425. The invention of claim 182, wherein said drug comprises Humira.
426. The invention of claim 182, wherein said drug comprises Humulin.
427. The invention of claim 182, wherein said drug comprises Ibandr8nate Sodium Injection (Boniva Injection).
428. The invention of claim 182, wherein said drug comprises Ibuprofen Lysine Injection (NeoProfen).
429. The invention of claim 182, wherein said drug comprises Ibutilide Fumarate Injection (Corvert).
430. The invention of claim 182, wherein said drug comprises Idamycin PFS (Idarubicin Hydrochloride Injection).
431 . The invention of claim 182, wherein said drug comprises Idarubicin Hydrochloride Injection (Idamycin PFS).
432. The invention of claim 182, wherein said drug comprises Maris (Canakinumab Injection).
433. The invention of claim 182, wherein said drug comprises Imipenem and Cilastatin for Injection (Primaxin I.V.).
434. The invention of claim 182, wherein said drug comprises Imitrex.
435. The invention of claim 182, wherein said drug comprises Incobotulinumtoxin A for Injection (Xeomin).
436. The invention of claim 182, wherein said drug comprises Increlex (Mecasermin [rDNA origin] Injection).
437. The invention of claim 182, wherein said drug comprises Indocin IV (Indomethacin Inj).
438. The invention of claim 182, wherein said drug comprises Indomethacin Inj (Indocin IV).
439. The invention of claim 182, wherein said drug comprises Infanrix.
440. The invention of claim 182, wherein said drug comprises Innohep.
441 . The invention of claim 182, wherein said drug comprises Insulin/
442. The invention of claim 182, wherein said drug comprises Insulin Aspart [rDNA origin] Inj (NovoLog).
443. The invention of claim 182, wherein said drug comprises Insulin Glargine [rDNA origin] Injection (Lantus).
444. The invention of claim 182, wherein said drug comprises Insulin Glulisine [rDNA origin] Inj (Apidra).
445. The invention of claim 182, wherein said drug comprises Interferon alfa- 2b, Recombinant for Injection (Intron A).
446. The invention of claim 182, wherein said drug comprises Intron A (Interferon alfa-2b, Recombinant for Injection).
447. The invention of claim 182, wherein said drug comprises Invanz (Ertapenem Injection).
448. The invention of claim 182, wherein said drug comprises Invega Sustenna (Paliperidone Palmitate Extended- Release Injectable Suspension).
449. The invention of claim 182, wherein said drug comprises lobenguane I 123 Injection for Intravenous Use (AdreView).
450. The invention of claim 182, wherein said drug comprises lopromide Injection (Ultravist).
451 . The invention of claim 182, wherein said drug comprises loversol Injection (Optiray Injection).
452. The invention of claim 182, wherein said drug comprises Iplex (Mecasermin Rinfabate [rDNA origin] Injection).
453. The invention of claim 182, wherein said drug comprises Iprivask.
454. The invention of claim 182, wherein said drug comprises Irinotecan Hydrochloride (Camptosar Injection).
455. The invention of claim 182, wherein said drug comprises Iron Sucrose Injection (Venofer).
456. The invention of claim 182, wherein said drug comprises Istodax (Romidepsin for Injection).
457. The invention of claim 182, wherein said drug comprises Itraconazole Injection (Sporanox Injection).
458. The invention of claim 182, wherein said drug comprises Jevtana (Cabazitaxel Injection).
459. The invention of claim 182, wherein said drug comprises Kalbitor (Ecallantide Injection).
460. The invention of claim 182, wherein said drug comprises KCL in D5NS (Potassium Chloride in 5% Dextrose and Sodium Chloride Injection).
461 . The invention of claim 182, wherein said drug comprises KCL in D5W.
462. The invention of claim 182, wherein said drug comprises KCL in NS.
463. The invention of claim 182, wherein said drug comprises Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension).
464. The invention of claim 182, wherein said drug comprises Keppra Injection (Levetiracetam).
465. The invention of claim 182, wherein said drug comprises Kineret.
466. The invention of claim 182, wherein said drug comprises Kinlytic (Urokinase Injection).
467. The invention of claim 182, wherein said drug comprises Kinrix.
468. The invention of claim 182, wherein said drug comprises Kytril Injection (Granisetron Hydrochloride).
469. The invention of claim 182, wherein said drug comprises lacosamide Tablet and Injection (Vimpat).
470. The invention of claim 182, wherein said drug comprises Lactated Ringer's.
471 . The invention of claim 182, wherein said drug comprises Lanoxin Injection (Digoxin Injection).
472. The invention of claim 182, wherein said drug comprises Lansoprazole for Injection (Prevacid I.V.).
473. The invention of claim 182, wherein said drug comprises Lantus.
474. The invention of claim 182, wherein said drug comprises Leucovorin Calcium (Leucovorin Calcium Injection).
475. The invention of claim 182, wherein said drug comprises Lente (L).
476. The invention of claim 182, wherein said drug comprises Levemir.
477. The invention of claim 182, wherein said drug comprises Leuproide Acetate.
478. The invention of claim 182, wherein said drug comprises Levothyroxine.
479. The invention of claim 182, wherein said drug comprises Levetiracetam (Keppra Injection).
480. The invention of claim 182, wherein said drug comprises Lovenox.
481 . The invention of claim 182, wherein said drug comprises Levocarnitine Injection (Carnitor Injection).
482. The invention of claim 182, wherein said drug comprises Lexiscan (Regadenoson Injection).
483. The invention of claim 182, wherein said drug comprises Lioresal Intrathecal (Baclofen Injection).
484. The invention of claim 182, wherein said drug comprises Liraglutide [rDNA] Injection (Victoza).
485. The invention of claim 182, wherein said drug comprises Lovenox (Enoxaparin Sodium Injection).
486. The invention of claim 182, wherein said drug comprises Lucentis (Ranibizumab Injection).
487. The invention of claim 182, wherein said drug comprises Lupron (Leuprolide Acetate Injection).
488. The invention of claim 182, wherein said drug comprises Lusedra (Fospropofol Disodium Injection).
489. The invention of claim 182, wherein said drug comprises Magnesium Sulfate (Magnesium Sulfate Injection).
490. The invention of claim 182, wherein said drug comprises Mannitol Injection (Mannitol IV).
491 . The invention of claim 182, wherein said drug comprises Marcaine (Bupivacaine Hydrochloride and Epinephrine Injection).
492. The invention of claim 182, wherein said drug comprises Maxipime (Cefepime Hydrochloride for Injection).
493. The invention of claim 182, wherein said drug comprises MDP Multidose Kit of Technetium Injection (Technetium Tc99m Medronate Injection).
494. The invention of claim 182, wherein said drug comprises Mecasermin [rDNA origin] Injection (Increlex).
495. The invention of claim 182, wherein said drug comprises Mecasermin Rinfabate [rDNA origin] Injection (Iplex).
496. The invention of claim 182, wherein said drug comprises Melphalan Hcl Injection (Alkeran Injection).
497. The invention of claim 182, wherein said drug comprises Methotrexate.
498. The invention of claim 182, wherein said drug comprises Menactra.
499. The invention of claim 182, wherein said drug comprises Menopur (Menotropins Injection).
500. The invention of claim 182, wherein said drug comprises Menotropins for Injection (Repronex).
501 . The invention of claim 182, wherein said drug comprises Methohexital Sodium for Injection (Brevital Sodium).
502. The invention of claim 182, wherein said drug comprises Methyldopate Hydrochloride Injection, Solution (Methyldopate Hcl).
503. The invention of claim 182, wherein said drug comprises Methylene Blue (Methylene Blue Injection).
504. The invention of claim 182, wherein said drug comprises Methylprednisolone Acetate Injectable Suspension (Depo Medrol).
505. The invention of claim 182, wherein said drug comprises Metoclopramide Injection (Reglan Injection).
506. The invention of claim 182, wherein said drug comprises Metrodin (Urofollitropin for Injection).
507. The invention of claim 182, wherein said drug comprises Metronidazole Injection (Flagyl Injection).
508. The invention of claim 182, wherein said drug comprises Miacalcin.
509. The invention of claim 182, wherein said drug comprises Midazolam (Midazolam Injection).
510. The invention of claim 182, wherein said drug comprises Minocin Injection (Minocycline Inj).
51 1 . The invention of claim 182, wherein said drug comprises Minocycline Inj (Minocin Injection).
512. The invention of claim 182, wherein said drug comprises Mitoxantrone for Injection Concentrate (Novantrone).
513. The invention of claim 182, wherein said drug comprises Morphine Injection (Duramorph).
514. The invention of claim 182, wherein said drug comprises Morphine Sulfate XR Liposome Injection (DepoDur).
515. The invention of claim 182, wherein said drug comprises Morrhuate Sodium (Morrhuate Sodium Injection).
516. The invention of claim 182, wherein said drug comprises Mozobil (Plerixafor Injection).
517. The invention of claim 182, wherein said drug comprises Multihance (Gadobenate Dimeglumine Injection).
518. The invention of claim 182, wherein said drug comprises Multiple Electrolytes and Dextrose Injection.
519. The invention of claim 182, wherein said drug comprises Multiple Electrolytes Injection .
520. The invention of claim 182, wherein said drug comprises Mylotarg (Gemtuzumab Ozogamicin for Injection).
521 . The invention of claim 182, wherein said drug comprises Nafcillin Injection (Nafcillin Sodium).
522. The invention of claim 182, wherein said drug comprises Nafcillin Sodium (Nafcillin Injection).
523. The invention of claim 182, wherein said drug comprises Naltrexone XR Inj (Vivitrol).
524. The invention of claim 182, wherein said drug comprises NeoProfen (Ibuprofen Lysine Injection).
525. The invention of claim 182, wherein said drug comprises Nandrol Decanoate.
526. The invention of claim 182, wherein said drug comprises Neostigmine Methylsulfate (Neostigmine Methylsulfate Injection).
527. The invention of claim 182, wherein said drug comprises NeoTect (Technetium Tc 99m Depreotide Injection).
528. The invention of claim 182, wherein said drug comprises Nephramine (Essential Amino Acid Injection).
529. The invention of claim 182, wherein said drug comprises Neulasta.
530. The invention of claim 182, wherein said drug comprises Neupogen.
531 . The invention of claim 182, wherein said drug comprises Novolin.
532. The invention of claim 182, wherein said drug comprises Novolog.
533. The invention of claim 182, wherein said drug comprises NeoRecormon.
534. The invention of claim 182, wherein said drug comprises Neutrexin (Trimetrexate Glucuronate Inj).
535. The invention of claim 182, wherein said drug comprises NPH (N).
536. The invention of claim 182, wherein said drug comprises Nexterone (Amiodarone HCI Injection).
537. The invention of claim 182, wherein said drug comprises Norditropin (Somatropin Injection).
538. The invention of claim 182, wherein said drug comprises Normal Saline (Sodium Chloride Injection).
539. The invention of claim 182, wherein said drug comprises Novantrone (Mitoxantrone for Injection Concentrate).
540. The invention of claim 182, wherein said drug comprises Novolin 70/30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection).
541 . The invention of claim 182, wherein said drug comprises NovoLog (Insulin Aspart [rDNA origin] Inj).
542. The invention of claim 182, wherein said drug comprises Nutropin (Somatropin (rDNA origin) for Inj).
543. The invention of claim 182, wherein said drug comprises Nutropin Depot (Somatropin (rDNA origin) for Inj).
544. The invention of claim 182, wherein said drug comprises Octreotide Acetate Injection (Sandostatin LAR).
545. The invention of claim 182, wherein said drug comprises Ocrelizumab.
546. The invention of claim 182, wherein said drug comprises Ofatumumab Injection (Arzerra).
547. The invention of claim 182, wherein said drug comprises Olanzapine Extended Release Injectable Suspension (Zyprexa Relprevv).
548. The invention of claim 182, wherein said drug comprises Omnitrope (Somatropin [ rDNA origin] Injection).
549. The invention of claim 182, wherein said drug comprises Ondansetron Hydrochloride Injection (Zofran Injection).
550. The invention of claim 182, wherein said drug comprises OptiMARK (Gadoversetamide Injection).
551 . The invention of claim 182, wherein said drug comprises Optiray Injection (loversol Injection).
552. The invention of claim 182, wherein said drug comprises Orencia.
553. The invention of claim 182, wherein said drug comprises Osmitrol Injection in Aviva (Mannitol Injection in Aviva Plastic Vessel).
554. The invention of claim 182, wherein said drug comprises Osmitrol Injection in Viaflex (Mannitol Injection in Viaflex Plastic Vessel).
555. The invention of claim 182, wherein said drug comprises Ovidrel (Choriogonadotropin Alfa Injection).
556. The invention of claim 182, wherein said drug comprises Oxacillin (Oxacillin for Injection).
557. The invention of claim 182, wherein said drug comprises Oxaliplatin Injection (Eloxatin).
558. The invention of claim 182, wherein said drug comprises Oxytocin Injection (Pitocin).
559. The invention of claim 182, wherein said drug comprises Paliperidone Palmitate Extended-Release Injectable Suspension (Invega Sustenna).
560. The invention of claim 182, wherein said drug comprises Pamidronate Disodium Injection (Pamidronate Disodium Injection).
561 . The invention of claim 182, wherein said drug comprises Panitumumab Injection for Intravenous Use (Vectibix).
562. The invention of claim 182, wherein said drug comprises Papaverine Hydrochloride Injection (Papaverine Injection).
563. The invention of claim 182, wherein said drug comprises Papaverine Injection (Papaverine Hydrochloride Injection).
564. The invention of claim 182, wherein said drug comprises Parathyroid Hormone.
565. The invention of claim 182, wherein said drug comprises Paricalcitol Injection Fliptop Vial (Zemplar Injection).
566. The invention of claim 182, wherein said drug comprises Pediarix.
567. The invention of claim 182, wherein said drug comprises PEGIntron.
568. The invention of claim 182, wherein said drug comprises Peginterferon.
569. The invention of claim 182, wherein said drug comprises Pegfilgrastim.
570. The invention of claim 182, wherein said drug comprises Penicillin G Benzathine and Penicillin G Procaine.
571 . The invention of claim 182, wherein said drug comprises Pentetate Calcium Trisodium Inj (Ca-DTPA).
572. The invention of claim 182, wherein said drug comprises Pentetate Zinc Trisodium Injection (Zn-DTPA).
573. The invention of claim 182, wherein said drug comprises Pepcid Injection (Famotidine Injection).
574. The invention of claim 182, wherein said drug comprises Pergonal.
575. The invention of claim 182, wherein said drug comprises Phentolamine Mesylate (Phentolamine Mesylate for Injection).
576. The invention of claim 182, wherein said drug comprises Physostigmine Salicylate (Physostigmine Salicylate (injection)).
577. The invention of claim 182, wherein said drug comprises Physostigmine Salicylate (injection) (Physostigmine Salicylate).
578. The invention of claim 82, wherein said drug comprises Piperacillin and Tazobactam Injection (Zosyn).
579. The invention of claim 182, wherein said drug comprises Pitocin (Oxytocin Injection).
580. The invention of claim 182, wherein said drug comprises Plasma-Lyte 148 (Multiple Electrolytes Inj).
581 . The invention of claim 182, wherein said drug comprises Plasma-Lyte 56 and Dextrose (Multiple Electrolytes and Dextrose Injection in Viaflex Plastic Vessel).
582. The invention of claim 182, wherein said drug comprises PlasmaLyte.
583. The invention of claim 182, wherein said drug comprises Plerixafor Injection (Mozobil).
584. The invention of claim 182, wherein said drug comprises Polidocanol Injection (Asclera).
585. The invention of claim 182, wherein said drug comprises Potassium Chloride.
586. The invention of claim 182, wherein said drug comprises Pralatrexate Solution for Intravenous Injection (Folotyn).
587. The invention of claim 182, wherein said drug comprises Pramlintide Acetate Injection (Symlin).
588. The invention of claim 182, wherein said drug comprises Premarin Injection (Conjugated Estrogens for Injection).
589. The invention of claim 182, wherein said drug comprises Prep kit for Technetium Tc99 Sestamibi for Injection (Cardiolite).
590. The invention of claim 182, wherein said drug comprises Prevacid I.V. (Lansoprazole for Injection).
591 . The invention of claim 182, wherein said drug comprises Primaxin I.V. (Imipenem and Cilastatin for Injection).
592. The invention of claim 182, wherein said drug comprises Progesterone.
593. The invention of claim 182, wherein said drug comprises ProHance (Gadoteridol Injection Solution).
594. The invention of claim 182, wherein said drug comprises Prolia (Denosumab Injection).
595. The invention of claim 182, wherein said drug comprises Promethazine HCI Injection (Promethazine Hydrochloride Injection).
596. The invention of claim 182, wherein said drug comprises Propranolol Hydrochloride Injection (Propranolol Hydrochloride Injection).
597. The invention of claim 182, wherein said drug comprises Quinidine Gluconate Injection (Quinidine Injection).
598. The invention of claim 182, wherein said drug comprises Quinidine Injection (Quinidine Gluconate Injection).
599. The invention of claim 182, wherein said drug comprises R-Gene 10 (Arginine Hydrochloride Injection).
600. The invention of claim 182, wherein said drug comprises Ranibizumab Injection (Lucentis).
601 . The invention of claim 182, wherein said drug comprises Ranitidine Hydrochloride Injection (Zantac Injection).
602. The invention of claim 182, wherein said drug comprises Reclast (Zoledronic Acid Injection).
603. The invention of claim 182, wherein said drug comprises Recombivarix
HB.
304. The invention of claim 182, wherein said drug comprises Regadenoson Injection (Lexiscan).
605. The invention of claim 182, wherein said drug comprises Reglan Injection (Metoclopramide Injection).
606. The invention of claim 182, wherein said drug comprises Remicade.
607. The invention of claim 182, wherein said drug comprises Repronex (Menotropins for Injection).
608. The invention of claim 182, wherein said drug comprises Retrovir IV (Zidovudine Injection).
609. The invention of claim 182, wherein said drug comprises Ringer's and 5% Dextrose Injection (Ringers in Dextrose).
610. The invention of claim 182, wherein said drug comprises Ringer's Injection (Ringers Injection).
61 1 . The invention of claim 182, wherein said drug comprises Rituxan.
612. The invention of claim 182, wherein said drug comprises Rituximab.
613. The invention of claim 182, wherein said drug comprises Rocuronium Bromide Injection (Zemuron).
614. The invention of claim 182, wherein said drug comprises Romidepsin for Injection (Istodax).
615. The invention of claim 182, wherein said drug comprises Saizen (Somatropin Injection).
616. The invention of claim 182, wherein said drug comprises Sandostatin LAR (Octreotide Acetate Injection).
617. The invention of claim 182, wherein said drug comprises Sensorcaine (Bupivacaine HCI Injections).
618. The invention of claim 182, wherein said drug comprises Septocaine (Articane HCI and Epinephrine Injection).
619. The invention of claim 182, wherein said drug comprises Serostim LQ (Somatropin (rDNA origin) Injection).
620. The invention of claim 182, wherein said drug comprises Simponi Injection (Golimumab Injection).
621 . The invention of claim 182, wherein said drug comprises Sodium Acetate (Sodium Acetate Injection).
622. The invention of claim 182, wherein said drug comprises Sodium Bicarbonate (Sodium Bicarbonate 5% Injection).
623. The invention of claim 182, wherein said drug comprises Sodium Lactate (Sodium Lactate Injection in AVIVA).
624. The invention of claim 182, wherein said drug comprises Sodium Phenylacetate and Sodium Benzoate Injection (Ammonul).
625. The invention of claim 182, wherein said drug comprises Somatropin (rDNA origin) for Inj (Nutropin).
626. The invention of claim 182, wherein said drug comprises Sporanox Injection (Itraconazole Injection).
627. The invention of claim 182, wherein said drug comprises Stelara Injection (Ustekinumab).
628. The invention of claim 182, wherein said drug comprises Sufenta (Sufentanil Citrate Injection).
629. The invention of claim 182, wherein said drug comprises Sufentanil Citrate Injection (Sufenta ).
630. The invention of claim 182, wherein said drug comprises Sumavel.
631 . The invention of claim 182, wherein said drug comprises Sumatriptan Injection (Alsuma).
632. The invention of claim 182, wherein said drug comprises Symlin.
633. The invention of claim 182, wherein said drug comprises Symlin Pen.
634. The invention of claim 182, wherein said drug comprises Synvisc-One (Hylan G-F 20 Single Intra-articular Injection).
635. The invention of claim 182, wherein said drug comprises Taxotere (Docetaxel for Injection).
636. The invention of claim 182, wherein said drug comprises vvTechnetium Tc
99m.
637. The invention of claim 182, wherein said drug comprises Telavancin for Injection (Vibativ).
638. The invention of claim 182, wherein said drug comprises Temsirolimus Injection (Torisel).
639. The invention of claim 182, wherein said drug comprises Tenormin I.V. Injection (Atenolol Inj).
640. The invention of claim 182, wherein said drug comprises Teriparatide (rDNA origin) Injection (Forteo).
641 . The invention of claim 182, wherein said drug comprises Testosterone Cypionate.
642. The invention of claim 182, wherein said drug comprises Testosterone Enanthate.
643. The invention of claim 182, wherein said drug comprises Testosterone Propionate.
644. The invention of claim 182, wherein said drug comprises Tev-Tropin (Somatropin, rDNA Origin, for Injection).
645. The invention of claim 182, wherein said drug comprises tgAAC94.
646. The invention of claim 182, wherein said drug comprises Thallous Chloride.
647. The invention of claim 182, wherein said drug comprises Theophylline.
648. The invention of claim 182, wherein said drug comprises Thiotepa (Thiotepa Injection).
649. The invention of claim 182, wherein said drug comprises Thyrogen (Thyrotropin Alfa for Injection).
650. The invention of claim 182, wherein said drug comprises Ticarcillin Disodium and Clavulanate Potassium Galaxy (Timentin Injection).
651 . The invention of claim 182, wherein said drug comprises Tigan Injection (Trimethobenzamide Hydrochloride Injectable).
652. The invention of claim 182, wherein said drug comprises Timentin Injection (Ticarcillin Disodium and Clavulanate Potassium Galaxy).
653. The invention of claim 182, wherein said drug comprises Tobramycin Injection (Tobramycin Injection).
654. The invention of claim 182, wherein said drug comprises Tocilizumab Injection (Actemra).
655. The invention of claim 182, wherein said drug comprises Torisel (Temsirolimus Injection).
656. The invention of claim 182, wherein said drug comprises Totect (Dexrazoxane for Injection, Intravenous Infusion Only ).
567. The invention of claim 182, wherein said drug comprises Travasol (Amino Acids (Injection)).
668. The invention of claim 182, wherein said drug comprises Treanda (Bendamustine Hydrochloride Injection).
669. The invention of claim 182, wherein said drug comprises Trelstar (Triptorelin Pamoate for Injectable Suspension).
670. The invention of claim 182, wherein said drug comprises Triamcinolone Acetonide.
671 . The invention of claim 182, wherein said drug comprises Triamcinolone Di acetate.
672. The invention of claim 182, wherein said drug comprises Triamcinolone Hexacetonide Injectable Suspension (Aristospan Injection 20 mg).
673. The invention of claim 182, wherein said drug comprises Triesence (Triamcinolone Acetonide Injectable Suspension).
674. The invention of claim 182, wherein said drug comprises Trimethobenzamide Hydrochloride Injectable (Tigan Injection).
675. The invention of claim 182, wherein said drug comprises Trimetrexate Glucuronate Inj (Neutrexin).
676. The invention of claim 182, wherein said drug comprises Triptorelin Pamoate for Injectable Suspension (Trelstar).
677. The invention of claim 182, wherein said drug comprises Twinject.
678. The invention of claim 182, wherein said drug comprises Trivaris (Triamcinolone Acetonide Injectable Suspension).
679. The invention of claim 182, wherein said drug comprises Trisenox (Arsenic Trioxide Injection).
680. The invention of claim 182, wherein said drug comprises Twinrix.
681 . The invention of claim 182, wherein said drug comprises Typhoid Vi.
682. The invention of claim 182, wherein said drug comprises Ultravist (lopromide Injection).
683. The invention of claim 182, wherein said drug comprises Urofollitropin for Injection (Metrodin).
684. The invention of claim 182, wherein said drug comprises Urokinase Injection (Kinlytic).
685. The invention of claim 182, wherein said drug comprises Ustekinumab (Stelara Injection).
686. The invention of claim 182, wherein said drug comprises Ultralente (U).
687. The invention of claim 182, wherein said drug comprises Valproate Sodium Injection (Depacon).
688. The invention of claim 182, wherein said drug comprises Valtropin (Somatropin Injection).
689. The invention of claim 182, wherein said drug comprises Vancomycin Hydrochloride (Vancomycin Hydrochloride Injection).
690. The invention of claim 182, wherein said drug comprises Vancomycin Hydrochloride Injection (Vancomycin Hydrochloride).
691 . The invention of claim 182, wherein said drug comprises Vaprisol (Conivaptan Hcl Injection).
692. The invention of claim 182, wherein said drug comprises VAQTA.
693. The invention of claim 182, wherein said drug comprises Vasovist (Gadofosveset Trisodium Injection for Intravenous Use).
694. The invention of claim 182, wherein said drug comprises Vectibix (Panitumumab Injection for Intravenous Use).
695. The invention of claim 182, wherein said drug comprises Venofer (Iron Sucrose Injection).
696. The invention of claim 182, wherein said drug comprises Verteporfin Inj (Visudyne).
697. The invention of claim 182, wherein said drug comprises Vibativ (Telavancin for Injection).
698. The invention of claim 182, wherein said drug comprises Victoza (Liraglutide [rDNA] Injection).
699. The invention of claim 182, wherein said drug comprises Vimpat (lacosamide Tablet and Injection).
700. The invention of claim 182, wherein said drug comprises Vinblastine Sulfate (Vinblastine Sulfate Injection).
701 . The invention of claim 182, wherein said drug comprises Vincasar PFS (Vincristine Sulfate Injection).
702. The invention of claim 182, wherein said drug comprises Victoza.
703. The invention of claim 182, wherein said drug comprises Vincristine Sulfate (Vincristine Sulfate Injection).
704. The invention of claim 182, wherein said drug comprises Visudyne (Verteporfin Inj).
705. The invention of claim 182, wherein said drug comprises Vitamin B-12.
706. The invention of claim 182, wherein said drug comprises Vivitrol (Naltrexone XR Inj).
707. The invention of claim 182, wherein said drug comprises Voluven (Hydroxyethyl Starch in Sodium Chloride Injection).
708. The invention of claim 182, wherein said drug comprises Xeomin (Incobotulinumtoxin A for Injection).
709. The invention of claim 182, wherein said drug comprises Zantac Injection (Ranitidine Hydrochloride Injection).
710. The invention of claim 182, wherein said drug comprises Zemplar Injection (Paricalcitol Injection Fliptop Vial).
71 1 . The invention of claim 182, wherein said drug comprises Zemuron (Rocuronium Bromide Injection).
712. The invention of claim 182, wherein said drug comprises Zevalin.
713. The invention of claim 182, wherein said drug comprises Zidovudine Injection (Retrovir IV).
714. The invention of claim 182, wherein said drug comprises Zithromax Injection (Azithromycin).
715. The invention of claim 182, wherein said drug comprises Zn-DTPA (Pentetate Zinc Trisodium Injection).
716. The invention of claim 182, wherein said drug comprises Zofran Injection (Ondansetron Hydrochloride Injection).
717. The invention of claim 182, wherein said drug comprises Zingo.
718. The invention of claim 182, wherein said drug comprises Zoledronic Acid for Inj (Zometa).
719. The invention of claim 182, wherein said drug comprises Zoledronic Acid Injection (Reclast).
720. The invention of claim 182, wherein said drug comprises Zometa (Zoledronic Acid for Inj).
721 . The invention of claim 182, wherein said drug comprises Zosyn (Piperacillin and Tazobactam Injection).
722. The invention of claim 182, wherein said drug comprises Zyprexa Relprevv (Olanzapine Extended Release Injectable Suspension).
723. The invention of claim 182, wherein said drug comprises Ability.
724. The invention of claim 182, wherein said drug comprises AccuNeb (Albuterol Sulfate Inhalation Solution).
725. The invention of claim 182, wherein said drug comprises Actidose Aqua (Activated Charcoal Suspension).
726. The invention of claim 182, wherein said drug comprises Activated Charcoal Suspension (Actidose Aqua).
727. The invention of claim 182, wherein said drug comprises Advair.
728. The invention of claim 182, wherein said drug comprises Agenerase Oral Solution (Amprenavir Oral Solution).
729. The invention of claim 182, wherein said drug comprises Akten (Lidocaine Hydrochloride Ophthalmic Gel).
730. The invention of claim 182, wherein said drug comprises Alamast (Pemirolast Potassium Ophthalmic Solution).
731 . The invention of claim 182, wherein said drug comprises Albumin (Human) 5% Solution (Buminate 5%).
732. The invention of claim 182, wherein said drug comprises Albuterol Sulfate Inhalation Solution.
733. The invention of claim 182, wherein said drug comprises Alinia.
734. The invention of claim 182, wherein said drug comprises Alocril.
735. The invention of claim 182, wherein said drug comprises Alphagan.
736. The invention of claim 182, wherein said drug comprises Alrex.
737. The invention of claim 182, wherein said drug comprises Alvesco.
738. The invention of claim 182, wherein said drug comprises Amprenavir Oral Solution.
739. The invention of claim 182, wherein said drug comprises Analpram-HC.
740. The invention of claim 182, wherein said drug comprises Arformoterol Tartrate Inhalation Solution (Brovana).
741 . The invention of claim 182, wherein said drug comprises Aristospan Injection 20 mg (Triamcinolone Hexacetonide Injectable Suspension).
742. The invention of claim 182, wherein said drug comprises Asacol.
743. The invention of claim 182, wherein said drug comprises Asmanex Astepro.
744. The invention of claim 182, wherein said drug comprises Astepro (Azelastine Hydrochloride Nasal Spray).
745. The invention of claim 182, wherein said drug comprises Atrovent Nasal Spray (Ipratropium Bromide Nasal Spray).
746. The invention of claim 182, wherein said drug comprises Atrovent Nasal Spray .06.
747. The invention of claim 182, wherein said drug comprises Augmentin ES-
600.
748. The invention of claim 182, wherein said drug comprises Azasite (Azithromycin Ophthalmic Solution).
749. The invention of claim 182, wherein said drug comprises Azelaic Acid (Finacea Gel).
750. The invention of claim 182, wherein said drug comprises Azelastine Hydrochloride Nasal Spray (Astepro).
751 . The invention of claim 182, wherein said drug comprises Azelex (Azelaic Acid Cream).
752. The invention of claim 182, wherein said drug comprises Azopt (Brinzolamide Ophthalmic Suspension).
753. The invention of claim 182, wherein said drug comprises Bacteriostatic
Saline.
754. The invention of claim 182, wherein said drug comprises Balanced Salt.
755. The invention of claim 182, wherein said drug comprises Bepotastine.
756. The invention of claim 182, wherein said drug comprises Bactroban Nasal.
757. The invention of claim 182, wherein said drug comprises Bactroban.
758. The invention of claim 182, wherein said drug comprises Beclovent.
759. The invention of claim 182, wherein said drug comprises Benzac W.
760. The invention of claim 182, wherein said drug comprises Betimol.
761 . The invention of claim 182, wherein said drug comprises Betoptic S.
762. The invention of claim 182, wherein said drug comprises Bepreve.
763 The invention of claim 182, wherein said drug comprises Bimatoprost Ophthalmic Solution.
764. The invention of claim 182, wherein said drug comprises Bleph 10 (Sulfacetamide .Sodium Ophthalmic Solution 10%).
765. The invention of claim 182, wherein said drug comprises Brinzolamide Ophthalmic Suspension (Azopt).
766. The invention of claim 182, wherein said drug comprises Bromfenac Ophthalmic Solution (Xibrom).
767. The invention of claim 182, wherein said drug comprises Bromhist.
768. The invention of claim 182, wherein said drug comprises Brovana (Arformoterol Tartrate Inhalation Solution).
769. The invention of claim 182, wherein said drug comprises Budesonide Inhalation Suspension (Pulmicort Respules).
770. The invention of claim 182, wherein said drug comprises Cambia (Diclofenac Potassium for Oral Solution).
771 . The invention of claim 182, wherein said drug comprises Capex.
772. The invention of claim 182, wherein said drug comprises Carac.
773. The invention of claim 182, wherein said drug comprises Carboxine-PSE.
774. The invention of claim 182, wherein said drug comprises Carnitor.
775. The invention of claim 182, wherein said drug comprises Cayston (Aztreonam for Inhalation Solution).
776. The invention of claim 182, wherein said drug comprises Cellcept.
777. The invention of claim 182, wherein said drug comprises Centany .
778. The invention of claim 182, wherein said drug comprises Cerumenex.
779. The invention of claim 182, wherein said drug comprises Ciloxan Ophthalmic Solution (Ciprofloxacin HCL Ophthalmic Solution).
780. The invention of claim 182, wherein said drug comprises Ciprodex.
781 . The invention of claim 182, wherein said drug comprises Ciprofloxacin HCL Ophthalmic Solution (Ciloxan Ophthalmic Solution).
782. The invention of claim 182, wherein said drug comprises Clemastine Fumarate Syrup (Clemastine Fumarate Syrup).
783. The invention of claim 182, wherein said drug comprises CoLyte (PEG Electrolytes Solution).
784. The invention of claim 182, wherein said drug comprises Combiven.
785. The invention of claim 182, wherein said drug comprises Comtan.
786. The invention of claim 182, wherein said drug comprises Condylox.
787. The invention of claim 182, wherein said drug comprises Cordran.
788. The invention of claim 182, wherein said drug comprises Cortisporin Ophthalmic Suspension.
789. The invention of claim 182, wherein said drug comprises Cortisporin Otic Suspension.
790. The invention of claim 182, wherein said drug comprises Cromolyn Sodium Inhalation Solution (Intal Nebulizer Solution).
791 . The invention of claim 182, wherein said drug comprises Cromolyn Sodium Ophthalmic Solution (Opticrom).
792. The invention of claim 182, wherein said drug comprises Crystalline Amino Acid Solution with Electrolytes (Aminosyn Electrolytes).
793. The invention of claim 182, wherein said drug comprises Cutivate.
794. The invention of claim 182, wherein said drug comprises Cuvposa (Glycopyrrolate Oral Solution).
795. The invention of claim 182, wherein said drug comprises Cyanocobalamin (CaloMist Nasal Spray).
796. The invention of claim 182, wherein said drug comprises Cyclosporine Oral Solution (Gengraf Oral Solution).
797. The invention of claim 182, wherein said drug comprises Cyclogyl.
798. The invention of claim 182, wherein said drug comprises Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution).
799. The invention of claim 182, wherein said drug comprises DermOtic Oil (Fluocinolone Acetonide Oil Ear Drops).
800. The invention of claim 182, wherein said drug comprises Desmopressin Acetate Nasal Spray.
801 . The invention of claim 182, wherein said drug comprises DDAVP.
802. The invention of claim 182, wherein said drug comprises Derma- Smoothe/FS.
803. The invention of claim 182, wherein said drug comprises Dexamethasone Intensol.
804. The invention of claim 182, wherein said drug comprises Dianeal Low Calcium.
805. The invention of claim 182, wherein said drug comprises Dianeal PD.
806. The invention of claim 182, wherein said drug comprises Diclofenac Potassium for Oral Solution (Cambia).
807. The invention of claim 182, wherein said drug comprises Didanosine Pediatric Powder for Oral Solution (Videx).
808. The invention of claim 182, wherein said drug comprises Differin.
809. The invention of claim 182, wherein said drug comprises Dilantin 125 (Phenytoin Oral Suspension).
810. The invention of claim 182, wherein said drug comprises Ditropan.
81 1 . The invention of claim 182, wherein said drug comprises Dorzolamide Hydrochloride Ophthalmic Solution (Trusopt).
812. The invention of claim 182, wherein said drug comprises Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution (Cosopt).
813. The invention of claim 182, wherein said drug comprises Dovonex Scalp (Calcipotriene Solution).
814. The invention of claim 182, wherein said drug comprises Doxycycline Calcium Oral Suspension (Vibramycin Oral).
815. The invention of claim 182, wherein said drug comprises Efudex.
816. The invention of claim 182, wherein said drug comprises Elaprase (Idursulfase Solution).
817. The invention of claim 182, wherein said drug comprises Elestat (Epinastine HCI Ophthalmic Solution).
818. The invention of claim 182, wherein said drug comprises Elocon.
819. The invention of claim 182, wherein said drug comprises Epinastine HCI Ophthalmic Solution (Elestat).
820. The invention of claim 182, wherein said drug comprises Epivir HBV.
821 . The invention of claim 182, wherein said drug comprises Epogen.
822. The invention of claim 182, wherein said drug comprises Erythromycin Topical Solution 1 .5% (Staticin).
823. The invention of claim 182, wherein said drug comprises Ethiodol (Ethiodized Oil).
824. The invention of claim 182, wherein said drug comprises Ethosuximide Oral Solution (Zarontin Oral Solution).
825. The invention of claim 182, wherein said drug comprises Eurax.
826. The invention of claim 182, wherein said drug comprises Extraneal (lcodextrin Peritoneal Dialysis Solution).
827. The invention of claim 182, wherein said drug comprises Felbatol.
828. The invention of claim 182, wherein said drug comprises Feridex I.V. (Ferumoxides Injectable Solution).
829. The invention of claim 182, wherein said drug comprises Flovent.
830. The invention of claim 182, wherein said drug comprises Floxin Otic (Ofloxacin Otic Solution).
831 . The invention of claim 182, wherein said drug comprises Flo-Pred (Prednisolone Acetate Oral Suspension).
832. The invention of claim 182, wherein said drug comprises Fluoroplex.
833. The invention of claim 182, wherein said drug comprises Flunisolide Nasal Solution (Flunisolide Nasal Spray .025%).
834. The invention of claim 182, wherein said drug comprises Fluorometholone Ophthalmic Suspension (FML).
835. The invention of claim 182, wherein said drug comprises Flurbiprofen Sodium Ophthalmic Solution (Ocufen).
836. The invention of claim 182, wherein said drug comprises FML.
837. The invention of claim 182, wherein said drug comprises Foradil.
838. The invention of claim 182, wherein said drug comprises Formoterol Fumarate Inhalation Solution (Perforomist).
839. The invention of claim 182, wherein said drug comprises Fosamax.
840. The invention of claim 182, wherein said drug comprises Furadantin (Nitrofurantoin Oral Suspension).
841 . The invention of claim 182, wherein said drug comprises Furoxone.
842. The invention of claim 182, wherein said drug comprises Gammagard Liquid (Immune Globulin Intravenous (Human) 10%).
843. The invention of claim 182, wherein said drug comprises Gantrisin (Acetyl Sulfisoxazole Pediatric Suspension).
844. The invention of claim 182, wherein said drug comprises Gatifloxacin Ophthalmic Solution (Zymar).
845. The invention of claim 182, wherein said drug comprises Gengraf Oral Solution (Cyclosporine Oral Solution).
846. The invention of claim 182, wherein said drug comprises Glycopyrrolate Oral Solution (Cuvposa).
847. The invention of claim 182, wherein said drug comprises Halcinonide Topical Solution (Halog Solution).
848. The invention of claim 182, wherein said drug comprises Halog Solution (Halcinonide Topical Solution).
849. The invention of claim 182, wherein said drug comprises HEP-LOCK U/P (Preservative- Free Heparin Lock Flush Solution).
850. The invention of claim 182, wherein said drug comprises Heparin Lock Flush Solution (Hepflush 10).
851 . The invention of claim 182, wherein said drug comprises Hexaminolevulinate Hydrochloride Intravesical Solution (Cysview).
852. The invention of claim 182, wherein said drug comprises Hydrocodone Bitartrate and Acetaminophen Oral Solution (Lortab Elixir).
853. The invention of claim 182, wherein said drug comprises Hydroquinone 3% Topical Solution (Melquin-3 Topical Solution).
854. The invention of claim 182, wherein said drug comprises Isopto.
855. The invention of claim 182, wherein said drug comprises Ipratropium Bromide Nasal Spray (Atrovent Nasal Spray).
856. The invention of claim 182, wherein said drug comprises Itraconazole Oral Solution (Sporanox Oral Solution).
857. The invention of claim 182, wherein said drug comprises Ketorolac Tromethamine Ophthalmic Solution (Acular LS).
858. The invention of claim 182, wherein said drug comprises Kaletra .
859. The invention of claim 182, wherein said drug comprises Lanoxin .
860. The invention of claim 182, wherein said drug comprises Lexiva.
861 . The invention of claim 182, wherein said drug comprises Leuprolide Acetate for Depot Suspension (Lupron Depot 1 1 .25 mg).
862. The invention of claim 182, wherein said drug comprises Levobetaxolol Hydrochloride Ophthalmic Suspension (Betaxon).
863. The invention of claim 182, wherein said drug comprises Levocarnitine Tablets, Oral Solution, Sugar-Free (Carnitor).
864. The invention of claim 182, wherein said drug comprises Levofloxacin Ophthalmic Solution 0.5% (Quixin).
865. The invention of claim 182, wherein said drug comprises Lidocaine HCI Sterile Solution (Xylocaine MPF Sterile Solution).
866. The invention of claim 182, wherein said drug comprises Lok Pak (Heparin Lock Flush Solution).
867. The invention of claim 182, wherein said drug comprises Lorazepam Intensol.
868. The invention of claim 182, wherein said drug comprises Lortab Elixir (Hydrocodone Bitartrate and Acetaminophen Oral Solution).
869. The invention of claim 182, wherein said drug comprises Lotemax (Loteprednol Etabonate Ophthalmic Suspension).
870. The invention of claim 182, wherein said drug comprises Loteprednol Etabonate Ophthalmic Suspension (Alrex).
871 . The invention of claim 182, wherein said drug comprises Low Calcium Peritoneal Dialysis Solutions (Dianeal Low Calcium).
872. The invention of claim 182, wherein said drug comprises Lumigan (Bimatoprost Ophthalmic Solution 0.03% for Glaucoma).
873. The invention of claim 182, wherein said drug comprises Lupron Depot 1 1 .25 mg (Leuprolide Acetate for Depot Suspension).
874. The invention of claim 182, wherein said drug comprises Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension).
875. The invention of claim 182, wherein said drug comprises Mepron.
876. The invention of claim 182, wherein said drug comprises Mesnex.
877. The invention of claim 182, wherein said drug comprises Mestinon.
878. The invention of claim 182, wherein said drug comprises Mesalamine Rectal Suspension Enema (Rowasa).
879. The invention of claim 182, wherein said drug comprises Melquin-3 Topical Solution (Hydroquinone 3% Topical Solution).
880. The invention of claim 182, wherein said drug comprises Methyldopate Hcl (Methyldopate Hydrochloride Injection, Solution).
881 . The invention of claim 182, wherein said drug comprises Methylin Oral Solution (Methylphenidate HCI Oral Solution 5 mg/5 ml_ and 10 mg/5 ml_).
882. The invention of claim 182, wherein said drug comprises Methylprednisolone Acetate Injectable Suspension (Depo Medrol).
883. The invention of claim 182, wherein said drug comprises Methylphenidate HCI Oral Solution 5 mg/5 ml_ and 10 mg/5 ml_ (Methylin Oral Solution).
884. The invention of claim 182, wherein said drug comprises Methylprednisolone sodium succinate (Solu Medrol).
885. The invention of claim 182, wherein said drug comprises Metipranolol Ophthalmic Solution (Optipranolol).
886. The invention of claim 182, wherein said drug comprises Migranal.
887. The invention of claim 182, wherein said drug comprises Miochol-E (Acetylcholine Chloride Intraocular Solution).
888. The invention of claim 182, wherein said drug comprises Micro-K for Liquid Suspension (Potassium Chloride Extended Release Formulation for Liquid Suspension).
889. The invention of claim 182, wherein said drug comprises Minocin (Minocycline Hydrochloride Oral Suspension).
890. The invention of claim 182, wherein said drug comprises Nasacort.
891 . The invention of claim 182, wherein said drug comprises Neomycin and Polymyxin B Sulfates and Hydrocortisone.
892. The invention of claim 182, wherein said drug comprises Nepafenac Ophthalmic Suspension (Nevanac).
893. The invention of claim 182, wherein said drug comprises Nevanac (Nepafenac Ophthalmic Suspension).
894. The invention of claim 182, wherein said drug comprises Nitrofurantoin Oral Suspension (Furadantin).
895. The invention of claim 182, wherein said drug comprises Noxafil (Posaconazole Oral Suspension).
896. The invention of claim 182, wherein said drug comprises Nystatin (oral) (Nystatin Oral Suspension).
897. The invention of claim 182, wherein said drug comprises Nystatin Oral Suspension (Nystatin (oral)).
898. The invention of claim 182, wherein said drug comprises Ocufen (Flurbiprofen Sodium Ophthalmic Solution).
899. The invention of claim 182, wherein said drug comprises Ofloxacin Ophthalmic Solution (Ofloxacin Ophthalmic Solution).
900. The invention of claim 182, wherein said drug comprises Ofloxacin Otic Solution (Floxin Otic).
901 . The invention of claim 182, wherein said drug comprises Olopatadine Hydrochloride Ophthalmic Solution (Pataday).
902. The invention of claim 182, wherein said drug comprises Opticrom (Cromolyn Sodium Ophthalmic Solution).
903. The invention of claim 182, wherein said drug comprises Optipranolol (Metipranolol Ophthalmic Solution).
904. The invention of claim 182, wherein said drug comprises Patanol
905. The invention of claim 182, wherein said drug comprises Pediapred.
906. The invention of claim 182, wherein said drug comprises PerioGard.
907. The invention of claim 182, wherein said drug comprises Phenytoin Oral Suspension (Dilantin 125).
908. The invention of claim 182, wherein said drug comprises Phisohex.
909. The invention of claim 182, wherein said drug comprises Posaconazole Oral Suspension (Noxafil).
910. The invention of claim 182, wherein said drug comprises Potassium Chloride Extended Release Formulation for Liquid Suspension (Micro-K for Liquid Suspension).
91 1 . The invention of claim 182, wherein said drug comprises Pataday (Olopatadine Hydrochloride Ophthalmic Solution).
912. The invention of claim 182, wherein said drug comprises Patanase Nasal Spray (Olopatadine Hydrochloride Nasal Spray).
913. The invention of claim 182, wherein said drug comprises PEG Electrolytes Solution (CoLyte).
914. The invention of claim 182, wherein said drug comprises Pemirolast Potassium Ophthalmic Solution (Alamast).
915. The invention of claim 182, wherein said drug comprises Penlac (Ciclopirox Topical Solution).
916. The invention of claim 182, wherein said drug comprises PENNSAID (Diclofenac Sodium Topical Solution).
917. The invention of claim 182, wherein said drug comprises Perforomist (Formoterol Fumarate Inhalation Solution).
918. The invention of claim 182, wherein said drug comprises Peritoneal Dialysis Solution.
919. The invention of claim 182, wherein said drug comprises Phenylephrine Hydrochloride Ophthalmic Solution (Neo-Synephrine).
920. The invention of claim 182, wherein said drug comprises Phospholine Iodide (Echothiophate Iodide for Ophthalmic Solution).
921 . The invention of claim 182, wherein said drug comprises Podofilox (Podofilox Topical Solution).
922. The invention of claim 182, wherein said drug comprises Pred Forte (Prednisolone Acetate Ophthalmic Suspension).
923. The invention of claim 182, wherein said drug comprises Pralatrexate Solution for Intravenous Injection (Folotyn).
924. The invention of claim 182, wherein said drug comprises Pred Mild.
925. The invention of claim 182, wherein said drug comprises Prednisone Intensol.
926. The invention of claim 182, wherein said drug comprises Prednisolone Acetate Ophthalmic Suspension (Pred Forte).
927. The invention of claim 182, wherein said drug comprises Prevacid.
928. The invention of claim 182, wherein said drug comprises PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution).
929. The invention of claim 182, wherein said drug comprises ProAir.
930. The invention of claim 182, wherein said drug comprises Proglycem.
931 . The invention of claim 182, wherein said drug comprises ProHance (Gadoteridol Injection Solution).
932. The invention of claim 182, wherein said drug comprises Proparacaine Hydrochloride Ophthalmic Solution (Alcaine).
933. The invention of claim 182, wherein said drug comprises Propine.
934. The invention of claim 182, wherein said drug comprises Pulmicort.
935. The invention of claim 182, wherein said drug comprises Pulmozyme.
936. The invention of claim 182, wherein said drug comprises Quixin (Levofloxacin Ophthalmic Solution 0.5%).
937. The invention of claim 182, wherein said drug comprises QVAR.
938. The invention of claim 182, wherein said drug comprises Rapamune.
939. The invention of claim 182, wherein said drug comprises Rebetol.
940. The invention of claim 182, wherein said drug comprises Relacon-HC.
941 . The invention of claim 182, wherein said drug comprises Rotarix (Rotavirus Vaccine, Live, Oral Suspension).
942. The invention of claim 182, wherein said drug comprises Rotavirus Vaccine, Live, Oral Suspension (Rotarix).
943. The invention of claim 182, wherein said drug comprises Rowasa (Mesalamine Rectal Suspension Enema).
944. The invention of claim 182, wherein said drug comprises Sabril (Vigabatrin Oral Solution).
945. The invention of claim 182, wherein said drug comprises Sacrosidase Oral Solution (Sucraid).
946. The invention of claim 182, wherein said drug comprises Sandimmune.
947. The invention of claim 182, wherein said drug comprises Serevent Diskus.
948. The invention of claim 182, wherein said drug comprises Solu Cortef (Hydrocortisone Sodium Succinate).
949. The invention of claim 182, wherein said drug comprises Solu Medrol (Methylprednisolone sodium succinate).
950. The invention of claim 182, wherein said drug comprises Spiriva.
951 . The invention of claim 182, wherein said drug comprises Sporanox Oral Solution (Itraconazole Oral Solution).
952. The invention of claim 182, wherein said drug comprises Staticin (Erythromycin Topical Solution 1 .5%).
953. The invention of claim 182, wherein said drug comprises Stalevo.
954. The invention of claim 182, wherein said drug comprises Starlix.
955. The invention of claim 182, wherein said drug comprises Sterile Hemofiltration Hemodiafiltration Solution (PrismaSol Solution).
956. The invention of claim 182, wherein said drug comprises Stimate.
957. The invention of claim 182, wherein said drug comprises Sucralfate (Carafate Suspension).
958. The invention of claim 182, wherein said drug comprises Sulfacetamide Sodium Ophthalmic Solution 10% (Bleph 10).
959. The invention of claim 182, wherein said drug comprises Synarel Nasal Solution (Nafarelin Acetate Nasal Solution for Endometriosis).
960. The invention of claim 182, wherein said drug comprises Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension).
961 . The invention of claim 182, wherein said drug comprises Tamiflu.
962. The invention of claim 182, wherein said drug comprises Tobi.
963. The invention of claim 182, wherein said drug comprises TobraDex.
964. The invention of claim 182, wherein said drug comprises Tobradex ST (Tobramycin / Dexamethasone Ophthalmic Suspension 0.3%/0.05%).
965. The invention of claim 182, wherein said drug comprises Tobramycin / Dexamethasone Ophthalmic Suspension 0.3%/0.05% (Tobradex ST).
966. The invention of claim 182, wherein said drug comprises Timolol.
967. The invention of claim 182, wherein said drug comprises Timoptic.
968. The invention of claim 182, wherein said drug comprises Travatan Z.
969. The invention of claim 182, wherein said drug comprises Treprostinil Inhalation Solution (Tyvaso).
970. The invention of claim 182, wherein said drug comprises Trusopt (Dorzolamide Hydrochloride Ophthalmic Solution).
971 . The invention of claim 182, wherein said drug comprises Tyvaso (Treprostinil Inhalation Solution).
972. The invention of claim 182, wherein said drug comprises Ventolin.
973. The invention of claim 182, wherein said drug comprises Vfend.
974. The invention of claim 182, wherein said drug comprises Vibramycin Oral (Doxycycline Calcium Oral Suspension).
975. The invention of claim 182, wherein said drug comprises Videx (Didanosine Pediatric Powder for Oral Solution).
976. The invention of claim 182, wherein said drug comprises Vigabatrin Oral Solution (Sabril).
977. The invention of claim 182, wherein said drug comprises Viokase.
978. The invention of claim 182, wherein said drug comprises Viracept.
979. The invention of claim 182, wherein said drug comprises Viramune.
980. The invention of claim 182, wherein said drug comprises Vitamin K1 (Aqueous Colloidal Solution of Vitamin K1 ).
981 . The invention of claim 182, wherein said drug comprises Voltaren Ophthalmic (Diclofenac Sodium Ophthalmic Solution).
982. The invention of claim 182, wherein said drug comprises Zarontin Oral Solution (Ethosuximide Oral Solution).
983. The invention of claim 182, wherein said drug comprises Ziagen.
984. The invention of claim 182, wherein said drug comprises Zyvox.
985. The invention of claim 182, wherein said drug comprises Zymar (Gatifloxacin Ophthalmic Solution).
986. The invention of claim 182, wherein said drug comprises Zymaxid (Gatifloxacin Ophthalmic Solution)
987 The invention of any preceding claim, wherein said fluid composition comprises a diagnostic test material.
988. The invention of claim 987, wherein said diagnostic test material comprises 17-Hydroxyprogesterone.
989. The invention of claim 987, wherein said diagnostic test material comprises ACE (Angiotensin I converting enzyme)
990. The invention of claim 987, wherein said diagnostic test material comprises Acetaminophen.
991 . The invention of claim 987, wherein said diagnostic test material comprises Acid phosphatase.
992. The invention of claim 987, wherein said diagnostic test material comprises ACTH.
993. The invention of claim 987, wherein said diagnostic test material comprises Activated clotting time.
994. The invention of claim 987, wherein said diagnostic test material comprises Activated protein C resistance.
995. The invention of claim 987, wherein said diagnostic test material comprises Adrenocorticotropic hormone (ACTH).
996. The invention of claim 987, wherein said diagnostic test material comprises Alanine aminotransferase (ALT).
997. The invention of claim 987, wherein said diagnostic test material comprises Albumin.
998. The invention of claim 987, wherein said diagnostic test material comprises Aldolase.
999. The invention of claim 987, wherein said diagnostic test material comprises Aldosterone.
1000. The invention of claim 987, wherein said diagnostic test material comprises Alkaline phosphatase.
1001 . The invention of claim 987, wherein said diagnostic test material comprises Alkaline phosphatase (ALP).
1002. The invention of claim 987, wherein said diagnostic test material comprises Alphal -antitrypsin.
1003. The invention of claim 987, wherein said diagnostic test material comprises Alpha-fetoprotein.
1004. The invention of claim 987, wherein said diagnostic test material comprises Alpha-fetoprotien .
1005. The invention of claim 987, wherein said diagnostic test material comprises Ammonia levels.
1006. The invention of claim 987, wherein said diagnostic test material comprises Amylase.
1007. The invention of claim 987, wherein said diagnostic test material comprises ANA (antinuclear antbodies).
1008. The invention of claim 987, wherein said diagnostic test material comprises ANA (antinuclear antibodies).
1009. The invention of claim 987, wherein said diagnostic test material comprises Angiotensin-converting enzyme (ACE).
1010. The invention of claim 987, wherein said diagnostic test material comprises Anion gap.
101 1 . The invention of claim 987, wherein said diagnostic test material comprises Anticardiolipin antibody.
1012. The invention of claim 987, wherein said diagnostic test material comprises Anticardiolipin antivbodies (ACA).
1013. The invention of claim 987, wherein said diagnostic test material comprises Anti-centromere antibody.
1014. The invention of claim 987, wherein said diagnostic test material comprises Antidiuretic hormone.
1015. The invention of claim 987, wherein said diagnostic test material comprises Anti-DNA.
1016. The invention of claim 987, wherein said diagnostic test material comprises Anti-Dnase-B.
1017. The invention of claim 987, wherein said diagnostic test material comprises Anti-Gliadin antibody.
1018. The invention of claim 987, wherein said diagnostic test material comprises Anti-glomerular basement membrane antibody.
1019. The invention of claim 987, wherein said diagnostic test material comprises Anti-HBc (Hepatitis B core antibodies.
1020. The invention of claim 987, wherein said diagnostic test material comprises Anti-HBs (Hepatitis B surface antibody.
1021 . The invention of claim 987, wherein said diagnostic test material comprises Antiphospholipid antibody.
1022. The invention of claim 987, wherein said diagnostic test material comprises Anti-RNA polymerase.
1023. The invention of claim 987, wherein said diagnostic test material comprises Anti-Smith (Sm) antibodies.
1024. The invention of claim 987, wherein said diagnostic test material comprises Anti-Smooth Muscle antibody.
1025. The invention of claim 987, wherein said diagnostic test material comprises Antistreptolysin O (ASO).
1026. The invention of claim 987, wherein said diagnostic test material comprises Antithrombin III.
1027. The invention of claim 987, wherein said diagnostic test material comprises Anti-Xa activity.
1028. The invention of claim 987, wherein said diagnostic test material comprises Anti-Xa assay.
1029. The invention of claim 987, wherein said diagnostic test material comprises Apolipoproteins.
1030. The invention of claim 987, wherein said diagnostic test material comprises Arsenic.
1031 . The invention of claim 987, wherein said diagnostic test material comprises Aspartate aminotransferase (AST).
1032. The invention of claim 987, wherein said diagnostic test material comprises B12.
1033. The invention of claim 987, wherein said diagnostic test material comprises Basophil.
1034. The invention of claim 987, wherein said diagnostic test material comprises Beta-2-. Microglobulin
1035. The invention of claim 987, wherein said diagnostic test material comprises Beta-hydroxybutyrate.
1036. The invention of claim 987, wherein said diagnostic test material comprises B-HCG.
1037. The invention of claim 987, wherein said diagnostic test material comprises Bilirubin.
1038. The invention of claim 987, wherein said diagnostic test material comprises Bilirubin, direct.
1039. The invention of claim 987, wherein said diagnostic test material comprises Bilirubin, indirect.
1040. The invention of claim 987, wherein said diagnostic test material comprises Bilirubin, total.
1041 . The invention of claim 987, wherein said diagnostic test material comprises Bleeding time.
1042. The invention of claim 987, wherein said diagnostic test material comprises Blood gases (arterial).
1043. The invention of claim 987, wherein said diagnostic test material comprises Blood urea nitrogen (BUN).
1044. The invention of claim 987, wherein said diagnostic test material comprises BUN.
1045. The invention of claim 987, wherein said diagnostic test material comprises BUN (blood urea nitrogen).
1046. The invention of claim 987, wherein said diagnostic test material comprises CA 125.
1047. The invention of claim 987, wherein said diagnostic test material comprises CA 15-3.
1048. The invention of claim 987, wherein said diagnostic test material comprises CA 19-9.
1049. The invention of claim 987, wherein said diagnostic test material comprises Calcitonin.
1050. The invention of claim 987, wherein said diagnostic test material comprises Calcium.
1051 . The invention of claim 987, wherein said diagnostic test material comprises Calcium .(ionized)
1052. The invention of claim 987, wherein said diagnostic test material comprises Carbon monoxide (CO).
1053. The invention of claim 987, wherein said diagnostic test material comprises Carcinoembryonic antigen (CEA).
1054. The invention of claim 987, wherein said diagnostic test material comprises CBC.
1055. The invention of claim 987, wherein said diagnostic test material comprises CEA.
1056. The invention of claim 987, wherein said diagnostic test material comprises CEA (carcinoembryonic antigen).
1057. The invention of claim 987, wherein said diagnostic test material comprises Ceruloplasmin.
1058. The invention of claim 987, wherein said diagnostic test material comprises CH50Chloride.
1059. The invention of claim 987, wherein said diagnostic test material comprises Cholesterol.
1060. The invention of claim 987, wherein said diagnostic test material comprises Cholesterol, HDL.
1061 . The invention of claim 987, wherein said diagnostic test material comprises Clot lysis time.
1062. Clot The invention of claim 987, wherein said diagnostic test material comprises retraction time.
1063. The invention of claim 987, wherein said diagnostic test material comprises CMP.
1064. The invention of claim 987, wherein said diagnostic test material comprises C02.
1065. The invention of claim 987, wherein said diagnostic test material comprises Cold agglutinins.
1066. The invention of claim 987, wherein said diagnostic test material comprises Complement C3.
1067. The invention of claim 987, wherein said diagnostic test material comprises Copper.
1068. The invention of claim 987, wherein said diagnostic test material comprises Corticotrophin releasing hormone (CRH) stimulation test.
1069. The invention of claim 987, wherein said diagnostic test material comprises Cortisol.
1070. The invention of claim 987, wherein said diagnostic test material comprises Cortrosyn stimulation test.
1071 . The invention of claim 987, wherein said diagnostic test material comprises C-peptide.
1072. The invention of claim 987, wherein said diagnostic test material comprises CPK (Total).
1073. The invention of claim 987, wherein said diagnostic test material comprises CPK-MB.
1074. The invention of claim 987, wherein said diagnostic test material comprises C-reactive protein.
1075. The invention of claim 987, wherein said diagnostic test material comprises Creatinine.
1076. The invention of claim 987, wherein said diagnostic test material comprises Creatinine kinase (CK).
1077. The invention of claim 987, wherein said diagnostic test material comprises Cryoglobulins.
1078. The invention of claim wherein said diagnostic test material prises DAT (Direct antiglobulin test).
1079. The invention of claim 987, wherein said diagnostic test material comprises D-Dimer.
1080. The invention of claim 987, wherein said diagnostic test material comprises Dexamethasone suppression test/
1081 . The invention of claim 987, wherein said diagnostic test material comprises DHEA-S.
1082. The invention of claim 987, wherein said diagnostic test material comprises Dilute Russell viper venom.
1083. The invention of claim 987, wherein said diagnostic test material comprises Elliptocytes.
1084. The invention of claim 987, wherein said diagnostic test material comprises Eosinophil.
1085. The invention of claim 987, wherein said diagnostic test material comprises Erythrocyte sedimentation rate (ESR).
1086. The invention of claim 987, wherein said diagnostic test material comprises Estradiol.
1087. The invention of claim 987, wherein said diagnostic test material comprises Estriol.
1088. The invention of claim 987, wherein said diagnostic test material comprises Ethanol.
1089. The invention of claim 987, wherein said diagnostic test material comprises Ethylene glycol.
1090. The invention of claim 987, wherein said diagnostic test material comprises Euglobulin lysis.
1091 . The invention of claim 987, wherein said diagnostic test material comprises Factor V Leiden.
1092. The invention of claim 987, wherein said diagnostic test material comprises Factor VIII inhibitor.
1093. The invention of claim 987, wherein said diagnostic test material comprises Factor VIII level.
1094. The invention of claim 987, wherein said diagnostic test material comprises Ferritin.
1095. The invention of claim 987, wherein said diagnostic test material comprises Fibrin split products.
1096. The invention claim 987, wherein said diagnostic test material prises Fibrinogen.
1097. The invention claim 987, wherein said diagnostic test material comprises Folate.
1098. The invention claim 987, wherein said diagnostic test material prises Folate (serum).
1099. The invention of claim 987, wherein diagnostic test material comprises Fractional excretion c sodium (FENA).
1 100. The invention of claim 987, wherein said diagnostic test material comprises FSH (follicle stimulating factor).
1 101 . The invention of claim 987, wherein said diagnostic test material comprises FTA-ABS.
1 102. The invention of claim 987, wherein said diagnostic test material comprises Gamma glutamyl transferase (GGT).
1 103. The invention of claim 987, wherein said diagnostic test material comprises Gastrin.
1 104. The invention of claim 987, wherein said diagnostic test material comprises GGTP (Gamma glutamyl transferase).
1 105. The invention of claim 987, wherein said diagnostic test material comprises Glucose.
1 106. The invention of claim 987, wherein said diagnostic test material comprises Growth hormone.
1 107. The invention of claim 987, wherein said diagnostic test material comprises Haptoglobin.
1 108. The invention of claim 987, wherein said diagnostic test material comprises HBeAg (Hepatitis Be antigen).
1 109. The invention of claim 987, wherein said diagnostic test material comprises HBs-Ag (Hepatitis B surface antigen).
1110. The invention of claim 987, wherein said diagnostic test material comprises Helicobacter pylori .
1111. The invention of claim 987, wherein said diagnostic test material comprises Hematocrit.
1112. The invention of claim 987, wherein said diagnostic test material comprises Hematocrit (HCT).
1113. The invention of claim 987, wherein said diagnostic test material comprises Hemoglobin.
1114. The invention of claim 987, wherein said diagnostic test material comprises Hemoglobin A1C.
1115. The invention of claim 987, wherein said diagnostic test material comprises Hemoglobin electrophoresis.
1116. The invention of claim 987, wherein said diagnostic test material comprises Hepatitis A antibodies.
1117. The invention of claim 987, wherein said diagnostic test material comprises Hepatitis C antibodies.
1118. The invention of claim 987, wherein said diagnostic test material comprises IAT (Indirect antiglobulin test).
1119. The invention of claim 987, wherein said diagnostic test material comprises Immunofixation (IFE).
1 120. The invention of claim 987, wherein said diagnostic test material comprises Iron.
1 121 . The invention of claim 987, wherein said diagnostic test material comprises Lactate dehydrogenase (LDH).
1 122. The invention of claim 987, wherein said diagnostic test material comprises Lactic acid (lactate).
1 123. The invention of claim 987, wherein said diagnostic test material comprises LDH.
1 124. The invention of claim 987, wherein said diagnostic test material comprises LH (Leutinizing hormone.
1 125. The invention of claim 987, wherein said diagnostic test material comprises Lipase.
1 126. The invention of claim 987, wherein said diagnostic test material comprises Lupus anticoagulant.
1 127. The invention of claim 987, wherein said diagnostic test material comprises Lymphocyte.
1 128. The invention of claim 987, wherein said diagnostic test material comprises Magnesium.
1 129. The invention of claim 987, wherein said diagnostic test material comprises MCH (mean corpuscular hemoglobin.
1 130. The invention of claim 987, wherein said diagnostic test material comprises MCHC (mean corpuscular hemoglobin concentration).
1 131 . The invention of claim 987, wherein said diagnostic test material comprises MCV (mean corpuscular volume).
1 132. The invention of claim 987, wherein said diagnostic test material comprises Methylmalonate.
1 133. The invention of claim 987, wherein said diagnostic test material comprises Monocyte.
1 134. The invention of claim 987, wherein said diagnostic test material comprises MPV (mean platelet volume).
1 135. The invention of claim 987, wherein said diagnostic test material comprises Myoglobin.
1 136. The invention of claim 987, wherein said diagnostic test material comprises Neutrophil.
1 137. The invention of claim 987, wherein said diagnostic test material comprises Parathyroid hormone (PTH).
1 138. The invention of claim 987, wherein said diagnostic test material comprises Phosphorus.
1 139. The invention of claim 987, wherein said diagnostic test material comprises Platelets (pit).
1 140. The invention of claim 987, wherein said diagnostic test material comprises Potassium.
1 141 . The invention of claim 987, wherein said diagnostic test material comprises Prealbumin.
1 142. The invention of claim 987, wherein said diagnostic test material comprises Prolactin.
1 143. The invention of claim 987, wherein said diagnostic test material comprises Prostate specific antigen (PSA).
1 144. The invention of claim 987, wherein said diagnostic test material comprises Protein C.
1 145. The invention of claim 987, wherein said diagnostic test material comprises Protein S.
1 146. The invention of claim 987, wherein said diagnostic test material comprises PSA (prostate specific antigen).
1 147. The invention of claim 987, wherein said diagnostic test material comprises PT (Prothrombin time).
1 148. The invention of claim 987, wherein said diagnostic test material comprises PTT (Partial thromboplastin time).
1 149. The invention of claim 987, wherein said diagnostic test material comprises RDW (red cell distribution width).
1 150. The invention of claim 987, wherein said diagnostic test material comprises Renin.
1 151 . The invention of claim 987, wherein said diagnostic test material comprises Rennin.
1 152. The invention of claim 987, wherein said diagnostic test material comprises Reticulocyte count.
1 153. The invention of claim 987, wherein said diagnostic test material comprises reticulocytes.
1 154. The invention of claim 987, wherein said diagnostic test material comprises Rheumatoid factor (RF).
1 155. The invention of claim 987, wherein said diagnostic test material comprises Sed Rate.
1 156. The invention of claim 987, wherein said diagnostic test material comprises Serum glutamic-pyruvic transaminase (SGPT).
1 157. The invention of claim 987, wherein said diagnostic test material comprises Serum protein electrophoresis (SPEP).
1 158. The invention of claim 987, wherein said diagnostic test material comprises Sodium.
1 159. The invention of claim 987, wherein said diagnostic test material comprises T3-resin uptake (T3RU).
1 160. The invention of claim 987, wherein said diagnostic test material comprises T4, Free.
1 161 . The invention of claim 987, wherein said diagnostic test material comprises Thrombin time.
1 162. The invention of claim 987, wherein said diagnostic test material comprises Thyroid stimulating hormone (TSH)
1 163. The invention of claim 987, wherein said diagnostic test material comprises Thyroxine (T4).
1 164. The invention of claim 987, wherein said diagnostic test material comprises Total iron binding capacity (TIBC).
1 165. The invention of claim 987, wherein said diagnostic test material comprises Total protein.
1 166. The invention of claim 987, wherein said diagnostic test material comprises Transferrin.
1 167. The invention of claim 987, wherein said diagnostic test material comprises Transferrin saturation.
1 168. The invention of claim 987, wherein said diagnostic test material comprises Triglyceride (TG).
1 169. The invention of claim 987, wherein said diagnostic test material comprises Troponin.
1 170. The invention of claim 987, wherein said diagnostic test material comprises Uric acid.
1 171 . The invention of claim 987, wherein said diagnostic test material comprises Vitamin B12.
1 172. The invention of claim 987, wherein said diagnostic test material comprises White blood cells (WBC).
1 173. The invention of claim 987, wherein said diagnostic test material comprises Widal test.
PCT/US2013/040380 2009-05-13 2013-05-09 Saccharide protective coating for pharmaceutical package WO2013170052A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP13723390.4A EP2846755A1 (en) 2012-05-09 2013-05-09 Saccharide protective coating for pharmaceutical package
CA2887352A CA2887352A1 (en) 2012-05-09 2013-05-09 Saccharide protective coating for pharmaceutical package
US14/399,678 US9545360B2 (en) 2009-05-13 2013-05-09 Saccharide protective coating for pharmaceutical package

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644961P 2012-05-09 2012-05-09
US61/644,961 2012-05-09

Publications (1)

Publication Number Publication Date
WO2013170052A1 true WO2013170052A1 (en) 2013-11-14

Family

ID=48446703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/040380 WO2013170052A1 (en) 2009-05-13 2013-05-09 Saccharide protective coating for pharmaceutical package

Country Status (4)

Country Link
US (1) US9545360B2 (en)
EP (1) EP2846755A1 (en)
CA (1) CA2887352A1 (en)
WO (1) WO2013170052A1 (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9272095B2 (en) 2011-04-01 2016-03-01 Sio2 Medical Products, Inc. Vessels, contact surfaces, and coating and inspection apparatus and methods
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9540439B2 (en) 2012-10-08 2017-01-10 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
US9545360B2 (en) 2009-05-13 2017-01-17 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
US9554968B2 (en) 2013-03-11 2017-01-31 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging
US9572526B2 (en) 2009-05-13 2017-02-21 Sio2 Medical Products, Inc. Apparatus and method for transporting a vessel to and from a PECVD processing station
US9662450B2 (en) 2013-03-01 2017-05-30 Sio2 Medical Products, Inc. Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus
US9664626B2 (en) 2012-11-01 2017-05-30 Sio2 Medical Products, Inc. Coating inspection method
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9764093B2 (en) 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
US9863042B2 (en) 2013-03-15 2018-01-09 Sio2 Medical Products, Inc. PECVD lubricity vessel coating, coating process and apparatus providing different power levels in two phases
US9878101B2 (en) 2010-11-12 2018-01-30 Sio2 Medical Products, Inc. Cyclic olefin polymer vessels and vessel coating methods
US9903782B2 (en) 2012-11-16 2018-02-27 Sio2 Medical Products, Inc. Method and apparatus for detecting rapid barrier coating integrity characteristics
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US9937099B2 (en) 2013-03-11 2018-04-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging with low oxygen transmission rate
CN107952125A (en) * 2017-12-16 2018-04-24 嘉兴新博信息科技有限公司 A kind of anorectal surgical flusher of efficient quick
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10189603B2 (en) 2011-11-11 2019-01-29 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10201660B2 (en) 2012-11-30 2019-02-12 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition on medical syringes, cartridges, and the like
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10973890B2 (en) 2016-09-13 2021-04-13 Allergan, Inc. Non-protein clostridial toxin compositions
US11066745B2 (en) 2014-03-28 2021-07-20 Sio2 Medical Products, Inc. Antistatic coatings for plastic vessels
US11077233B2 (en) 2015-08-18 2021-08-03 Sio2 Medical Products, Inc. Pharmaceutical and other packaging with low oxygen transmission rate
US11116695B2 (en) 2011-11-11 2021-09-14 Sio2 Medical Products, Inc. Blood sample collection tube
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2022258713A1 (en) * 2021-06-08 2022-12-15 Glycome Biopharma Limited Methods of coating substrates
US11624115B2 (en) 2010-05-12 2023-04-11 Sio2 Medical Products, Inc. Syringe with PECVD lubrication
US20230132721A1 (en) * 2021-11-02 2023-05-04 Hikma Pharmaceuticals Usa Inc. Succinylcholine Chloride Prefilled Syringe

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009248885B2 (en) * 2008-05-23 2015-02-05 Hospira, Inc. Packaged iron sucrose products
CA3202964A1 (en) 2011-12-06 2013-06-13 Delta Faucet Company Ozone distribution in a faucet
ES2897540T3 (en) * 2012-05-29 2022-03-01 Becton Dickinson France Lubricant coating and injection medical device comprising said coating
CN105408735A (en) * 2013-07-03 2016-03-16 怀亚特技术公司 Method and apparatus to control sample carryover in analytical instruments
KR102254473B1 (en) * 2014-03-03 2021-05-25 피코순 오와이 Protecting an interior of a gas container with an ald coating
WO2016196112A1 (en) * 2015-05-29 2016-12-08 Zebrasci, Inc. Biopolymer-based emulsion lubricants for syringe barrels
CN108463437B (en) 2015-12-21 2022-07-08 德尔塔阀门公司 Fluid delivery system comprising a disinfection device
US11166876B2 (en) * 2016-02-24 2021-11-09 Neomed, Inc. Fluid transfer connector
US20230052782A1 (en) 2019-12-12 2023-02-16 Novartis Ag Injection device and injection solution transferring system
WO2022026798A1 (en) 2020-07-30 2022-02-03 Sio2 Medical Products, Inc. Common contact surfaces for use in the manufacture, packaging, delivery, and assessment of biopharmaceutical products
JP2024506464A (en) 2021-01-04 2024-02-14 グライコム バイオファーマ リミテッド Polymer coating methods and methods for reducing protein aggregation
US11903902B2 (en) 2022-01-03 2024-02-20 Benjamin Martin DAVIS Fluid transfer couplings

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844986A (en) 1988-02-16 1989-07-04 Becton, Dickinson And Company Method for preparing lubricated surfaces and product
EP0619178A1 (en) * 1992-10-20 1994-10-12 Toppan Printing Co., Ltd. Multi-layered film material
US6068884A (en) 1998-04-28 2000-05-30 Silcon Valley Group Thermal Systems, Llc Method of making low κ dielectric inorganic/organic hybrid films
US6165566A (en) 1996-01-30 2000-12-26 Becton Dickinson And Company Method for depositing a multilayer barrier coating on a plastic substrate
DE10242698B3 (en) * 2002-09-13 2004-03-25 Fresenius Hemocare Gmbh Container made from silica-coated entropy-elastic film, useful especially as blood transfusion bag, has increased water vapor permeability after stretching
US20040267194A1 (en) 2003-01-28 2004-12-30 Minoru Sano Prefilled syringe and production method for a barrel thereof
US20060046006A1 (en) 2004-08-31 2006-03-02 Bastion Bradley J Multilayer polymeric barrier film, flexible packaging made therewith, and methods
US20070051629A1 (en) * 2005-09-08 2007-03-08 Vladislav Dolnik Poly(amino saccharide) wall coating for electrophoretic separations in capillaries and microchannels
US20080090039A1 (en) 2006-10-14 2008-04-17 Schott Ag PICVD coating for plastic containers
US20110152820A1 (en) 2009-12-22 2011-06-23 Medtronic Minimed, Inc. Barrier coatings for fluids contacting medical devices
US7985188B2 (en) 2009-05-13 2011-07-26 Cv Holdings Llc Vessel, coating, inspection and processing apparatus

Family Cites Families (973)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR891892A (en) 1942-11-17 1944-03-22 Injection needle
GB752822A (en) 1953-03-12 1956-07-18 Onera (Off Nat Aerospatiale) Improvements in rate of flow meters, especially for liquids
US3355947A (en) 1959-02-26 1967-12-05 Rockwell Mfg Co Viscosity compensated turbine flow meter
DE1147836B (en) 1959-09-26 1963-04-25 Nadler Werke Process for the sterilization of pulpy vegetable foods
DE1147838B (en) 1960-10-12 1963-04-25 Andre Michels Drive of the corner locking elements of a stamp in a device for erecting a blank made of paper, cardboard or the like to form a box
US3274267A (en) 1963-09-23 1966-09-20 Union Carbide Corp Cyclic alpha-perfluoro-di-p-xylylenes
US3297465A (en) 1963-12-31 1967-01-10 Ibm Method for producing organic plasma and for depositing polymer films
US3442686A (en) 1964-03-13 1969-05-06 Du Pont Low permeability transparent packaging films
FR1475825A (en) 1966-02-21 1967-04-07 Compteurs Comp D Improvements to turbine meters for metering volumes of fluids
US3838598A (en) 1969-03-28 1974-10-01 Brunswick Corp Capillary flow meter
US3590634A (en) 1969-05-05 1971-07-06 Stanford Research Inst Instrument for determining permeation rates through a membrane
GB1363762A (en) 1971-06-28 1974-08-14 Atomic Energy Authority Uk Fluid flow meters
US3957653A (en) 1975-04-03 1976-05-18 Becton, Dickinson And Company Apparatus for collection, separation and isolation of blood
US4187952A (en) 1976-03-04 1980-02-12 Becton, Dickinson And Company Cannula pierceable, self-sealing closure
US4111326A (en) 1976-03-04 1978-09-05 Becton, Dickinson And Company Closure for air evacuated container
US4162528A (en) 1976-05-18 1979-07-24 Bell Telephone Laboratories, Incorporated X-ray-fluorescence measurement of thin film thicknesses
GB1513426A (en) 1976-06-01 1978-06-07 Aspro Nicholas Ltd Packaging
NO137663C (en) 1976-09-30 1978-03-29 Ken Heimreid PROCEDURES FOR EXAMINATION OF UNCOAGULATED BLOOD
GB1566251A (en) 1976-10-15 1980-04-30 Gervase Instr Ltd Flow meters
US4168330A (en) 1977-10-13 1979-09-18 Rca Corporation Method of depositing a silicon oxide layer
US4484479A (en) 1978-04-05 1984-11-27 Richard Eckhardt Gas flow metering
US4392218A (en) 1979-01-02 1983-07-05 Lanier Business Products, Inc. Apparatus for identifying a dictate station by providing an automatically generated sequence of signals and a manually entered sequence of signals
US4289726A (en) 1979-07-02 1981-09-15 Potoczky Joseph B Apparatus and method for injection molding of elongated hollow plastic container walls
JPS5627330A (en) 1979-08-15 1981-03-17 Yoshino Kogyosho Co Ltd Heat treatment for internal wall surface of saturated polyester resin biaxially stretched bottle
US4293078A (en) 1979-11-01 1981-10-06 Becton, Dickinson And Company Vacuum indicator closure for a blood collection tube
US4486378A (en) 1980-05-07 1984-12-04 Toyo Seikan Kaisha Ltd. Plastic bottles and process for preparation thereof
US4391128A (en) 1981-04-20 1983-07-05 Air Products And Chemicals, Inc. Back-diffusion quality control method for barrier treated containers
US4452679A (en) 1981-10-07 1984-06-05 Becton Dickinson And Company Substrate with chemically modified surface and method of manufacture thereof
US4422896A (en) 1982-01-26 1983-12-27 Materials Research Corporation Magnetically enhanced plasma process and apparatus
JPS58154602A (en) 1982-03-10 1983-09-14 Nippon Kokan Kk <Nkk> Method and apparatus for measuring film thickness of surface of tin-free steel
JPH0635323B2 (en) 1982-06-25 1994-05-11 株式会社日立製作所 Surface treatment method
US4522510A (en) 1982-07-26 1985-06-11 Therma-Wave, Inc. Thin film thickness measurement with thermal waves
DE3239379A1 (en) 1982-10-23 1984-04-26 Helmut Fischer GmbH & Co Institut für Elektronik und Meßtechnik, 7032 Sindelfingen DEVICE FOR MEASURING THE THICKNESS LAYERS
JPS5987307A (en) 1982-11-11 1984-05-19 Nippon Kokan Kk <Nkk> Measuring device of thickness of surface film
US4483737A (en) 1983-01-31 1984-11-20 University Of Cincinnati Method and apparatus for plasma etching a substrate
JPS59168310A (en) 1983-03-02 1984-09-22 エナ−ジ−・コンバ−シヨン・デバイセス・インコ−ポレ−テツド Method and device for measuring thickness of thin-film
JPS59154029U (en) 1983-04-04 1984-10-16 ヤンマー農機株式会社 glen tank equipment
US4478873A (en) 1983-05-23 1984-10-23 American Optical Corporation Method imparting anti-static, anti-reflective properties to ophthalmic lenses
CA1199854A (en) 1983-08-31 1986-01-28 Majesty (Her) The Queen In Right Of Canada As Represented By The Minister Of National Defence Laminar flow element
US4524616A (en) 1983-09-02 1985-06-25 Tylan Corporation Adjustable laminar flow bypass
US4552791A (en) 1983-12-09 1985-11-12 Cosden Technology, Inc. Plastic container with decreased gas permeability
JPH0627323B2 (en) 1983-12-26 1994-04-13 株式会社日立製作所 Sputtering method and apparatus
AT379069B (en) 1984-01-11 1985-11-11 Greiner & Soehne C A BLOOD SAMPLES
JPS60158316A (en) 1984-01-30 1985-08-19 Osaka Gas Co Ltd Turbine type flowmeter
GR850153B (en) 1984-02-06 1985-03-29 Obrist Ag Crown
JPS6113626A (en) 1984-06-29 1986-01-21 Hitachi Ltd Plasma processor
JPS6130036A (en) 1984-07-23 1986-02-12 Fujitsu Ltd Microwave plasma processing apparatus
DE3566194D1 (en) 1984-08-31 1988-12-15 Hitachi Ltd Microwave assisting sputtering
US4668365A (en) 1984-10-25 1987-05-26 Applied Materials, Inc. Apparatus and method for magnetron-enhanced plasma-assisted chemical vapor deposition
US4648107A (en) 1984-12-05 1987-03-03 Latter Terence D Device for measuring the thickness of thin films
JPH0740468B2 (en) 1984-12-11 1995-05-01 株式会社日立製作所 High frequency plasma generator
JPS61183462A (en) 1985-02-06 1986-08-16 Yuugou Giken:Kk Apparatus and method for ion plating inner surface of pipe and the like utilizing magnetic field of magnet and coil
CH667528A5 (en) 1985-03-15 1988-10-14 Alusuisse METHOD FOR DETERMINING THE THICKNESS OF TRANSPARENT PAINT LAYERS AND DEVICE FOR IMPLEMENTING IT.
US4767414A (en) 1985-05-16 1988-08-30 Becton, Dickinson And Company Ionizing plasma lubricant method
US4667620A (en) 1985-10-29 1987-05-26 Cosden Technology, Inc. Method and apparatus for making plastic containers having decreased gas permeability
JPS62180069A (en) 1986-02-05 1987-08-07 Kobe Steel Ltd Method for coating inside surface of pipe
US4824444A (en) 1986-04-11 1989-04-25 Applied Membrane Technology, Inc. Gas permselective composite membrane prepared by plasma polymerization coating techniques
JP2575653B2 (en) 1986-06-06 1997-01-29 日新電機株式会社 Method for forming a thin film on the inner surface of a metal cylindrical coated material
US6248219B1 (en) 1986-06-23 2001-06-19 Unaxis Balzers Aktiengesellschaft Process and apparatus for sputter etching or sputter coating
JPS638524A (en) 1986-06-30 1988-01-14 Yamatake Honeywell Co Ltd Differential pressure transmitter
ZA874580B (en) 1986-07-04 1988-01-04
US4778721A (en) 1986-07-09 1988-10-18 Battelle Memorial Institute Method of forming abrasion-resistant plasma coatings and resulting articles
US4697717A (en) 1986-08-18 1987-10-06 Becton, Dickinson And Company Rubber/plastic stopper composite with mechanical adhesive joints
DE3729347A1 (en) 1986-09-05 1988-03-17 Mitsubishi Electric Corp PLASMA PROCESSOR
DE3632748A1 (en) 1986-09-26 1988-04-07 Ver Foerderung Inst Kunststoff Method of coating hollow bodies
US4756964A (en) 1986-09-29 1988-07-12 The Dow Chemical Company Barrier films having an amorphous carbon coating and methods of making
JP2587924B2 (en) 1986-10-11 1997-03-05 日本電信電話株式会社 Thin film forming equipment
US4725481A (en) 1986-10-31 1988-02-16 E. I. Du Pont De Nemours And Company Vapor-permeable, waterproof bicomponent structure
US4741446A (en) 1986-12-29 1988-05-03 Becton, Dickinson And Company Computer generated stopper
DE3774098D1 (en) 1986-12-29 1991-11-28 Sumitomo Metal Ind PLASMA UNIT.
US4853102A (en) 1987-01-07 1989-08-01 Hitachi, Ltd. Sputtering process and an apparatus for carrying out the same
SU1530913A1 (en) 1987-01-13 1989-12-23 Казахский научно-исследовательский институт энергетики Flow meter
KR960015609B1 (en) 1987-01-19 1996-11-18 미쓰다 가쓰시게 Plasma operation apparatus
JPS63124521U (en) 1987-02-07 1988-08-15
EP0284867A2 (en) 1987-04-03 1988-10-05 Tegal Corporation Dry etching apparatus using surface magnetic field confinement of plasma
US5028566A (en) 1987-04-10 1991-07-02 Air Products And Chemicals, Inc. Method of forming silicon dioxide glass films
US4973504A (en) 1987-04-13 1990-11-27 The West Company Incorporated Pharmaceutical elastomeric coating
US4808453A (en) 1987-04-13 1989-02-28 Romberg Val G Pharmaceutical elastomeric coating
US5000994A (en) 1987-04-13 1991-03-19 The West Company, Incorporated Pharmaceutical elastomeric coating
JPH0672306B2 (en) 1987-04-27 1994-09-14 株式会社半導体エネルギー研究所 Plasma processing apparatus and plasma processing method
US5203959A (en) 1987-04-27 1993-04-20 Semiconductor Energy Laboratory Co., Ltd. Microwave plasma etching and deposition method employing first and second magnetic fields
WO1988010130A1 (en) 1987-06-19 1988-12-29 Terumo Kabushiki Kaisha Medical instrument and production thereof
ZA884511B (en) 1987-07-15 1989-03-29 Boc Group Inc Method of plasma enhanced silicon oxide deposition
KR920002864B1 (en) 1987-07-20 1992-04-06 가부시기가이샤 히다찌세이사꾸쇼 Apparatus for treating matrial by using plasma
JPS6428509A (en) 1987-07-23 1989-01-31 Nippon Kokan Kk Apparatus for measuring thickness of film
US4842704A (en) 1987-07-29 1989-06-27 Collins George J Magnetron deposition of ceramic oxide-superconductor thin films
US4809876A (en) 1987-08-27 1989-03-07 Aluminum Company Of America Container body having improved gas barrier properties
US4880120A (en) 1987-09-02 1989-11-14 The Coca-Cola Company Plastic container inspection process
GB2210826B (en) 1987-10-19 1992-08-12 Bowater Packaging Ltd Barrier packaging materials
DE3738993A1 (en) 1987-11-17 1989-05-24 Philips Patentverwaltung METHOD FOR THE GLIMATE CHARGE-ACTIVATED REACTIVE DEPOSITION OF METAL FROM A GAS PHASE
US4886086A (en) 1987-12-23 1989-12-12 Graco, Inc. Non-degrading pressure regulator
JPH0668152B2 (en) 1988-01-27 1994-08-31 株式会社半導体エネルギー研究所 Thin film forming equipment
US5798027A (en) 1988-02-08 1998-08-25 Optical Coating Laboratory, Inc. Process for depositing optical thin films on both planar and non-planar substrates
JPH01225775A (en) 1988-03-04 1989-09-08 Toyo Sutoufuaa Chem:Kk Formation of ceramic coating film on inner surface of tubular material
US5041303A (en) 1988-03-07 1991-08-20 Polyplasma Incorporated Process for modifying large polymeric surfaces
US5275299A (en) 1988-04-15 1994-01-04 C. A. Greiner & Sohne Gesellschaft Mbh Closure device for an in particular evacuable cylindrical housing
US4880675A (en) 1988-04-25 1989-11-14 Air Products And Chemicals, Inc. Hot-fillable plastic containers
US5409782A (en) 1988-05-02 1995-04-25 Orient Watch Company Composite film
EP0343017A3 (en) 1988-05-20 1990-05-23 Nec Corporation Reactive ion etching apparatus
US4883686A (en) 1988-05-26 1989-11-28 Energy Conversion Devices, Inc. Method for the high rate plasma deposition of high quality material
DE3820237C1 (en) 1988-06-14 1989-09-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften Ev, 3400 Goettingen, De
US4948628A (en) 1988-07-01 1990-08-14 Becton, Dickinson And Company Method for plasma treatment of small diameter tubes
US4846101A (en) 1988-07-01 1989-07-11 Becton, Dickinson And Company Apparatus for plasma treatment of small diameter tubes
JPH0224502A (en) 1988-07-12 1990-01-26 Dainippon Screen Mfg Co Ltd Film-thickness measuring method
US4869203A (en) 1988-07-18 1989-09-26 Vapor Technologies Inc. Apparatus for coating a metal gas-pressure bottle or tank
DE3926023A1 (en) 1988-09-06 1990-03-15 Schott Glaswerke CVD COATING METHOD FOR PRODUCING LAYERS AND DEVICE FOR CARRYING OUT THE METHOD
GB8905075D0 (en) 1989-03-06 1989-04-19 Nordiko Ltd Electrode assembly and apparatus
US5472660A (en) 1989-03-08 1995-12-05 Fortex, Inc. Method for the manufacture of shaped products of biaxially oriented polymeric material
DE3908418C2 (en) 1989-03-15 1999-06-02 Buck Chem Tech Werke Process for the internal coating of plastic containers and device for coating
US4999014A (en) 1989-05-04 1991-03-12 Therma-Wave, Inc. Method and apparatus for measuring thickness of thin films
US5042951A (en) 1989-09-19 1991-08-27 Therma-Wave, Inc. High resolution ellipsometric apparatus
US5225024A (en) 1989-05-08 1993-07-06 Applied Materials, Inc. Magnetically enhanced plasma reactor system for semiconductor processing
EP0396919A3 (en) 1989-05-08 1991-07-10 Applied Materials, Inc. Plasma reactor and method for semiconductor processing
JPH02298024A (en) 1989-05-12 1990-12-10 Tadahiro Omi Reactive ion etching apparatus
US5429070A (en) 1989-06-13 1995-07-04 Plasma & Materials Technologies, Inc. High density plasma deposition and etching apparatus
US5032202A (en) 1989-10-03 1991-07-16 Martin Marietta Energy Systems, Inc. Plasma generating apparatus for large area plasma processing
US5044199A (en) 1989-11-13 1991-09-03 Dxl International, Inc. Flowmeter
JP2905828B2 (en) 1989-12-05 1999-06-14 株式会社吉野工業所 Syringe cylinder molding apparatus and syringe cylinder molding method
US5067491A (en) 1989-12-08 1991-11-26 Becton, Dickinson And Company Barrier coating on blood contacting devices
US5064083A (en) 1990-03-08 1991-11-12 The West Company, Incorporated Closure device
JP2706546B2 (en) 1990-03-08 1998-01-28 日東工器株式会社 Coating method for inner peripheral cylindrical body
AT401341B (en) 1990-03-09 1996-08-26 Greiner & Soehne C A LOCKING DEVICE FOR A PARTICULARLY EVACUABLE HOUSING
DE4008405C1 (en) 1990-03-16 1991-07-11 Schott Glaswerke, 6500 Mainz, De
JPH03271374A (en) 1990-03-22 1991-12-03 Toshiba Corp Thin film forming device
US5084356A (en) 1990-04-20 1992-01-28 E. I. Du Pont De Nemours And Company Film coated with glass barrier layer with metal dopant
US5085904A (en) 1990-04-20 1992-02-04 E. I. Du Pont De Nemours And Company Barrier materials useful for packaging
US5443645A (en) 1990-05-19 1995-08-22 Canon Kabushiki Kaisha Microwave plasma CVD apparatus comprising coaxially aligned multiple gas pipe gas feed structure
DE4026367A1 (en) 1990-06-25 1992-03-12 Leybold Ag DEVICE FOR COATING SUBSTRATES
US5131752A (en) 1990-06-28 1992-07-21 Tamarack Scientific Co., Inc. Method for film thickness endpoint control
US6251792B1 (en) 1990-07-31 2001-06-26 Applied Materials, Inc. Plasma etch processes
US5079481A (en) 1990-08-02 1992-01-07 Texas Instruments Incorporated Plasma-assisted processing magneton with magnetic field adjustment
US5082542A (en) 1990-08-02 1992-01-21 Texas Instruments Incorporated Distributed-array magnetron-plasma processing module and method
EP0470777A3 (en) 1990-08-07 1993-06-02 The Boc Group, Inc. Thin gas barrier films and rapid deposition method therefor
US5192849A (en) 1990-08-10 1993-03-09 Texas Instruments Incorporated Multipurpose low-thermal-mass chuck for semiconductor processing equipment
JPH04110617A (en) 1990-08-31 1992-04-13 Nippon Tairan Kk Divided flow structure of mass flow controller
JP2916942B2 (en) 1990-09-14 1999-07-05 住友重機械工業株式会社 Plasma CVD treatment method and apparatus for inner surface of tube
CA2051219C (en) 1990-09-14 2001-06-19 Yuji Komiya Method of preparing laminated packaging material
EP0484746B1 (en) 1990-10-25 1996-09-18 Matsushita Electric Industrial Co., Ltd. Chemically adsorbed monomolecular lamination film and method of manufacturing the same
US5240774A (en) 1990-10-25 1993-08-31 Matsushita Electric Industrial Co., Ltd. Fluorocarbon-based coating film and method of manufacturing the same
US5779802A (en) 1990-12-10 1998-07-14 Imec V.Z.W. Thin film deposition chamber with ECR-plasma source
JPH04236770A (en) 1991-01-17 1992-08-25 Kobe Steel Ltd Method for controlling arc spot in vacuum arc deposition and vaporization source
FR2671931A1 (en) 1991-01-22 1992-07-24 Metal Process DEVICE FOR DISTRIBUTING MICROWAVE ENERGY FOR EXCITATION OF PLASMA
US5330578A (en) 1991-03-12 1994-07-19 Semiconductor Energy Laboratory Co., Ltd. Plasma treatment apparatus
DE4109619C1 (en) 1991-03-23 1992-08-06 Leybold Ag, 6450 Hanau, De
CA2067691C (en) 1991-05-13 1995-12-12 James A. Burns Stopper-shield combination closure
US5189446A (en) 1991-05-17 1993-02-23 International Business Machines Corporation Plasma wafer processing tool having closed electron cyclotron resonance
DE4119362A1 (en) 1991-06-12 1992-12-17 Leybold Ag PARTICLE SOURCE, ESPECIALLY FOR REACTIVE ION NETWORK AND PLASMA SUPPORTED CVD PROCESSES
JPH056688A (en) 1991-06-20 1993-01-14 Fujitsu Ltd Sample and hold circuit
JP2635267B2 (en) 1991-06-27 1997-07-30 アプライド マテリアルズ インコーポレイテッド RF plasma processing equipment
US5888414A (en) 1991-06-27 1999-03-30 Applied Materials, Inc. Plasma reactor and processes using RF inductive coupling and scavenger temperature control
US6518195B1 (en) 1991-06-27 2003-02-11 Applied Materials, Inc. Plasma reactor using inductive RF coupling, and processes
US5633711A (en) 1991-07-08 1997-05-27 Massachusettes Institute Of Technology Measurement of material properties with optically induced phonons
DE4122802C1 (en) 1991-07-10 1992-12-17 Schott Glaswerke, 6500 Mainz, De
US5198725A (en) 1991-07-12 1993-03-30 Lam Research Corporation Method of producing flat ecr layer in microwave plasma device and apparatus therefor
US5271274A (en) 1991-08-14 1993-12-21 The Board Of Trustees Of The Leland Stanford Junior University Thin film process monitoring techniques using acoustic waves
US5204141A (en) 1991-09-18 1993-04-20 Air Products And Chemicals, Inc. Deposition of silicon dioxide films at temperatures as low as 100 degree c. by lpcvd using organodisilane sources
JP3105962B2 (en) 1991-09-20 2000-11-06 株式会社豊田中央研究所 Amorphous thin film having solid lubricity and method for producing the same
US5224441A (en) 1991-09-27 1993-07-06 The Boc Group, Inc. Apparatus for rapid plasma treatments and method
CA2268719C (en) 1991-10-03 2001-08-28 Becton, Dickinson And Company Blood collection tube assembly
DE69208793T2 (en) 1991-10-03 1996-09-19 Becton Dickinson Co Blood collection tube
EP0537950B1 (en) 1991-10-17 1997-04-02 Applied Materials, Inc. Plasma reactor
JP2647585B2 (en) 1991-11-28 1997-08-27 三菱電機株式会社 Automatic thin film measuring device
US5333049A (en) 1991-12-06 1994-07-26 Hughes Aircraft Company Apparatus and method for interferometrically measuring the thickness of thin films using full aperture irradiation
US5372851A (en) 1991-12-16 1994-12-13 Matsushita Electric Industrial Co., Ltd. Method of manufacturing a chemically adsorbed film
US5397956A (en) 1992-01-13 1995-03-14 Tokyo Electron Limited Electron beam excited plasma system
DE4204082A1 (en) 1992-02-12 1993-08-19 Leybold Ag METHOD FOR PRODUCING A ADHESIVE LAYER ON WORKPIECE SURFACES
JPH05263223A (en) 1992-03-14 1993-10-12 Nitto Kohki Co Ltd Method for coating body to be coated having inner part and device therefor
US5302266A (en) 1992-03-20 1994-04-12 International Business Machines Corporation Method and apparatus for filing high aspect patterns with metal
DE4209384C1 (en) 1992-03-23 1993-04-22 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5444207A (en) 1992-03-26 1995-08-22 Kabushiki Kaisha Toshiba Plasma generating device and surface processing device and method for processing wafers in a uniform magnetic field
EP0574100B1 (en) 1992-04-16 1999-05-12 Mitsubishi Jukogyo Kabushiki Kaisha Plasma CVD method and apparatus therefor
DE4214401C1 (en) 1992-04-30 1993-03-11 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften Ev, 3400 Goettingen, De Plasma-aided CVD of coating inside hollow body - by introducing atmos. contg. cpd. vapour into cavity at below atmos. pressure and passing microwaves into cavity
CA2095674A1 (en) 1992-05-13 1993-11-14 Nicholas A. Grippi Blood collection tube assembly
DE69304252T2 (en) 1992-05-27 1997-01-09 Matsushita Electric Ind Co Ltd Process for the production of a chemically adsorbed film
MX9303141A (en) 1992-05-28 1994-04-29 Polar Materials Inc METHODS AND DEVICES FOR DEPOSITING BARRIER COATINGS.
US5486701A (en) 1992-06-16 1996-01-23 Prometrix Corporation Method and apparatus for measuring reflectance in two wavelength bands to enable determination of thin film thickness
US5252178A (en) 1992-06-24 1993-10-12 Texas Instruments Incorporated Multi-zone plasma processing method and apparatus
US5286297A (en) 1992-06-24 1994-02-15 Texas Instruments Incorporated Multi-electrode plasma processing apparatus
US5308649A (en) 1992-06-26 1994-05-03 Polar Materials, Inc. Methods for externally treating a container with application of internal bias gas
US5812261A (en) 1992-07-08 1998-09-22 Active Impulse Systems, Inc. Method and device for measuring the thickness of opaque and transparent films
CA2100275A1 (en) 1992-07-22 1994-01-23 Mitchell K. Antoon, Jr. Blood collection assembly
US5272735A (en) 1992-08-03 1993-12-21 Combustion Engineering, Inc. Sputtering process burnable poison coating
US5531683A (en) 1992-08-13 1996-07-02 Science Incorporated Mixing and delivery syringe assembly
US5292370A (en) 1992-08-14 1994-03-08 Martin Marietta Energy Systems, Inc. Coupled microwave ECR and radio-frequency plasma source for plasma processing
US5260095A (en) 1992-08-21 1993-11-09 Battelle Memorial Institute Vacuum deposition and curing of liquid monomers
GB9219450D0 (en) 1992-09-15 1992-10-28 Glaverbel Thin film thickness monitoring and control
US5433345A (en) 1992-10-28 1995-07-18 Dai Nippon Printing Co., Ltd. Bag-in-carton and pouring spout thereof
JP2501490Y2 (en) 1992-11-24 1996-06-19 正雄 筑波 Frame attachment
CA2110761A1 (en) 1992-12-18 1994-06-19 Yelena G. Tropsha Barrier label
AU669754B2 (en) 1992-12-18 1996-06-20 Becton Dickinson & Company Barrier coating
CA2085805A1 (en) 1992-12-18 1994-06-19 Jaromir Friedrich Fluid flow rate measuring apparatus
US5298587A (en) 1992-12-21 1994-03-29 The Dow Chemical Company Protective film for articles and method
TW249313B (en) 1993-03-06 1995-06-11 Tokyo Electron Co
AU5914994A (en) 1993-04-21 1994-10-27 Bend Research, Inc. Plasma polymerization and surface modification inside hollow micro-substrates
US5494170A (en) 1993-05-06 1996-02-27 Becton Dickinson And Company Combination stopper-shield closure
US5632396A (en) 1993-05-06 1997-05-27 Becton, Dickinson And Company Combination stopper-shield closure
PE9895A1 (en) 1993-05-13 1995-05-15 Coca Cola Co METHOD FOR OBTAINING A BEVERAGE CONTAINER HAVING AN INTERNAL SURFACE WITH A RELATIVELY LOW PERMEABILITY / ABSORPTION
IL109589A0 (en) 1993-05-14 1994-08-26 Hughes Aircraft Co Apparatus and method for performing high spatial resolution thin film layer thickness metrology
DE4316349C2 (en) 1993-05-15 1996-09-05 Ver Foerderung Inst Kunststoff Process for the internal coating of hollow bodies with organic cover layers by plasma polymerization, and device for carrying out the process
CA2164223A1 (en) 1993-06-01 1994-12-08 Klaus Esser A procedure and a device for producing a plastic coating on hollow plastic articles
CH685755A5 (en) 1993-06-03 1995-09-29 Tetra Pak Suisse Sa A process for preparing a laminate.
JP2803017B2 (en) 1993-06-07 1998-09-24 工業技術院長 Antithrombotic medical material and medical device, and their manufacturing method, manufacturing apparatus, and plasma processing apparatus
US5361921A (en) 1993-06-29 1994-11-08 Becton Dickinson And Company Combination stopper-shield closure
US5356029A (en) 1993-08-25 1994-10-18 Kaneka Texas Corporation Bin-type bulk fluid container
JP3183759B2 (en) 1993-08-26 2001-07-09 株式会社三協精機製作所 Load measuring device
US5433786A (en) 1993-08-27 1995-07-18 The Dow Chemical Company Apparatus for plasma enhanced chemical vapor deposition comprising shower head electrode with magnet disposed therein
US5512399A (en) 1993-09-21 1996-04-30 Fuji Electric Co., Ltd. Organic photo sensitive member for electrophotography
CA2130388A1 (en) 1993-09-23 1995-03-24 Joel L. Williams Process for barrier coating of plastic objects
US5364666A (en) 1993-09-23 1994-11-15 Becton, Dickinson And Company Process for barrier coating of plastic objects
BR9407741A (en) 1993-10-04 1997-02-12 Catalina Coatings Inc Acrylate coating
US5440446A (en) 1993-10-04 1995-08-08 Catalina Coatings, Inc. Acrylate coating material
KR100276736B1 (en) 1993-10-20 2001-03-02 히가시 데쓰로 Plasma processing equipment
US5449432A (en) 1993-10-25 1995-09-12 Applied Materials, Inc. Method of treating a workpiece with a plasma and processing reactor having plasma igniter and inductive coupler for semiconductor fabrication
FR2711647B1 (en) 1993-10-27 1996-01-19 Europ Propulsion Process for the chemical vapor infiltration of a material into a porous substrate at a controlled surface temperature.
US5679412A (en) 1993-10-28 1997-10-21 Manfred R. Kuehnle Method and apparatus for producing gas impermeable, chemically inert container structures for food and volatile substances
US5413813A (en) 1993-11-23 1995-05-09 Enichem S.P.A. CVD of silicon-based ceramic materials on internal surface of a reactor
US5354286A (en) 1993-12-07 1994-10-11 Survival Technology, Inc. Injection device having polyparaxylylene coated container
AT400802B (en) 1993-12-16 1996-03-25 Greiner & Soehne C A HOLDING DEVICE FOR A BLOOD SAMPLING TUBE OF A BLOOD SAMPLING DEVICE
US5871700A (en) 1993-12-21 1999-02-16 C.A. Greiner & Sohne Gesellschaft M.B.H. Holding device with a cylindrical container and blood sampling tube with such a holding device
US5439736A (en) 1994-01-21 1995-08-08 Neomecs Incorporated Gas plasma polymerized permselective membrane
DE69500531T2 (en) 1994-01-31 1998-02-26 Nissin Electric Co Ltd Process for producing a tube with a film covering on the inner peripheral surface and device for producing it
CH687601A5 (en) 1994-02-04 1997-01-15 Tetra Pak Suisse Sa Process for the production of internally sterile packaging with excellent barrier properties.
US5565248A (en) 1994-02-09 1996-10-15 The Coca-Cola Company Method and apparatus for coating hollow containers through plasma-assisted deposition of an inorganic substance
US6149982A (en) 1994-02-16 2000-11-21 The Coca-Cola Company Method of forming a coating on an inner surface
ES2131810T5 (en) 1994-02-16 2004-02-16 The Coca-Cola Company HOLLOW CONTAINERS WITH INERT OR WATERPROOF INTERIOR SURFACES PRODUCED BY SURFACE REACTION ASSISTED BY PLASMA OR POLYMERIZATION ON THE SURFACE.
US5618619A (en) 1994-03-03 1997-04-08 Monsanto Company Highly abrasion-resistant, flexible coatings for soft substrates
US5569810A (en) 1994-03-18 1996-10-29 Samco International, Inc. Method of and system for processing halogenated hydrocarbons
US5620523A (en) 1994-04-11 1997-04-15 Canon Sales Co., Inc. Apparatus for forming film
US5593550A (en) 1994-05-06 1997-01-14 Medtronic, Inc. Plasma process for reducing friction within the lumen of polymeric tubing
JPH07304127A (en) 1994-05-13 1995-11-21 Toppan Printing Co Ltd Gas barrier packaging material and production thereof
US5670415A (en) 1994-05-24 1997-09-23 Depositech, Inc. Method and apparatus for vacuum deposition of highly ionized media in an electromagnetic controlled environment
US5514246A (en) 1994-06-02 1996-05-07 Micron Technology, Inc. Plasma reactors and method of cleaning a plasma reactor
GB9411626D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Package
JP3687975B2 (en) 1994-07-01 2005-08-24 エドワーズ ライフサイエンシーズ コーポレイション Method for collecting adipose tissue containing autologous microvascular endothelial cells
US5452082A (en) 1994-07-05 1995-09-19 Uop Flow cell with leakage detection
US5536253A (en) 1994-07-15 1996-07-16 Habley Medical Technology Corporation Pre-filled safety syringe having a retractable needle
US5578103A (en) 1994-08-17 1996-11-26 Corning Incorporated Alkali metal ion migration control
US5521351A (en) 1994-08-30 1996-05-28 Wisconsin Alumni Research Foundation Method and apparatus for plasma surface treatment of the interior of hollow forms
US5510155A (en) 1994-09-06 1996-04-23 Becton, Dickinson And Company Method to reduce gas transmission
US5545375A (en) 1994-10-03 1996-08-13 Becton, Dickinson And Company Blood collection tube assembly
DE4437050A1 (en) 1994-10-17 1996-04-18 Leybold Ag Device for treating surfaces of hollow bodies, in particular inner surfaces of fuel tanks
DE4438360C2 (en) 1994-10-27 1999-05-20 Schott Glas Pre-fillable, low-particle, sterile disposable syringe for the injection of preparations and methods for their manufacture
DE4438359C2 (en) 1994-10-27 2001-10-04 Schott Glas Plastic container with a barrier coating
US6083628A (en) 1994-11-04 2000-07-04 Sigma Laboratories Of Arizona, Inc. Hybrid polymer film
DE4445427C2 (en) 1994-12-20 1997-04-30 Schott Glaswerke Plasma CVD method for producing a gradient layer
DE4445969C1 (en) 1994-12-22 1996-03-14 Schott Glaswerke Syringe cylinder with two compartments for two constituents
JP3022229B2 (en) 1994-12-26 2000-03-15 東洋製罐株式会社 Method for forming silicon oxide film of uniform thickness on three-dimensional container made of plastics material
JPH08288096A (en) 1995-02-13 1996-11-01 Mitsubishi Electric Corp Plasma treatment device
EP0728676A1 (en) 1995-02-25 1996-08-28 TNT Limited Sampling device for a flexible container
US5877895A (en) 1995-03-20 1999-03-02 Catalina Coatings, Inc. Multicolor interference coating
JP2920187B2 (en) 1995-04-28 1999-07-19 日新電機株式会社 Method and apparatus for forming a film on the peripheral surface of a tube
US5674321A (en) 1995-04-28 1997-10-07 Applied Materials, Inc. Method and apparatus for producing plasma uniformity in a magnetic field-enhanced plasma reactor
US5485091A (en) 1995-05-12 1996-01-16 International Business Machines Corporation Contactless electrical thin oxide measurements
US5513515A (en) 1995-05-15 1996-05-07 Modern Controls, Inc. Method for measuring permeability of a material
US5555471A (en) 1995-05-24 1996-09-10 Wyko Corporation Method for measuring thin-film thickness and step height on the surface of thin-film/substrate test samples by phase-shifting interferometry
JP4245661B2 (en) 1995-06-26 2009-03-25 ゼネラル・エレクトリック・カンパニイ Thermal barrier coating composite protected by multiple coatings
US5840167A (en) 1995-08-14 1998-11-24 Lg Semicon Co., Ltd Sputtering deposition apparatus and method utilizing charged particles
WO1997011482A2 (en) 1995-09-05 1997-03-27 Lsi Logic Corporation Removal of halogens and photoresist from wafers
US5837903A (en) 1995-09-22 1998-11-17 The Scott Fetzer Company Inc. Device for measuring exhaust flowrate using laminar flow element
US5779716A (en) 1995-10-06 1998-07-14 Metamorphic Surgical Devices, Inc. Device for removing solid objects from body canals, cavities and organs
US5591898A (en) 1995-10-12 1997-01-07 Modern Controls, Inc. Method for measuring material permeability characteristics
KR100418145B1 (en) 1995-10-13 2005-01-31 다우 글로벌 테크놀로지스 인크. Laminates with Covered Plastic Substrates
EP0819617B1 (en) 1995-10-18 2001-01-31 Daikyo Seiko, Ltd. A plastic cap and a process for the production of the same
US6210791B1 (en) 1995-11-30 2001-04-03 General Electric Company Article with a diffuse reflective barrier coating and a low-emissity coating thereon, and its preparation
US5985103A (en) 1995-12-19 1999-11-16 Micron Technology, Inc. Method for improved bottom and side wall coverage of high aspect ratio features
US5658438A (en) 1995-12-19 1997-08-19 Micron Technology, Inc. Sputter deposition method for improved bottom and side wall coverage of high aspect ratio features
TW303480B (en) 1996-01-24 1997-04-21 Applied Materials Inc Magnetically confined plasma reactor for processing a semiconductor wafer
US6471822B1 (en) 1996-01-24 2002-10-29 Applied Materials, Inc. Magnetically enhanced inductively coupled plasma reactor with magnetically confined plasma
US5702770A (en) 1996-01-30 1997-12-30 Becton, Dickinson And Company Method for plasma processing
US5683771A (en) 1996-01-30 1997-11-04 Becton, Dickinson And Company Blood collection tube assembly
TW434301B (en) 1996-01-30 2001-05-16 Becton Dickinson Co Non-ideal barrier coating composition comprising organic and inorganic materials
US5738920A (en) 1996-01-30 1998-04-14 Becton, Dickinson And Company Blood collection tube assembly
US5686157A (en) 1996-01-30 1997-11-11 Becton, Dickinson And Company Blood collection tube assembly
CA2277679C (en) 1996-01-30 2003-06-10 Becton, Dickinson And Company Blood collection tube assembly
US5716683A (en) 1996-01-30 1998-02-10 Becton, Dickinson And Company Blood collection tube assembly
US5763033A (en) 1996-01-30 1998-06-09 Becton, Dickinson And Company Blood collection tube assembly
US5737179A (en) 1996-02-07 1998-04-07 Catalina Coatings, Inc. Metallized film capacitor
US5667840A (en) 1996-02-27 1997-09-16 Becton Dickinson And Company Lubricant soluble fluorescent agent and method for its use in a system for detection of lubricant coatings
US6160350A (en) 1996-03-25 2000-12-12 Sumitomo Heavy Industries, Ltd. Ion plating apparatus
US6106678A (en) 1996-03-29 2000-08-22 Lam Research Corporation Method of high density plasma CVD gap-filling
WO1997040207A1 (en) 1996-04-22 1997-10-30 N.V. Bekaert S.A. Diamond-like nanocomposite compositions
US5888591A (en) 1996-05-06 1999-03-30 Massachusetts Institute Of Technology Chemical vapor deposition of fluorocarbon polymer thin films
US6020196A (en) 1996-05-09 2000-02-01 Baxter International Inc. Devices for harvesting and homogenizing adipose tissue containing autologous endothelial cells
JP3256459B2 (en) * 1996-05-20 2002-02-12 株式会社大協精工 Sanitary goods container and method for producing the same
EP0814114A1 (en) 1996-06-18 1997-12-29 Becton, Dickinson and Company Barrier coating
JPH108254A (en) 1996-06-21 1998-01-13 Toyota Motor Corp Formation of silicon dioxide layer
US6190992B1 (en) 1996-07-15 2001-02-20 Micron Technology, Inc. Method to achieve rough silicon surface on both sides of container for enhanced capacitance/area electrodes
US6161712A (en) 1996-07-22 2000-12-19 Becton Dickinson And Company Ball and socket closure
DE19629877C1 (en) 1996-07-24 1997-03-27 Schott Glaswerke CVD for internal coating of hollow articles with barrier film
US5900284A (en) 1996-07-30 1999-05-04 The Dow Chemical Company Plasma generating device and method
AT404317B (en) 1996-08-02 1998-10-27 Greiner & Soehne C A LOCKING DEVICE, DISCONNECTING DEVICE AND RECEIVING CONTAINER FOR A RECEIVING DEVICE
JP3198065B2 (en) 1996-08-19 2001-08-13 株式会社大協精工 Hygiene container
JP3945664B2 (en) 1996-09-06 2007-07-18 治 高井 Method for producing water-repellent silicon oxide film
US5750892A (en) 1996-09-27 1998-05-12 Teledyne Industries, Inc. Laminar flow element with inboard sensor taps and coaxial laminar flow guides
US5691007A (en) 1996-09-30 1997-11-25 Becton Dickinson And Company Process for depositing barrier film on three-dimensional articles
US5792940A (en) 1996-09-30 1998-08-11 Becton, Dickinson And Company Rapid evaluation of thin-film barrier coatings on thick substrates via transient response measurements
US5807343A (en) 1996-09-30 1998-09-15 Becton Dickinson And Company Protective sealing barrier for a syringe
US5766362A (en) 1996-09-30 1998-06-16 Becton Dickinson And Company Apparatus for depositing barrier film on three-dimensional articles
US6112695A (en) 1996-10-08 2000-09-05 Nano Scale Surface Systems, Inc. Apparatus for plasma deposition of a thin film onto the interior surface of a container
US6027619A (en) 1996-12-19 2000-02-22 Micron Technology, Inc. Fabrication of field emission array with filtered vacuum cathodic arc deposition
JP2001506887A (en) 1996-12-23 2001-05-29 ノボ ノルディスク アクティーゼルスカブ Drug container comprising a polymer of a cyclic hydrocarbon for storing a liquid drug
US5913140A (en) 1996-12-23 1999-06-15 Lam Research Corporation Method for reduction of plasma charging damage during chemical vapor deposition
US7268179B2 (en) 1997-02-03 2007-09-11 Cytonix Corporation Hydrophobic coating compositions, articles coated with said compositions, and processes for manufacturing same
US5824607A (en) 1997-02-06 1998-10-20 Applied Materials, Inc. Plasma confinement for an inductively coupled plasma reactor
DE19706255C2 (en) 1997-02-18 2000-11-30 Schott Glas Sterilizable glass container for medical purposes, in particular for storing pharmaceutical or diagnostic products
DE19707645A1 (en) 1997-02-26 1998-08-27 Leybold Ag Layer thickness determination
US20020155299A1 (en) 1997-03-14 2002-10-24 Harris Caroline S. Photo-induced hydrophilic article and method of making same
US6223683B1 (en) 1997-03-14 2001-05-01 The Coca-Cola Company Hollow plastic containers with an external very thin coating of low permeability to gases and vapors through plasma-assisted deposition of inorganic substances and method and system for making the coating
JP3582287B2 (en) 1997-03-26 2004-10-27 株式会社日立製作所 Etching equipment
US5800880A (en) 1997-03-26 1998-09-01 Tetra Laval Holdings & Finance, S.A. Process for coating the interior wall of a container with a SiOx barrier layer
US6017317A (en) 1997-03-26 2000-01-25 Becton Dickinson And Company Assembly for collecting blood or other body fluids
WO1998045871A1 (en) 1997-04-04 1998-10-15 Alexander Igorevich Dodonov Producing electric arc plasma in a curvilinear plasmaguide and substrate coating
US6261643B1 (en) 1997-04-08 2001-07-17 General Electric Company Protected thermal barrier coating composite with multiple coatings
US5880034A (en) 1997-04-29 1999-03-09 Princeton University Reduction of semiconductor structure damage during reactive ion etching
US5814738A (en) 1997-05-01 1998-09-29 Mccrometer, Inc. Fluid flow meter and mixer having removable and replaceable displacement member
US5837888A (en) 1997-05-14 1998-11-17 Modern Controls, Inc. Process for measuring vapor transmission through materials
JP3387775B2 (en) 1997-05-22 2003-03-17 株式会社大協精工 Sealing stopper for syringe and prefilled syringe
JPH10335314A (en) 1997-06-05 1998-12-18 Mitsubishi Electric Corp Plasma processing device and substrate processing method
JPH111770A (en) 1997-06-06 1999-01-06 Anelva Corp Sputtering apparatus and sputtering method
US6110544A (en) 1997-06-26 2000-08-29 General Electric Company Protective coating by high rate arc plasma deposition
JPH1171676A (en) 1997-06-26 1999-03-16 General Electric Co <Ge> Deposition of silicon dioxide by plasma-activated vaporization process
US6135053A (en) 1997-07-16 2000-10-24 Canon Kabushiki Kaisha Apparatus for forming a deposited film by plasma chemical vapor deposition
US6001429A (en) 1997-08-07 1999-12-14 Becton Dickinson And Company Apparatus and method for plasma processing
US5861546A (en) 1997-08-20 1999-01-19 Sagi; Nehemiah Hemi Intelligent gas flow measurement and leak detection apparatus
US6110395A (en) 1997-08-26 2000-08-29 Trikon Technologies, Inc. Method and structure for controlling plasma uniformity
US5902461A (en) 1997-09-03 1999-05-11 Applied Materials, Inc. Apparatus and method for enhancing uniformity of a metal film formed on a substrate with the aid of an inductively coupled plasma
DE19739321C2 (en) 1997-09-09 2001-09-27 Helmut Fischer Gmbh & Co Method and device for determining the measurement uncertainty in X-ray fluorescence layer thickness measurements
US5972297A (en) 1997-09-12 1999-10-26 Becton, Dickinson & Company Ball and socket closure for specimen collection container incorporating a septum
US5948364A (en) 1997-09-12 1999-09-07 Becton Dickinson & Company Ball and socket closure for specimen collection container
US6350415B1 (en) 1997-09-12 2002-02-26 Becton, Dickinson And Company Ball and socket closure for specimen collection container incorporating a dimple locking mechanism
US6032813A (en) 1997-09-12 2000-03-07 Becton, Dickinson And Company Ball and socket closure for specimen collection container incorporating an integral flexible seal
US5919420A (en) 1997-09-12 1999-07-06 Becton Dickinson And Company Ball and socket closure for specimen collection container incorporating a resilient elastomeric seal
US6757056B1 (en) 2001-03-26 2004-06-29 Candela Instruments Combined high speed optical profilometer and ellipsometer
JPH11102799A (en) 1997-09-26 1999-04-13 Mitsubishi Electric Corp Plasma generator
AU9092298A (en) 1997-09-30 1999-04-23 Tetra Laval Holdings & Finance Sa Device and method for treating the inside surface of a plastic container with a narrow opening in a plasma enhanced process
US6565791B1 (en) 1997-09-30 2003-05-20 Tetra Laval Holdings & Finance S.A. Method and apparatus for treating the inside surface of plastic bottles in a plasma enhanced process
JPH11108833A (en) 1997-10-06 1999-04-23 Mitsubishi Chemical Corp Method for spectroscopic analysis of substance
JPH11106920A (en) 1997-10-08 1999-04-20 Nissin Electric Co Ltd Container and its production
EP1029103B1 (en) 1997-11-03 2001-09-19 Siemens Aktiengesellschaft Coating method and device
GB9723222D0 (en) 1997-11-04 1998-01-07 Pilkington Plc Coating glass
US6051151A (en) 1997-11-12 2000-04-18 International Business Machines Corporation Apparatus and method of producing a negative ion plasma
SE511139C2 (en) 1997-11-20 1999-08-09 Hana Barankova Plasma processing apparatus with rotatable magnets
US6136165A (en) 1997-11-26 2000-10-24 Cvc Products, Inc. Apparatus for inductively-coupled-plasma-enhanced ionized physical-vapor deposition
US5961911A (en) 1997-12-05 1999-10-05 Becton Dickinson And Company Process for manufacture of closure assembly
KR100256173B1 (en) 1997-12-22 2000-05-15 윤종용 Plasma etching chamber for fabricating semiconductor device
JPH11193470A (en) 1997-12-26 1999-07-21 Canon Inc Deposited film forming device and formation of deposited film
US6162443A (en) 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
DE19801861C2 (en) 1998-01-20 2001-10-18 Schott Glas Process for producing a hollow, internally coated molded glass body
JPH11218418A (en) 1998-02-03 1999-08-10 Seiko Instruments Inc In-line fluorescence x-ray film thickness monitor
US6163006A (en) 1998-02-06 2000-12-19 Astex-Plasmaquest, Inc. Permanent magnet ECR plasma source with magnetic field optimization
US6103074A (en) 1998-02-14 2000-08-15 Phygen, Inc. Cathode arc vapor deposition method and apparatus
US5993745A (en) 1998-03-04 1999-11-30 Roche Diagnostics Corporation Archival storage tray for multiple test tubes
JP3669138B2 (en) 1998-03-05 2005-07-06 日新電機株式会社 Plasma CVD method, plasma CVD apparatus and electrode
US6482509B2 (en) 1998-03-06 2002-11-19 Novo Nordisk A/S Coating system providing low friction
US6189484B1 (en) 1999-03-05 2001-02-20 Applied Materials Inc. Plasma reactor having a helicon wave high density plasma source
JP3698887B2 (en) 1998-03-16 2005-09-21 株式会社アルバック Diamond-like carbon film production equipment
US6243938B1 (en) 1998-03-17 2001-06-12 Becton, Dickinson And Company Low silicone plastic prefillable syringe
DE19912737A1 (en) 1998-03-19 2000-06-21 Henning Nagel Production of porous silicon oxide film useful as antireflection coating on glass or transparent plastics, involves using self-shading or atoms and molecules in plasma-enhanced chemical vapor deposition
FR2776540B1 (en) 1998-03-27 2000-06-02 Sidel Sa BARRIER-EFFECT CONTAINER AND METHOD AND APPARATUS FOR ITS MANUFACTURING
KR20010042128A (en) 1998-03-31 2001-05-25 드로그.와이.윌렘스,렉토 Method and apparatus for deposition of biaxially textured coatings
JPH11297673A (en) 1998-04-15 1999-10-29 Hitachi Ltd Plasma processor and cleaning method
US6753972B1 (en) 1998-04-21 2004-06-22 Hitachi, Ltd. Thin film thickness measuring method and apparatus, and method and apparatus for manufacturing a thin film device using the same
CA2236703C (en) 1998-05-05 2002-01-29 Morihiro Sudo Sliding piston for syringe
US6217716B1 (en) 1998-05-06 2001-04-17 Novellus Systems, Inc. Apparatus and method for improving target erosion in hollow cathode magnetron sputter source
US6035717A (en) 1998-05-12 2000-03-14 Krautkramer Branson, Inc. Method and apparatus for measuring the thickness of a coated material
US6271047B1 (en) 1998-05-21 2001-08-07 Nikon Corporation Layer-thickness detection methods and apparatus for wafers and the like, and polishing apparatus comprising same
US6015595A (en) 1998-05-28 2000-01-18 Felts; John T. Multiple source deposition plasma apparatus
JPH11344316A (en) 1998-05-29 1999-12-14 Futec Inc Film thickness measuring method
US6093175A (en) 1998-06-05 2000-07-25 Becton Dickinson And Company Localized lubrication of syringe barrels and stoppers
US6544610B1 (en) 1998-06-30 2003-04-08 Zeon Corporation Container and blow-molded product
US20010042510A1 (en) 1998-07-08 2001-11-22 The Coca-Cola Company Hollow containers with inert or impermeable inner surface through plasma-assisted surface reaction or on-surface polymerization
DE19830794B4 (en) 1998-07-09 2005-10-27 Singulus Technologies Ag Coating thickness measurement system and method
US7798993B2 (en) 1998-07-29 2010-09-21 Becton, Dickinson And Company Single use syringe
US6018987A (en) 1998-08-03 2000-02-01 Mocon, Inc. Apparatus for measuring gas transmission through container closures
JP3437772B2 (en) 1998-08-17 2003-08-18 長崎県 Surface treatment method and apparatus for pipe inner surface
US6125687A (en) 1998-08-20 2000-10-03 International Business Machines Corporation Apparatus for measuring outgassing of volatile materials from an object
US6009743A (en) 1998-08-24 2000-01-04 Mocon, Inc. Apparatus and method for online or offline measurement of vapor transmission through sheet materials
WO2000019507A1 (en) 1998-09-28 2000-04-06 Tokyo Electron Limited Method of plasma-assisted film deposition
JP2000127290A (en) 1998-09-30 2000-05-09 Becton Dickinson & Co Barrier covering and method for stacking barrier covering on plastic material by high output plasma chemical gas phase growth process
US6165138A (en) 1998-09-30 2000-12-26 Becton Dickinson And Company Self-sealing closure for a medical speciman collection container
JP2000109076A (en) 1998-10-01 2000-04-18 Toppan Printing Co Ltd Inner surface-coated bottle and manufacture thereof
US6236459B1 (en) 1998-11-05 2001-05-22 University Of Miami Thin film measuring device and method
US6596401B1 (en) 1998-11-10 2003-07-22 C. R. Bard Inc. Silane copolymer compositions containing active agents
KR100341565B1 (en) 1998-11-11 2002-06-22 김윤 Fluorinated resins having a surface with high wettability
US6486081B1 (en) 1998-11-13 2002-11-26 Applied Materials, Inc. Gas distribution system for a CVD processing chamber
US6263249B1 (en) 1999-02-26 2001-07-17 Medtronic, Inc. Medical electrical lead having controlled texture surface and method of making same
US6204922B1 (en) 1998-12-11 2001-03-20 Filmetrics, Inc. Rapid and accurate thin film measurement of individual layers in a multi-layered or patterned sample
EP1140278B1 (en) 1998-12-14 2004-05-19 Tre Esse Progettazione Biomedica S.r.l Catheter system for performing intramyocardiac therapeutic treatment
US6207238B1 (en) 1998-12-16 2001-03-27 Battelle Memorial Institute Plasma enhanced chemical deposition for high and/or low index of refraction polymers
US6165542A (en) 1998-12-23 2000-12-26 United Technologies Corporation Method for fabricating and inspecting coatings
AU2212200A (en) 1998-12-23 2000-07-12 Applied Science And Technology, Inc. Permanent magnet ecr plasma source with integrated multipolar magnetic confinement
AT407007B (en) 1998-12-23 2000-11-27 Greiner Labortechnik Gmbh RECEIVING DEVICE FOR AN INSERT ELEMENT
US6188079B1 (en) 1999-01-12 2001-02-13 Owens-Brockway Glass Container Inc. Measurement of hot container wall thickness
US6774018B2 (en) 1999-02-01 2004-08-10 Sigma Laboratories Of Arizona, Inc. Barrier coatings produced by atmospheric glow discharge
US6193853B1 (en) 1999-02-25 2001-02-27 Cametoid Limited Magnetron sputtering method and apparatus
US6284986B1 (en) 1999-03-15 2001-09-04 Seh America, Inc. Method of determining the thickness of a layer on a silicon substrate
SE520491C2 (en) 1999-04-07 2003-07-15 Tetra Laval Holdings & Finance Packaging laminate with barrier properties against gas and flavorings
US6929727B2 (en) 1999-04-12 2005-08-16 G & H Technologies, Llc Rectangular cathodic arc source and method of steering an arc spot
US6645354B1 (en) 2000-04-07 2003-11-11 Vladimir I. Gorokhovsky Rectangular cathodic arc source and method of steering an arc spot
EP1048746B1 (en) 1999-04-28 2005-09-21 Alcan Technology & Management AG Method and apparatus for making packages
US6582823B1 (en) 1999-04-30 2003-06-24 North Carolina State University Wear-resistant polymeric articles and methods of making the same
DE19921303C1 (en) 1999-05-07 2000-10-12 Schott Glas Medical glass container, for holding pharmaceutical or medical diagnostic solution, has an inner PECVD non-stick layer containing silicon, oxygen, carbon and hydrogen
WO2000073163A1 (en) 1999-05-28 2000-12-07 Novo Nordisk A/S Injection-moulded stopper for medical containers
US6306132B1 (en) 1999-06-17 2001-10-23 Vivant Medical Modular biopsy and microwave ablation needle delivery apparatus adapted to in situ assembly and method of use
US6399944B1 (en) 1999-07-09 2002-06-04 Fei Company Measurement of film thickness by inelastic electron scattering
DE19932082A1 (en) 1999-07-12 2001-01-18 Schott Glas Interference optical narrow band filter
US6085927A (en) 1999-07-12 2000-07-11 Owens-Illinois Closure Inc. Container with insert to reduce effective volume and package incorporating same
US6185992B1 (en) 1999-07-15 2001-02-13 Veeco Instruments Inc. Method and system for increasing the accuracy of a probe-based instrument measuring a heated sample
JP3226512B2 (en) 1999-07-19 2001-11-05 東洋ガラス株式会社 Glass container coating inspection method and apparatus
US6083313A (en) 1999-07-27 2000-07-04 Advanced Refractory Technologies, Inc. Hardcoats for flat panel display substrates
US6054188A (en) 1999-08-02 2000-04-25 Becton Dickinson And Company Non-ideal barrier coating architecture and process for applying the same to plastic substrates
DE19938724A1 (en) 1999-08-16 2001-02-22 Tetra Laval Holdings & Finance Device for the production of plastic containers by means of stretch blow molding
US6143140A (en) 1999-08-16 2000-11-07 Applied Materials, Inc. Method and apparatus to improve the side wall and bottom coverage in IMP process by using magnetic field
US6602206B1 (en) 1999-08-18 2003-08-05 Becton, Dickinson And Company Stopper-shield assembly
US6410926B1 (en) 1999-10-01 2002-06-25 Ppg Industries Ohio, Inc. Coating with optical taggent
CA2286414A1 (en) 1999-10-04 2001-04-04 Zhibo Gan Non-separation heterogenous assay for biological substance
US6413645B1 (en) 2000-04-20 2002-07-02 Battelle Memorial Institute Ultrabarrier substrates
US6623861B2 (en) 2001-04-16 2003-09-23 Battelle Memorial Institute Multilayer plastic substrates
US6322661B1 (en) 1999-11-15 2001-11-27 Lam Research Corporation Method and apparatus for controlling the volume of a plasma
SE521904C2 (en) 1999-11-26 2003-12-16 Ladislav Bardos Hybrid Plasma Treatment Device
SE0004353L (en) 1999-12-06 2001-06-07 Greiner Bio One Gmbh Device in the form of a vessel and / or seal
US6308556B1 (en) 1999-12-17 2001-10-30 Atc, Inc. Method and apparatus of nondestructive testing a sealed product for leaks
US6584828B2 (en) 1999-12-17 2003-07-01 Atc, Inc. Method and apparatus of nondestructive testing a sealed product for leaks
DE19963122A1 (en) 1999-12-24 2001-06-28 Tetra Laval Holdings & Finance Plasma chemical vapor deposition assembly has a cylindrical structure with a waveguide system to couple the microwave energy with a gas feed to coat the interior of plastics containers of all shapes and sizes without modification
AU2001229866A1 (en) 2000-01-27 2001-08-07 Greiner Bio-One Gmbh Container for holding fluids
DE10004274A1 (en) 2000-02-01 2001-08-02 Tetra Laval Holdings & Finance Apparatus to coat the inner surface of a hollow body comprises a feed pipe for process gas and a waste gas line outside of the hollow body connected to a waste gas pipe
JP3697250B2 (en) 2000-02-24 2005-09-21 三菱重工業株式会社 Plasma processing apparatus and method for producing carbon coating-formed plastic container
JP4492985B2 (en) 2000-02-24 2010-06-30 三菱商事プラスチック株式会社 Liquid medicine plastic container and liquid medicine storage and recovery method
US6985221B2 (en) 2000-03-01 2006-01-10 Petwall, Llc Method and apparatus for measuring wall thickness of plastic container
DE10010831A1 (en) 2000-03-10 2001-09-13 Pierre Flecher Low pressure microwave plasma treatment method for plastic bottles involves filling bottles with process gas and subjecting to microwaves from a plasma in a vacuum chamber
US20010038894A1 (en) 2000-03-14 2001-11-08 Minoru Komada Gas barrier film
DE10012446B4 (en) 2000-03-15 2007-06-14 Tetra Laval Holdings & Finance S.A. Method for measuring the gas permeability of a coating on a plastic wall and apparatus for carrying out the method
US6853141B2 (en) 2002-05-22 2005-02-08 Daniel J. Hoffman Capacitively coupled plasma reactor with magnetic plasma control
AT414209B (en) 2000-03-17 2006-10-15 Greiner Bio One Gmbh COLLECTION TANK FOR LIQUIDS
US6382441B1 (en) 2000-03-22 2002-05-07 Becton, Dickinson And Company Plastic tube and resealable closure having protective collar
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
EP1199378A4 (en) 2000-03-27 2006-09-20 Mitsubishi Heavy Ind Ltd Method for forming metallic film and apparatus for forming the same
US7067034B2 (en) 2000-03-27 2006-06-27 Lam Research Corporation Method and apparatus for plasma forming inner magnetic bucket to control a volume of a plasma
US20040039401A1 (en) 2000-03-31 2004-02-26 Chow Alan Y. Implant instrument
CA2305938C (en) 2000-04-10 2007-07-03 Vladimir I. Gorokhovsky Filtered cathodic arc deposition method and apparatus
DE10018015A1 (en) 2000-04-11 2001-10-25 Infineon Technologies Ag Arrangement for carrying out plasma-based process especially for ionised physical vapour deposition (IPVD) for metal deposition in microelectronics components manufacture
DE10019355A1 (en) 2000-04-18 2001-10-31 Schott Glas Vitreous body with increased strength
US6562189B1 (en) 2000-05-19 2003-05-13 Applied Materials Inc. Plasma reactor with a tri-magnet plasma confinement apparatus
GB0012170D0 (en) 2000-05-20 2000-07-12 Harcostar Drums Limited Treatment of plastics containers
JP2001338912A (en) 2000-05-29 2001-12-07 Tokyo Electron Ltd Plasma processing equipment and method for processing thereof
EP1299461A2 (en) 2000-06-06 2003-04-09 The Dow Chemical Company Barrier layer for polymers and containers
US6394979B1 (en) 2000-06-09 2002-05-28 Inviro Medical Devices Ltd. Cannula for use with a medical syringe
KR100767334B1 (en) 2000-06-20 2007-10-17 미쓰이 가가쿠 가부시키가이샤 Crosslinkable rubber composition and use thereof
US6375022B1 (en) 2000-06-30 2002-04-23 Becton, Dickinson And Company Resealable closure for containers
JP3860954B2 (en) 2000-07-07 2006-12-20 株式会社日立グローバルストレージテクノロジーズ Plasma processing apparatus with real-time particle filter
US6352629B1 (en) 2000-07-10 2002-03-05 Applied Materials, Inc. Coaxial electromagnet in a magnetron sputtering reactor
US6346596B1 (en) 2000-07-14 2002-02-12 Valspar Corporation Gas barrier polymer composition
US6354452B1 (en) 2000-07-25 2002-03-12 Becton, Dickinson And Company Collection container assembly
US6749078B2 (en) 2000-07-25 2004-06-15 Becton, Dickinson And Company Collection assembly
JP2002107134A (en) 2000-07-27 2002-04-10 Seiko Instruments Inc Thickness meter for x-ray fluorescence film
EP1178134A1 (en) 2000-08-04 2002-02-06 Cold Plasma Applications C.P.A. Process and apparatus for the continuous plasma treatment of metallic substrates
GB0100958D0 (en) 2001-01-13 2001-02-28 Surface Technology Systems Ltd Plasma processing apparatus
US20020185226A1 (en) 2000-08-10 2002-12-12 Lea Leslie Michael Plasma processing apparatus
US6720052B1 (en) 2000-08-24 2004-04-13 The Coca-Cola Company Multilayer polymeric/inorganic oxide structure with top coat for enhanced gas or vapor barrier and method for making same
JP2002089717A (en) 2000-09-14 2002-03-27 Terumo Corp Gasket
CN100342500C (en) 2000-09-19 2007-10-10 马特森技术公司 Method for forming dielectric film
US20020190207A1 (en) 2000-09-20 2002-12-19 Ady Levy Methods and systems for determining a characteristic of micro defects on a specimen
CH694949A5 (en) 2000-09-22 2005-09-30 Tetra Laval Holdings & Finance Method and apparatus for the treatment of surfaces by means of a glow discharge plasma.
KR100823858B1 (en) 2000-10-04 2008-04-21 다우 코닝 아일랜드 리미티드 Method and apparatus for forming a coating
US6551267B1 (en) 2000-10-18 2003-04-22 Becton, Dickinson And Company Medical article having blood-contacting surface
FR2815954B1 (en) 2000-10-27 2003-02-21 Commissariat Energie Atomique PROCESS AND DEVICE FOR DEPOSIT BY PLASMA AT THE ELECTRONIC CYCLOTRON RESONANCE OF MONOPAROIS CARBON NANOTUBES AND NANOTUBES THUS OBTAINED
EP1330839A2 (en) 2000-11-01 2003-07-30 Applied Materials, Inc. Etching of high aspect ratio features in a substrate
US20050054942A1 (en) 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
US20070258894A1 (en) 2000-11-08 2007-11-08 Melker Richard J System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring
FR2816926B1 (en) 2000-11-20 2003-02-14 Becton Dickinson France MULTIFUNCTIONAL PACKAGING, AND MORE PARTICULARLY PACKAGING INTENDED TO TRANSPORT STERILIZED OR PRODUCTS INTENDED TO BE STERILIZED
US20020070647A1 (en) 2000-12-11 2002-06-13 Andrey Ginovker Nanostructure plasma source
JP4698020B2 (en) 2000-12-19 2011-06-08 テルモ株式会社 Drug storage container
WO2002049925A1 (en) 2000-12-21 2002-06-27 Mitsubishi Shoji Plastics Corporation Apparatus for manufacturing dlc-film-coated plastic container, method of manufacturing the same, and method for cleaning inner electrode
JP2002206167A (en) 2000-12-28 2002-07-26 Toshiba Corp Plasma coating apparatus, and plasma coating method
US6866656B2 (en) 2001-01-24 2005-03-15 Becton, Dickinson And Company Lubricious coating for a medical device
US6597193B2 (en) 2001-01-26 2003-07-22 Semiconductor Diagnostics, Inc. Steady state method for measuring the thickness and the capacitance of ultra thin dielectric in the presence of substantial leakage current
US6680621B2 (en) 2001-01-26 2004-01-20 Semiconductor Diagnostics, Inc. Steady state method for measuring the thickness and the capacitance of ultra thin dielectric in the presence of substantial leakage current
US6640615B1 (en) 2001-01-26 2003-11-04 Darrell R. Morrow System for determining the integrity of a package or packaging material based on its transmission of a test gas
DE60206084T2 (en) 2001-02-06 2006-01-12 Shibuya Kogyo Co., Ltd., Kanazawa Method and apparatus for modifying the inner surface of plastic containers
US6673199B1 (en) 2001-03-07 2004-01-06 Applied Materials, Inc. Shaping a plasma with a magnetic field to control etch rate uniformity
DE10112731A1 (en) 2001-03-14 2002-10-02 Schott Glas Coating of substrates
DE10114401B4 (en) 2001-03-23 2005-03-17 Tetra Laval Holdings & Finance S.A. Method for blow molding a container made of plastic and for coating the container interior
US20020182101A1 (en) 2001-03-27 2002-12-05 Pavel Koulik Process and device for plasma surface treatment
US7288293B2 (en) 2001-03-27 2007-10-30 Apit Corp. S.A. Process for plasma surface treatment and device for realizing the process
JP3833900B2 (en) 2001-03-28 2006-10-18 株式会社東芝 Etching apparatus and etching method
JP3954319B2 (en) 2001-03-28 2007-08-08 株式会社東芝 Thin film thickness monitoring method and substrate temperature measurement method
JP4085593B2 (en) 2001-03-29 2008-05-14 日新電機株式会社 Vacuum arc evaporation system
US20040161623A1 (en) 2001-03-29 2004-08-19 Domine Joseph D Ionomer laminates and articles formed from ionomer laminates
AT500247B1 (en) 2001-03-30 2007-06-15 Greiner Bio One Gmbh RECEIVING DEVICE, ESPECIALLY FOR BODY FLUIDS, WITH A SEPARATION DEVICE AND SEPARATING DEVICE THEREFOR
US20020150709A1 (en) 2001-04-16 2002-10-17 Hetzler Kevin George Method of fusing a component to a medical storage or transfer device and container assembly
US6595961B2 (en) 2001-04-16 2003-07-22 Becton, Dickinson And Company Sterilizable transfer or storage device for medicaments, drugs and vaccines
DE60238979D1 (en) 2001-04-20 2011-03-03 Gen Plasma Inc PENNING DISCHARGE PLASMA SOURCE
US20020153103A1 (en) 2001-04-20 2002-10-24 Applied Process Technologies, Inc. Plasma treatment apparatus
DE10119571C1 (en) 2001-04-21 2002-11-28 Schott Glas Process for the uniform coating of hollow bodies and their use
DE60101209T2 (en) 2001-04-27 2004-09-02 European Community Method and device for sequential plasma treatment
JP4014440B2 (en) 2001-05-11 2007-11-28 松下電器産業株式会社 Information recording apparatus, information recording method, and information recording system
TW570876B (en) 2001-05-11 2004-01-11 Toyo Seikan Kaisha Ltd Silicon oxide film
US20020170495A1 (en) 2001-05-17 2002-11-21 Ngk Insulators, Ltd. Method for fabricating a thin film and apparatus for fabricating a thin film
US7362425B2 (en) 2001-05-18 2008-04-22 Meeks Steven W Wide spatial frequency topography and roughness measurement
US7180849B2 (en) 2001-05-18 2007-02-20 Sharp Kabushiki Kaisha Optical storage medium enabling uniform light transmittance, optical read/write apparatus for same, and optical read/write method for same
DE10124225B4 (en) 2001-05-18 2006-03-02 Tetra Laval Holdings & Finance S.A. Method and device for determining the permeation of a barrier layer
US20030215652A1 (en) 2001-06-04 2003-11-20 O'connor Paul J. Transmission barrier layer for polymers and containers
JP3678361B2 (en) 2001-06-08 2005-08-03 大日本印刷株式会社 Gas barrier film
US6397776B1 (en) 2001-06-11 2002-06-04 General Electric Company Apparatus for large area chemical vapor deposition using multiple expanding thermal plasma generators
JP4774635B2 (en) 2001-06-15 2011-09-14 凸版印刷株式会社 Thin film deposition apparatus for three-dimensional hollow container and thin film deposition method using the same
EP2305446B1 (en) 2001-06-18 2018-08-01 Becton, Dickinson and Company Process for forming multilayer containers
WO2003006181A1 (en) 2001-07-10 2003-01-23 3M Innovative Properties Company Coated medicinal inhalation devices and components method
JP3932836B2 (en) 2001-07-27 2007-06-20 株式会社日立製作所 Thin film thickness measuring method and apparatus, and device manufacturing method using the same
DE10139305A1 (en) 2001-08-07 2003-03-06 Schott Glas Composite material made of a substrate material and a barrier layer material
DE10138696A1 (en) 2001-08-07 2003-03-06 Schott Glas Method and device for simultaneously coating and shaping a three-dimensional body
JP2003050115A (en) 2001-08-07 2003-02-21 Seiko Instruments Inc X-ray film thickness meter
US20030029837A1 (en) 2001-08-10 2003-02-13 Applied Materials, Inc. Dielectric etch plasma chamber utilizing a magnetic filter to optimize plasma characteristics
KR20040027940A (en) 2001-08-20 2004-04-01 노바-플라즈마 인크. Coatings with low permeation of gases and vapors
US7507378B2 (en) 2001-08-21 2009-03-24 Becton, Dickinson And Company Collection assembly
JP4812991B2 (en) 2001-09-20 2011-11-09 東京エレクトロン株式会社 Plasma processing equipment
CN1556914A (en) 2001-09-21 2004-12-22 Kmac株式会社 Apparatus for measuring thickness profile and refractive index distribution of multiple layers of thin films by means of two-dimensional reflectometry and method of measuring the same
DE10150738C1 (en) 2001-10-13 2003-05-22 Schott Glas Process for producing a glass tube with a radiation-absorbing, aging-resistant coating and its use
US6766682B2 (en) 2001-10-19 2004-07-27 Desert Cryogenics Llc Precise measurement system for barrier materials
EP1448807A4 (en) 2001-10-30 2005-07-13 Massachusetts Inst Technology Fluorocarbon-organosilicon copolymers and coatings prepared by hot-filament chemical vapor deposition
US7569035B1 (en) 2001-11-02 2009-08-04 Meridian Medical Technologies, Inc. Automatic injector with anti-coring needle
DE10154404C1 (en) 2001-11-06 2003-06-18 Ovd Kinegram Ag Zug Method and device for measuring physical parameters of thin, optically transparent layers and device for carrying out the method
WO2003044240A1 (en) 2001-11-15 2003-05-30 Ionic Fusion Corporation Ionic plasma deposition apparatus
US6948448B2 (en) 2001-11-27 2005-09-27 General Electric Company Apparatus and method for depositing large area coatings on planar surfaces
JP2003234331A (en) 2001-12-05 2003-08-22 Tokyo Electron Ltd Plasma etching method and apparatus
JP4067817B2 (en) 2001-12-07 2008-03-26 日精エー・エス・ビー機械株式会社 Container coating equipment
KR100782651B1 (en) 2001-12-13 2007-12-07 미츠비시 쥬고교 가부시키가이샤 Apparatus for forming carbon film on inner surface of plastic container and method of manufacturing plastic container having inner surface coated with carbon film
US7348055B2 (en) 2001-12-21 2008-03-25 Surmodics, Inc. Reagent and method for providing coatings on surfaces
DE10201110B4 (en) 2002-01-15 2006-09-28 Schott Ag Container for Parenteralia / Injectabila
US6752899B1 (en) 2002-01-16 2004-06-22 Advanced Micro Devices, Inc. Acoustic microbalance for in-situ deposition process monitoring and control
JP3953821B2 (en) 2002-01-17 2007-08-08 ファブソリューション株式会社 Film thickness measuring method and film thickness measuring apparatus
JP2003305121A (en) 2002-04-16 2003-10-28 Jfe Steel Kk Method for manufacturing medical ceramic-coated needle
EP1491154A1 (en) 2002-01-22 2004-12-29 JFE Steel Corporation Ceramic-coated instruments for medical use, ceramic-coated instruments for studying living organisms and process for producing the same
DE10202311B4 (en) 2002-01-23 2007-01-04 Schott Ag Apparatus and method for the plasma treatment of dielectric bodies
EP1472387B1 (en) 2002-02-05 2008-07-23 Dow Global Technologies Inc. Corona-generated chemical vapor deposition on a substrate
US6684683B2 (en) 2002-02-27 2004-02-03 General Electric Company Method and apparatus for characterizing the barrier properties of members of combinatorial libraries
US6816570B2 (en) 2002-03-07 2004-11-09 Kla-Tencor Corporation Multi-technique thin film analysis tool
JP4031654B2 (en) 2002-03-12 2008-01-09 三菱商事プラスチック株式会社 CVD film forming apparatus and method for cleaning internal electrode for CVD film forming apparatus
JP4124609B2 (en) 2002-04-03 2008-07-23 エスアイアイ・ナノテクノロジー株式会社 Method and apparatus for measuring film thickness of pattern part in semiconductor manufacturing process
TWI233644B (en) 2002-04-08 2005-06-01 Tokyo Electron Ltd Plasma etching method and plasma etching apparatus
JP4431402B2 (en) 2002-04-08 2010-03-17 東京エレクトロン株式会社 Plasma etching method
GB0209291D0 (en) 2002-04-24 2002-06-05 Trikon Technologies Ltd Plasma processing apparatus
US6876154B2 (en) 2002-04-24 2005-04-05 Trikon Holdings Limited Plasma processing apparatus
US20050233091A1 (en) 2002-05-08 2005-10-20 Devendra Kumar Plasma-assisted coating
US20060228497A1 (en) 2002-05-08 2006-10-12 Satyendra Kumar Plasma-assisted coating
EP1507886B1 (en) 2002-05-24 2015-09-30 KHS Corpoplast GmbH Method and device for plasma treating workpieces
AU2003232621A1 (en) 2002-05-24 2003-12-12 Sig Technology Ltd. Method and device for plasma treating workpieces
EP1367145B1 (en) 2002-05-24 2006-05-17 Schott Ag CVD apparatus
MXPA04011431A (en) 2002-05-24 2005-08-15 Schott Ag Device and method for treating workpieces.
US20050229850A1 (en) 2002-05-24 2005-10-20 Stephan Behle Rotary machine for cvd coatings
EP1365043B1 (en) 2002-05-24 2006-04-05 Schott Ag CVD apparatus
WO2003099688A1 (en) 2002-05-24 2003-12-04 Sig Technology Ltd. Method and device for handling workpieces
US7699933B2 (en) 2002-05-24 2010-04-20 Khs Corpoplast Gmbh & Co. Kg Method and device for the plasma treatment of workpieces
CN1656249A (en) 2002-05-24 2005-08-17 肖特股份公司 Multistation coating device and method for plasma coating
CN100412230C (en) 2002-05-24 2008-08-20 肖特股份公司 Multistation coating device and method for plasma coating
WO2003101847A1 (en) 2002-05-28 2003-12-11 Kirin Brewery Company, Limited Dlc film coated plastic container, and device and method for manufacturing the plastic container
CN2546041Y (en) 2002-05-28 2003-04-23 无锡市宇寿医疗器械有限公司 Safety self-destroy injector
JP4168671B2 (en) 2002-05-31 2008-10-22 凸版印刷株式会社 Thin film deposition system for 3D hollow containers
JP3611324B2 (en) 2002-06-03 2005-01-19 信越化学工業株式会社 Magnetron plasma magnetic field generator
JP3595334B2 (en) 2002-06-05 2004-12-02 三菱商事プラスチック株式会社 Method and apparatus for cleaning source gas introduction pipe used in CVD film forming apparatus
JP2004008509A (en) 2002-06-07 2004-01-15 Terumo Corp Syringe gasket and manufacturing method therefor, and syringe
US6764714B2 (en) 2002-06-11 2004-07-20 Southwest Research Institute Method for depositing coatings on the interior surfaces of tubular walls
US7052736B2 (en) 2002-06-11 2006-05-30 Southwest Research Institute Method for depositing coatings on the interior surfaces of tubular structures
JP4080799B2 (en) 2002-06-28 2008-04-23 三井金属鉱業株式会社 Method for forming polyimide film containing dielectric filler on metal material surface, method for producing copper clad laminate for forming capacitor layer for printed wiring board, and copper clad laminate obtained by the method
TWI283899B (en) 2002-07-09 2007-07-11 Applied Materials Inc Capacitively coupled plasma reactor with magnetic plasma control
JP4385657B2 (en) 2002-07-15 2009-12-16 凸版印刷株式会社 Film forming apparatus and film forming method
KR100390540B1 (en) 2002-07-31 2003-07-04 에이엔 에스 주식회사 Magnetron plasma etching apparatus
US6995377B2 (en) 2002-08-02 2006-02-07 Plastipak Packaging, Inc. Process and apparatus for testing bottles
US7399500B2 (en) 2002-08-07 2008-07-15 Schott Ag Rapid process for the production of multilayer barrier layers
US7109070B2 (en) 2002-08-07 2006-09-19 Schot Glas Production of a composite material having a biodegradable plastic substrate and at least one coating
EP1388594B1 (en) 2002-08-07 2010-01-06 Schott Ag Composite material with smooth barrier layer and process for its production
EP1388593B1 (en) 2002-08-07 2015-12-30 Schott AG Rapid process for producing multilayer barrier coatings
TWI309861B (en) 2002-08-21 2009-05-11 Shinetsu Chemical Co Magnetic field generator for magnetron plasma
US20040040372A1 (en) 2002-08-30 2004-03-04 George Plester Method for determining the permeation of gases into or out of plastic packages and for determination of shelf-life with respect to gas permeation
US7959866B2 (en) 2002-09-04 2011-06-14 Becton, Dickinson And Company Collection assembly
US6758949B2 (en) 2002-09-10 2004-07-06 Applied Materials, Inc. Magnetically confined metal plasma sputter source with magnetic control of ion and neutral densities
DE10242086A1 (en) 2002-09-11 2004-04-15 Sig Technology Ltd. Containers for packaging products, device for processing plastic and methods for producing containers
US7015640B2 (en) 2002-09-11 2006-03-21 General Electric Company Diffusion barrier coatings having graded compositions and devices incorporating the same
EP1537055A1 (en) 2002-09-14 2005-06-08 Schott AG Coated object
DE10246181A1 (en) 2002-10-02 2004-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Plasma coating, etching or treatment of concave surfaces in vacuum, directs electron beam from arc source along magnetic field lines into cavity of substrate
AT413648B (en) 2002-10-02 2006-04-15 Greiner Bio One Gmbh RECORDING DEVICE WITH ADJUSTABLE COVERING ELEMENT
CH707466B1 (en) 2002-10-03 2014-07-15 Tetra Laval Holdings & Finance Apparatus for performing a plasma-assisted process.
US6863731B2 (en) 2002-10-18 2005-03-08 Controls Corporation Of America System for deposition of inert barrier coating to increase corrosion resistance
JP2004156444A (en) 2002-11-01 2004-06-03 Mitsubishi Heavy Ind Ltd Thermal barrier coating degradation diagnosing method
AU2003290687A1 (en) 2002-11-12 2004-06-03 Dow Global Technologies Inc. Process and apparatus for depositing plasma coating onto a container
CN100347229C (en) 2002-11-12 2007-11-07 陶氏环球技术公司 Process and apparatus for depositing plasma coating onto a container
US6965221B2 (en) 2002-11-12 2005-11-15 O2Micro International Limited Controller for DC to DC converter
DE10353540A1 (en) 2002-11-15 2004-05-27 Laure, Stefan, Dr. Process for the plasma-supported coating of a tubular component comprises inserting a source containing coating material into the component, evacuating the inner chamber of the component, and producing a high frequency magnetic field
JP4238015B2 (en) 2002-11-19 2009-03-11 大日本印刷株式会社 Manufacturing method for plastic containers
JP3970169B2 (en) 2002-11-20 2007-09-05 三菱商事プラスチック株式会社 DLC film coated plastic container manufacturing method
US8066854B2 (en) 2002-12-18 2011-11-29 Metascape Llc Antimicrobial coating methods
US7059268B2 (en) 2002-12-20 2006-06-13 Tokyo Electron Limited Method, apparatus and magnet assembly for enhancing and localizing a capacitively coupled plasma
JP2004203682A (en) 2002-12-25 2004-07-22 Sumitomo Electric Ind Ltd Method and apparatus for manufacturing optical fiber preform
US6800852B2 (en) 2002-12-27 2004-10-05 Revera Incorporated Nondestructive characterization of thin films using measured basis spectra
US6891158B2 (en) 2002-12-27 2005-05-10 Revera Incorporated Nondestructive characterization of thin films based on acquired spectrum
CA2512181A1 (en) 2003-01-02 2004-07-22 Bioforce Nanosciences, Inc. Method and apparatus for molecular analysis in small sample volumes
US7252651B2 (en) 2003-01-07 2007-08-07 Becton, Dickinson And Company Disposable injection device
AT413947B (en) 2003-01-27 2006-07-15 Greiner Bio One Gmbh MEDICAL ASSEMBLY, AND A PROTECTION DEVICE, AN ARTICLE AND HANDLING DEVICE FOR THIS MODULE
US6989675B2 (en) 2003-03-13 2006-01-24 Multimetrixs Llc Method and apparatus for precision measurement of film thickness
US7288311B2 (en) 2003-02-10 2007-10-30 Dai Nippon Printing Co., Ltd. Barrier film
US7303789B2 (en) 2003-02-17 2007-12-04 Ngk Insulators, Ltd. Methods for producing thin films on substrates by plasma CVD
JP4233085B2 (en) 2003-02-17 2009-03-04 日本碍子株式会社 Thin film manufacturing method and apparatus
JP2004253683A (en) 2003-02-21 2004-09-09 Komatsu Ltd Resist outgas measuring instrument
WO2004075958A2 (en) 2003-02-27 2004-09-10 Baxter International Inc. Piston assembly for syringe
EP1602912A1 (en) 2003-02-28 2005-12-07 Kage, Tsuyoshi Method of measuring gas barrier property of plastic molding
US7332227B2 (en) 2003-03-14 2008-02-19 Becton, Dickinson And Company Non-volatile lubricant system for medical devices
ES2611429T3 (en) 2003-03-25 2017-05-08 Becton, Dickinson And Company Catheter and needle set IV, and method
US6946164B2 (en) 2003-03-26 2005-09-20 E.I. Du Pont Nemours And Company Thin nanometer-controlled polymer film gradient
WO2004087989A1 (en) 2003-03-28 2004-10-14 Toyo Seikan Kaisha, Ltd. Chemical vapor deposition film formed by plasma cvd process and method for forming same
US6864773B2 (en) 2003-04-04 2005-03-08 Applied Materials, Inc. Variable field magnet apparatus
JP4252347B2 (en) 2003-04-07 2009-04-08 三菱商事プラスチック株式会社 Method for producing gas barrier thin film coated plastic container
US7972467B2 (en) 2003-04-17 2011-07-05 Applied Materials Inc. Apparatus and method to confine plasma and reduce flow resistance in a plasma reactor
AT500525A1 (en) 2003-04-17 2006-01-15 Greiner Bio One Gmbh RECEIVING DEVICE AND SEALING DEVICE AND CAP SHAPED LOCKING DEVICE
US7431989B2 (en) 2003-05-06 2008-10-07 Tribofilm Research, Inc. Article with lubricated surface and method
KR100509298B1 (en) 2003-05-31 2005-08-22 한국과학기술연구원 Method to manufacture composite polymer electrolyte membranes coated with inorganic thin films for direct methanol fuel cells
JP4202841B2 (en) 2003-06-30 2008-12-24 株式会社Ｓｕｍｃｏ Surface polishing equipment
US20050057754A1 (en) 2003-07-08 2005-03-17 Smith David E. A. Measurement of thin film properties using plasmons
JP2005029855A (en) 2003-07-08 2005-02-03 Fuji Electric Device Technology Co Ltd Vacuum arc deposition system, vacuum arc deposition method, and magnetic recording medium
DE10330981B4 (en) 2003-07-09 2010-04-01 Medion Diagnostics Ag Apparatus and method for simultaneously performing blood grouping, serum cross-checking and antibody-screening
JP2005035597A (en) 2003-07-14 2005-02-10 Fuji Seal International Inc Method of protecting gas-barrier film in plastic container
JP4437647B2 (en) 2003-07-17 2010-03-24 三菱商事プラスチック株式会社 Method for producing gas container coated plastic container
JP4179941B2 (en) 2003-07-24 2008-11-12 独立行政法人科学技術振興機構 X-ray diffraction measurement container for thin film sample
US20050037331A1 (en) 2003-08-13 2005-02-17 William Galbraith Apparatuses and methods for reducing albumin in samples
KR20060120613A (en) 2003-09-05 2006-11-27 쇼오트 아게 Attenuated phase shift mask blank and photomask
JP3811150B2 (en) 2003-09-05 2006-08-16 株式会社東芝 Film thickness measuring method, film thickness measuring system, semiconductor device manufacturing method, and film thickness measuring system control program
US7029803B2 (en) 2003-09-05 2006-04-18 Schott Ag Attenuating phase shift mask blank and photomask
US7932678B2 (en) 2003-09-12 2011-04-26 General Plasma, Inc. Magnetic mirror plasma source and method using same
US7150299B2 (en) 2003-09-12 2006-12-19 Air Products And Chemicals, Inc. Assembly and method for containing, receiving and storing fluids and for dispensing gas from a fluid control and gas delivery assembly having an integrated fluid flow restrictor
US7087437B2 (en) 2003-09-16 2006-08-08 Vici Gig Harbor Group, Inc. Direct vial surface sorbent micro extraction device and method
JP4000373B2 (en) 2003-09-26 2007-10-31 独立行政法人物質・材料研究機構 Synthesis method of zinc sulfide in zinc oxide crystals by co-implantation of ions
US20070017870A1 (en) 2003-09-30 2007-01-25 Belov Yuri P Multicapillary device for sample preparation
US20050075611A1 (en) 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
US20050075612A1 (en) 2003-10-03 2005-04-07 Baxter International Inc. Parylene coated fluid flow regulator
US6844075B1 (en) 2003-10-06 2005-01-18 General Electric Company Environmental barrier coating
JP2005114461A (en) 2003-10-06 2005-04-28 Hitachi Industries Co Ltd Thin film thickness measurement method and apparatus
JP4000374B2 (en) 2003-10-10 2007-10-31 独立行政法人物質・材料研究機構 Semiconductor metal oxide photocatalyst and method for decomposing hazardous chemicals using the same
DE10347338A1 (en) 2003-10-11 2005-05-19 Schott Ag Dünnstsubstrathalter
US7381311B2 (en) 2003-10-21 2008-06-03 The United States Of America As Represented By The Secretary Of The Air Force Filtered cathodic-arc plasma source
FR2861386B1 (en) 2003-10-23 2006-02-17 Saint Gobain SUBSTRATE, IN PARTICULAR GLASS SUBSTRATE, CARRYING A PHOTOCATALYTIC LAYER COATED WITH A PROTECTIVE THIN LAYER.
JP2005132416A (en) 2003-10-30 2005-05-26 Toppan Printing Co Ltd Silicon oxide film coating hollow container
US6981403B2 (en) 2003-10-31 2006-01-03 Mocon, Inc. Method and apparatus for measuring gas transmission rates of deformable or brittle materials
DE10351467B4 (en) 2003-11-04 2011-07-07 Schott Ag, 55122 An article with an easily cleanable surface and process for its preparation
JP4000375B2 (en) 2003-11-19 2007-10-31 独立行政法人産業技術総合研究所 Stimulated scattering container
TW200527513A (en) 2003-11-20 2005-08-16 Hitachi Int Electric Inc Method for manufacturing semiconductor device and substrate processing apparatus
CA2945455C (en) 2003-11-20 2019-11-26 Sigma-Aldrich Co. Llc Polysilazane thermosetting polymers for use in chromatographic systems and applications
DE10354625A1 (en) 2003-11-22 2005-06-30 Sig Technology Ltd. Method for determining the gas permeability of container walls, containers with surface coating and coating device with measuring device
WO2005051525A1 (en) 2003-11-25 2005-06-09 Polyvalor, Limited Partnership Permeation barrier coating or layer with modulated properties and methods of making the same
US7513953B1 (en) 2003-11-25 2009-04-07 Nano Scale Surface Systems, Inc. Continuous system for depositing films onto plastic bottles and method
JP2005160888A (en) 2003-12-05 2005-06-23 Terumo Corp Gasket for syringe, and manufacturing method for syringe and gasket for syringe
JP2007515235A (en) 2003-12-22 2007-06-14 ノボ・ノルデイスク・エー／エス Transparent, flexible and impervious plastic container for storing medicinal fluids
US8110043B2 (en) 2004-01-08 2012-02-07 University Of Virginia Patent Foundation Apparatus and method for applying coatings onto the interior surfaces of components and related structures produced therefrom
DE102004001603B4 (en) 2004-01-09 2009-03-05 Schott Ag Container with interior decor
JP2005200044A (en) 2004-01-14 2005-07-28 Dainippon Printing Co Ltd Plastic container and manufacturing method for the same
KR20050076827A (en) 2004-01-22 2005-07-28 쇼오트 아게 Ultra high transmission phase shift mask blanks
AT500459B1 (en) 2004-01-23 2010-08-15 Greiner Bio One Gmbh METHOD FOR ASSEMBLING A CAP WITH A RECEIVING CONTAINER
JP3914925B2 (en) 2004-01-28 2007-05-16 株式会社リガク Film thickness measuring method and apparatus
KR20070001160A (en) 2004-02-12 2007-01-03 발스파 소싱 인코포레이티드 Methods of coating interior container surfaces and containers containing internal coatings
US7534733B2 (en) 2004-02-23 2009-05-19 Corning Incorporated Synthetic silica glass optical material having high resistance to laser induced damage
JP2005241524A (en) 2004-02-27 2005-09-08 Sii Nanotechnology Inc Scanning probe microscope and measuring method using it
WO2005087978A1 (en) 2004-03-09 2005-09-22 Exatec, Llc Plasma coating system for non-planar substrates
EP1725698A1 (en) 2004-03-09 2006-11-29 Exatec, LLC. Expanding thermal plasma deposition system
JP4323991B2 (en) 2004-03-19 2009-09-02 大日本スクリーン製造株式会社 Spectral reflectance measuring device, film thickness measuring device, and spectral reflectance measuring method
JP2005271997A (en) 2004-03-22 2005-10-06 Kazuo Saito Protective film of inner wall of pet bottle
DE102004017236B4 (en) 2004-04-05 2012-10-25 Schott Ag Composite having improved chemical resistance and method of making the same
JP4527431B2 (en) 2004-04-08 2010-08-18 東京エレクトロン株式会社 Plasma processing equipment
US20050260504A1 (en) 2004-04-08 2005-11-24 Hans Becker Mask blank having a protection layer
WO2005103605A1 (en) 2004-04-22 2005-11-03 Opo Sprl Instrument for measuring the thickness of a coating on bottles
US7232038B2 (en) 2004-04-27 2007-06-19 Whitney Steven G Disposable test tube rack
US8038858B1 (en) 2004-04-28 2011-10-18 Alameda Applied Sciences Corp Coaxial plasma arc vapor deposition apparatus and method
US7867366B1 (en) 2004-04-28 2011-01-11 Alameda Applied Sciences Corp. Coaxial plasma arc vapor deposition apparatus and method
US20080131638A1 (en) 2004-05-04 2008-06-05 Becton, Dickinson And Company Multilayer barrier containers having increased adhesion and durability
US7112541B2 (en) 2004-05-06 2006-09-26 Applied Materials, Inc. In-situ oxide capping after CVD low k deposition
US7815922B2 (en) 2004-05-14 2010-10-19 Becton, Dickinson And Company Articles having bioactive surfaces and solvent-free methods of preparation thereof
GB0410749D0 (en) 2004-05-14 2004-06-16 Dow Corning Ireland Ltd Coating apparatus
US7444955B2 (en) 2004-05-19 2008-11-04 Sub-One Technology, Inc. Apparatus for directing plasma flow to coat internal passageways
EP1600190B1 (en) 2004-05-29 2007-08-29 Gerresheimer Bünde GmbH Syringe cap and method of producing a syringe cap
DE102004028369B4 (en) 2004-06-11 2007-05-31 Schott Ag Method and device for treating substrates in a rotary machine
JP4918857B2 (en) 2004-06-11 2012-04-18 株式会社豊田中央研究所 Metal oxide nanoporous material, coating composition for obtaining the same, and method for producing the same
US7220687B2 (en) 2004-06-25 2007-05-22 Applied Materials, Inc. Method to improve water-barrier performance by changing film surface morphology
US7421885B2 (en) 2004-06-28 2008-09-09 Air Products And Chemicals, Inc. Method for characterizing porous low dielectric constant films
US20060079848A1 (en) 2004-06-29 2006-04-13 Becton, Dickinson And Company Non-skin penetrating reconstituting syringe
US20060079839A1 (en) 2004-06-29 2006-04-13 Becton, Dickinson And Company Single-use syringe
US20060014309A1 (en) 2004-07-13 2006-01-19 Sachdev Krishna G Temporary chip attach method using reworkable conductive adhesive interconnections
DE102004034418B4 (en) 2004-07-15 2009-06-25 Schott Ag Process for producing structured optical filter layers on substrates
DE102004034417B4 (en) 2004-07-15 2007-09-27 Schott Ag Process for the preparation of a coated substrate with a curved surface
US7300684B2 (en) 2004-07-15 2007-11-27 Sub-One Technology, Inc. Method and system for coating internal surfaces of prefabricated process piping in the field
US7118538B2 (en) 2004-07-19 2006-10-10 Greiner Bio-One Gmbh Holding device for a medical device
DE102004035336A1 (en) 2004-07-21 2006-02-16 Schott Ag Cleanable coating system
DE102004035335A1 (en) 2004-07-21 2006-02-16 Schott Ag Cleanable coating system
DE102004036170B4 (en) 2004-07-26 2007-10-11 Schott Ag Vacuum coating system and method for vacuum coating and their use
US7238382B2 (en) 2004-07-30 2007-07-03 Tokyo Electron Limited Method and system for characterizing porous materials
EP1626278A3 (en) 2004-08-03 2006-06-21 OnChip Cellomics Consortium Cellomics system
KR101210859B1 (en) 2004-08-18 2012-12-11 다우 코닝 코포레이션 Coated substrates and methods for their preparation
JP2006064416A (en) 2004-08-24 2006-03-09 Takeshi Kage Method and apparatus for measuring gas barrier property of plastic molded body
FR2874606B1 (en) 2004-08-26 2006-10-13 Saint Gobain METHOD FOR TRANSFERRING A FUNCTIONAL ORGANIC MOLECULE TO A TRANSPARENT SUBSTRATE
US20060042755A1 (en) 2004-08-30 2006-03-02 Plasmamed, Llc Large surface area dry etcher
DE102004042431B4 (en) 2004-08-31 2008-07-03 Schott Ag Method and device for plasma coating of workpieces with spectral evaluation of the process parameters and use of the device
GB0419772D0 (en) 2004-09-07 2004-10-06 Scalar Technologies Ltd Method and apparatus for thin film metrology
JP2008512128A (en) 2004-09-09 2008-04-24 マイクロフルイディク システムズ インコーポレイテッド Extraction apparatus and sample preparation method
JP2006083408A (en) 2004-09-14 2006-03-30 Shin Meiwa Ind Co Ltd Vacuum film-forming apparatus
ATE404451T1 (en) 2004-09-14 2008-08-15 Daikyo Seiko Ltd CONTAINERS FOR MEDICATIONS AND RUBBER CLOSURE
US20070048456A1 (en) 2004-09-14 2007-03-01 Keshner Marvin S Plasma enhanced chemical vapor deposition apparatus and method
DE102004045046B4 (en) 2004-09-15 2007-01-04 Schott Ag Method and device for applying an electrically conductive transparent coating to a substrate
US7480363B2 (en) 2004-09-15 2009-01-20 Ge Betz, Inc. Converting a digital radiograph to an absolute thickness map
JP4545073B2 (en) 2004-09-17 2010-09-15 三菱重工業株式会社 Gas barrier membrane and container
EP1640031A3 (en) 2004-09-28 2006-06-07 Nipro Corporation Syringe coated with lubricant containing silicone oil and silica powder
EP1809351A2 (en) 2004-09-28 2007-07-25 Mallinckrodt, Inc. Container with constrained quality maintenance agent
FR2876094B1 (en) 2004-10-04 2009-01-09 Saint Gobain GLASS SUBSTRATE FOR DISPLAY SCREEN.
MX2007003850A (en) 2004-10-05 2007-11-21 Genzyme Corp Stepped cannula.
US7520965B2 (en) 2004-10-12 2009-04-21 Southwest Research Institute Magnetron sputtering apparatus and method for depositing a coating using same
US20060076231A1 (en) 2004-10-12 2006-04-13 Southwest Research Institute Method for magnetron sputter deposition
JP2008516089A (en) 2004-10-13 2008-05-15 ダウ グローバル テクノロジーズ インコーポレイティド Plasma coating method
JP4412661B2 (en) 2004-10-15 2010-02-10 信越化学工業株式会社 Plasma processing apparatus and plasma processing method
JP4171452B2 (en) 2004-10-18 2008-10-22 三菱重工食品包装機械株式会社 Barrier film forming internal electrode and film forming apparatus
BE1016251A3 (en) 2004-10-27 2006-06-06 Ct Rech Metallurgiques Asbl Improved method and apparatus for measuring the thickness of a layer oxide.
DE102004053706A1 (en) 2004-11-03 2006-05-04 Schott Ag Barrier coated article and method of making such article
DE102004053707B8 (en) 2004-11-03 2008-08-28 Schott Ag Process for producing a glass-ceramic article with diffusion barrier and use of a glass-ceramic article produced according to the method
DE102004053708A1 (en) 2004-11-03 2006-05-04 Schott Ag Process for the production of a product with anti-fog coating, as well as product according to the method
EP1808056B1 (en) 2004-11-05 2015-08-26 Dow Corning Ireland Limited Plasma process
AT414322B (en) 2004-11-29 2007-03-15 Greiner Bio One Gmbh SEPARATING DEVICE, ESPECIALLY FOR BODY FLUIDS, AND RECORDING EQUIPMENT WITH SUCH A SEPARATING DEVICE
JP2006153770A (en) 2004-11-30 2006-06-15 Omron Corp Spectral measurement apparatus
JP4566719B2 (en) 2004-12-02 2010-10-20 麒麟麦酒株式会社 Carbon film coated plastic container manufacturing method, plasma CVD film forming apparatus and plastic container
US8097725B2 (en) 2004-12-03 2012-01-17 Roche Diagnostics Operations, Inc. Luminescent indicator dye and optical sensor
US7534615B2 (en) 2004-12-03 2009-05-19 Cryovac, Inc. Process for detecting leaks in sealed packages
CN2766863Y (en) 2004-12-23 2006-03-29 许亮 Painless injection needle
WO2006069469A1 (en) 2004-12-27 2006-07-06 Sae Magnetics (H.K.) Ltd. Method of nano thin film thickness measurement by auger electron spectrscopy
JP2006181027A (en) 2004-12-27 2006-07-13 Daikyo Seiko Ltd Piston for syringe
DE102004063703A1 (en) 2004-12-28 2006-07-06 Schott Ag Vacuum coating system
JP4929727B2 (en) 2005-02-14 2012-05-09 東洋製罐株式会社 Gas supply pipe for plasma processing
US7202564B2 (en) 2005-02-16 2007-04-10 International Business Machines Corporation Advanced low dielectric constant organosilicon plasma chemical vapor deposition films
JP4515280B2 (en) 2005-02-17 2010-07-28 麒麟麦酒株式会社 Apparatus and method for manufacturing a plastic container having a gas barrier thin film formed thereon
US7339682B2 (en) 2005-02-25 2008-03-04 Verity Instruments, Inc. Heterodyne reflectometer for film thickness monitoring and method for implementing
US7541069B2 (en) 2005-03-07 2009-06-02 Sub-One Technology, Inc. Method and system for coating internal surfaces using reverse-flow cycling
US7608151B2 (en) 2005-03-07 2009-10-27 Sub-One Technology, Inc. Method and system for coating sections of internal surfaces
AU2005329089A1 (en) 2005-03-16 2006-09-21 Attogenix Biosystems Pte Ltd. Methods and device for transmitting, enclosing and analysing fluid samples
US20060210425A1 (en) 2005-03-21 2006-09-21 Laura Mirkarimi Inorganic coatings for optical and other applications
CN101151544B (en) 2005-03-28 2011-08-03 株式会社半导体能源研究所 Semiconductor device, and method for manufacturing and measuring same
US7785862B2 (en) 2005-04-07 2010-08-31 454 Life Sciences Corporation Thin film coated microwell arrays
US7682816B2 (en) 2005-04-07 2010-03-23 454 Life Sciences Corporation Thin film coated microwell arrays and methods of using same
EP1869433A1 (en) 2005-04-15 2007-12-26 Luxcel Biosciences Limited Assessment of biological or chemical samples
JP4122011B2 (en) 2005-04-15 2008-07-23 株式会社アルバック Method for forming diamond-like carbon film
EP1715289A1 (en) 2005-04-21 2006-10-25 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno An optical light reflection method
DE102005023582B4 (en) 2005-05-18 2009-04-16 Schott Ag Process for the production of internally tempered glass tubes
EP1888150A1 (en) 2005-05-31 2008-02-20 Baxter International Inc. Polypropylene hollow barrel with sliding coated rubber piston
US20070005024A1 (en) 2005-06-10 2007-01-04 Jan Weber Medical devices having superhydrophobic surfaces, superhydrophilic surfaces, or both
US20090142227A1 (en) 2005-07-01 2009-06-04 Manfred Fuchs Parylene Coating and Method for the Production Thereof
US20070009673A1 (en) 2005-07-06 2007-01-11 Asm Japan K.K. Insulation film and method for manufacturing same
FR2889204B1 (en) 2005-07-26 2007-11-30 Sidel Sas APPARATUS FOR THE PECVD DEPOSITION OF AN INTERNAL BARRIER LAYER ON A CONTAINER, COMPRISING A GAS LINE ISOLATED BY ELECTROVANNE
US7745547B1 (en) 2005-08-05 2010-06-29 Becton, Dickinson And Company Multi-arm cyclic or cubic siloxane-based formulations for drug delivery
US8475886B2 (en) 2005-08-05 2013-07-02 Corning Incorporated Methods for producing surfaces that resist non-specific protein binding and cell attachment
JP2007050898A (en) 2005-08-17 2007-03-01 Toppan Printing Co Ltd Method and apparatus for manufacturing film deposition container
CN101243329B (en) 2005-08-17 2011-05-25 西门子公司 Method for determining the layer thickness of a tbc coating of at least one blade of a non-positive-displacement machine, a corresponding tbc layer thickness measuring device for carrying out the method and uses of tbc thickness measuring device
US9212947B2 (en) 2005-08-24 2015-12-15 New Sts Limited Measurement, coating and monitoring system and method
DE102005040266A1 (en) 2005-08-24 2007-03-01 Schott Ag Method and device for inside plasma treatment of hollow bodies
JP5275543B2 (en) 2005-08-31 2013-08-28 株式会社吉野工業所 Synthetic resin container with high barrier properties
US20070049048A1 (en) 2005-08-31 2007-03-01 Shahid Rauf Method and apparatus for improving nitrogen profile during plasma nitridation
WO2007089216A1 (en) 2005-09-01 2007-08-09 Gorokhovsky Vladimir I Plasma vapor deposition method and apparatus utilizing bipolar bias controller
US8786439B2 (en) 2005-09-02 2014-07-22 Wg Security Products Active antenna
WO2006073012A1 (en) 2005-09-05 2006-07-13 Fukuwauchi Technologies Inc. Dlc film-forming apparatus
US20080268252A1 (en) 2005-09-20 2008-10-30 Juan Garces Process for Plasma Coating a Nanocomposite Object
US20090022981A1 (en) 2005-09-20 2009-01-22 Mitsubishi Plastics, Inc. Laminated film having gas barrier characteristics
FR2891279B1 (en) 2005-09-27 2007-12-14 Centre Nat Rech Scient NEW CHIPS FOR SURFACE PLASMON DETECTION (SPR)
AT502522A3 (en) 2005-10-04 2007-12-15 Greiner Bio One Gmbh DISCONNECTION DEVICE, RECORDING DEVICE AND METHOD OF DISCONNECTING
DE102005050432A1 (en) 2005-10-21 2007-05-03 Rap.Id Particle Systems Gmbh Measurement method for measuring layer thicknesses and layer homogeneity in containers coated with slip additives and water-repellant finishings focuses polychromatic light inside the containers
US20090117389A1 (en) 2005-11-07 2009-05-07 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Coating Materials with Oxygen Scavenger and/or Oxygen Indicator Function for Coating or Bonding and Products Produced Therewith
DE102005058133A1 (en) 2005-11-30 2007-05-31 Schott Ag Syringe, has sealing element and syringe body whereby annular, flexible deformable area can be pressed in sealing manner, by means of closing cap, on outer surface of cannula
EP1960279B1 (en) 2005-12-01 2011-10-19 CSP Technologies, Inc. Bottle shaped container
US7409313B2 (en) 2005-12-16 2008-08-05 General Electric Company Method and apparatus for nondestructive evaluation of insulative coating
US20070148326A1 (en) 2005-12-28 2007-06-28 Hastings Mitchell R Syringe
US8025915B2 (en) 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
US20070166187A1 (en) 2006-01-18 2007-07-19 Song Jing F Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
CN104859908B (en) 2006-02-08 2018-04-06 贝克顿·迪金森公司 Improved label processor and its correlation technique
US20070184657A1 (en) 2006-02-09 2007-08-09 Tokyo Electron Limited Etching method
US20080045880A1 (en) 2006-02-11 2008-02-21 Rune Kjeken Device and method for single-needle in vivo electroporation
CA3063263C (en) 2006-02-11 2024-01-16 Genetronics, Inc. Device and method for single-needle in vivo electroporation
BRPI0707814B1 (en) 2006-02-14 2018-05-02 Hitachi Zosen Corporation Electron beam emitter and method for radiating inside a bottle
DE102006009822B4 (en) 2006-03-01 2013-04-18 Schott Ag Process for the plasma treatment of glass surfaces, their use and glass substrate and its use
JP2007231386A (en) 2006-03-02 2007-09-13 Toppan Printing Co Ltd Container treatment apparatus using plasma
US20070205096A1 (en) 2006-03-06 2007-09-06 Makoto Nagashima Magnetron based wafer processing
JP4693120B2 (en) 2006-03-15 2011-06-01 国立大学法人 長崎大学 Coating method for extra-long shaft body and coating apparatus for extra-long shaft body
EP2007916A2 (en) 2006-03-17 2008-12-31 General Plasma, Inc. Mirror magnetron plasma source
US8545865B2 (en) 2006-03-24 2013-10-01 Boston Scientific Scimed, Inc. Medical devices having polymer brushes
CA2643758C (en) 2006-03-24 2014-12-09 University Of Utah Research Foundation Measurement of thickness of dielectric films on surfaces
US7943242B2 (en) 2006-03-30 2011-05-17 Becton, Dickinson And Company Sealing members, articles using the same and methods of reducing sticktion
US8075995B2 (en) 2006-03-30 2011-12-13 Becton, Dickinson And Company Coating system, articles and assembly using the same and methods of reducing sticktion
US8916001B2 (en) 2006-04-05 2014-12-23 Gvd Corporation Coated molds and related methods and components
US20070243618A1 (en) 2006-04-11 2007-10-18 Oxysense, Inc. Device and method for non-invasive oxygen sensing of sealed packages
US20070259184A1 (en) 2006-05-04 2007-11-08 Commonwealth Scientific And Industrial Research Organisation Method of mounting objects for chemical vapour deposition
WO2007133378A1 (en) 2006-05-11 2007-11-22 Dow Global Technologies Inc. Multi-wall plastic sheet having an internal plasma-enhanced chemical vapor deposition coating and process for manufacturing the same
US8273222B2 (en) 2006-05-16 2012-09-25 Southwest Research Institute Apparatus and method for RF plasma enhanced magnetron sputter deposition
DE102006023018A1 (en) 2006-05-17 2007-11-22 Strämke, Siegfried, Dr. Plasma process for surface treatment of workpieces
AT503747B1 (en) 2006-05-18 2009-05-15 Greiner Bio One Gmbh RECORDING DEVICE FOR A MEDICAL DEVICE
ITRM20060277A1 (en) 2006-05-24 2007-11-25 Sipa Societa Industrializzazio PLANT AND PROCESS OF CONTAINER PAINTING
US7624622B1 (en) 2006-05-26 2009-12-01 Mocon, Inc. Method of measuring the transmission rate of a permeant through a container and determining shelf life of a packaged product within the container
US7825038B2 (en) 2006-05-30 2010-11-02 Applied Materials, Inc. Chemical vapor deposition of high quality flow-like silicon dioxide using a silicon containing precursor and atomic oxygen
US20070281117A1 (en) 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
JP2008000287A (en) 2006-06-21 2008-01-10 Terumo Corp Sliding composition for coating medical appliance and medical appliance with sliding coat
US7645696B1 (en) 2006-06-22 2010-01-12 Novellus Systems, Inc. Deposition of thin continuous PVD seed layers having improved adhesion to the barrier layer
FR2903622B1 (en) 2006-07-17 2008-10-03 Sidel Participations DEVICE FOR DEPOSITING A COATING ON AN INTERNAL SIDE OF A CONTAINER
US8197452B2 (en) 2006-07-28 2012-06-12 Becton, Dickinson And Company Vascular access device non-adhering surfaces
JP5127180B2 (en) 2006-07-31 2013-01-23 株式会社大協精工 MEDICAL CONTAINER AND METHOD FOR TREATING THE MEDICAL CONTAINER
US7740792B2 (en) 2006-08-03 2010-06-22 Medrad, Inc. Methods of molding a syringe
US20080033370A1 (en) 2006-08-03 2008-02-07 Becton, Dickinson And Company Binary needle attachment mechanisms
US20080050932A1 (en) 2006-08-23 2008-02-28 Applied Materials, Inc. Overall defect reduction for PECVD films
DE102006061585B4 (en) 2006-08-23 2013-11-28 Singulus Technologies Ag Method and device for spin coating substrates
US7555934B2 (en) 2006-09-07 2009-07-07 3M Innovative Properties Company Fluid permeation testing apparatus employing mass spectrometry
US7552620B2 (en) 2006-09-07 2009-06-30 3M Innovative Properties Company Fluid permeation testing method employing mass spectrometry
EP2081615B1 (en) 2006-09-15 2011-07-06 Becton, Dickinson and Company Medical components having coated surfaces exhibiting low friction and methods of reducing sticktion
US20080071228A1 (en) 2006-09-15 2008-03-20 Becton, Dickinson And Company Medical Components Having Coated Surfaces Exhibiting Low Friction and Methods of Reducing Sticktion
JP5257915B2 (en) 2006-09-29 2013-08-07 国立大学法人東北大学 Film coating apparatus and film coating method
JP2008086855A (en) 2006-09-29 2008-04-17 Fujifilm Corp Biochemical instrument
WO2008042878A1 (en) 2006-10-05 2008-04-10 Polyone Corporation Thermoplastic elastomers containing organoclays
US8062266B2 (en) 2006-10-11 2011-11-22 Becton, Dickinson And Company Vascular access device including a tear-resistant septum
US20080139003A1 (en) 2006-10-26 2008-06-12 Shahid Pirzada Barrier coating deposition for thin film devices using plasma enhanced chemical vapor deposition process
US20080102206A1 (en) 2006-11-01 2008-05-01 Sigurd Wagner Multilayered coatings for use on electronic devices or other articles
EP1918966A1 (en) 2006-11-02 2008-05-07 Dow Corning Corporation Method for forming a film with a graded bandgap by deposition of an amorphous material from a plasma
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
DE102006053366A1 (en) 2006-11-10 2008-05-15 Schott Ag Method and apparatus for plasma enhanced chemical vapor deposition
DE102007037527B4 (en) 2006-11-10 2013-05-08 Schott Ag Process for coating objects with alternating layers
US7780866B2 (en) 2006-11-15 2010-08-24 Applied Materials, Inc. Method of plasma confinement for enhancing magnetic control of plasma radial distribution
US7744567B2 (en) 2006-11-22 2010-06-29 Becton, Dickinson And Company Reducing withdrawal force in a safety IV catheter
US8092605B2 (en) 2006-11-28 2012-01-10 Applied Materials, Inc. Magnetic confinement of a plasma
US8115326B2 (en) 2006-11-30 2012-02-14 Corning Incorporated Flexible substrates having a thin-film barrier
AT504533A1 (en) 2006-12-05 2008-06-15 Greiner Bio One Gmbh SAMPLE PACKAGE
DE102006058771B4 (en) 2006-12-12 2018-03-01 Schott Ag Container with improved emptiness and method for its production
US20080145271A1 (en) 2006-12-19 2008-06-19 Kidambi Srikanth S Method of using sulfur-based corrosion inhibitors for galvanized metal surfaces
FR2911071A1 (en) 2007-01-09 2008-07-11 Becton Dickinson France Soc Pa METHOD AND EQUIPMENT FOR RADIATION DECONTAMINATION OF A PRODUCT SUCH AS A PACKAGE CONTAINING MEDICAL DEVICES
CN201002786Y (en) 2007-01-12 2008-01-09 石家庄第一橡胶股份有限公司 Bottle stopper coated with film
JP2008174793A (en) 2007-01-18 2008-07-31 Nanotec Corp Film-forming apparatus and film-forming method
WO2008093335A2 (en) 2007-01-29 2008-08-07 Greenkote (Israel) Ltd. Methods of preparing thin polymetal diffusion coatings
US20080202414A1 (en) 2007-02-23 2008-08-28 General Electric Company Methods and devices for coating an interior surface of a plastic container
US8409441B2 (en) 2007-02-27 2013-04-02 Deka Products Limited Partnership Blood treatment systems and methods
DE102007011589A1 (en) 2007-03-08 2008-09-11 Schott Ag Conveyor for precursor
US20100178490A1 (en) 2007-03-28 2010-07-15 Glenn Cerny Roll-to-roll plasma enhanced chemical vapor deposition method of barrier layers comprising silicon and carbon
US20080260966A1 (en) 2007-04-22 2008-10-23 Applied Materials, Inc. Plasma processing method
WO2008139982A1 (en) 2007-04-26 2008-11-20 Daikyo Seiko, Ltd. Syringe barrel with injection needle, syringe with injection needle, die for molding syringe barrel with injection needle, and method of molding syringe barrel with injection needle
US20080277332A1 (en) 2007-05-11 2008-11-13 Becton, Dickinson And Company Micromachined membrane filter device for a glaucoma implant and method for making the same
MY154004A (en) 2007-05-23 2015-04-30 Southwest Res Inst Plasma immersion ion processing fro coating of hollow substrates
US7922880B1 (en) 2007-05-24 2011-04-12 Novellus Systems, Inc. Method and apparatus for increasing local plasma density in magnetically confined plasma
KR20080105617A (en) 2007-05-31 2008-12-04 삼성모바일디스플레이주식회사 Chemical vapor deposition apparatus and plasma enhanced chemical vapor deposition apparatus
CN201056331Y (en) 2007-05-31 2008-05-07 许奕新 Packing bottle with coating
US8723332B2 (en) 2007-06-11 2014-05-13 Invensas Corporation Electrically interconnected stacked die assemblies
KR20080111801A (en) 2007-06-20 2008-12-24 삼성전자주식회사 Plasma processing apparatus and method thereof
US20100174239A1 (en) 2007-06-27 2010-07-08 Ofer Yodfat Tubing for Fluid Delivery Device
FR2918301B1 (en) 2007-07-06 2011-06-24 Sidel Participations PLASMA REMOVABLE BARRIER COATING COMPRISING AT LEAST THREE LAYERS, PROCESS FOR OBTAINING SUCH COATING AND CONTAINER COATED WITH SUCH COATING
CH702317B1 (en) 2007-08-02 2011-06-15 Stevanato Group Internat As Structure of the pack of glass vials for pharmaceutical use.
US20100098761A1 (en) 2007-08-03 2010-04-22 University Of Massachusetts Medical School Polymer Compositions For Biomedical And Material Applications
CN101785088B (en) 2007-08-08 2013-06-05 株式会社爱发科 Plasma processing method and plasma processing apparatus
WO2009021257A1 (en) 2007-08-13 2009-02-19 Greiner Bio-One Gmbh Medical separator
US20090061237A1 (en) 2007-08-28 2009-03-05 International Business Machines Corporation LOW k POROUS SiCOH DIELECTRIC AND INTEGRATION WITH POST FILM FORMATION TREATMENT
JP2010538108A (en) 2007-08-31 2010-12-09 コーニング インコーポレイテッド Reaction surface of polymer substrate
WO2009030975A1 (en) 2007-09-03 2009-03-12 Becton Dickinson France Medical device comprising a siliconized chamber and a coated closure means
WO2009030976A1 (en) 2007-09-03 2009-03-12 Becton Dickinson France Medical device and smooth coating therefor
WO2009030974A1 (en) 2007-09-03 2009-03-12 Becton Dickinson France Medical device and lubricant coating therefor
KR100917913B1 (en) 2007-09-05 2009-09-16 한국표준과학연구원 Spectral analyzer for measuring the thickness and identification of chemicals of organic thin films using CARS microscopy
DE102007045455A1 (en) 2007-09-24 2009-04-09 Schott Ag Process for producing wafers from ingots
JP5711868B2 (en) 2007-09-28 2015-05-07 テルモ株式会社 Stable edaravone-containing aqueous formulation
US8231568B2 (en) 2007-10-16 2012-07-31 Nordson Corporation Syringes with a reduced susceptibility to freeze-thaw void formation and methods of manufacturing such syringes
CN106443002A (en) 2007-10-22 2017-02-22 贝克顿·迪金森公司 Methods for evaluating the aggregation of a protein in a suspension including organic polysiloxane
WO2009053947A2 (en) 2007-10-22 2009-04-30 Becton Dickinson France Surface coating to prevent cation leaching
CN100566764C (en) 2007-10-26 2009-12-09 哈尔滨医科大学 A kind of preparation method that is used for the medicine coating carrier and the medicine coating blood vessel support of medicine coating blood vessel support
US8227025B2 (en) 2007-11-02 2012-07-24 Gvd Corporation Conductive polymer coatings and methods of forming the same
DE102007056240A1 (en) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh syringe
KR100935976B1 (en) 2007-12-07 2010-01-08 삼성전기주식회사 Method of transmitting data to multi destinations in wireless lan system
JP5230185B2 (en) 2007-12-13 2013-07-10 富士フイルム株式会社 Reactive sputtering apparatus and reactive sputtering method
GB2468240A (en) 2007-12-19 2010-09-01 Ajjer Llc high throughput methods for analysis of contamination in environmental samples
DE102007062977B4 (en) 2007-12-21 2018-07-19 Schott Ag Process for the production of process gases for the vapor phase separation
JP5286553B2 (en) 2008-02-05 2013-09-11 東洋製罐株式会社 High frequency plasma processing apparatus and high frequency plasma processing method
RU2476953C2 (en) 2008-03-12 2013-02-27 Алитус Корпорейшн, С.А. Plasma system
FR2929295A1 (en) 2008-03-25 2009-10-02 Becton Dickinson France Soc Pa APPARATUS FOR PLASMA TREATMENT OF HOLLOW BODIES
US20110079582A1 (en) 2008-03-31 2011-04-07 Akira Yonesu Plasma generating device and method
US20090263668A1 (en) 2008-04-21 2009-10-22 3M Innovative Properties Company Durable coating of an oligomer and methods of applying
CA2723723C (en) 2008-05-08 2019-06-25 Replenish Pumps, Llc Implantable drug-delivery devices, and apparatus and methods for filling the devices
DE102008023027B4 (en) 2008-05-09 2012-06-28 Von Ardenne Anlagentechnik Gmbh Electrode arrangement for magnetic-field-guided plasma-assisted processes in vacuum
US8062470B2 (en) 2008-05-12 2011-11-22 Yuri Glukhoy Method and apparatus for application of thin coatings from plasma onto inner surfaces of hollow containers
US7967945B2 (en) 2008-05-30 2011-06-28 Yuri Glukhoy RF antenna assembly for treatment of inner surfaces of tubes with inductively coupled plasma
WO2009158613A1 (en) 2008-06-26 2009-12-30 West Pharmaceutical Services, Inc. Method of coating polyxylylene onto flouropolymer surfaces and devices coated thereby
US20090326517A1 (en) 2008-06-27 2009-12-31 Toralf Bork Fluidic capillary chip for regulating drug flow rates of infusion pumps
KR100995700B1 (en) 2008-07-14 2010-11-22 한국전기연구원 Method And Chamber For Inductively Coupled Plasma Processing For Cylinderical Material With Three-dimensional Surface
DE102009034872A1 (en) 2008-07-25 2010-02-18 Dr. Laure Plasmatechnologie Gmbh Device for plasma-assisted coating of the inside of tubular components by means of a high-frequency magnetic field
US8288513B2 (en) 2008-07-25 2012-10-16 Becton, Dickinson And Company Defined cell culturing surfaces and methods of use
CN105154856B (en) 2008-08-04 2018-08-10 北美Agc平板玻璃公司 Plasma source and with the chemical vapor deposition of plasma enhancing come the method for depositing thin film coatings
DE102008037159A1 (en) 2008-08-08 2010-02-11 Krones Ag Apparatus and method for the plasma treatment of hollow bodies
CN102209800A (en) 2008-09-22 2011-10-05 贝克顿·迪金森公司 Systems, apparatus and methods for coating the interior of a container using a photolysis and/or thermal chemical vapor deposition process
DE102008051614B4 (en) 2008-10-09 2012-09-20 Schott Ag Process for the production of glass packaging materials for pharmaceutical products
US9018098B2 (en) 2008-10-23 2015-04-28 Lam Research Corporation Silicon etch with passivation using chemical vapor deposition
EP2349034A4 (en) 2008-10-24 2013-12-11 Gvd Corp Coating methods, systems and related articles
JP5012762B2 (en) 2008-10-30 2012-08-29 大日本印刷株式会社 Manufacturing method for plastic containers
JP5012761B2 (en) 2008-10-30 2012-08-29 大日本印刷株式会社 Manufacturing method for plastic containers
US20100132762A1 (en) 2008-12-02 2010-06-03 Georgia Tech Research Corporation Environmental barrier coating for organic semiconductor devices and methods thereof
DE102008062881B4 (en) 2008-12-16 2021-04-08 Schott Ag Process for the production of a hollow molded glass body
US20100174245A1 (en) 2009-01-08 2010-07-08 Ward Dean Halverson System for pretreating the lumen of a catheter
US20100190036A1 (en) 2009-01-27 2010-07-29 Kyriakos Komvopoulos Systems and Methods for Surface Modification by Filtered Cathodic Vacuum Arc
EP2218465A1 (en) 2009-02-02 2010-08-18 KHS GmbH Apparatus for sterilising a container
US8679063B2 (en) 2009-02-11 2014-03-25 Becton, Dickinson And Company Systems and methods for providing a catheter assembly
US8574203B2 (en) 2009-02-11 2013-11-05 Becton, Dickinson And Company Systems and methods for providing a flushable catheter assembly
US8469928B2 (en) 2009-02-11 2013-06-25 Becton, Dickinson And Company Systems and methods for providing a flushable catheter assembly
US8388583B2 (en) 2009-08-20 2013-03-05 Becton, Dickinson And Company Systems and methods for providing a flushable catheter assembly
EP2589680B1 (en) 2009-02-18 2014-12-24 Council of Scientific & Industrial Research Apparatus for the deposition of diamondlike carbon as protective coating on an inner surface of a shaped object
DE102009011960B4 (en) 2009-03-10 2013-06-13 Schott Ag Method for monitoring plasma discharges
KR20100104119A (en) 2009-03-16 2010-09-29 삼성전자주식회사 Thin film forming apparatus and method for forming the thin film with the same
WO2010107720A2 (en) 2009-03-18 2010-09-23 Tuan Vo-Dinh Up and down conversion systems for production of emitted light from various energy sources
US8197910B2 (en) 2009-04-27 2012-06-12 Becton, Dickinson And Company Methods for producing synthetic surfaces that mimic collagen coated surfaces for cell culture
KR102003651B1 (en) 2009-05-13 2019-07-24 에스아이오2 메디컬 프로덕츠, 인크. Pecvd coating using an organosilicon precursor
ES2452519T3 (en) 2009-05-13 2014-04-01 Sio2 Medical Products, Inc. Container holder
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
FR2948177B1 (en) 2009-07-16 2011-08-05 Inst Francais Du Petrole CHEMICAL LOOP COMBUSTION PROCESS WITH INDEPENDENT CONTROL OF SOLIDS CIRCULATION
US20120097527A1 (en) 2009-07-17 2012-04-26 Ulvac, Inc. Film formation apparatus and film forming method
JP2011060885A (en) 2009-09-08 2011-03-24 Tokyo Electron Ltd Plasma processing apparatus and plasma processing method
DE102009041132B4 (en) 2009-09-14 2014-08-14 Schott Ag Method for producing a sliding layer and pharmaceutical packaging with sliding layer
US20110065798A1 (en) 2009-09-17 2011-03-17 Becton, Dickinson And Company Anti-infective lubricant for medical devices and methods for preparing the same
WO2011035449A2 (en) 2009-09-22 2011-03-31 Medmix System Ag Sealed container comprising a displaceable piston
US9586737B2 (en) 2009-10-09 2017-03-07 West Pharmaceutical Services Deutschland Gmbh & Co. Kg Elastomeric closure with barrier layer and method for its manufacture
CN102725012B (en) 2009-10-29 2016-01-06 W.L.戈尔及同仁股份有限公司 The syringe plug of coating intumescent PTFE
US20110111132A1 (en) 2009-11-09 2011-05-12 Electric Power Research Institute, Inc. System and method for depositing coatings on inner surface of tubular structure
EP2499677B1 (en) 2009-11-10 2022-03-30 Immunolight, LLC Up coversion system for production of light for treatment of a cell proliferation related disorder
JP5357710B2 (en) 2009-11-16 2013-12-04 東京エレクトロン株式会社 Substrate processing method, substrate processing apparatus, and recording medium recording program
FR2954326B1 (en) 2009-12-23 2013-01-18 Valois Sas METHOD FOR SURFACE TREATMENT OF A FLUID PRODUCT DISPENSING DEVICE
WO2011090717A1 (en) 2009-12-28 2011-07-28 Gvd Corporation Coating methods, systems, and related articles
EP2519270B1 (en) 2009-12-31 2017-02-15 Surmodics, Inc. Silyl ether-modified hydrophilic polymers and uses for medical articles
WO2011080543A1 (en) 2009-12-31 2011-07-07 Becton Dickinson France Medical components having coated surfaces exhibiting low friction and/or low gas/liquid permeability
EP2531232B1 (en) 2010-02-05 2016-10-19 DEKA Products Limited Partnership Infusion pump apparatus and heated fill adapter system
US8747631B2 (en) 2010-03-15 2014-06-10 Southwest Research Institute Apparatus and method utilizing a double glow discharge plasma for sputter cleaning
JP5226031B2 (en) 2010-04-13 2013-07-03 テルモ株式会社 Drug container
EP2381246A1 (en) 2010-04-26 2011-10-26 Becton Dickinson France Device, kit and method for inspection of an article
US20130126559A1 (en) 2010-04-30 2013-05-23 Bayer Intellectual Property Gmbh Displacement Syringe
WO2011143509A1 (en) 2010-05-12 2011-11-17 Cv Holdings, Llc Vessel outgassing inspection methods
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
US8628475B2 (en) 2010-06-24 2014-01-14 Cdw Investments, Llc Hyperechogenic needles
JP5900825B2 (en) 2010-06-29 2016-04-06 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド Syringe with integrated needle
CA2805668C (en) 2010-07-16 2020-01-28 Cv Holdings, Llc Injection molding process and product produced using the same
US20120021136A1 (en) 2010-07-20 2012-01-26 Varian Semiconductor Equipment Associates, Inc. System and method for controlling plasma deposition uniformity
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
US9145874B2 (en) 2010-08-09 2015-09-29 Msnw Llc Apparatus, systems and methods for establishing plasma and using plasma in a rotating magnetic field
US8932259B2 (en) 2010-09-13 2015-01-13 Becton, Dickinson And Company Catheter assembly
US8773020B2 (en) 2010-10-22 2014-07-08 Applied Materials, Inc. Apparatus for forming a magnetic field and methods of use thereof
US8476162B2 (en) 2010-10-27 2013-07-02 Applied Materials, Inc. Methods of forming layers on substrates
UA97584C2 (en) 2010-11-08 2012-02-27 Национальный Научный Центр "Харьковский Физико-Технический Институт" METHOD For TRANSPORTATION vacuum-arc cathode plasma with FILTERING OF MACROparticles AND DEVICE FOR realization thereof
US9878101B2 (en) 2010-11-12 2018-01-30 Sio2 Medical Products, Inc. Cyclic olefin polymer vessels and vessel coating methods
US8921516B2 (en) 2010-12-08 2014-12-30 Corning Incorporated Synthetic, defined fibronectin mimetic peptides and surfaces modified with the same
JP6563173B2 (en) 2011-01-19 2019-08-21 プレジデント アンド フェローズ オブ ハーバード カレッジ Porous surface infused with slippery liquid and its biological use
DE102011009057B4 (en) 2011-01-20 2015-12-10 Schott Ag Plasma treatment apparatus for the production of coatings and methods for the internal plasma treatment of containers
WO2012122559A2 (en) 2011-03-10 2012-09-13 KaiaTech, Inc. Method and apparatus for treating containers
JP5801586B2 (en) 2011-03-31 2015-10-28 テルモ株式会社 Fat emulsion prefilled syringe formulation
US9272095B2 (en) 2011-04-01 2016-03-01 Sio2 Medical Products, Inc. Vessels, contact surfaces, and coating and inspection apparatus and methods
US8871319B2 (en) 2011-04-12 2014-10-28 The Procter & Gamble Company Flexible barrier packaging derived from renewable resources
DE102011076754A1 (en) 2011-05-31 2012-12-06 Schott Ag Substrate element for the coating with an easy-to-clean coating
US20140190846A1 (en) 2011-07-29 2014-07-10 Dsm Ip Assets B.V Medical device comprising a wetted hydrophilic coating
US10388493B2 (en) 2011-09-16 2019-08-20 Lam Research Corporation Component of a substrate support assembly producing localized magnetic fields
EP4218862A1 (en) 2011-09-27 2023-08-02 Becton Dickinson France Medical injection device comprising a lubricant coating
FR2980789B1 (en) 2011-09-29 2013-10-25 Commissariat Energie Atomique METHOD FOR MANUFACTURING AN OBJECT FROM A SOL-GEL SOLUTION
SE1250261A1 (en) 2011-10-31 2013-05-01 Billerudkorsnaes Gaevle Froevi Ab Coating composition, a method for coating a substrate, a coated substrate, a packaging material and liquid packaging
CN103930595A (en) 2011-11-11 2014-07-16 Sio2医药产品公司 Passivation, ph protective or lubricity coating for pharmaceutical package, coating process and apparatus
FR2982914B1 (en) 2011-11-22 2014-01-17 Snecma HALL EFFECTOR
EP2602354A1 (en) 2011-12-05 2013-06-12 Pivot a.s. Filtered cathodic vacuum arc deposition apparatus and method
DE102012201955A1 (en) 2012-02-09 2013-08-14 Krones Ag Power lance and plasma-enhanced coating with high-frequency coupling
CN102581274B (en) 2012-03-08 2014-06-11 中国工程物理研究院化工材料研究所 Method for coating micro/nano-metal powder by chemical vapor deposition
US9068565B2 (en) 2012-05-03 2015-06-30 Becton, Dickinson And Company Container and method for storing a pharmaceutical agent
JP2015526693A (en) 2012-05-09 2015-09-10 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド PECVD coating inspection method
CA2887352A1 (en) 2012-05-09 2013-11-14 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
ES2897540T3 (en) 2012-05-29 2022-03-01 Becton Dickinson France Lubricant coating and injection medical device comprising said coating
US9034442B2 (en) 2012-11-30 2015-05-19 Corning Incorporated Strengthened borosilicate glass containers with improved damage tolerance
WO2014008138A2 (en) 2012-07-03 2014-01-09 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
TWI501441B (en) 2012-08-24 2015-09-21 Ind Tech Res Inst Discontinuous compound barrier layer, method for forming the same and package using the same
FR2994851B1 (en) 2012-09-04 2015-08-21 Rexam Healthcare La Verpillier APPARATUS FOR INJECTING PHARMACEUTICAL LIQUID CONFIGURED TO BE PRE-FILLED
WO2014059012A1 (en) 2012-10-12 2014-04-17 Sio2 Medical Products, Inc. Process for the internal coating of hollow bodies
CN104854257B (en) 2012-11-01 2018-04-13 Sio2医药产品公司 coating inspection method
US9903782B2 (en) 2012-11-16 2018-02-27 Sio2 Medical Products, Inc. Method and apparatus for detecting rapid barrier coating integrity characteristics
US10117806B2 (en) 2012-11-30 2018-11-06 Corning Incorporated Strengthened glass containers resistant to delamination and damage
WO2014085348A2 (en) 2012-11-30 2014-06-05 Sio2 Medical Products, Inc. Controlling the uniformity of pecvd deposition on medical syringes, cartridges, and the like
US20160015898A1 (en) 2013-03-01 2016-01-21 Sio2 Medical Products, Inc. Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus
KR102336796B1 (en) 2013-03-11 2021-12-10 에스아이오2 메디컬 프로덕츠, 인크. Coated Packaging
WO2014144926A1 (en) 2013-03-15 2014-09-18 Sio2 Medical Products, Inc. Coating method
DE102013103676A1 (en) 2013-04-11 2014-10-30 Schott Ag Containers with low particulate emission and frictionally controlled dry sliding surface, and process for its production

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844986A (en) 1988-02-16 1989-07-04 Becton, Dickinson And Company Method for preparing lubricated surfaces and product
EP0619178A1 (en) * 1992-10-20 1994-10-12 Toppan Printing Co., Ltd. Multi-layered film material
US6165566A (en) 1996-01-30 2000-12-26 Becton Dickinson And Company Method for depositing a multilayer barrier coating on a plastic substrate
US7901783B2 (en) 1998-04-28 2011-03-08 Applied Materials, Inc. Low κ dielectric inorganic/organic hybrid films and method of making
US6068884A (en) 1998-04-28 2000-05-30 Silcon Valley Group Thermal Systems, Llc Method of making low κ dielectric inorganic/organic hybrid films
DE10242698B3 (en) * 2002-09-13 2004-03-25 Fresenius Hemocare Gmbh Container made from silica-coated entropy-elastic film, useful especially as blood transfusion bag, has increased water vapor permeability after stretching
US20040267194A1 (en) 2003-01-28 2004-12-30 Minoru Sano Prefilled syringe and production method for a barrel thereof
US20060046006A1 (en) 2004-08-31 2006-03-02 Bastion Bradley J Multilayer polymeric barrier film, flexible packaging made therewith, and methods
US20070051629A1 (en) * 2005-09-08 2007-03-08 Vladislav Dolnik Poly(amino saccharide) wall coating for electrophoretic separations in capillaries and microchannels
US20080090039A1 (en) 2006-10-14 2008-04-17 Schott Ag PICVD coating for plastic containers
US8067070B2 (en) 2006-10-14 2011-11-29 Schott Ag PICVD coating for plastic containers
US7985188B2 (en) 2009-05-13 2011-07-26 Cv Holdings Llc Vessel, coating, inspection and processing apparatus
US20110152820A1 (en) 2009-12-22 2011-06-23 Medtronic Minimed, Inc. Barrier coatings for fluids contacting medical devices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JING YU; XAVIER BANQUY; GEORGE W. GREENE; DANIEL D. LOWREY; JACOB N. ISRAELACHVILI: "Langmuir", vol. 28, 2012, DEPARTMENT OF CHEMICAL ENGINEERING AND MATERIALS DEPARTMENT, article "The Boundary Lubrication of Chemically Grafted and CrossLinked Hyaluronic Acid in Phosphate Buffered Saline and Lipid Solutions Measured by the Surface Forces Apparatus", pages: 2244 - 2250

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537273B2 (en) 2009-05-13 2020-01-21 Sio2 Medical Products, Inc. Syringe with PECVD lubricity layer
US10390744B2 (en) 2009-05-13 2019-08-27 Sio2 Medical Products, Inc. Syringe with PECVD lubricity layer, apparatus and method for transporting a vessel to and from a PECVD processing station, and double wall plastic vessel
US9572526B2 (en) 2009-05-13 2017-02-21 Sio2 Medical Products, Inc. Apparatus and method for transporting a vessel to and from a PECVD processing station
US9545360B2 (en) 2009-05-13 2017-01-17 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US11624115B2 (en) 2010-05-12 2023-04-11 Sio2 Medical Products, Inc. Syringe with PECVD lubrication
US11123491B2 (en) 2010-11-12 2021-09-21 Sio2 Medical Products, Inc. Cyclic olefin polymer vessels and vessel coating methods
US9878101B2 (en) 2010-11-12 2018-01-30 Sio2 Medical Products, Inc. Cyclic olefin polymer vessels and vessel coating methods
US9272095B2 (en) 2011-04-01 2016-03-01 Sio2 Medical Products, Inc. Vessels, contact surfaces, and coating and inspection apparatus and methods
US11116695B2 (en) 2011-11-11 2021-09-14 Sio2 Medical Products, Inc. Blood sample collection tube
US11724860B2 (en) 2011-11-11 2023-08-15 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
US11884446B2 (en) 2011-11-11 2024-01-30 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
US10577154B2 (en) 2011-11-11 2020-03-03 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
US10189603B2 (en) 2011-11-11 2019-01-29 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
US11148856B2 (en) 2011-11-11 2021-10-19 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
US11793819B2 (en) 2011-11-23 2023-10-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8993548B2 (en) 2011-11-23 2015-03-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9114145B2 (en) 2011-11-23 2015-08-25 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10675288B2 (en) 2011-11-23 2020-06-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103516B2 (en) 2011-11-23 2021-08-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8993549B2 (en) 2011-11-23 2015-03-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9114146B2 (en) 2011-11-23 2015-08-25 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US11166963B2 (en) 2012-06-18 2021-11-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US11110099B2 (en) 2012-06-18 2021-09-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11865179B2 (en) 2012-06-18 2024-01-09 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11033626B2 (en) 2012-06-18 2021-06-15 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11529360B2 (en) 2012-06-18 2022-12-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
US9540439B2 (en) 2012-10-08 2017-01-10 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
US9664626B2 (en) 2012-11-01 2017-05-30 Sio2 Medical Products, Inc. Coating inspection method
US9903782B2 (en) 2012-11-16 2018-02-27 Sio2 Medical Products, Inc. Method and apparatus for detecting rapid barrier coating integrity characteristics
US9764093B2 (en) 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
US10201660B2 (en) 2012-11-30 2019-02-12 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition on medical syringes, cartridges, and the like
US10363370B2 (en) 2012-11-30 2019-07-30 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
US11406765B2 (en) 2012-11-30 2022-08-09 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
US11304959B2 (en) 2012-12-21 2022-04-19 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11116717B2 (en) 2012-12-21 2021-09-14 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11241445B2 (en) 2012-12-21 2022-02-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11065197B2 (en) 2012-12-21 2021-07-20 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11497709B2 (en) 2012-12-21 2022-11-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11622933B2 (en) 2012-12-21 2023-04-11 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11123283B2 (en) 2012-12-21 2021-09-21 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11351182B2 (en) 2012-12-21 2022-06-07 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10835487B2 (en) 2012-12-21 2020-11-17 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10888516B2 (en) 2012-12-21 2021-01-12 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9662450B2 (en) 2013-03-01 2017-05-30 Sio2 Medical Products, Inc. Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus
US10537494B2 (en) 2013-03-11 2020-01-21 Sio2 Medical Products, Inc. Trilayer coated blood collection tube with low oxygen transmission rate
US10016338B2 (en) 2013-03-11 2018-07-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging
US9937099B2 (en) 2013-03-11 2018-04-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging with low oxygen transmission rate
US11684546B2 (en) 2013-03-11 2023-06-27 Sio2 Medical Products, Inc. PECVD coated pharmaceutical packaging
US11344473B2 (en) 2013-03-11 2022-05-31 SiO2Medical Products, Inc. Coated packaging
US9554968B2 (en) 2013-03-11 2017-01-31 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging
US10912714B2 (en) 2013-03-11 2021-02-09 Sio2 Medical Products, Inc. PECVD coated pharmaceutical packaging
US11298293B2 (en) 2013-03-11 2022-04-12 Sio2 Medical Products, Inc. PECVD coated pharmaceutical packaging
US9863042B2 (en) 2013-03-15 2018-01-09 Sio2 Medical Products, Inc. PECVD lubricity vessel coating, coating process and apparatus providing different power levels in two phases
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US11066745B2 (en) 2014-03-28 2021-07-20 Sio2 Medical Products, Inc. Antistatic coatings for plastic vessels
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103513B2 (en) 2014-05-22 2021-08-31 TherapeuticsMD Natural combination hormone replacement formulations and therapies
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10398708B2 (en) 2014-10-22 2019-09-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10668082B2 (en) 2014-10-22 2020-06-02 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11077233B2 (en) 2015-08-18 2021-08-03 Sio2 Medical Products, Inc. Pharmaceutical and other packaging with low oxygen transmission rate
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10973890B2 (en) 2016-09-13 2021-04-13 Allergan, Inc. Non-protein clostridial toxin compositions
CN107952125B (en) * 2017-12-16 2020-09-25 东莞瑞景医疗科技有限公司 Efficient and quick irrigator for anorectal surgery
CN107952125A (en) * 2017-12-16 2018-04-24 嘉兴新博信息科技有限公司 A kind of anorectal surgical flusher of efficient quick
WO2022258713A1 (en) * 2021-06-08 2022-12-15 Glycome Biopharma Limited Methods of coating substrates
US20230132721A1 (en) * 2021-11-02 2023-05-04 Hikma Pharmaceuticals Usa Inc. Succinylcholine Chloride Prefilled Syringe

Also Published As

Publication number Publication date
US9545360B2 (en) 2017-01-17
US20150126941A1 (en) 2015-05-07
CA2887352A1 (en) 2013-11-14
EP2846755A1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
US9545360B2 (en) Saccharide protective coating for pharmaceutical package
US11684546B2 (en) PECVD coated pharmaceutical packaging
US11884446B2 (en) Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
US10537494B2 (en) Trilayer coated blood collection tube with low oxygen transmission rate
US9662450B2 (en) Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus
US20130041241A1 (en) Pecvd coating methods for capped syringes, cartridges and other articles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13723390

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2887352

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14399678

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013723390

Country of ref document: EP